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Abstract	  
The	   aim	   of	   this	   thesis	   was	   to	   investigate	   whether	   manipulation	   of	   the	   tumour	  
microenvironment	   can	   suppress	   the	   proliferation	   of	   malignant	   cells	   in	   Chronic	  
Lymphocytic	   Leukaemia	   (CLL).	   It	   has	   been	   established	   the	   CLL	   cells	   undergo	  
proliferation	   in	   the	   lymph-­‐node	  compartment,	  where	   they	   interact	  with	  components	  
of	   the	   tumour	   microenvironment	   including	   activated	   CD4	   T	   cells.	   We	   therefore	  
explored	  whether	  T	  cell	  suppression	  using	  ciclosporin	  (CsA)	  could	  inhibit	  the	  activation	  
and	  proliferation	  of	  CLL	  cells.	  	  
A	   series	  of	   in-­‐vitro	   assays	  was	  developed	   to	   characterise	   the	  effect	  of	  CsA	  on	  CD4	  T	  
cells	   in	  CLL.	   In	  view	  of	   the	   fact	   that	  CsA	   inhibits	  NFAT	   (Nuclear	  Factor	  of	  Activated	  T	  
cells),	   which	   plays	   a	   role	   in	   B	   cell	   receptor	   (BCR)	   signalling	   in	   CLL,	   we	   investigated	  
whether	  CsA	  has	  a	  direct	  effect	  on	  malignant	  cells.	  Having	  shown	  that	  CsA	  has	  a	  major	  
T	   cell-­‐dependent	   effect	   and	   a	   smaller	   direct	   effect	   on	   the	   activation	   of	   CLL	   cells	   in-­‐
vitro,	  we	  developed	  a	  Phase	  2	  clinical	  trial	  (CyCLLe)	  to	  investigate	  the	  effect	  of	  CsA	  on	  
the	  proliferation	  of	  CLL	  cells	  in	  patients	  with	  early	  stage,	  adverse	  risk	  disease.	  
The	  proliferation	  of	  CLL	  cells	  was	  measured	  using	   in-­‐vivo	  deuterium	  labelling,	  a	  novel	  
method	  of	  assessing	  drug	  effect.	  Despite	   the	  promising	   in-­‐vitro	   findings,	  CsA	  did	  not	  
inhibit	  in-­‐vivo	  proliferation.	  
A	   further	   study	   of	   in-­‐vivo	   labelling	   was	   designed	   to	   assess	   intra-­‐patient	   variation	   in	  
proliferation	   rates	   in	   CLL.	   Using	   ‘pulse-­‐labelling’	   with	   deuterated	   glucose,	   it	   was	  
possible	   to	   investigate	   the	   trafficking	   of	   CLL	   cells	   between	   the	   lymph-­‐node	   and	  
peripheral	   blood.	   Furthermore,	   it	   was	   possible	   to	   explore	   the	   relationship	   between	  
sIgM	   expression,	   proliferation	   and	   trafficking	   of	   CLL	   cells.	   Importantly,	   these	   studies	  
found	   that	   in	  patients	  with	  mutated	   IgVH	   genes,	   there	   is	   an	  apparently	   independent	  
sub-­‐population	   of	   cells,	   characterised	   by	   low	   sIgM	   expression	   and	   low	   BCR	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Abbreviations	  
Abbreviation	   Meaning	  
AID	  	   Activation	  Induced	  cytidine	  Deaminase	  
AIHA	   Autoimmune	  Haemolytic	  Anaemia	  
APC	   Allophycocyanin	  
APRIL	   A	  Proliferation	  Induced	  Ligand	  
ATG	   Antithymocyte	  globulin	  
ATM	   Ataxia	  Telangiectasia	  Mutated	  
B-­‐ALL	   B-­‐Acute	  lymphoblastic	  Leukaemia	  
BAFF	   B-­‐Cell	  Activating	  Factor	  
BCL	   B-­‐Cell	  lymphoma	  
BCR	   B	  Cell	  Receptor	  
BIRC-­‐3	   Baculoviral	  IAP	  Repeat	  Containing	  3	  
BR	   Bendamstine	  Rituximab	  
BSA	   Bovine	  Serum	  Albumin	  
BTK	   Bruton’s	  tyrosine	  kinase	  
CCR	   C-­‐C	  motif	  Chemokine	  Receptor	  	  
CD	   Cluster	  of	  Differentiation	  
CLL	   Chronic	  Lymphocytic	  Leukaemia	  
CM	  	   Complete	  Medium	  
CMV	   Cytomegalovirus	  
ConA	   Concanavalin	  
CR	   Complete	  Response	  
CsA	   Ciclosporin	  
CTC	   Common	  Toxicity	  Criteria	  
CTLA-­‐4	   Cytotoxic	  T-­‐lymphocyte	  antigen	  4	  
CXCR	   C-­‐X-­‐C	  motif	  Chemokine	  Receptor	  
CY	   Cyanine	  
CyCLLe	   Ciclosporin	  A	  in	  Chronic	  Lymphocytic	  Leukemia	  
CYP3A	   Cytochrome	  P450	  family	  3,	  subfamily	  A	  
DAPI	   4’,	  6-­‐Diamidino-­‐2-­‐Phenylindole	  
DMEM	   Dulbecco’s	  Modified	  Eagle	  Medium	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DMSO	   Dimethyl	  Sulphoxide	  
DNA	   Deoxyribonucleic	  Acid	  
DTT	   1,4	  Dithiothreitol	  
EBV	   Epstein	  Barr	  Virus	  
ECG	   Electrocardiogram	  
ECL	   Enhanced	  chemo-­‐luminesence	  
EDTA	   Ethylenediaminetetraacetic	  Acid	  
ELISA	   Enzyme	  Linked	  Immunosorbent	  Assay	  
EMSA	   Electrophoretic	  Mobility	  Shift	  Assays	  
ERK	   Extracellular	  signal-­‐	  related	  kinase	  
FACS	   Fluoresence	  Activated	  Cell	  Sorting	  
FBS	   Foetal	  Bovine	  Serum	  
FCR	   Fludarabine	  Cyclophosphamide	  and	  Rituximab	  
FCR	   Fludarabine	  Cyclophosphamide	  Rituximab	  
FDA	   Food	  and	  Drug	  Administration	  
FISH	   Fluorescence	  in-­‐situ	  hybridization	  
FOXP3	   Forkhead	  Box	  P3	  
GCMS	   Gas	  Chromatography	  Mass	  Spectrometry	  
GFR	   Glomerular	  Filtration	  Rate	  
HEV	   High	  Endothelial	  Venule	  
HRP	   Horse	  Radish	  Peroxidase	  
HSC	   Haematopoietic	  Stem	  Cell	  
HTA	   Human	  Tissue	  Authority	  
HTA	   Human	  Tissue	  Authority	  
ICAM	   Intercellular	  Adhesion	  Molecule	  
IFN	   Interferon	  
IgH	   Immunoglobulin	  Heavy	  Chains	  
IgL	   Immunoglobulin	  Light	  Chains	  
IgVH	   Immunoglobulin	  Variable	  Heavy	  Chain	  
IKK	   Inhibitor	  of	  NFκB	  kinase	  
IL	   Interleukin	  
IRF	   Interferon	  Regulatory	  Factor	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ITAM	  
Immunoreceptor	  tyrosine	  based	  activation	  motif	  
ITP	   Immune	  Thrombocytopenia	  
IWCLL	   International	  Workshop	  on	  Chronic	  Lymphocytic	  Leukaemia	  
KCL	   King’s	  College	  London	  
KD	   Kilodalton	  
LDH	   Lactate	  Dehydrogenase	  
LFA	   Lymphocyte	  Function	  Associated	  Antigen	  
LPS	   Lipopolysaccharide	  
MAP	   Mitogen	  Activated	  Protein	  
MAPK	   Mitogen	  Activated	  Protein	  Kinase	  
MAPKK	   MAPK	  Kinase	  
MBL	   Monoclonal	  B	  Lymphocytosis	  
MCL	   Myeloid	  Cell	  Leukaemia	  
MFI	   Mean	  Fluorescence	  Intensity	  
MHC	   Major	  Histocompatibility	  Complex	  
MRD	   Minimal	  Residual	  Disease	  
MYD88	   Myeloid	  Differentiation	  Primary	  Response	  88	  
NFAT	   Nuclear	  Factor	  of	  Activated	  T	  cells	  
NFκB	   Nuclear	  Factor	  kappa	  B	  
NK	   Natural	  Killer	  
NLC	   Nurse	  Line	  Cell	  
NRES	   National	  Research	  Ethics	  Committee	  
NRES	   National	  Research	  Ethics	  Service	  
NSG	   Non-­‐obese	  diabetes/severe	  combined	  immunodeficiency/γcnull	  
ORR	   Overall	  Response	  Rate	  
OS	   Overall	  Survival	  
PAGE	   Polyacrylamide	  Gel	  Electrophoresis	  
PAMP	   Pathogen	  Associated	  Molecular	  Pattern	  
PBMC	   Peripheral	  Blood	  Mononuclear	  Cell	  
PBS	   Phosphate	  Buffered	  Saline	  
PCR	   Polymerase	  Chain	  Reaction	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PD	   Programmed	  Death	  
PDL	   Programmed	  Death	  Ligand	  
PE	   Phycoerythrin	  
PERCP	   Peridinin	  Chrorophyll	  Protein	  
PFA	   Paraformaldehyde	  
PFS	   Progression	  Free	  Survival	  
PI3K	   Phosphatidylinositol	  3-­‐Kinase	  
PKC	   Protein	  Kinase	  C	  
PLC	   Phospohlipase	  C	  
PLC	   Phospholiase	  C	  
PMA	   Phorbol	  Myristate	  13-­‐Acetate	  
PMT	   Photomultiplier	  Tube	  
PRCA	   Pure	  Red	  Cell	  Aplasia	  
PRR	   Pathogen	  Recognition	  Receptor	  
PTFE	   Polytetrafluoroethylene	  
RNA	   Ribonucleic	  Acid	  
RPMI	   Roswell	  Park	  Memorial	  Institute	  
S1P	   Sphinosine-­‐1-­‐phosphate	  
S1P1	   Sphingosine-­‐1-­‐phosphate-­‐receptor-­‐1	  
SDF	   Stromal	  Derived	  Factor	  
SDS	   Sodium	  Dodecyl	  Sulfate	  
SEER	   Surveillance,	  Epidemiology	  and	  End	  Results	  Program	  
SF3B1	   Splicing	  Factor	  3b	  Subunit	  
STELA	   Single	  telomere	  length	  analysis	  
sIgM	   Surface	  Immunoglobulin	  M	  
SLL	   Small	  Lymphocytic	  Leukaemia	  
SYK	   Spleen	  Tyrosine	  Kinase	  
T	  CM	  	   Central	  Memory	  T-­‐Cell	  
T	  EM	   Effector	  Memory	  T-­‐Cell	  
T	  EMRA	   Terminal	  Differentiated	  Effector	  Memory	  T-­‐Cell	  
TAA	   Tumour	  Associated	  Antigen	  
TAP	   Trials	  Acceleration	  Program	  
	   19	  
TCR	   T	  cell	  receptor	  
Tfh	   T-­‐follicular	  helper	  
TGF-­‐β	   Transforming	  Growth	  Factor	  Beta	  
Th	   T	  helper	  	  
TK	   Thymidine	  Kinase	  
TLR	   Toll-­‐like	  Receptor	  
TP53	   Tumour	  Protein	  53	  
Treg	   T	  regulatory	  
UHW	   University	  Hospital	  Wales	  
v/v	   Volume/	  Volume	  
Vβ	   Variable	  Beta	  
VC	   Vehicle	  Control	  
WES	   Whole	  Exome	  Sequencing	  
WGS	   Whole	  Genome	  Sequencing	  
WHO	   World	  Health	  Organisation	  
Β2-­‐M	   Beta-­‐2	  microglobulin	  
7-­‐AAD	   7-­‐Aminoactinomycin	  D	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 .	  Introduction	  Chapter	  1
1.1	  The	  Human	  Immune	  System	  
The	  immune	  system	  is	  critical	  in	  maintaining	  the	  integrity	  of	  the	  human	  body	  through	  
recognition	   and	   elimination	   of	   foreign	   substances	   and	   organisms.	   Robust	  
discrimination	   between	   ‘self’	   and	   non-­‐self’	   forms	   the	   foundation	   of	   the	   immune	  
system	  in	  all	  organisms;	  from	  the	  most	  basic	  to	  the	  most	  complex	  system	  that	  protects	  
human	  beings.	  	  
The	   human	   immune	   system	   has	   evolved	   into	   a	   highly	   sophisticated	   defence	   system	  
that	   includes	   both	   immediate	   (innate)	   and	   specific	   (adaptive)	   components	   with	  
‘memory’	  that	  enables	  enhanced	  efficiency	  following	  repeated	  pathogen	  exposure.	  	  
In	   addition	   to	   protecting	   against	   infection,	   the	   immune	   system	   provides	   an	   early	  
response	   system	   to	   recognise	   and	   eliminate	   malignant	   cells	   before	   they	   undergo	  
tumorigenesis.	  However,	   it	   is	  becoming	   increasingly	  recognised	  that	  cancers	  are	  able	  
to	  bypass,	  and	  in	  some	  cases	  co-­‐opt	  the	  immune	  system	  to	  support	  their	  survival	  and	  
proliferation.	  
1.1.1	  Phylogeny	  
In	   its	   simplest	   form,	   immunity	   is	   evident	   in	   marine	   sponges,	   where	   ‘grafts’	   from	  
sponges	  of	  a	  different	  colony	  are	  recognised	  as	  non-­‐self	  and	  are	  rejected.	  The	  protein	  
structure	  motif	  that	  permits	  antigen	  recognition	  (pathogen	  recognition	  receptors)	  has	  
been	  highly	  conserved	  throughout	  evolution	  and	  is	  evident	  in	  plants,	  invertebrates	  and	  
human	  beings.	  	  
Adaptive	   immunity	   has	   evolved	   in	   the	   lower,	   jawless	   vertebrates	   including	   the	  
lamprey,	  in	  which	  lymphocyte-­‐like	  cells	  express	  a	  receptor	  that	  mediates	  the	  immune	  
response.	   T	   and	  B	   cell	   responses	   are	  well	   defined	   in	   jawed	  vertebrates	   in	  which	   the	  
development	   of	   separate	   sites	   of	   differentiation	   appears	   to	   have	   contributed	   to	  
evolution	   of	   the	   immune	   system.	   The	   thymus	   is	   evident	   in	   teleosts	   	   	   	   	   	   (bony	   fish,	  
amphibians,	   reptiles,	   birds	   and	   mammals),	   where	   there	   is	   evidence	   of	   major	  
histocompatibility	  complex	  (MHC)	  molecules,	  cell-­‐mediated	  immunity	  and	  cytotoxic	  T	  
cells.	   At	   the	   highest	   level	   of	   evolution	   of	   the	   immune	   system,	   warm-­‐blooded	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vertebrates	   have	   germinal	   centres	   that	   enable	   T	   cell	   dependent,	   high	   affinity	  
secondary	  antibody	  responses.	  
1.1.2	  Ontogeny	  
Cells	  of	  the	  human	  immune	  system,	  in	  addition	  to	  red	  blood	  cells	  and	  megakaryocytes,	  
originate	  from	  haematopoietic	  stem	  cells	  (HSCs)	  that	  are	  characterised	  by	  the	  property	  
of	   self-­‐renewal.	   During	   embryogenesis,	   haematopoiesis	   takes	   place	   in	   the	   yolk-­‐sac,	  
followed	  by	  the	  fetal	  liver	  and	  eventually	  the	  bone	  marrow	  where	  HSCs	  receive	  growth	  
and	  differentiation	  signals	  from	  the	  bone	  marrow	  stromal	  cells.	  	  
T	  cell	  progenitors	  that	  lack	  CD4	  and	  CD8	  expression	  travel	  to	  the	  thymus	  and	  under	  the	  
influence	   of	   chemokines,	   they	   migrate	   through	   the	   cortex	   where	   they	   express	   a	  
randomly	  generated	  T	   cell	   receptor	   (TCR)	  and	   switch	  on	   the	  expression	  of	  both	  CD4	  
and	  CD8.	  The	  TCR	  is	  generated	  by	  rearrangement	  of	  V-­‐,	  D-­‐	  and	  J-­‐	  region	  genes	  to	  form	  
the	  α	  and	  β	  chains	  that	  are	  required	  for	  antigen	  specificity.	  CD4	  and	  CD8	  expression	  is	  
necessary	   for	   the	  recognition	  of	  antigen	  presented	  by	  MHC	  and	  determines	  whether	  
the	   cells	   become	   T	   helper	   or	   cytotoxic	   T	   cells	   respectively.	   T	   cells	   subsequently	  
undergo	  ‘thymic	  education’	  that	  involves	  both	  negative	  and	  positive	  selection	  so	  that	  
they	  exit	  the	  thymus	  bearing	  either	  CD4	  or	  CD8	  and	  a	  TCR	  that	  can	  recognise	  foreign	  
antigen	   bound	   to	   MHC.	   Negative	   selection	   of	   strongly	   self-­‐reactive	   T	   cells	   in	   the	  
thymus	  underpins	  immune	  ‘tolerance’.	  
A	  smaller	  population	  of	  T	  cells	  (γδ	  T	  cells)	  arises	  earlier	  in	  thymic	  development;	  these	  
cells	  do	  not	  require	  antigen	  to	  be	  presented	  by	  MHC	  and	  do	  not	  express	  CD4	  or	  CD8;	  
they	  are	  thought	  to	  play	  an	  immune	  regulatory	  role.	  
B	   lymphocyte	  precursors	   (pro-­‐B	  cells)	  are	  dependent	  upon	  on	  the	  expression	  of	  E2A,	  
early	   B	   cell	   factor,	   and	   the	   PAX	   5	   gene	   that	   encodes	   B	   cell	   activator	   protein	   for	  
development	  into	  pre-­‐B	  cells.	  The	  B-­‐1	  subset	  of	  progenitors	  that	  expresses	  surface	  IgM	  
(sIgM)	   and	  CD5	  moves	   from	   the	   fetal	   liver	   to	   the	  peritoneal	   cavity	   early	   in	  neonatal	  
period,	  where	  these	  cells	  produce	  low	  affinity,	  multi-­‐specific	  IgM	  	  (natural	  antibodies)	  
in	   the	   absence	   of	   antigen.	   Conventional	   B	   cells	   (B-­‐2	   cells)	   express	   lower	   levels	   of	  
surface	  IgM	  and	  lack	  CD5	  expression	  and	  represent	  a	  separate	  developmental	  lineage.	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B	  cells	  develop	  their	  specificity	  in	  a	  specific	  sequence.	  The	  D-­‐J	  segments	  of	  both	  alleles	  
of	   the	   heavy	   chain	   Immunoglobulin	   loci	   rearrange	   followed	   by	   a	   single	   V-­‐DJ	  
rearrangement.	  This	  is	  followed	  by	  V-­‐J	  recombination	  of	  first	  one	  kappa	  light	  chain	  and	  
then	  the	  other.	   If	   this	   is	  not	  productive,	  an	  attempt	   is	  made	  to	  achieve	  a	  productive	  
lambda	   light	   chain	   allele	   rearrangement.	   This	   is	   followed	   by	   the	   synthesis	   of	   sIgM,	  
which	   suppresses	   any	   further	   gene	   rearrangement	   by	   exclusion	   of	   non-­‐rearranged	  
alleles	  so	  that	  each	  B	  cell	  can	  only	  express	  one	  heavy	  chain	  and	  one	   light	  chain.	  This	  
forms	  the	  basis	  of	  clonal	  selection.	  
As	  in	  T	  cell	  mediated	  tolerance,	  deletion	  of	  auto-­‐reactive	  B	  cells	  and	  anergy	  contribute	  
to	   tolerance	   in	   B	   lymphocytes.	   Evidence	   for	   B	   cell	   anergy	   derives	   from	   the	   double	  
transgenic	  mice	  made	  to	  express	  both	  soluble	  lysozyme	  and	  a	  high	  affinity	  antibody	  to	  
lysozyme.	   The	   mice	   were	   tolerant	   and	   could	   not	   be	   immunised	   to	   produce	   anti-­‐
lysozyme;	  although	  the	  antibody	  was	  present	  on	  the	  surface	  of	  the	  B	  lymphocytes,	   it	  
was	  not	  secreted	  in	  the	  serum.	  In	  the	  case	  of	  soluble	  proteins,	  T	  cells	  are	  more	  easily	  
tolerised	  such	  that	  B	  cells	  cannot	  be	  triggered	  to	  produce	  high	  affinity	  antibody	  as	  the	  
T	  cells	  required	  for	  T-­‐B	  help	  are	  already	  tolerant.	  
Natural	  killer	  cells	  that	  provide	  innate	  immunity	  arise	  from	  HSCs	  in	  the	  bone	  marrow	  
and	  from	  early	  lymphoid	  precursors	  in	  the	  thymus.	  Maturation	  into	  functional	  NK	  cells	  
requires	   the	   expression	   of	   inhibitory	   receptors	   that	   recognise	   ‘self’	   MHC,	   following	  
which	  they	  migrate	  to	  mucosal	  surfaces	  where	  they	  may	  encounter	  antigen.	  
1.1.3	  The	  Normal	  Immune	  Response	  
The	   first	   line	  of	  defence	  against	   infectious	  agents	   in	  vertebrates	   is	  a	  physical	  barrier;	  
skin	   provides	   the	   external	   barrier	   whilst	   mucous	   secretions	   covering	   the	   epidermal	  
layers	   of	   the	   inner	   surfaces	   of	   the	   respiratory,	   digestive	   and	   reproductive	   tracts	  
provide	  the	  internal	  barrier.	  	  
Secondly,	   innate	   immunity	   provides	   the	   immediate	   but	   non-­‐specific	   defence	   against	  
infectious	   agents	   through	   recognition	   of	   the	   highly	   conserved	   pathogen	   associated	  
molecular	   patterns	   (PAMPs).	   The	   Toll-­‐like	   receptors	   (TLRs),	   positioned	   in	   the	   plasma	  
membrane	   of	   sentinel	   cells	   including	   macrophages	   and	   dendritic	   cells,	   constitute	   a	  
major	   sub-­‐set	   of	   the	   pathogen	   recognition	   receptors	   (PRRs).	   They	   recognise	   PAMPs	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and	   trigger	   the	   activation	   of	   transcription	   factors	   including	   nuclear	   factor	   kappa	   B	  
(NFκB)	   and	   members	   of	   the	   interferon	   regulated	   factor	   (IRF)	   family,	   leading	   to	   the	  
expression	   of	   cytokines	   and	   chemokines.	   Macrophage	   and	   neutrophil	   mediated	  
phagocytosis,	   first	   described	   by	   Metchnikoff	   in	   1883,	   involves	   the	   engulfment	   and	  
digestion	  of	  microorganisms.	   The	   complement	   system,	  again	   reported	  at	   the	   turn	  of	  
the	  twentieth	  century,	  involving	  a	  cascade	  of	  proteins	  contributes	  to	  the	  elimination	  of	  
microorganisms	  via	  direct	  lysis	  and	  opsonisation	  (coating)	  that	  enhances	  phagocytosis.	  
Additionally,	   lysozyme,	   a	  muramidase	  enzyme	   that	   splits	   the	  peptidoglycan	  bacterial	  
wall,	  provides	  an	  important	  component	  of	  the	  immediate	  defence.	  	  
The	   innate	   immune	   system	   triggers	   the	   activation	   of	   the	   adaptive	   immune	   system,	  
composed	   of	   B	   and	   T	   lymphocytes,	   and	   provides	   critical	   information	   regarding	   the	  
nature	  and	  duration	  of	  response	  that	  is	  required	  to	  eliminate	  the	  pathogen.	  Dendritic	  
cells	   provide	   the	   conduit	   between	   innate	   and	   adaptive	   systems;	   first	   described	   by	  
Steinman	  and	  Cohn	  in	  1973,	  they	  continuously	  sample	  the	  environment	  by	  pinocytosis	  
and	   migrate	   to	   the	   lymph-­‐node,	   where	   they	   present	   antigen	   via	   MHC	   to	   T	  
lymphocytes.	   In	   addition	   to	   flagging	   the	   presence	   of	   a	   pathogen	   via	   antigen	  
presentation,	  the	  antigen	  presenting	  cells	  provide	  a	  second	  signal	  (co-­‐stimulation)	  via	  
expression	  of	  CD80	  and	  CD86	  that	  is	  necessary	  for	  the	  successful	  activation	  of	  naïve	  T	  
lymphocytes	  (Owen,	  Punt,	  Stranford	  2013).	  	  	  	  
1.1.4	  Lymphocyte	  Trafficking	  
Immune	  surveillance	  is	  provided	  by	  lymphocytes	  that	  continuously	  traffic	  between	  the	  
peripheral	   blood	   and	   lymph-­‐node	   compartments	   in	   search	   of	   antigen.	   Using	  
radioactively	   labelled	   lymphocytes	   that	  were	   injected	   into	   the	   circulation	  of	   rats,	   Sir	  
James	  Gowans	  demonstrated	   that	   lymphocytes	   rapidly	  migrate	   into	   lymph-­‐nodes	  by	  
crossing	   high	   endothelial	   venules	   (HEVs)	   and	   recirculate	   between	   blood	   and	   lymph-­‐
node	  up	  to	  two	  times	  per	  day.	  
Naïve	  lymphocytes	  ‘home’	  to	  lymph-­‐nodes	  via	  a	  multistep	  adhesion	  cascade.	  Primary	  
adhesion	   (rolling),	   via	   interaction	   between	   L-­‐selectin	   expressed	   by	   lymphocytes	   and	  
glycoproteins	   expressed	   by	   HEV	   cells	   is	   transient	   and	   unstable	   but	   allows	   the	  
lymphocyte	   to	   sample	   the	   environment.	   Naïve	   T	   cells	   express	   CCR7	   and	   CXCR4	   (	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receptors	   for	   CCL21	   and	   SDF-­‐1	   respectively)	   and	   naïve	   B	   cells	   express	   additionally	  
express	   CXCR5	   (receptor	   for	   CXCL13),	   ligation	   of	  which	   leads	   to	   chemokine	   induced	  
activation.	   Conformation	   change	   in	   LFA-­‐1	   (lymphocyte	   function	   antigen	   1)	  
subsequently	  leads	  to	  stable	  attachment	  to	  ICAM1	  and	  ICAM	  2	  (intercellular	  adhesion	  
molecules	   1	   and	   2).	   Lymphocytes	   subsequently	   ‘crawl’	   along	   the	   HEV	   before	  
transmigrating	  across	  the	  endothelium	  (diapedesis)	  and	  undergoing	  chemotaxis	  within	  
the	  cortex.	  	  
The	  lymph,	  which	  contains	  foreign	  antigens	  present	  in	  tissues,	  enters	  the	  subcapsular	  
sinus	   via	   the	   afferent	   vessels.	   Within	   the	   lymph-­‐node,	   B	   and	   T	   lymphocytes	   are	  
relatively	   separated	   into	   different	   structures;	   B	   lymphocytes	   are	   located	   in	   follicles	  
that	   consist	   of	   a	  mantle	   of	   resting	   small	   B	   lymphocytes	   and	   a	   pale	   germinal	   centre	  
containing	  mostly	  proliferating	  B	  cells	  and	  few	  T	  cells.	  Following	  exposure	  to	  antigen,	  
the	  primary	  follicles	  develop	  into	  secondary	  follicles	  with	  highly	  proliferative	  germinal	  
centres.	   	   Recruitment	   of	   lymphocytes	   to	   the	   germinal	   centre	   depends	   on	   the	   local	  
expression	  of	  SDF-­‐1	  that	  attracts	  cells	  expressing	  the	  chemokine	  receptor	  CXCR4.	  
Antigen-­‐activated	   lymphocytes	   are	   held	   within	   the	   lymph-­‐node	   for	   a	   period	   of	  
approximately	   three	  days	  whilst	  naïve	   lymphocytes	   that	  do	  not	   interact	  with	  antigen	  
leave	   via	   efferent	   lymphatics.	   S1P	   (sphingosine	   1	   phosphate)	   and	   its	   receptor	   S1P1	  
(sphingosine	   1	   phosphate	   receptor	   type	   1)	   have	   been	   shown	   to	   play	   a	   key	   role	   in	  
lymphocyte	   egress.	   Expression	   of	   S1P1	   is	   cyclical;	   high	   S1P	   levels	   in	   the	   lymph	   and	  
blood	  leads	  to	  S1P1	  internalisation	  and	  down	  regulation,	  whilst	  within	  the	  lymph-­‐node	  
parenchyma,	  expression	   is	  upregulated.	  Egress	   from	  the	   lymph-­‐node	   results	   from	  an	  
S1P	   gradient	   in	   cortical	   sinuses	   that	   allows	   lymphocytes	   to	   overcome	   retention	  
mediated	  by	  G	  αi-­‐coupled	  receptors	  (CCR7	  and	  CXCR5).	  	  
The	   spleen	   is	   divided	   into	   the	  white	   pulp	   (secondary	   lymphoid	   tissue)	   and	   red	   pulp	  
which	   is	   responsible	   for	   removal	   of	   red	   cells,	   platelets	   and	   some	   blood	   borne	  
pathogens	  via	  phagocytosis.	  Plasmablasts	  and	  plasma	  cells	  are	  present	  in	  the	  marginal	  
zones.	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1.1.5	  Antigen	  Recognition	  
The	   specific	   acquired	   immune	   system	   depends	   on	   the	   recognition	   of	   ‘antigen’	   via	  
antigen-­‐receptors	   expressed	   by	   B	   and	   T	   lymphocytes	   as	   well	   as	   antibody	   that	   is	  
secreted	  by	  mature	  B	  lymphocytes	  (plasma	  cells).	  The	  ‘antibody	  formation	  theory’	  was	  
first	   described	   by	   Ehrlich	   in	   1900	   and	   was	   further	   developed	   by	   Marrack	   who	  
described	   the	   antigen-­‐antibody	   binding	   hypothesis	   in	   1938.	   Antibodies	   not	   only	  
recognise	  antigens	  but	  they	  recruit	  components	  of	  the	   immune	  system	  to	  potentiate	  
the	   immune	   response.	   The	   structure	   of	   antibodies	   was	   elucidated	   by	   Porter	   and	  
Endelman	  in	  1959-­‐1962;	  critically	  it	  was	  shown	  that	  antibodies	  have	  a	  ‘variable	  region’	  
involved	  in	  antigen	  recognition	  and	  a	  ‘constant	  region’	  that	  engages	  with	  complement	  
and	  macrophages	  to	  effect	  a	  response.	  Antibody-­‐coated	  microorganisms	  are	  therefore	  
susceptible	   to	   elimination	   via	   complement-­‐mediated	   lysis	   and	   by	   phagocytosis	   with	  
enhanced	  affinity.	  
Each	   B	   lymphocyte	   produces	   a	   specific	   antibody	   and	   expresses	   a	   trans-­‐membrane	  
version	  of	  the	  antibody	  on	  its	  cell	  surface	  to	  act	  as	  a	  receptor	  for	  the	  specific	  antigen.	  
Following	   receptor	   ligation,	   the	   plasma	   cell	   secretes	   antibody	   that	   is	   specific	   to	   the	  
antigen.	   Clonal	   selection	  of	   the	  B	   lymphocytes	   that	   are	   triggered	  by	   antigen	   ligation	  
leads	  to	  successive	  rounds	  of	  proliferation	  to	  provide	  sufficient	  quantities	  of	  antibody	  
to	   eliminate	   the	   infection.	   Subsequent	   exposure	   to	   the	  microorganism	   stimulates	   a	  
faster	   response	   of	   greater	   magnitude	   that	   demonstrates	   immunological	   ‘memory’.	  
Indeed,	  this	  is	  the	  basis	  of	  vaccination,	  first	  described	  by	  Jenner	  in	  1796	  in	  the	  context	  
of	  smallpox	  and	  later	  developed	  in	  1878	  by	  Pasteur,	  who	  developed	  a	  live-­‐attenuated	  
vaccine	  against	  rabies.	  
Inadvertent	   recognition	   of	   ‘self’	   antigens	   is	   pathological	   and	   is	   the	   basis	   of	   auto-­‐
immune	   disease.	   	   In	   health,	   this	   is	   avoided	   by	   ‘tolerance’,	   a	   permanent	   state	   of	  
unresponsiveness	  to	  self	  that	  involves	  the	  suppression	  of	  self-­‐reacting	  lymphocytes	  by	  
a	  number	  of	  mechanisms	   including	   thymic	  deletion	  and	   the	  adoption	  of	   an	   ‘anergic’	  
state.	  
B	   lymphocytes	   rely	   on	   help	   from	   activated	   CD4+	   T	   cells	   to	   generate	   high	   affinity	  
antibody	  and	  to	  under-­‐go	  class	  switching;	  in	  the	  absence	  of	  the	  thymus,	  IgM	  responses	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are	   low	   affinity	   and	   exhibit	   limited	   memory.	   B	   lymphocytes	   become	   activated	  
following	   antigen	   engagement	   of	   the	   B	   cell	   receptor	   (BCR).	   Propagation	   of	   the	  
activation	  signal	  requires	  a	  cascade	  of	  signalling	  that	  is	  initiated	  upon	  the	  recruitment	  
of	  the	  BCR	  to	  the	  lipid	  raft;	  this	  allows	  LYN	  to	  phosphorylate	  the	  ITAM	  domains	  of	  the	  
cytoplasmic	   tails	   of	   the	   BCR-­‐	   associated	   immunoglobulin,	   which	   leads	   to	   the	  
recruitment	   and	   activation	   of	   SYK	   and	   BTK.	   In	   turn,	   this	   activates	   the	   transcription	  
factors	  NFAT	  and	  NFκB	  that	  leads	  to	  the	  expression	  of	  interleukins	  and	  interferons	  and	  
to	  proliferation	  and	  differentiation.	  Efficient	  BCR	  effector-­‐responses	  are	  enhanced	  by	  
the	   B	   cell	   co-­‐receptor	   complex,	   comprised	   of	   CD19,	   CD21,	   CD81	   and	   CD225,	   that	  
reduces	   the	   threshold	   for	   activation	   of	   the	   BCR.	   Secondly,	   T	   cell	   dependent	   B	   cells	  
receive	   co-­‐stimulation	   from	   T-­‐helper	   cells	   that	   express	   CD40L	   following	   antigen	  
presentation	  by	  B	  cells	  with	  MHC	  class	  II.	  CD40L	  engagement	  with	  CD40	  expressed	  by	  
B	   cells	   enables	   full	   activation,	   somatic	   hypermutation	   and	   immunoglobulin	   class	  
switching.	  
T	   lymphocytes	   provide	   cell-­‐mediated	   immunity,	   providing	   defence	   against	   intra-­‐
cellular	   pathogens.	   Antigen	   recognition	   via	   the	   T	   cell	   receptor	   (TCR),	   only	   recently	  
discovered	   in	   1983,	   requires	   the	   presentation	   of	   processed	   antigen	   with	   MHC.	  
Cytotoxic	   T	   cells	   recognise	   peptides	   presented	   by	   MHC	   class	   I,	   present	   on	   most	  
nucleated	   cells,	   and	  T-­‐helper	  and	   regulatory	   cells	   recognise	  MHC	  class	   II,	   present	  on	  
‘professional’	   antigen	   presenting	   cells	   including	   dendritic	   cells,	   macrophages	   and	   B	  
lymphocytes.	  Naïve	  T	  cells	  only	  recognise	  antigen	  presented	  by	  dendritic	  cells,	  whereas	  
primed	  T	  cells	  can	  recognise	  antigen	  presented	  by	  macrophages	  and	  B	  lymphocytes.	  	  
In	  addition	  to	  TCR-­‐mediated	  T	  cell	  activation,	  a	  second	  co-­‐stimulatory	  signal	  (CD28)	  is	  
required	  to	  fully	  activate	  resting	  T-­‐helper	  cells	  and	  to	  induce	  the	  cells	  to	  enter	  the	  cell	  
cycle.	   The	   B7	   family	   ligands	   (CD80	   and	   CD86)	   expressed	   by	   mature	   dendritic	   cells	  
provide	  potent	  co-­‐stimulation	  via	  binding	  with	  the	  CD28	  receptor.	  
Following	   receptor	   ligation,	   CD4	   or	   CD8	   is	   recruited	   into	   the	   CD3/	   CD3	   co-­‐receptor	  
complex	  and	  a	  signalling	  cascade	   is	  activated	  that	   involves	   the	  RAS/	  MAP	  kinase	  and	  
phosphatidylinositol	  signalling	  pathways.	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Antigen-­‐driven	   T	   cell	   activation	   and	   proliferation	   gives	   rise	   to	   clonal	   expansion	   and	  
differentiation	  to	  cytotoxic	  T-­‐effectors,	  T-­‐helpers	  and	  regulatory	  T	  cells	  (Tregs)	  as	  well	  
as	   producing	   an	   enlarged	   population	   of	   memory	   cells.	   T	   helpers	   become	   polarised	  
towards	   a	   response	   to	   intracellular	   pathogens	   (Th1),	   a	   response	   to	   extracellular	  
antigens	   (Th2)	  or	  an	  acute	   inflammatory	   response	  against	  extracellular	  bacterial	   and	  
fungal	  infections	  (Th17),	  each	  characterised	  by	  a	  specific	  cytokine	  profile.	  	  
Following	  activation,	  a	  number	  of	  mechanisms	  operate	  to	  dampen	  T-­‐cell	  activity	  that	  
act	   at	   the	   level	   of	   the	   T	   cell	   itself	   or	   involve	   other	   T-­‐subsets	   (Tregs).	   Cytotoxic	   T-­‐
lymphocyte	  antigen	  4	  (CTLA-­‐4)	  is	  expressed	  following	  the	  activation	  of	  T	  cells	  and	  acts	  
a	  repressor	  of	  activation	  by	  engaging	  CD80	  and	  CD86	  with	  higher	  affinity	  than	  the	  co-­‐
stimulatory	   molecule	   CD28.	   In	   a	   similar	   fashion,	   PD-­‐1	   expressed	   by	   chronically	  
activated	  T	  cells	  engages	  PDL-­‐1	  and	  PDL-­‐2	  expressed	  by	  antigen	  presenting	  cells	  and	  
inhibits	   further	   T-­‐cell	   activation	   and	   IL-­‐2	   production.	   Notably,	   this	   axis	   has	   been	   co-­‐
opted	   by	   cancer	   cells	   e.g.	   melanoma	   and	   Hodgkin’s	   lymphoma	   cells	   that	   evade	  
immune	  recognition	  by	  silencing	  T-­‐cells.	  
Following	  successful	  eradication	  of	  the	  antigen,	  most	  of	  the	  B	  and	  T	   lymphocytes	  die	  
by	   apoptosis;	   however	   a	   small	   proportion	   with	   the	   highest	   antigen	   affinity	   survival	  
providing	  ‘immune	  memory’.	  
1.1.6	  Diseases	  of	  the	  Immune	  System	  
The	  human	  immune	  system	  has	  evolved	  to	  detect	  and	  to	  provide	  a	  tailored	  response	  
to	  wide	   range	  of	   pathogens	   and	   tumour	   antigens.	  Disease	   arises	   from	   failure	   of	   the	  
immune	   system	   to	   respond	   appropriately;	   this	   may	   be	   due	   to	   dysfunction	   (either	  
inherited	  or	  acquired)	  or	  due	  to	  the	  development	  of	  evasive	  strategies	  by	  pathogens	  
and	   tumours.	   Conversely,	   disease	   can	   arise	   from	   over-­‐activation	   of	   the	   immune	  
system,	   which	   can	   lead	   to	   hypersensitivity	   reactions	   and	   to	   haematological	  
malignancies.	   Failure	   of	   immunological	   tolerance	   mechanisms	   gives	   rise	   to	  
autoimmune	  disease.	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1.1.7	  Immunosenescence	  
The	  immune	  system	  undergoes	  significant	  change	  over	  time,	  a	  process	  that	  has	  been	  
termed	   immunosenescence	   and	   contributes	   to	   an	   increased	   risk	   of	   infection,	  
malignancy,	  autoimmunity	  and	  an	  impaired	  response	  to	  vaccination	  with	  age.	  Changes	  
are	  most	  noticeable	   in	   the	  T	  cell	   component	  of	   the	  adaptive	   immune	  system,	  where	  
there	   is	   a	   proportionate	   increase	   in	   memory	   T	   cells	   in	   both	   CD4	   and	   CD8	  
compartments	  and	  a	   reduction	   in	  naïve	  T	   cells	  due	   to	   involution	  of	   the	   thymus	  with	  
age	  and	  ongoing	  exposure	  to	  antigen.	  
Longitudinal	   studies	   have	   demonstrated	   that	   an	   inverted	   CD4/	   CD8	   ratio	   associated	  
with	   expansion	   of	   CD8+	   CD28-­‐	   T	   cells,	   reduced	   proliferative	   response	   to	   T	   cell	  
mitogens,	   low	  B	  cell	  counts	  and	  cytomegalovirus	  (CMV)	  seropositivity	   is	  predictive	  of	  
mortality	  (Olsson	  et	  al.,	  2000,	  Wikby	  et	  al.,	  2002).	  However,	  it	  is	  likely	  that	  pathogens	  
other	  than	  CMV	  play	  a	  role	  in	  the	  chronic	  antigen	  stimulation	  that	  contributes	  to	  the	  
age-­‐related	  changes.	  
1.1.8	  Tumour	  Immunology	  
Tumours	  arise	  from	  a	  multistep	  process	  that	  overcomes	  the	  mechanisms	  that	  normally	  
protect	  cells	   from	  mutagenesis	  and	  unchecked	  proliferation,	  culminating	   in	  a	  growth	  
advantage.	   Evasion	   of	   the	   immune	   system	   via	   the	   expansion	   of	   non-­‐immunogenic	  
clones	  is	  now	  recognized	  as	  a	  hallmark	  of	  cancer.	  	  
Three	   phases	   of	   tumour	   evolution	   have	   been	   described,	   involving	   ‘elimination’,	  
‘equilibrium’	   and	   ‘escape’	   phases	   whereby	   the	   tumour	   cells	   progressively	   acquire	  
mechanisms	  to	  evade	  the	   immune	  system	  over	  time	  (Pizzi,	  Boi,	  Bertoni,	  &	   Inghirami,	  
2016).	  The	   initial	  phase	  of	  elimination	   involves	   the	   recognition	  of	   tumour	  associated	  
antigens	  (TAAs)	  and	  stress	  molecules	  and	  elimination	  by	  NK	  cells	  and	  cytotoxic	  T	  cells.	  
The	  second	  phase	  of	  equilibrium	  allows	  sub-­‐populations	  of	  non-­‐immunogenic	  cells	  to	  
emerge	   and	   survive	   whilst	   those	   expressing	   TAAs	   are	   eliminated.	   Eventually	   the	  
tumour	  escapes	  immune	  recognition	  by	  loss	  of	  TAAs,	   inhibition	  of	  antigen	  processing	  
and	   expression	   of	   MHC,	   the	   development	   of	   an	   immunosuppressive	  
microenvironment,	   up-­‐regulation	   of	   regulatory	   T	   cells	   and	   suppression	   of	   T-­‐effector	  
activity.	  The	  profound	  efficacy	  of	   immune-­‐checkpoint	   inhibitors	   in	  solid	   tumours	  and	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some	   haematological	   malignancies	   has	   recently	   highlighted	   the	   importance	   of	  
immune-­‐evasion	  in	  tumour	  biology.	  
1.1.9	  Lymphoid	  Neoplasia	  
It	   is	   now	   clear	   that	   many,	   if	   not	   the	   majority	   of	   lymphoid	   neoplasms	   arise	   from	  
dysfunctional	   lymphocyte	   development	   or	   from	   persistent	   or	   abnormal	   immune	  
responses.	  B	  cell	  neoplasms	  mimic	  stages	  of	  normal	  B	  cell	  differentiation;	  precursor	  B	  
cell	   neoplasms	   e.g.	   B-­‐acute	   lymphoblastic	   leukaemia	   (B-­‐ALL)	   arise	   from	   aberrant	  
immunoglobulin	  gene	  rearrangement.	  Mantle	  cell	  lymphoma	  is	  thought	  to	  correspond	  
to	   CD5+	   naïve	   B	   cells	   whilst	   germinal-­‐centre	   derived	   lymphomas	   e.g.	   follicular	  
lymphoma	   arise	   during	   somatic	   hypermutation	   and	   class-­‐switch	   recombination.	  
Finally,	  post	  germinal-­‐centre	   type	   lymphomas	  arise	   from	  ongoing	  BCR	  activation	  due	  
to	   mutations	   as	   in	   activated	   B	   cell	   type	   diffuse	   large	   B	   cell	   lymphoma,	   or	   antigen/	  
autoimmunity	  as	  in	  marginal	  zone	  lymphoma.	  
As	   in	   the	   normal	   immune	   system,	   lymphoid	   tumours	   are	   subject	   to	   regulatory	  
influences	   from	   other	   cells	   in	   the	   microenvironment	   including	   macrophages,	  
endothelial	  cells,	  stromal	  cells	  and	  T-­‐cells.	  
In	   this	   thesis,	   I	  will	   focus	  on	  chronic	   lymphocytic	   leukaemia,	  a	   common	  neoplasm	  of	  
mature	   B	   lymphocytes	   in	   which	   both	   BCR	   signalling	   and	   microenvironmental	  
influences,	  particularly	  T	  cells	  play	  a	  major	  role.	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1.2	  Chronic	  Lymphocytic	  Leukaemia	  
1.2.1	  Epidemiology	  
Chronic	   lymphocytic	   leukaemia	  (CLL)	   is	  the	  most	  prevalent	   leukaemia	   in	  the	  Western	  
Hemisphere.	   It	   is	  a	  disease	  of	   the	  elderly	  with	  an	   incidence	  of	  0.1	  cases	  per	  100,000	  
rising	  to	  32	  cases	  per	  100,000	  between	  the	  ages	  of	  30	  and	  80	  years	  (Howlader,	  2014).	  
Men	  are	  more	  commonly	  affected	  and	  the	  disease	  is	  rare	  in	  people	  of	  Asian	  origin.	  In	  
view	   of	   the	   aging	   population	   and	   improved	   survival	   following	   diagnosis,	   CLL	   is	   of	  
increasing	  socioeconomic	  importance.	  
1.2.2	  Cell	  of	  Origin	  
CLL	  cells	  are	  characterised	  by	  the	  co-­‐expression	  of	  CD19,	  a	  B	  cell	   lineage	  marker,	  and	  
CD5,	  a	  T	  cell	  lineage	  marker,	  and	  the	  cell	  of	  origin	  is	  a	  subject	  of	  ongoing	  investigation.	  
Recent	  global	  gene	  expression	  studies	  have	  compared	  CLL	  cells	  with	  peripheral	  blood	  
naïve	   B	   cells,	   splenic	  marginal	   zone	  B	   cells,	  mature	   CD5+	  B	   cells,	   class-­‐switched	   and	  
IgM+	  memory	  B	  cells.	  The	  investigators	  found	  that	  CLL	  cells	  are	  most	  similar	  to	  mature	  
CD5+	  B	  cells,	  a	  minor	  B	  cell	  subset	  in	  healthy	  individuals	  (Macallan	  et	  al.,	  2009;	  Seifert	  
et	  al.,	  2012).	  
In	  60-­‐65	  %	  cases	  of	  CLL,	  the	  immunoglobulin	  heavy	  chain	  variable	  region	  genes	  (IgVH)	  
are	  mutated,	  reflecting	  that	  T	  cell	  dependent	  somatic	  hypermutation	  has	  taken	  place	  
in	   the	   lymph-­‐node	   germinal	   centre.	   In	   the	   remainder	   of	   cases,	   IgVH	   is	   unmutated,	  
reflecting	   germinal	   centre-­‐independent	   maturation.	   Gene	   expression	   studies	  
investigating	   the	   cell	   of	   origin,	   demonstrated	   that	   that	   CLL	   cells	   with	   mutated	   IgVH	  
were	  most	   similar	   to	   a	   subset	   of	   CD5+	   B	   cells	   that	   expressed	   CD27	   and	   have	   BCL6	  
mutations,	  demonstrating	   that	   they	  have	  undergone	  a	   germinal	   centre	   reaction.	  CLL	  
with	  unmutated	  IgVH	  	  genes	  are	  most	  similar	  to	  mature	  CD5+	  B	  cells	  that	  are	  CD27-­‐	  and	  
have	   not	   undergone	   a	   germinal	   centre	   reaction	   (Borel,	   Feurer,	   Gubler,	   &	   Stähelin,	  
1976;	  Seifert	  et	  al.,	  2012).	  
A	  major	  contribution	  to	  our	  current	  understanding	  of	  the	  pathogenesis	  of	  CLL	  was	  the	  
finding	  that	  in	  one	  third	  of	  cases,	  there	  is	  highly	  restricted	  IgVH	  	  gene	  use	  by	  the	  B	  cell	  
receptor	  (BCR)	  (Agathangelidis	  et	  al.,	  2012).	  Restricted	  IgVH	  gene	  usage	  provides	  strong	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evidence	  that	  in	  some	  cases,	  the	  tumour	  is	  driven	  by	  distinct	  antigens,	  hypothesised	  to	  
include	  viral	  and	  bacterial	  antigens	  and	  auto-­‐antigens	  expressed	  by	  dying	  cells	  (Chu	  et	  
al.,	  2008;	  Lanemo	  Myhrinder	  et	  al.,	  2008;	  Steininger	  et	  al.,	  2012).	  A	  number	  of	  distinct	  
stereotypes	   have	   been	   described	   with	   quasi-­‐identical	   variable	   heavy	   chain	  
complementarity	   determining	   region	   3	   (H-­‐CDR3)	   sequences	   and	   common	   biological	  
and	  clinical	  characteristics	  (Agathangelidis	  et	  al.,	  2012).	  
In	  addition	  to	  the	  widely	  accepted	  theory	  that	  chronic	  stimulation	  of	  B	  cells	  by	  extrinsic	  
antigen	   drives	   CLL	   pathogenesis,	   a	   recent	   study	   has	   identified	   that	   CLL	   BCRs	   are	  
capable	   of	   antigen-­‐independent	   cell	   autonomous	   signalling	   (Minden	   et	   al.,	   2012).	  
Transplantation	   of	   CLL	   derived	   H-­‐CDR3	   (an	   internal	   epitope	   of	   the	   BCR)	   into	   BCR-­‐
deficient	   cells	   induced	  calcium	  signaling,	  which	  was	  abolished	  by	   the	   introduction	  of	  
mutations	   into	   the	  H-­‐CDR3.	   It	   is	   possible	   that	   both	   antigen-­‐dependent	   and	   antigen-­‐
independent	  signalling	  cascades	  are	  active	  in	  CLL	  pathogenesis.	  
1.2.3	  The	  Genetic	  Landscape	  of	  CLL	  
In	  CLL,	  it	  has	  been	  documented	  that	  there	  is	  a	  comparatively	  small	  number	  of	  genetic	  
mutations	   within	   the	   malignant	   clone.	   Whole	   exome	   sequencing	   (WES)	   and	   whole	  
genome	   sequencing	   (WGS)	   on	   large	   cohorts	   of	   patients	   with	   CLL	   have	   recently	  
identified	  recurrent	  mutations	  (Wang	  et	  al.,	  2011),	  in	  turn	  providing	  important	  insight	  
into	  disease	  pathogenesis.	  The	  most	  frequent	  mutations	  and	  their	  proposed	  role	  in	  the	  
biology	   of	   disease	   are	   listed	   in	   Table	   1.1.	   These	   mutations	   can	   be	   considered	   as	  
founder	   mutations,	   i.e.	   present	   from	   the	   outset,	   or	   as	   secondary	   driver	   mutations,	  
occurring	  as	  a	  later	  event.	  	  
Longitudinal	  studies	  that	  repeated	  WES	  after	  a	  median	  of	  3.5	  years	  have	  demonstrated	  
that	   in	   a	   proportion	   of	   patients,	   sub-­‐clonal	   evolution	   takes	   place	  where	   there	   is	   an	  
expansion	   of	   sub-­‐clones	   towards	   clonality.	   Although	   this	   may	   be	   accelerated	   by	  
chemotherapy	   which	   is	   thought	   to	   allow	   the	   expansion	   of	   aggressive	   subclones	  
following	  removal	  of	  the	  incumbent	  clone,	  this	  phenomenon	  may	  also	  take	  place	  in	  the	  
absence	  of	  therapy	  (Landau	  et	  al.,	  2013).	  The	  presence	  of	  subclonal	  driver	  mutations	  
has	  been	  demonstrated	  to	  be	  an	  independent	  risk	  factor	  for	  rapid	  disease	  progression.	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Table	  1.1	  Frequently	  Occuring	  mutations	  in	  CLL	  
Mutation	   Frequency	   Association	   Pathway	   Reference	  
ATM	   10-­‐15	  %	   	   DNA	   damage	  
repair	  
(Guarini	   et	   al.,	  
2012)	  
NOTCH-­‐1	   5-­‐11	  %	   Trisomy	  12	   NOTCH	  	   (Sportoletti	   et	   al.,	  
2010)	  
(Puente	   et	   al.,	  
2011)	  
MYD88	   3	  %	   	   	   (Puente	   et	   al.,	  
2011)	  
SF3B1	   15	  %	   11q	  del	   Spliceosome	   (Wang	  et	  al.,	  2011)	  
(Quesada	   et	   al.,	  
2011)	  
BIRC-­‐3	   4	  %	   	   NFκB	   (Rossi	  et	  al.,	  2012)	  
	  
1.2.4	  Pathogenesis	  
For	  many	  years,	  CLL	  was	  considered	  to	  be	  a	  disease	  of	  failed	  apoptosis,	  characterised	  
by	   accumulation	   of	   cells	   arrested	   in	   G0-­‐G1	   stage	   of	   the	   cell	   cycle.	   Up-­‐regulated	  
expression	  of	  the	  anti-­‐apoptotic	  genes	  BCL2	  and	  MCL1	  supports	  this	  theory	  (Hanada,	  
Delia,	  Aiello,	  Stadtmauer,	  &	  Reed,	  1993;	  Johnston	  et	  al.,	  2004).	  However,	   in	  2005,	   in-­‐
vivo	   labelling	   studies	   using	   deuterated	   water	   in	   19	   patients	   with	   CLL	   revealed	  
substantial	  proliferation	  rates	  of	  up	  to	  2	  %	  of	  the	  tumour	  clone	  each	  day,	  as	  illustrated	  
in	  Figure	  1.1	   (Messmer	  et	  al.,	   2005).	  Patients	  with	  progressive	  disease	  generally	  had	  
proliferation	  rates	  of	  ≥	  0.35	  %	  per	  day.	  Lin	  et	  al	  went	  on	  to	  report	  that	  CLL	  telomere	  
length	  was	  the	  shortest	  ever	  recorded	  in	  primary	  tissue	  and	  that	  extensive	  erosion	  was	  
associated	  with	  telomere	  dysfunction,	  genetic	   instability	  and	  disease	  progression	  (Lin	  
et	  al.,	  2009).	  Furthermore,	  proliferation	   is	  a	  necessary	  factor	  for	  the	  accumulation	  of	  
mutations	  that	  provide	  a	  selective	  advantage	  leading	  to	  evolution	  of	  the	  CLL	  genome.	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Messmer	  et	  al	  2005	  
Figure	  1.1	  CLL	  birth	  and	  death	  rates	  measured	  using	  in-­‐vivo	  deuterium	  
Recognition	   that	   proliferation	   is	   a	   key	   feature	   in	   CLL	   pathogenesis	   prompted	  
investigators	  to	  further	  define	  the	  factors	  that	  drive	  proliferation	  of	  CLL	  cells.	  A	  major	  
contribution	   to	   this	   work	   was	   the	   finding	   that	   proliferation	   takes	   place	   in	   the	   CLL	  
lymph-­‐node.	  Gene	   expression	   studies	   that	   compared	   the	   lymph-­‐node,	   bone	  marrow	  
and	  peripheral	  blood	  compartments	  identified	  that	  there	  was	  upregulated	  expression	  
of	  genes	  associated	  with	  BCR	  signalling	  in	  the	  lymph-­‐node	  compared	  to	  the	  peripheral	  
blood	   and	   that	   gene	   expression	   was	   greatest	   in	   cases	   of	   CLL	   with	   unmutated	   IgVH	  
genes	  (Herishanu	  et	  al.,	  2011).	  Consistent	  with	  this	  finding,	  CLL	  proliferation	  measured	  
by	   Ki67	   expression	   was	   four	   fold	   greater	   in	   the	   lymph-­‐node	   than	   in	   the	   peripheral	  
blood	   and	   there	   was	   a	   trend	   towards	   increased	   Ki67	   expression	   in	   unmutated	   CLL	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1.2.5	  The	  CLL	  Microenvironment	  
The	  survival	  and	  proliferation	  of	  CLL	  cells	   is	  dependent	  on	  complex	   interactions	  with	  
components	   of	   the	   tumour	  microenvironment.	   This	   is	   clearly	   evidenced	   by	   the	   fact	  
that	   CLL	   cells	   cultured	   ex-­‐vivo	   rapidly	   undergo	   apoptosis	   but	   can	   be	   rescued	   by	   co-­‐
culture	  with	  stromal	  cells	  or	  endothelial	  cells,	  a	  phenomenon	  that	  is	  not	  observed	  with	  
healthy	   B	   lymphocytes	   (Buggins	   et	   al.,	   2010;	   Lagneaux,	   Delforge,	   Bron,	   De	   Bruyn,	  &	  
Stryckmans,	   1998;	   Panayiotidis,	   Jones,	   Ganeshaguru,	   Foroni,	   &	   Hoffbrand,	   1996).	  
Activated	   CD4+	   T	   cells	   have	   also	   been	   demonstrated	   to	   promote	   CLL	   cell	   survival,	  
activation	  and	  proliferation	   (Ghia	  et	   al.,	   2005;	  Patten	  et	   al.,	   2005;	  Ranheim	  &	  Kipps,	  
1993).	   The	   pathological	   features	   of	   T	   cells	   in	   CLL	  will	   be	   further	   explored	   in	   section	  
1.2.8.	  
1.2.6	  B	  Cell	  Receptor	  Signalling	  in	  CLL	  
The	  role	  of	  B	  cell	  receptor	  signalling	  in	  the	  pathogenesis	  of	  CLL	  has	  been	  a	  major	  area	  
of	   focus	   since	   it	   became	   apparent	   that	   the	   mutational	   status	   of	   IgVH	   genes	   was	  
recognised	   to	   be	   an	   important	   determinant	   of	   disease	   course	   (Damle	   et	   al.,	   1999;	  
Hamblin,	   Davis,	   Gardiner,	   Oscier,	   &	   Stevenson,	   1999;	   Stevenson,	   Krysov,	   Davies,	  
Steele,	  &	  Packham,	  2011).	  
The	  BCR	  is	  composed	  of	  antigen-­‐binding	  heavy	  chains	  (IgH)	  and	  light	  chains	  (IgL)	  that	  
are	   non-­‐covalently	   coupled	   to	   Igα	   (CD79a)	   and	   Igβ	   (CD79b)	   subunits.	   Upon	   antigen-­‐
engagement,	   there	   is	   clustering	   of	   BCRs	   that	   leads	   to	   tyrosine	   phosphorylation	   of	  
immunoreceptor	   tyrosine	   based	   activation	  motifs	   (ITAMs)	   in	   the	   cytoplasmic	   tails	   of	  
CD79a/b	   by	   src	   family	   kinases.	   This	   leads	   to	   recruitment	   of	   SYK	   that	   activates	   a	  
signalling	  cascade	  that	  engages	  BTK,	  PI3	  kinases,	  NFκB,	  PLCγ,	  NFAT,	  MAP	  kinases	  and	  
RAS	  (see	  Figure	  1.2).	  This	  signalling	  culminates	  in	  the	  survival	  and	  proliferation	  of	  the	  
malignant	  cell.	  
The	  ability	  of	  a	  CLL	  cell	  to	  signal	  through	  the	  BCR	  depends	  not	  only	  on	  the	  strength	  of	  
the	  signal	  but	  on	  the	  disease	  biology	  i.e.	  the	  IgVH	  mutational	  status	  (Mockridge	  et	  al.,	  
2007).	   CLL	   cells	   with	   unmutated	   IgVH	   genes	   are	   generally	   more	   responsive	   to	  
stimulation	  through	  the	  BCR,	  with	  the	  strength	  of	  the	  BCR	  signal	  partially	  reflecting	  the	  
degree	  of	  sIgM	  expression	  (Mockridge	  et	  al.,	  2007).	  CLL	  cells	  with	  mutated	  IgVH	  genes	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have	  been	  characterised	  to	  have	  poor	  BCR	  mediated	  signalling	  capacity,	  with	  low	  sIgM	  
expression,	  inability	  to	  mobilise	  calcium	  upon	  antigen	  engagement	  and	  by	  constitutive	  
activation	  of	  ERK	  and	  NFAT	  (Apollonio	  et	  al.,	  2013).	  In	  healthy	  B	  cells,	  anergy	  functions	  
to	  silence	  autoreactive	  B	  cells	  upon	  low	  affinity	  binding	  with	  self-­‐antigen,	  culminating	  
in	  these	  cells	  undergoing	  apoptosis	  (Goodnow,	  1997).	  However,	  CLL	  cells	  express	  anti-­‐
apoptotic	  proteins,	  including	  BCL2	  and	  MCL1,	  leading	  to	  prolonged	  survival	  despite	  an	  
anergic	  phenotype.	  The	  state	  of	  anergy	  in	  CLL	  can	  be	  overcome	  by	  inhibition	  of	  NFAT	  
signalling	  using	  the	  cell-­‐permeable	  VIVIT	  peptide	  that	  prevents	  nuclear	  translocation	  of	  
NFAT.	  Following	  reversal	  of	  anergy,	  CLL	  cells	  rapidly	  undergo	  apoptosis.	  Furthermore,	  
NFAT	   inhibition	   using	   the	   VIVIT	   peptide	   in	   the	   MEC-­‐1	   transplanted	   xenograft	  	  	  	  	  	  	  	  	  	  	  
Rag2-­‐/-­‐γ	  c-­‐/-­‐	  mouse	  model	  has	  been	  shown	  to	  delay	  tumour	  growth	  and	  prolong	  survival	  
(Apollonio	  et	  al.,	  2013).	  
A	  direct	  relationship	  between	  signalling	  from	  the	  tumour	  microenvironment	  and	  BCR	  
expression	   and	   downstream	   signalling	   by	   CLL	   cells	   has	   recently	   been	   proposed	  
whereby	   interleukin	   4	   (IL4),	   expressed	   by	   T	   cells,	   restores	   CD79b	   expression,	   sIgM	  
expression	  and	  BCR	  signalling	  and	  that	   this	   finding	   is	  most	  pronounced	   in	  cases	  with	  
unmutated	   IgVH	   genes	   (Aguilar-­‐Hernandez	   et	   al.,	   2016;	   Guo,	   Zhang,	   Chiorazzi,	   &	  
Rothstein,	  2016).	  
The	  overwhelming	  clinical	  success	  of	  drugs	  that	  inhibit	  BCR	  signalling	  has	  emphasised	  
the	   importance	  of	   the	  BCR	   in	  CLL	  pathogenesis.	  However,	   it	  must	  not	  be	  overlooked	  
that	   in	   addition	   to	   inhibiting	   BCR	   induced	   proliferation,	   BTK	   inhibition	  with	   ibrutinib	  
and	  PI3K	   inhibition	  with	   idelalisib	   additionally	   abrogates	   the	   protective	   effect	   of	   the	  
tumour	  microenvironment	  (Herman	  et	  al.,	  2011;	  2010).	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(Stevenson	  et	  al.,	  2011)	  
Figure	   1.2	   Principal	   downstream	   signalling	   pathways	   linking	   the	   BCR	   to	   biological	  
pathways	  in	  CLL	  
1.2.7	  Trafficking	  of	  CLL	  cells	  
It	   is	   currently	   believed	   that	   CLL	   is	   a	   two-­‐compartment	   disease.	   In	   the	   lymphnode	  
compartment,	   interaction	  with	  the	  microenvironment	  and	  signalling	  through	  the	  BCR	  
enables	  CLL	  cells	  to	  proliferate,	  after	  which	  they	  are	  released	  into	  the	  peripheral	  blood	  
compartment	   where	   they	   receive	   survival	   signalling	   from	   the	   vascular	   endothelium	  
(Buggins	  et	  al.,	  2010).	  It	  is	  thought	  that	  some	  cells	  re-­‐circulate	  to	  the	  lymph-­‐node	  but	  
evidence	   for	   this	   is	   lacking.	   Characterisation	   of	   trafficking	   is	   essential	   to	   fully	  
understand	   the	   pathophysiology	   of	   CLL,	   particularly	   as	   disruption	   of	   trafficking	   is	  
thought	   to	   contribute	   to	   the	   efficacy	   of	   the	   novel	   agents	   in	   CLL.	   Furthermore,	   it	   is	  
necessary	  to	  understand	  whether	  CLL	  cells	  behave	  as	  a	  uniform	  clone	  or	  whether	  there	  
is	  sub-­‐clonal	  heterogeneity	  in	  proliferation	  and	  trafficking.	  
Previous	  studies	  have	  shown	  that	  recently	  proliferated	  cells	  express	  low	  levels	  CXCR4,	  
the	  receptor	  for	  the	  chemokine	  SDF-­‐1,	  and	  high	  levels	  of	  CD5,	  a	  marker	  of	  recent	  BCR	  
activation	  (Calissano	  &	  Damle,	  2011)	  CXCR4	  has	  long	  been	  regarded	  as	  a	  key	  molecule	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for	   lymphocyte	  homing,	  enabling	  CLL	  cells	   to	  bind	   to	  SDF-­‐1	   to	  enter	   the	   lymph-­‐node	  
and	   bone	  marrow	   compartments	   (J.	   A.	   Burger,	   Burger,	  &	   Kipps,	   1999).	   Comparative	  
studies	  of	  CXCR4	  expression	  have	  revealed	  that	  expression	  is	  lower	  in	  the	  lymph-­‐node	  
than	   in	   the	  peripheral	  blood	   (Pasikowska	  et	  al.,	  2016),	  where	   it	   is	   thought	   that	   sIgM	  
internalisation	  and	  IL4	  signalling	  downregulates	  expression	  (Quiroga	  et	  al.,	  2009;	  Vlad	  
et	   al.,	   2009)	   (Aguilar-­‐Hernandez	   et	   al.,	   2016).	   Following	   release	   into	   the	   peripheral	  
blood,	  it	  is	  hypothesised	  that	  CXCR4	  is	  re-­‐expressed,	  enabling	  CLL	  cells	  to	  home	  to	  the	  
lymph-­‐node.	  Evidence	  for	  this	  is	  based	  on	  in-­‐vitro	  studies	  that	  have	  shown	  that	  CXCR4	  
is	  rapidly	  re-­‐expressed	  both	  in	  CLL	  cell	  culture	  and	  in	  the	  circulation	  model	  (Coelho	  et	  
al.,	   2013;	   Walsby	   et	   al.,	   2014),	   however,	   in-­‐vivo	   evidence	   is	   lacking.	   Of	   particular	  
interest	   is	   whether	   CLL	   cells	   have	   an	   equal	   capacity	   to	   home	   to	   the	   lymph-­‐node	   to	  
proliferate	  or	  whether	  this	  function	  is	  specific	  to	  a	  proliferative	  sub-­‐population.	  
BCR	   expression	   has	   been	   linked	   with	   CXCR4	   expression,	   with	   the	   hypothesis	   that	  
expression	  is	  trans-­‐regulated	  (Coelho	  et	  al.,	  2013).	  If	  this	  is	  the	  case,	  one	  would	  expect	  
BCR	   expression	   to	   be	   lowest	   in	   the	   lymph-­‐node	   compartment,	   where	   antigen	  
engagement	  induces	  receptor	  internalisation.	  Recently	  proliferated	  CLL	  cells	  would	  be	  
characterised	  by	  low	  BCR	  expression,	  with	  subsequent	  up-­‐regulation	  in	  the	  peripheral	  
blood	   compartment.	   However,	   at	   odds	   with	   this	   theory	   is	   the	   finding	   that	   BCR	  
expression	   is	  upregulated	   in	  the	   lymph-­‐node	  compartment	  (Coulter	  et	  al,	  manuscript	  
submitted)	   and	   that	   the	   recently	   proliferated	   CXCR4lo/CD5	   hi	   sub-­‐population	  
expresses	   higher	   sIgM	   than	   the	   resting	   fraction	   (Calissano	   &	   Damle,	   2011).	   One	  
explanation	   for	   this	   observation	   is	   that	   in	   the	   lymph-­‐node,	   CLL	   cell	   expression	   of	  
CD79b	   and	   sIgM	   is	   rescued	   by	   IL4	   signalling	   from	   T	   cells	   (Aguilar-­‐Hernandez	   et	   al.,	  
2016;	  Guo	  et	  al.,	  2016).	  Dynamic	  studies	  of	  BCR	  expression	  have	  not	  been	  performed	  
in-­‐vivo;	   such	   studies	  would	  provide	  critical	   information	   regarding	   the	  kinetics	  of	  BCR	  
expression	   in	  the	   lymph-­‐node	  and	  peripheral	  blood	  compartments.	  A	  comprehensive	  
understanding	  of	  the	  dynamics	  of	  BCR	  expression	  and	  signalling	  is	  particularly	  relevant	  
in	  an	  era	  when	  BCR	  targeting	  drugs	  will	  are	  increasingly	  used	  in	  clinical	  practice.	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1.2.8	  Characterisation	  of	  T	  Cells	  in	  CLL	  
It	   is	   evident	   that	   although	   the	   absolute	   number	   of	   T	   cells	   is	   increased	   in	   untreated	  
patients,	   there	   is	   a	   reduction	   in	   the	   proportion	   of	   naïve	   CD4	   and	   CD8	   T	   cells.	  	  
Furthermore,	  in	  early-­‐stage	  patients	  with	  progressive	  disease,	  there	  is	  an	  inversion	  of	  
the	   normal	   CD4:CD8	   T	   cell	   ratio,	   with	   expansion	   of	   the	   CD8+	   compartment	   and	  
skewing	  towards	  an	  effector-­‐memory	  PD-­‐1	  positive	  phenotype,	  consistent	  with	  a	  state	  
of	  replicative	  senescence	  (Nunes	  et	  al.,	  2012).	  	  
Comparative	   gene	   expression	   profiling	   of	   peripheral	   blood	   derived	   CLL	   T	   cells	   with	  
healthy	   T	   cells	   demonstrated	   that	   key	   differences	   in	   gene	   expression	   in	   CD4	   T	   cells	  
involved	  skewing	  of	  T	  cell	  differentiation	  towards	  Th2	  phenotype.	  CLL	  CD8	  T	  cells	  had	  
impaired	   cytoskeletal	   formation,	   vesicle	   trafficking	   and	   cytotoxicity	   compared	   with	  
healthy	   CD8	   T	   cells	   (Görgün,	   Holderried,	   Zahrieh,	   Neuberg,	   &	   Gribben,	   2005).	  
Functionally,	   these	   differences	   in	   gene	   expression	   have	   been	   shown	   to	   lead	   to	  
impaired	  F-­‐actin	  polymerization	  and	  immune-­‐synapse	  formation	  (Ramsay	  et	  al.,	  2008).	  
It	  has	  been	  shown	  that	  the	  changes	  seen	  in	  CLL	  T	  cells	  result	  from	  direct	  contact	  with	  
peripheral	  blood	  derived	  CLL	  cells	  and	  can	  be	  induced	  in	  healthy	  T	  cells	  (Görgün	  et	  al.,	  
2005;	  Ramsay	  et	  al.,	  2008).	  
Molecular	  characterisation	  of	  defective	  interaction	  between	  peripheral	  blood	  derived	  
CLL	   cells	   and	   T	   cells	   has	   identified	   that	   the	   PD-­‐1:	   PDL-­‐1	   axis	   plays	   a	   role	   in	   immune	  
evasion	  (Ramsay,	  Clear,	  Fatah,	  &	  Gribben,	  2012).	  PD-­‐1	  expression	   is	  enhanced	   in	  CLL	  
peripheral	  blood	  CD4	  and	  CD8	  T	  cells	  compared	  with	  age	  matched	  controls	  and	  is	  even	  
higher	  in	  the	  CLL	  lymph-­‐node	  where	  it	  is	  thought	  that	  engagement	  with	  PDL-­‐1	  on	  CLL	  
cells	   suppresses	   T	   cell	   activation	   (Brusa	   et	   al.,	   2013)(Yallop	   et	   al,	   manuscript	   in	  
preparation).	  	  
To	   investigate	   the	  process	  driving	  PD-­‐1	  up-­‐regulation	   in	  CLL	  CD4	  T	   cells,	   Yallop	  et	   al	  
performed	   T	   cell	   receptor	   Vβ	   spectratyping	   on	   PD-­‐1	   high	   and	   PD-­‐1	   low	   subsets	   of	  
lymph-­‐node	  and	  peripheral	  blood	  derived	  CD4+	  T	  cells	  and	  demonstrated	  a	  loss	  of	  TCR	  
diversity	   in	   the	  PD-­‐1	  high	  subset	  of	  both	  compartments.	  These	   findings	  were	   further	  
corroborated	  by	   sequencing	  of	   the	  TCR	  Vβ	  CDR3	   regions	  of	  CD4+	  T	   cells	   taken	   from	  
paired	  lymph-­‐nodes	  and	  the	  peripheral	  blood	  of	  individual	  patients.	  There	  was	  a	  high	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degree	   of	   commonality	   between	   the	   TCR	   sequence	   from	   the	   lymph-­‐nodes	   and	  
divergence	   from	   that	   seen	   in	   the	   peripheral	   blood.	   These	   findings	   point	   towards	  
antigen	  driven	  activation	  and	  proliferation	  of	  CD4+	  T	  cells	  within	  the	  lymph-­‐node	  and	  a	  
subsequent	  state	  of	  replicative	  senescence.	  
	  The	   role	   of	   T	   cells	   in	   CLL	   pathogenesis	   has	   been	   suggested	   by	   the	   observation	   that	  
within	  the	  CLL	  microenvironment,	  recently	  proliferated	  CLL	  cells	  are	  closely	  associated	  
with	  CD4+,	  CD25+	  FOXP3-­‐	  T	  cells	   (Patten,	  Buggins,	  Richards,	  Wotherspoon,	  Salisbury,	  
Mufti,	  Hamblin,	  &	  Devereux,	  2008a)	   .	   In-­‐vitro	  studies	   revealed	   that	  co-­‐culture	  of	  CLL	  
cells	  with	  activated	  autologous	  CD4	  T	  cells	   leads	  to	  up-­‐regulation	  of	  CD38	  expression	  
and	   proliferation	   of	   CLL	   cells	   (Patten,	   Buggins,	   Richards,	   Wotherspoon,	   Salisbury,	  
Mufti,	  Hamblin,	  &	  Devereux,	  2008a).	  
Furthermore,	  it	  has	  been	  found	  that	  activated	  autologous	  CD4+	  T	  cells	  are	  essential	  for	  
CLL	   cells	   to	   successfully	   engraft,	   survive,	   and	   proliferate	   in	   the	   non-­‐obese	  
diabetes/severe	   combined	   immunodeficiency/γcnull	   (NSG)	   mouse	   model	   (Bagnara	   et	  
al.,	   2011).	   Autologous	   CD4+	   T	   cells,	   activated	   in-­‐vivo	   by	   alloantigen	   were	   not	   only	  
necessary	   for	   the	   engraftment	   of	   CLL	   cells,	   they	   were	   also	   necessary	   for	   the	  
characteristic	  behavior	  of	  aggressive	  CLL	  cells	   in-­‐vivo	   i.e.	  CD38	  expression	  and	  growth	  
in	  secondary	  lymphoid	  tissue.	  
The	  mechanism	  of	  action	  CD4	  T	  cells	  in	  supporting	  the	  survival	  and	  proliferation	  of	  CLL	  
cells	   is	   multifactorial	   and,	   in	   addition	   to	   direct	   contact,	   involves	   the	   secretion	   of	  
cytokines.	  First	  and	  foremost,	  it	  is	  has	  been	  found	  that	  ligation	  of	  CD40	  in-­‐vitro	  leads	  to	  
NFκB	  activation	  and	  confers	  a	  survival	  phenotype	  in	  CLL	  cells	  that	  can	  be	  blocked	  using	  
an	  anti-­‐CD40L	  monoclonal	  antibody	  (Furman,	  Asgary,	  Mascarenhas,	  Liou,	  &	  Schattner,	  
2000).	   CD40	   ligation	   also	   leads	   to	   the	   upregulation	   of	   CD38	   expression	   by	   CLL	   cells	  
cultured	   in	   in-­‐vitro	   (Willimott,	   Baou,	  Huf,	  Deaglio,	  &	  Wagner,	   2007).	   In-­‐vivo,	   CD40L+	  
CD4+	  T	  cells	  have	  been	  shown	  to	  be	  present	  in	  the	  CLL	  lymph-­‐node,	  where	  they	  cluster	  
around	  Ki67+	  proliferating	  CLL	  cells	   (Ghia	  et	  al.,	  2002).	  Lymph-­‐node	  derived	  CLL	  cells	  
activated	   by	   CD40L	   have	   been	   found	   to	   attract	   CD40L	   positive	   CD4	   T	   cells	   through	  
secretion	  of	   the	  chemokine	  CCR22	   (Ghia	  et	  al.,	  2002).	  Furthermore,	  CLL	  cells	   secrete	  
IL6	  that	  leads	  to	  skewing	  of	  CD4	  T	  cells	  from	  Th1	  to	  Th2	  phenotype,	  and	  stimulates	  the	  
production	  of	  the	  pro-­‐survival	  cytokine	   IL4	  (Buggins	  et	  al.,	  2008).	  Ahearne	  et	  al	  went	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on	   to	   demonstrate	   that	   CD40L	   +	   IL4	   leads	   to	   enhanced	   proliferation	   of	   CLL	   cells	   in	  
response	   to	   IL21	   in-­‐vitro	   (Ahearne	   et	   al.,	   2013).	   	   Pascutti	   et	   al	   have	   subsequently	  
shown	  that	  CD40L	  +	   IL21	   induces	  a	  CLL	  phenotype	  and	  can	  stimulate	  proliferation	  of	  
CLL	  cells	  in	  a	  comparable	  manner	  to	  activated	  T	  cells	  (Pascutti	  et	  al.,	  2013).	  They	  found	  
that	  lymph-­‐node	  derived	  CLL	  cells	  showed	  evidence	  of	  IL21	  stimulation	  and	  that	  there	  
is	  detectable	  IL21	  expression	  in	  the	  lymph-­‐nodes	  of	  some	  patients	  with	  CLL,	  greatest	  in	  
CXCR5+,	  CD40L+	  CD4	  T	  cells.	  Pascutti	  et	  al	  propose	  that	  T	  follicular	  helper	  (Tfh)	  cells,	  
characterised	   by	   IL21	   secretion,	   play	   a	   role	   in	   CLL	   pathogenesis.	   This	   proposition	   is	  
supported	   by	   the	   observation	   that	   Tfh	   cells,	   characterised	   by	   CD4+CD45RO+CXCR5+	  
are	  increased	  in	  the	  peripheral	  blood	  of	  patients	  with	  CLL	  (Ahearne	  et	  al.,	  2013).	  
In	   summary,	   it	   is	   clear	   that	   interactions	   between	   CLL	   and	   T	   cells	   are	   complex	   and	  
bidirectional	  and	  are	  subject	  to	  microenvironmental	  influence	  i.e.	  they	  differ	  between	  
lymph-­‐node	   and	   peripheral	   blood	   compartments.	   In	   the	   lymph-­‐node,	   the	   site	   of	  
tumour	  proliferation,	   evidence	   is	  weighted	   towards	  a	  pro-­‐tumorigenic	   role	  of	   T	   cells	  
that	  involves	  both	  direct	  contact	  and	  cytokine	  signalling.	  Inhibition	  of	  T	  cell	  activation	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1.3	  Clinical	  Aspects	  of	  Chronic	  Lymphocytic	  Leukaemia	  
1.3.1	  Diagnosis	  
CLL	  is	  a	  neoplasm	  of	  mature	  B	  lymphocytes.	  A	  clinical	  diagnosis	  is	  made	  following	  the	  
detection	  of	  ≥	  5	  x	  109/L	  clonal	  B	  lymphocytes	  that	  is	  present	  for	  at	  least	  three	  months	  
(Hallek	  et	  al.,	  2008).	  CLL	  is	  accurately	  distinguished	  from	  other	  causes	  of	  a	  peripheral	  
blood	   lymphocytosis	  using	  a	   scoring	   system	  with	  one	  point	   awarded	   for	  each	  of	   the	  
following:	   CD5+,	   CD23+,	   FMC7-­‐,	   CD79b-­‐/weak,	   sIg	   weak.	   A	   score	   of	   at	   least	   three	  
points	  confirms	  the	  diagnosis	  with	  97	  %	  accuracy	  (Moreau	  et	  al.,	  1997).	  Monoclonal	  B	  
lymphocytosis,	   characterised	   by	   the	   presence	   of	   3.5-­‐5	   x	   109/L	   monoclonal	   B	  
lymphocytes,	  is	  considered	  to	  be	  a	  precursor	  to	  CLL;	  with	  1	  %	  cases	  progressing	  to	  CLL	  
that	  requires	  treatment	  each	  year	  (Rawstron	  et	  al.,	  2008).	  
CLL	  runs	  a	  highly	  variable	  course	  that	   is	  best	  considered	  as	  a	  spectrum	  of	  disease.	  At	  
one	  end	  of	  the	  spectrum,	  a	  patient	  may	  be	  diagnosed	  with	  CLL	  as	  an	  incidental	  finding	  
following	   a	   routine	   blood	   test	   and	   they	   may	   remain	   asymptomatic	   with	   a	   stable	  
lymphocyte	  count	  over	  decades.	  At	  the	  opposite	  end	  of	  the	  spectrum,	  a	  patient	  may	  
rapidly	  become	  symptomatic	  of	  progressive	  disease	  that	  requires	  early	  treatment.	  The	  
tempo	  of	  disease	  may	  change	  over	   time,	   such	   that	  a	  patient	  with	  slowly	  progressive	  
disease	   may	   undergo	   a	   period	   of	   rapid	   deterioration.	   It	   is	   estimated	   that	   5	   %	   of	  
patients	   with	   CLL	   will	   undergo	   high-­‐grade	   transformation	   (Richter’s	   Transformation)	  
into	  a	  high-­‐grade	  B	  cell	   lymphoma,	  pro-­‐lymphocytic	   leukaemia,	  Hodgkin’s	   lymphoma	  
or	  acute	  leukaemia	  (Tsimberidou	  &	  Keating,	  2005).	  
1.3.2	  Clinical	  Features	  
Clinical	   features	  arise	  as	  a	   result	  of	   the	   infiltration	  of	   lymph-­‐nodes,	   liver,	   spleen	  and	  
bone	   marrow	   with	   CLL	   cells.	   Infiltration	   leads	   to	   painless	   lymphadenopathy	   and	  
hepatosplenomegaly.	  Normal	  haematopoiesis	   is	   impaired	  as	  a	  result	  of	  bone	  marrow	  
infiltration,	  leading	  to	  anaemia,	  thrombocytopenia	  and	  neutropenia.	  Patients	  with	  CLL	  
have	  dysfunctional	  immunity	  that	  manifests	  with	  an	  increased	  frequency	  of	  infections,	  
an	   increased	   risk	   of	   malignancy	   and	   an	   increased	   incidence	   of	   auto-­‐immunity	  
(particularly	   autoimmune	   cytopenias).	   Constitutional	   symptoms	   of	   severe	   fatigue,	  
anorexia,	  weight-­‐loss	  and	  night	  sweats	  may	  be	  associated	  with	  progressive	  disease.	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1.3.3	  Prognosis	  
The	  clinical	  outcome	  of	  an	  individual	  with	  newly	  diagnosed	  CLL	  depends	  upon	  patient-­‐
specific	   factors	   i.e.	   age,	   performance	   status	   and	   presence	   of	   co-­‐morbidities,	   and	  
disease-­‐specific	   factors.	   Given	   the	   considerable	   heterogeneity	   of	   the	   disease,	   it	   is	  
useful	  to	  apply	  prognostic	  tests	  that	  reliably	  predict	  time	  to	  first	  treatment	  and	  overall	  
survival.	  For	  many	  years,	  CLL	  prognosis	  has	  been	  predicted	  according	  to	  the	  stage	  of	  
the	  disease	   in	  combination	  with	  the	  rate	  of	  progression	   i.e.	   the	   lymphocyte	  doubling	  
time.	  Disease	  stage	   is	  a	   ‘snap-­‐shot’	  of	  disease-­‐burden	  at	  any	  one	  time	  and	  is	  defined	  
according	  to	   the	  presence	  of	   lymphadenopathy,	  hepatosplenomegaly	  and	  cytopenias	  
using	  either	   the	  Binet	   (Binet,	  Auquier,	  Dighiero,	  &	  Chastang,	  1981)	  or	  Rai	   (Rai	  et	  al.,	  
1975)	  Classification	  Systems	  	  as	  illustrated	  in	  Table	  1.2.	  However,	  over	  recent	  years,	  a	  
multitude	   of	   prognostic	   biomarkers	   and	   genetic	   variables	   have	   been	   identified	   that	  
more	  accurately	  reflect	  disease	  biology.	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Biochemical	  Markers	  
Serum	   beta	   2-­‐microglobulin	   (sβ2-­‐M)	   is	   a	   polypeptide	   that	   stabilizes	   the	   tertiary	  
structure	  of	  the	  major	  histocompatibility	  complex	  -­‐class	  1	  (MHC-­‐class	  1)	  expressed	  on	  
nucleated	  cells	  and	  is	  physiologically	  present	  in	  extra-­‐cellular	  fluid.	  Serum	  β2-­‐M	  levels	  
reflect	  disease	  bulk	  and	  are	  predictive	  of	  progression	  free	  survival	  (Hallek	  et	  al.,	  1996).	  
As	  sβ2-­‐M	  levels	  are	  considerably	  affected	  by	  renal	  function,	  the	  prognostic	  value	  of	  this	  
biomarker	  is	  increased	  by	  adjusting	  for	  glomerular	  filtration	  rate	  (GFR)	  (Delgado	  et	  al.,	  
2009).	  
Serum	  tyrosine	  kinase	  is	  a	  cellular	  enzyme	  present	  in	  proliferating	  cells	  and	  levels	  have	  
been	  found	  to	  correlate	  with	  disease	  activity	  and	  to	  predict	  progression	  free	  survival.	  
However,	   tyrosine	   kinase	   levels	   are	   not	   routinely	   measured	   as	   conventional	   assays	  
involve	  the	  use	  of	  a	  radioactive	  isotope.	  
	  
Immunoglobulin	  Variable	  Heavy	  Chain	  Gene	  Mutational	  Status	  
The	   mutational-­‐status	   of	   the	   B	   cell	   receptor	   immunoglobulin	   variable	   heavy	   chain	  
genes	   (IgVH)	   indicates	  whether	   the	  cell	  has	  undergone	  somatic	  hypermutation	   in	   the	  
lymph-­‐node	   germinal	   centre.	   In	   1999,	   Hamblin	   and	   Damle	   independently	   reported	  
that	  in	  approximately	  one	  third	  of	  patients,	  the	  IgVH	  genes	  are	  unmutated,	  indicating	  
that	  the	  tumour	  is	  derived	  from	  a	  naïve	  B	  cell.	  Patients	  with	  Binet	  Stage	  A	  disease	  and	  
unmutated	  IgVH	  genes	  were	  found	  to	  undergo	  a	  more	  aggressive	  disease	  course	  with	  a	  
median	  overall	  survival	  of	  8	  years,	  compared	  with	  a	  median	  overall	  survival	  of	  25	  years	  
for	  patients	  with	  Binet	  Stage	  A	  disease	  and	  mutated	  IgVH	  genes,	  as	  depicted	  in	  Figure	  
1.3	  (Damle	  et	  al.,	  1999;	  Hamblin	  et	  al.,	  1999).	  Patients	  with	  mutated	   IgVH	  genes	  that	  
use	  the	   IgVH	  3-­‐21	  genes	  are	  an	  exception,	  with	  an	  unfavourable	  prognosis,	  similar	  to	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(Hamblin	  et	  al.,	  1999)	  
Figure	   1.3	   Kaplan	   Meier	   survival	   curve	   of	   CLL	   patients	   with	   Binet	   Stage	   A	   CLL	  
according	  to	  IgVH	  mutational	  status	  
Median	   survival	   =	   117	  months	  with	   unmutated	   IgVH	   genes	   versus	   293	  months	  with	  
mutated	  IgVH	  genes	  (p=0.001).	  
	  
CLL	  Immunophenotype	  
Expression	  of	  CD38,	  a	  type	  2	  trans-­‐membrane	  glycoprotein,	  was	  reported	  by	  Damle	  et	  
al	  to	  inversely	  correlate	  with	  IgVH	  mutational	  status	  with	  >30	  %	  expression	  conferring	  
an	  adverse	  prognosis	  (Damle	  et	  al.,	  1999).	  However,	  Hamblin	  et	  al	  found	  that	  although	  
there	   is	   significant	   correlation	  between	   IgVH	  mutational	   status	  and	  CD38	  expression,	  
there	   was	   a	   discordance	   in	   28	   %	   cases	   (Hamblin	   et	   al.,	   2002).	   It	   has	   since	   been	  
established	  that	  a	  threshold	  of	  7	  %	  CD38	  expression	  is	  a	  more	  stringent	  discriminator	  
of	  prognosis;	  with	  median	  overall	  survival	  estimated	  to	  be	  114	  months	  in	  patients	  with	  
<7	  %	  CD38	  compared	  to	  79	  months	  in	  those	  with	  >7	  %	  CD38	  expression	  (Kröber	  et	  al.,	  
2002;	  Thornton	  et	  al.,	  2004).	  	  
A	   recent	   word-­‐wide	   multi-­‐centre	   analysis	   demonstrated	   that	   CD49d,	   a	   CLL	   surface	  
antigen	   associated	   with	   proliferation	   is	   the	   most	   predictive	   flow-­‐cytometry	   based	  
prognostic-­‐marker.	  CD49d	  expression	  of	  >30	  %	  was	  associated	  with	  a	  10	  year	  overall	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Genetic	  Factors	  
Genomic	   aberrations	   can	   be	   detected	   in	   approximately	   80	   %	   cases	   of	   CLL	   using	  
Fluorescent	  In	  Situ	  Hybridisation	  (FISH)	  and	  have	  a	  variable	  prognostic	  significance,	  as	  
illustrated	  in	  Figure	  1.4.	  The	  commonest	  genomic	  aberration,	  affecting	  50-­‐55	  %	  cases	  
is	  13q	  deletion.	  It	  is	  considered	  as	  an	  initiating	  lesion	  that	  has	  the	  potential	  to	  disrupt	  
tumour	  suppressor	  function.	  Monoallelic	  loss	  of	  13q	  has	  a	  favourable	  clinical	  outcome	  
(Dohner	   et	   al.,	   2000),	   whereas	   prognosis	   conferred	   by	   biallelic	   loss	   remains	  
controversial	  (Dewald	  et	  al.,	  2003;	  Garg	  et	  al.,	  2012;	  Puiggros	  et	  al.,	  2013).	  The	  second	  
most	   common	   lesion	   is	   trisomy	   12	   (10-­‐20	   %	   newly	   diagnosed	   cases),	   which	   is	  
associated	   with	   an	   intermediate	   prognosis.	   Twenty	   percent	   of	   patients	   with	  
progressive	  disease	   that	   requires	   treatment	  have	   an	  11q	  deletion,	   leading	   to	   loss	   of	  
the	   ATM	   (Ataxia	   Telangiectasia)	   tumour	   suppressor	   gene	   in	   almost	   all	   cases.	   CLL	  
harbouring	  11q	  deletion	  is	  characterised	  by	  rapid	  progression,	  short	  survival	  and	  bulky	  
lymphadenopathy	  (Dohner	  et	  al.,	  1997).	  Deletion	  of	  the	  short	  arm	  of	  chromosome	  17	  
affects	  3-­‐8	  %	  of	  patients	  at	  diagnosis	  and	  31	  %	  at	  relapse.	  In	  all	  cases	  of	  17p	  deletion,	  
there	   is	   loss	   of	   the	   TP53	   tumour	   suppressor	   gene.	   In	   the	   majority	   of	   cases	   of	  
monoallellic	   loss	   of	   TP53,	   there	   is	   a	   TP53	   mutation	   in	   the	   remaining	   copy,	   further	  
contributing	   to	   loss	   of	   tumour	   suppressor	   activity.	   Additionally,	   4.5	   %	   have	   a	   TP53	  
mutation	   in	   the	   absence	   of	   17p	   deletion	   (Zenz	   et	   al.,	   2008).	   Patients	   with	   a	   17p	  
deletion	  or	  TP53	  mutation	  are	  resistant	  to	  standard	  chemotherapy	  and	  have	  the	  most	  
unfavorable	   prognosis	   with	   a	   median	   treatment	   free	   survival	   of	   9	   months	   and	   a	  
median	  overall	  survival	  of	  32	  months	  (Dohner	  et	  al.,	  2000;	  Zenz	  et	  al.,	  2008).	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Dohner	  et	  al.,	  2000	  
Figure	   1.4	   Probability	   of	   overall	   survival	   from	   time	  of	   diagnosis	   in	   patients	   from	  5	  
genetic	  risk	  categories	  
Whole	   genome	   sequencing	   and	   whole	   exome	   sequencing	   has	   recently	   identified	  
recurrently	  mutated	   genes	   that	   had	  not	   previously	   been	   associated	  with	   an	   adverse	  
prognosis;	  these	  include	  SF3B1,	  NOTCH1	  and	  BIRC3	  (Fabbri	  et	  al.,	  2011;	  Puente	  et	  al.,	  
2011;	  Quesada	  et	  al.,	  2011;	  Rossi	  et	  al.,	  2011;	  Wang	  et	  al.,	  2011).	  A	  recent	  multi-­‐centre	  
collaboration	  performed	  by	  the	  European	  Research	  Initiative	   in	  CLL	  sought	  to	  further	  
define	  the	  prognostic	  significance	  of	  these	  recurrent	  mutations	  in	  patients	  with	  CLL	  by	  
correlating	   presence	   of	   mutations	   with	   clinical	   characteristics	   in	   3490	   early	   stage	  
patients.	  They	  found	  that	  TP53,	  NOTCH-­‐1	  and	  SF3B-­‐1	  mutations	  were	  associated	  with	  
a	  shorter	   time	  to	   first	   treatment.	  SF3B1	  mutations	  were	   found	  to	   increase	  with	  time	  
from	  diagnosis	  and,	  along	  with	  TP53	  mutations,	  were	  found	  to	  confer	  a	  poor	  prognosis	  
independent	  of	   IgVH	   status	   (Baliakas	  et	   al.,	   2015).	  Whole	   genome	  and	  whole	  exome	  
sequencing	  currently	  remains	  in	  the	  research	  domain	  but	  is	  likely	  to	  be	  introduced	  into	  
clinical	   practice	   in	   the	   near	   future.	   TP53	   sequencing	   is	   currently	   available	   as	   a	  
diagnostic	   test	   for	   patients	   who	   do	   not	   have	   a	   17p	   deletion	   by	   FISH	   in	   the	   pre-­‐
treatment	  setting.	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1.3.4	  Treatment	  
Treatment	   is	   reserved	   for	   patients	   with	   symptomatic,	   progressive	   disease	   with	  
indications	   for	   first	   and	   second	   line	   treatment	   clearly	   defined	   by	   the	   International	  
Working	  Group	  in	  CLL	  (Hallek	  et	  al.,	  2008).	  It	  has	  been	  demonstrated	  that	  patients	  with	  
early	  stage,	  asymptomatic	  disease	  do	  not	  benefit	  from	  early	  treatment	  with	  alkylating	  
agents	  and	  these	  patients	  should	  undergo	  a	  period	  of	  active	  surveillance	  (Dighiero	  et	  
al.,	  1998).	  	  
Treatment	  options	   include	  chemotherapy	  and	  chemo-­‐immunotherapy	  based	  regimes	  
that	  can	  be	  challenging	  to	  deliver	  to	  elderly	  patients	  and	  to	  those	  with	  co-­‐morbidities.	  
However,	   the	   introduction	   of	   novel	   targeted	   therapies	   that	   are	   generally	   well	  
tolerated,	   has	   provided	   a	   viable	   treatment	   option	   to	   patients	   considered	   unfit	   for	  
conventional	  chemotherapy.	  The	  choice	  of	  treatment	  regimen	  takes	  into	  account	  the	  
patient’s	   physical	   fitness,	   presence	   of	   co-­‐morbidities,	   and	   any	   previous	   response	   to	  
therapy.	  It	  is	  essential	  to	  rule	  out	  a	  TP53	  abnormality;	  in	  the	  absence	  of	  a	  17p	  deletion	  
by	  fluorescence	  in-­‐situ	  hybridisation	  (FISH),	  Sanger	  sequencing	  should	  be	  performed	  to	  
rule	   out	   a	   mutation	   (Dohner	   et	   al.,	   1995).	   Patients	   with	   TP53	   abnormalities	   are	  
refractory	  to	  standard	  chemotherapy	  and	  should	  be	  treated	  with	  targeted	  therapies.	  
The	   German	   CLL	   Study	   Group	   has	   categorised	   patients	   into	   three	   broad	   groups	  
according	  to	  fitness	  for	  treatment;	  ‘Go-­‐Go’	  includes	  physically	  fit	  patients	  as	  defined	  by	  
a	   low	   Cumulative	   Illness	   Rating	   Score	   and	   a	   normal	   renal	   function,	   suitable	   for	  
standard	   therapy;	   ‘Slow-­‐Go’	   refers	   to	  patients	  with	   impaired	  physical	   fitness	   suitable	  
for	   less	   toxic	   therapies;	   and	   ‘No-­‐Go’	   is	   reserved	   for	   patients	  with	   severely	   impaired	  
physical	  fitness,	  best	  managed	  with	  symptom	  control	  (Hallek,	  2013).	  
In	   all	   cases,	   patients	   should	   be	   considered	   for	   entry	   into	   clinical	   trials.	   The	   gold-­‐
standard	   of	   treatment	   for	   previously	   untreated	   ‘Go-­‐Go’	   patients	   is	   currently	  
Fludarabine,	   Cyclophosphamide	   and	   Rituximab	   (FCR)	   which	   affords	   an	   overall	  	  
response	  rate	  (ORR)	  rate	  of	  90	  %,	  a	  5	  year	  progression	  free	  survival	  (PFS)	  of	  46.8	  %	  and	  
a	  5	  year	  overall	  survival	  (OS)	  of	  78.7	  %	  (Hallek	  et	  al.,	  2010).	  This	  regime	  is	  particularly	  
effective	   in	   patients	   with	  mutated	   IgVH	   genes,	   affording	   a	   PFS	   of	   66.6	   %	   at	   5	   years	  
compared	  with	  33.1	  %	  with	  unmutated	  IgVH	  genes	  (Fischer	  et	  al.,	  2016).	  However,	  due	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to	   the	   incidence	   of	   prolonged	   Common	   Toxicity	   Criteria	   scale	   (CTC)	   grade	   3-­‐4	  
neutropenias	  within	  12	  months	  of	   completion	  of	   chemoimmunotherapy,	   this	   regime	  
may	  be	  considered	  too	  toxic	  for	  older	  patients	  and	  those	  with	  co-­‐morbidities.	  
The	  CLL10	  study	  performed	  by	  the	  German	  CLL	  study	  group	  recently	  explored	  whether	  
Bendamustine	  +	  Rituximab	  (BR)	  was	  non-­‐inferior	  to	  FCR	  in	  the	  treatment-­‐naïve	  setting	  
for	  fit	  patients.	  They	  reported	  that	  although	  there	  were	  fewer	  complete	  responses	  in	  
the	  BR	  arm,	  there	  was	  no	  survival	  benefit	  of	  FCR	  due	  to	  the	  increased	  toxicity	  over	  BR.	  
They	  reported	  that	  severe	  neutropenia	  was	  more	  prevalent	  with	  FCR	  (84	  versus	  59	  %)	  
leading	   to	  an	   increased	  risk	  of	  severe	   infections	   (39	  %	  versus	  25	  %)	   (Eichhorst	  et	  al.,	  
2016).	   In	   the	   UK,	   Bendamustine	   is	   approved	   in	   the	   front	   line	   setting	   for	   patients	  
deemed	  unfit	  for	  FCR.	  
‘Slow-­‐Go’	   treatment-­‐naïve	   patients	   are	   currently	   treated	   with	   Chlorambucil	   in	  
combination	   with	   Obinutuzumab,	   a	   Type	   II	   glycoengineered	   anti-­‐CD20	   monoclonal	  
antibody.	  This	  regimen	  has	  recently	  been	  demonstrated	  to	  afford	  a	  median	  PFS	  of	  26.2	  
months	   versus	   15.4	   months	   with	   Chlorambucil	   and	   Rituximab	   in	   treatment	   naïve	  
patients	  with	  co-­‐morbidites	  or	  renal	  insufficiency	  (Goede	  et	  al.,	  2015).	  Overall	  survival	  
was	   improved	   with	   Chlorambucil	   plus	   Obinutuzumab	   versus	   Chlorambucil	   alone	  
(hazard	  ratio	  for	  death,	  0.41;	  95	  %	  CI,	  0.23	  to	  0.74;	  p=0.002)(Goede	  et	  al.,	  2014).	  
The	   treatment	   of	   CLL	   is	   currently	   undergoing	   a	   revolution,	   with	   the	   introduction	   of	  
novel	   targeted	   therapies	   that	   appear	   to	   be	   highly	   effective	   and	   are	   associated	  with	  
minimal	   toxicity.	   Drugs	   that	   target	   components	   of	   the	   B	   cell	   receptor-­‐signalling	  
pathway	   include	   ibrutinib,	   ACP-­‐196	   (Bruton’s	   Tyrosine	   Kinase	   (BTK)	   Inhibitors),	   and	  
idelalisib,	  an	  inhibitor	  of	  the	  delta	  isoform	  of	  phosphatidylinositol	  3-­‐kinase	  (PI3Kδ).	  	  
Ibrutinib	   irreversibly	   inactivates	  BTK	  by	  forming	  a	  covalent	  bond	  with	  cysteine-­‐481	   in	  
the	  active	   site.	  On	  a	   cellular	   level,	   this	   leads	   to	   reduced	  phosphorylation	  of	  ERK	  and	  
PLC γ2	  and	  reduced	  nuclear	  expression	  of	  NFκB	  Herman,	  2014	  (Herman,	  Niemann,	  et	  
al.,	  2014b).	  	  Clinically,	  there	  is	  rapid	  and	  dramatic	  resolution	  of	  lymphadenopathy	  with	  
a	  concurrent	  lymphocytosis.	  The	  observation	  that	  there	  is	  an	  abrupt	  increase	  in	  Ki67+	  
CLL	  cells	  in	  the	  peripheral	  blood,	  suggests	  that	  the	  lymphocytosis	  is	  caused	  by	  a	  release	  
of	   recently	   proliferated	   CLL	   cells	   from	   the	   lymph-­‐node	   into	   the	   peripheral	   blood	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(Herman,	  Niemann,	   et	   al.,	   2014b).	   The	   lymphocytosis	   is	   prolonged	   (persists	   for	   >	   12	  
months)	   in	   a	   sub-­‐set	   of	   patients,	   typically	   those	  with	  mutated	   IgVH	   genes	   (Woyach,	  
Smucker,	   et	   al.,	   2014c).	   It	   has	   been	   reported	   that	   the	   prolonged	   lymphocytes	   are	  
characterised	   by	   constitutive	   phosphorylation	   of	   ERK	   and	   NFκB,	   reduced	  
responsiveness	   to	   IgM	   stimulation	   and	   reduced	   Ki-­‐67	   expression;	   all	   hallmarks	   of	  
anergy	   (Woyach,	   Smucker,	   et	   al.,	   2014c).	   Furthermore,	   patients	   who	   exhibit	   a	  
prolonged	  lymphocytosis	  do	  not	  have	  an	  inferior	  clinical	  outcome,	  reflecting	  that	  this	  is	  
not	  a	  characteristic	  of	  treatment	  failure	  (Woyach,	  Bojnik,	  et	  al.,	  2014a).	  
In	  the	  relapsed/	  refractory	  setting,	  ibrutinib	  affords	  a	  PFS	  of	  88	  %	  at	  6	  months	  and	  an	  
OS	  of	  90	  %	  at	  12	  months	  (Byrd,	  Brown,	  O'Brien,	  Barrientos,	  Kay,	  Reddy,	  et	  al.,	  2014a).	  
Strikingly,	   in	  patients	  with	  relapsed	  CLL	  harbouring	  a	  17p	  deletion,	  PFS	  at	  26	  months	  
was	   56	   %	   (Byrd,	   Jones,	   Woyach,	   Johnson,	   &	   Flynn,	   2014b);	   this	   is	   in	   contrast	   to	   a	  
median	   PFS	   of	   11.8	   months	   in	   patients	   with	   TP53	   deletion	   treated	   with	   high	   dose	  
methylprednisolone	  and	  alemtuzumab	  (anti-­‐CD56	  monoclonal	  antibody),	  the	  previous	  
gold	  standard	  of	  therapy	  for	  this	  indication	  (Pettitt	  et	  al.,	  2012).	  	  
In	  addition	   to	   the	  FDA	  approval	   for	   ibrutinib	  use	   in	   the	   relapsed/refractory	  and	  17p-­‐
deletion	   settings,	   ibrutinib	   has	   recently	   been	   FDA	   approved	   in	   the	   treatment-­‐naïve	  
setting.	   This	   follows	   a	   large	   multicenter	   study	   of	   elderly,	   less-­‐fit	   patients	   were	  
randomized	   to	   receive	   chlorambucil	   or	   ibrutinib;	   patients	  who	   received	   single	   agent	  
Ibrutinib	  had	  an	  18	  month	  PFS	  of	  94	  %	  compared	  with	  45	  %	  with	  chlorambucil	  (Byrd,	  
Jones,	   Woyach,	   Johnson,	   &	   Flynn,	   2014b).	   Toxicity	   is	   limited,	   most	   adverse	   events	  
being	  Grade	  I-­‐II.	  Diarrhoea	  was	  the	  commonest	  adverse	  event,	  but	  it	  was	  rarely	  grade	  
III-­‐IV.	  Petechiae,	  predominantly	  grade	  I-­‐II,	  affected	  14	  %	  patients	  and	  was	  thought	  to	  
be	   due	   to	   inhibition	   of	   TEC	   kinases	   in	   platelets.	   Anti-­‐coagulation	   with	   warfarin	   is	  
contraindicated	   for	   patients	   in	   the	   UK	   following	   a	   small	   number	   of	   cases	   of	   fatal	  
intracranial	   haemorrhage	   in	   the	   phase	   II	   trial	   of	   ibrutinib.	   Furthermore,	   it	   is	  
recommended	   that	   ibrutinib	   should	  be	  held	   for	   three	  days	  pre-­‐	  and	  seven	  days	  post	  
major	  surgery	  to	  reduce	  peri-­‐operative	  bleeding	  complications.	  
Ibrutinib	   is	   currently	   given	   continuously;	   reasons	   for	   stopping	   include	   intolerance	   or	  
disease-­‐progression.	  Whole	   exome	   sequencing	   of	   the	   first	   six	   patients	   to	   relapse	   on	  
ibrutinib	   identified	   cysteine	   to	   serine	  mutations	   (C481S)	   in	   the	  BTK	   ibrutinib	   binding	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domain	   in	   five	   patients,	   and	   in	   PLCγ2,	   immediately	   downstream	   of	   BTK	   in	   the	   sixth	  
patient	  (Woyach,	  Furman,	  et	  al.,	  2014b).	  Functional	  analysis	  has	  revealed	  that	  the	  BTK	  
mutation	  confers	  reduced	  binding	  efficacy	  whilst	  the	  PLCγ2	  mutation	  leads	  to	  gain	  of	  
function	  irrespective	  of	  BTK	  inhibition	  (T.-­‐M.	  Liu	  et	  al.,	  2015;	  Woyach,	  Furman,	  et	  al.,	  
2014b).	  Analysis	   of	   sequential	   samples	   suggests	   that	   these	  mutations	  were	  acquired	  
during	  therapy	  and	  that	  expansion	  of	  the	  sub-­‐clone	  harbouring	  the	  mutation	  pre-­‐dates	  
clinical	   relapse,	   theoretically	   providing	   a	   window	   to	   intervene	   before	   clinical	  
progression.	  To	  date,	  cases	  of	  resistance	  to	  Ibrutinib	  have	  been	  limited	  to	  patients	  with	  
17p-­‐	  or	  complex	  cytogenetics.	  
Idelalisib,	   in	   combination	   with	   rituximab,	   has	   been	   approved	   by	   the	   FDA	   for	   the	  
treatment	  of	  relapsed/	  refractory	  CLL	  and	  treatment-­‐naïve	  CLL	  with	  TP53	  abnormality.	  
Approval	   was	   granted	   following	   the	   landmark	   trial	   that	   compared	   rituximab	   with	  
idelalisib	   or	   placebo	   for	   the	   treatment	   of	   patients	   unfit	   to	   receive	   standard	  
chemotherapy.	   Median	   PFS	   was	   5.5	   months	   with	   rituximab	   +	   placebo	   and	   was	   not	  
reached	  with	  rituximab	  +	   idelalisib	  (Furman	  et	  al.,	  2014).	  Serious	  adverse	  events	  that	  
have	   been	   reported	   since	   FDA	   approval	   include	   hepatotoxicity,	   colitis,	   intestinal	  
perforation	   and	   pneumonitis.	   The	   second	   licensed	   indication,	   for	   treatment-­‐naïve	  
patient	   with	   TP53	   abnormality	   is	   in	   response	   to	   a	   phase	   2	   study	   of	   idelalisib	   +	  
rituximab	  in	  the	  elderly;	  nine	  patients	  harboured	  a	  TP53	  abnormality	  and	  all	  were	  alive	  
at	  3	  years	  (O'Brien	  et	  al.,	  2015).	  
Drugs	   that	   promote	   apoptosis	   by	   mimicking	   physiological	   BCL-­‐2	   antagonists	   are	  
particularly	  attractive	  for	  the	  treatment	  of	  CLL,	  in	  which	  BCL-­‐2	  overexpression	  is	  a	  key	  
pathological	   feature.	   Venetoclax,	   a	   small	   molecule	   that	   directly	   targets	   BCL-­‐2	   is	  
showing	   particular	   promise	   in	   early	   phase	   clinical	   trials	   for	   patients	   with	   poor-­‐risk	  
relapsed/refractory	  disease.	   Initial	  studies	  were	   limited	  by	  cases	  of	   fatal	   tumour-­‐lysis	  
syndrome	  that	  mandated	  a	  cautious	  strategy	  of	  dose	  escalation	  followed	  by	  expansion	  
phases.	  PFS	  at	  15	  months	  was	  66	  %	  for	  the	  entire	  cohort	  and	  patients	  with	  17p-­‐	  had	  a	  
median	   PFS	   of	   16	   months.	   20	   %	   patients	   achieved	   a	   CR	   and	   5	   %	   achieved	   MRD	  
negativity	  (Roberts	  et	  al.,	  2016).	  Venetoclax	  has	  now	  been	  approved	  by	  the	  FDA	  for	  the	  
treatment	  of	   relapsed	  CLL	  with	  17p	  deletion	  and	   there	   is	  optimism	   that	   it	  may	  be	  a	  
viable	  treatment	  option	  for	  patients	  who	  become	  resistant	  to	  BCR	  antagonists.	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Lenalidomide,	  an	  immunomodulatory	  agent	  has	  shown	  activity	  as	  a	  single	  agent	  and	  is	  
also	  undergoing	   investigation	   in	   the	   clinical	   trial	   setting.	  A	  phase	  2	   study	   in	  patients	  
with	   relapsed/	   refractory	   disease	   recently	   tested	   three	   starting	   doses	   of	   5mg,	   10mg	  
and	  15mg	  followed	  by	  dose	  escalation	  by	  5mg	  every	  28	  days	  up	  to	  a	  maximum	  dose	  of	  
25mg.	  The	  ORR	  was	  40	  %,	  88	  %	  of	  whom	  received	  a	  dose	  ≥	  15	  mg/day.	  The	  average	  
daiy	  dose	  appeared	  to	  be	  higher	  in	  responders.	  PFS	  was	  21	  months.	  Toxicities	  included	  
neutropenia	   and	   thrombocytopenia	   which	   were	   independent	   of	   dose.	   There	   was	   a	  
12%	  risk	  of	  second	  primary	  malignancy.	  
In	  summary,	  it	  is	  a	  hugely	  exciting	  time	  in	  CLL	  therapeutics.	  We	  have	  been	  presented	  
with	  an	  armory	  of	  new	  drugs,	  which	  we	  are	  tasked	  with	  applying	  safely,	  effectively	  and	  
in	  a	  financially	  viable	  manner.	  These	  strategies	  will	  be	  determined	  by	  investigating	  the	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1.4	  Targeting	  the	  T	  Cell	  Component	  of	  the	  Tumour	  Microenvironment	  
In	   light	   of	   the	   similarities	   between	   early	   stage	   CLL	   and	   autoimmune	   disease,	   and	   in	  
view	  of	  the	  role	  of	  T	  cells	  in	  contributing	  to	  the	  survival	  and	  proliferation	  of	  leukaemic	  
B	   cells	   in	   the	   lymph-­‐node,	   we	   questioned	   whether	   suppression	   of	   T	   cell	   activation	  
could	   inhibit	   the	   pathogenesis	   of	   CLL.	   CLL	   T	   cells	   bear	   a	   number	   of	   phenotypic	   and	  
functional	  abnormalities	  including	  a	  preponderance	  of	  effector	  memory	  cells	  (Nunes	  et	  
al.,	   2012),	   evidence	   of	   chronic	   activation	   including	   PD-­‐1	   expression	   and	   shortened	  
telomeres	   (Röth	   et	   al.,	   2008),	   and	   a	   restricted	   T	   cell	   repertoire	   (Farace	   et	   al.,	   1994)	  
(Serrano	   et	   al.,	   1997)	   that	   are	   suggestive	   of	   an	   autologous	   antigen-­‐driven	   process	  
(Yallop,	   manuscript	   in	   preparation).	   Hypothetically,	   inhibition	   of	   proliferation	   in	  
patients	   with	   poor-­‐prognosis	   disease	   could	   delay	   disease	   progression	   and	   inhibit	  
telomere	   shortening,	   genomic	   instability	   and	   clonal	   evolution	   that	   contribute	   to	  
resistance	  to	  chemotherapy.	  Furthermore,	  by	   targeting	   the	  microenvironment	   rather	  
than	   the	   neoplastic	   clone,	   this	   strategy	   would	   be	   unlikely	   to	   drive	   therapeutic	  
resistance.	  
There	   are	  many	   drugs	   that	   have	   been	  developed	   to	   inhibit	   T	   cell	   activation	   and	   the	  
most	  widely	  used	  in	  clinical	  practice	  is	  ciclosporin	  (CsA),	  a	  fungal-­‐derived	  polypeptide,	  
that	  was	  initially	  discovered	  as	  a	  potent	  T	  cell	  immunosuppressant	  in	  1972	  (Borel	  et	  al.,	  
1976).	  CsA	  was	  found	  to	  successfully	  inhibit	  renal	  transplant	  rejection	  in	  dogs	  in	  1977	  
(Calne,	   1979)	   before	   being	   used	   in	   a	   clinical	   setting	   in	   1978	   (Calne,	   1978),	   where	   it	  
transformed	   the	   practice	   of	   organ	   transplantation.	   In	   addition	   to	   its	   ongoing	   use	   in	  
transplantation,	   CsA	   is	   an	   effective	   T	   cell	   immunosuppressant	   in	   a	   wide-­‐range	   of	  
autoimmune	  and	  inflammatory	  conditions.	  
The	  effective	  use	  of	  CsA	  in	  the	  treatment	  of	  pure	  red	  cell	  aplasia	  (PRCA)	  complicating	  
CLL	   was	   first	   reported	   by	   Chikkappa	   et	   al	   in	   1987	   (Chikkappa,	   Pasquale,	   Phillips,	  
Mangan,	  &	  Tsan,	  1987).	  They	  reported	  that	  the	  combined	  use	  of	  glucocorticoids	  and	  
CsA	   not	   only	   achieved	   a	   remission	   from	   the	   PRCA	   but	   that	   there	   was	   a	   significant	  
reduction	   in	   lymphocyte	   count,	   lymph-­‐node	   and	   spleen	   size	   and	   degree	   of	   bone	  
marrow	   infiltration.	   	   Similar	   responses	   have	   been	   reported	   by	   other	   investigators	   in	  
the	   setting	   of	   PRCA	   and	   in	   the	   treatment	   of	   autoimmune	   haemolytic	   anaemia	   and	  
immune	   thrombocytopenia	   complicating	   CLL.	   In	   a	   case	   series	   of	   31	   patients	   treated	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with	   CsA	   for	   AIHA	   and	   ITP	   secondary	   to	   CLL,	   5	   patients	   were	   reported	   to	   have	   a	  
significant	  reduction	  in	  the	  lymphocyte	  count	  from	  a	  median	  of	  47	  x	  109/L	  to	  15	  x	  109/L	  
with	  a	  variable	  duration	  of	  response	  (Cortes	  et	  al.,	  2001).	  
The	  anti-­‐tumour	  mechanism	  of	  action	  of	  CsA	  in	  CLL	  has	  not	  been	  fully	  elucidated.	  It	  has	  
been	   clearly	   established	   that	   CsA	   suppresses	   T	   cell	   activation,	   differentiation	   and	  
proliferation	   by	   forming	   a	   complex	   with	   cyclophillin	   that	   inhibits	   the	   capacity	   of	  
calcineurin	   to	  dephosphorylate	  NFAT,	  as	   illustrated	   in	  Figure	  1.5.	  NFAT	   is	  a	   family	  of	  
five	  transcription	  factors	  (NFAT1-­‐5)	  that	  share	  a	  highly	  conserved	  DNA	  binding	  domain	  
(Macian,	   2005).	   Dephosphorylation	   is	   required	   for	   nuclear	   translocation	   of	   NFAT,	  
following	  which	  it	  binds	  to	  upstream	  enhancer	  elements	  leading	  to	  the	  transcription	  of	  
IL2,	  IL4,	  IL10,	  IFNγ	  and	  TNFα	  	  (Flanagan,	  Corthésy,	  Bram,	  &	  Crabtree,	  1991).	  Secondly,	  
CsA	   inhibits	   the	   nuclear	   translocation	   of	   NFκB,	   a	   family	   of	   transcription	   factors	   that	  
share	   highly	   conserved	   DNA	   binding	   and	   dimerisation	   domains	   (Nishiyama	   et	   al.,	  
2005).	  In	  the	  inactive	  state,	  the	  nuclear	  localisation	  domain	  of	  NFκB-­‐p50/	  NFκB-­‐p65	  is	  
concealed	   as	   a	   result	   of	   binding	   to	   inhibitory	   kappa	   B	   (IκB);	   activation	   leads	   to	  
phosphorylation	   and	   ubiquitination	   of	   IκB,	   leading	   to	   nuclear	   localisation	   and	  
transcription	   of	   IL2,	   IL12	   and	   IFNγ.	   CsA	   inhibits	   proteasomal	   degradation	   of	   IκB,	  
inhibiting	   nuclear	   translocation	   of	   	   	   NFκB-­‐p50/	   NFκB-­‐p65	   (Marienfeld	   et	   al.,	   1997;	  
Meyer,	  Kohler,	  &	  Joly,	  1997).	  Inhibition	  of	  NFκB	  translocation	  is	  particularly	  relevant	  in	  
CLL,	  where	  it	  is	  thought	  to	  mediate	  the	  pro-­‐survival	  effect	  of	  CD40	  ligation	  (Furman	  et	  
al.,	  2000).	  
Furthermore,	  CsA	  inhibits	  the	  expression	  of	  CD40L	  and	  IL21	  by	  activated	  CD4+	  T	  cells	  
(Fuleihan	  et	  al.,	  1994;	  Kim,	  Korn,	  Gamero,	  &	  Leonard,	  2005)	  that	  normally	  functions	  to	  
stimulate	   the	   activation,	   differentiation,	   maturation,	   survival	   and	   proliferation	   of	   B	  
cells	  (Lederman	  et	  al.,	  1992;	  Noelle	  et	  al.,	  1992).	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Figure	  1.5	  A	  schematic	  of	  the	  mechanism	  of	  action	  of	  Ciclosporin	  	  
Following	  TCR	  engagement,	   there	   is	   an	   influx	  of	   calcium	   that	  binds	  with	   calmodulin.	  
The	   calcium-­‐calmodulin	   complex	   activates	   the	   phosphatase	   action	   of	   calcineurin,	  
leading	   to	   the	   dephosphorylation	   of	   NFAT.	   In	   the	   dephosphorylated	   state,	   NFAT	  
translocates	   to	   the	  nucleus	  and	  activates	   the	   transcription	  of	   IL2	  etc.	  CsA	  enters	   the	  
cell	  and	  binds	  with	  cyclophilin,	  inhibiting	  the	  phosphatase	  activity	  of	  calcineurin.	  
	  
In	   addition	   to	   its	   effects	   on	   T	   cells,	   CsA	   has	   been	   demonstrated	   to	   directly	   inhibit	  
nuclear	   translocation	  of	  NFAT	   in	   IgM	  stimulated	  and	  CD40L+IL4	   stimulated	  murine	  B	  
lymphocytes	   (Choi,	   Brines,	   Holman,	   &	   Klaus,	   1994;	   Venkataraman	   et	   al.,	   1994).	  
However,	   investigators	  who	  have	  studied	  the	  differential	  pathways	  activated	  via	   IgM	  
and	   CD40L	   stimulation	   of	   murine	   B	   lymphocytes	   reported	   that	   whilst	   IgM	   induced	  
proliferation	  was	  sensitive	  to	  CsA,	  CD40L	  induced	  proliferation	  was	  relatively	  resistant	  
(Wortis,	  Teutsch,	  Higer,	  Zheng,	  &	  Parker,	  1995).	  This	  finding	  is	  particularly	  relevant	  to	  
the	  theory	  that	  activated	  CD4+	  T	  cells	  expressing	  CD40L	  play	  a	  key	  role	  in	  driving	  the	  
proliferation	  of	  CLL	  cells.	   It	   suggests	   that	  any	  effect	  of	  CsA	  on	  CD40	  signalling	   in	  CLL	  
cells	   is	   likely	  to	  be	  due	  to	  down-­‐regulation	  of	  CD40L	  expression	  by	  CD4	  T	  cells	  rather	  
than	  inhibition	  of	  signalling	  downstream	  of	  CD40	  in	  CLL	  cells.	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In-­‐vitro	   studies	   of	   the	   effect	   of	   CsA	   in	   CLL	   are	   limited	   in	   number.	   Schmid	   et	   al	  
demonstrated	   that	   IL2	   and	  TNFα	  driven	  proliferation	  of	   highly	  purified	  CLL	   cells	  was	  
sensitive	   to	   CsA	   in	   a	   dose-­‐dependent	   manner	   (Schmid,	   Merk,	   &	   Porzsolt,	   1994).	  
However,	   it	   remains	   unanswered	  whether	   IgM,	   CD40L	   or	   activated	   T	   cell-­‐stimulated	  
CLL	  cells	  are	  directly	  sensitive	  to	  CsA.	  
Manipulation	  of	  the	  tumour	  microenvironment	  using	  CsA	  to	  inhibit	  T	  cell-­‐induced	  CLL	  
survival	   and	   proliferation	   is	   a	   novel	   approach	   to	   the	   management	   of	   patients	   with	  
adverse	   prognostic	   factors.	   Patients	   with	   early-­‐stage,	   asymptomatic	   CD38+	   CLL,	  
destined	  to	  have	  an	  inferior	  overall	  survival	  (Damle	  et	  al.,	  1999;	  Hamblin	  et	  al.,	  2002)	  
are	  currently	  understudied	  and	  would	  potentially	  benefit	  from	  an	  alternative	  strategy	  
to	  ‘watchful	  waiting’.	  We	  therefore	  opted	  to	  investigate	  the	  novel	  strategy	  of	  targeting	  
the	  microenvironment	  to	  inhibit	  CLL	  proliferation	  in	  this	  cohort	  of	  patients.	  We	  set	  up	  
a	   Phase	   II	   clinical	   trial	   (CyCLLe)	  with	   the	   support	   of	   Bloodwise	   (previously	   known	   as	  
Leukaemia	  and	  Lymphoma	  Research).	  	  The	  primary	  outcome	  of	  this	  study	  was	  change	  
in	  CLL	  proliferation	  rate	  after	  four	  weeks	  of	  CsA	  therapy.	  Secondary	  outcomes	  included	  
toxicity	  and	  disease	  response	  rates.	  The	  plan	  was	  to	  proceed	  to	  a	  larger	  cohort	  Phase	  3	  
study	  with	  clinical	  outcome	  measures	   if	  CyCLLe	  demonstrated	  a	  significant	  change	   in	  
proliferation.	  
In	  preparation	  for	  the	  in-­‐vivo	  study,	  the	  precise	  mechanism	  of	  action	  of	  CsA	  on	  CLL	  and	  
CLL	  T	  cells	  was	  investigated	  in	  a	  series	  of	   in-­‐vitro	  studies.	  We	  started	  by	  investigating	  
whether	  CLL	  T	  cells	  are	   indeed	  sensitive	  to	  the	  effect	  of	  CsA.	  Having	  established	  that	  
CLL	  T	  cells	  are	  sensitive	  to	  the	  effect	  of	  CsA,	  we	  went	  on	  to	   investigate	  whether	  CsA	  
has	  an	  additional,	  direct	  effect	  on	  CLL	  cells,	  independent	  of	  any	  T	  cell	  mediated	  effect.	  
As	   it	   is	   has	   been	   shown	   that	   CD40L	   signalling	   plays	   a	  major	   role	   in	   T	   cell	  mediated	  
activation	  and	  proliferation	  of	  CLL	  cells	   in	   the	   lymph-­‐node	   (Ghia	  et	  al.,	  2002;	  Patten,	  
Buggins,	   Richards,	  Wotherspoon,	   Salisbury,	  Mufti,	   Hamblin,	  &	  Devereux,	   2008b),	  we	  
investigated	   if	  CsA	  has	  a	  direct	  effect	  on	  CD40L	  activated	  CLL	  cells.	  We	  subsequently	  
investigated	  the	  effect	  of	  CsA	  on	  the	  interaction	  between	  CLL	  and	  activated	  autologous	  
CD4	  T	  cells,	  aiming	  to	  discern	  whether	  the	  effect	   in	  CLL	  cells	   is	  direct,	   indirect	   (T	  cell	  
dependent),	   or	   a	   combination	   of	   the	   two.	   The	   effect	   of	   CsA	   on	   NFAT	   and	   NFκB	  
activation	   in	   CLL	   and	   CD4	   T	   cells	  was	   performed	   to	   further	   define	   its	  mechanism	  of	  
action.	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In	  view	  of	  the	  role	  of	  NFAT	  and	  NFκB	  in	  mediating	  BCR	  signalling	  and	  in	  maintaining	  a	  
state	   of	   anergy	   in	   CLL,	   we	   then	   went	   on	   to	   investigate	   whether	   CLL	   cells	   activated	  
through	  the	  BCR	  are	  directly	  sensitive	  to	  CsA.	  As	  it	  has	  been	  shown	  that	  inhibition	  of	  
NFAT	   signalling	   reverses	   anergy	   and	   stimulates	   apoptosis	   in	   CLL	   with	   features	   of	  
anergy	   (Apollonio	  et	   al.,	   2013),	  we	  assessed	   the	  effect	  of	  CsA	  on	   the	   viability	  of	  CLL	  
cells.	   The	   in-­‐vitro	   studies	   were	   subsequently	   applied	   to	   patients	   recruited	   to	   the	  
clinical	  trial	  to	  further	  investigate	  the	  effect	  of	  CsA	  in	  in-­‐vivo.	  
The	   proliferation	   of	   CLL	   cells	   was	   measured	   in-­‐vivo	   using	   labelling	   with	   deuterated	  
glucose,	   an	  entirely	   novel	  method	  of	   investigating	   the	  effect	   of	   a	   therapeutic	   agent.	  
Since	   transit	  between	   lymph-­‐node	  and	   tissues	   is	   considered	   to	  play	  a	   role	   in	  disease	  
pathogenesis,	   the	   kinetics	   of	   release	   and	   disappearance	   of	   proliferating	   cells	   was	  
measured	  before	  and	  after	  treatment	  with	  CsA.	  
A	   second	   clinical	   study,	   ‘In-­‐vivo	   Kinetics	   in	   Chronic	   Lymphocytic	   Leukaemia’	   was	  
initiated	   to	   formally	   study	   the	   degree	   of	   intra-­‐patient	   variation	   in	   leukaemic	   cell	  
proliferation	   rates.	  Although	   it	  would	  have	  been	  preferable	   to	  measure	   intra-­‐patient	  
variation	   in	   proliferation	   rates	   before	   commencing	   CsA,	   this	   was	   deemed	   too	  
burdensome	   to	  mandate	   within	   the	   trial	   protocol	   and	   was	   therefore	   considered	   an	  
optional	   investigation.	  This	  observational	  study	  additionally	  provided	  the	  opportunity	  
to	  intensively	   investigate	  the	  kinetics	  of	  CLL	  proliferation	  and	  trafficking	  between	  the	  
lymph-­‐node	  and	  peripheral	  blood	  compartments.	  
In	  addition	  to	  studying	  the	  CLL	  population	  as	  a	  whole,	  we	  investigated	  the	  kinetics	  of	  
sub-­‐populations	  defined	  by	  a	  phenotype	  previously	  associate	  with	  trafficking	  (CXCR4/	  
CD5)	  and	  sIgM	  expression,	  previously	  associated	  with	  proliferation.	  Finally,	  the	  kinetics	  
of	  subpopulations	  defined	  by	  BCR	  internalisation	  was	  investigated	  in	  order	  to	  establish	  
the	   relationship	   between	   proliferation	   and	   a	   functional	   parameter	   related	   to	   CLL	  
biology.	  	  
We	  investigated	  the	  relationship	  between	  the	  various	  sub-­‐populations	  by	  performing	  
serial	  sampling	  of	   labelled	  CLL	  cells	  and	  by	  comparing	  the	  degree	  of	   labelling	   in	  each	  
sub-­‐population	  at	  regular	  intervals	  over	  an	  eight-­‐week	  period.	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1.5	  Aims	  and	  Objectives	  
1.	  To	  dissect	  the	  mechanism	  of	  action	  of	  CsA	  in	  CLL	  using	  in-­‐vitro	  methods:-­‐	  
• To	  investigate	  and	  fully	  characterise	  the	  direct	  effect	  of	  CsA	  on	  CLL	  B	  and	  CD4	  T	  
cells.	  
• To	   investigate	   if	   T	   cell	   suppression	   using	   CsA	   indirectly	   inhibits	   CLL	   cell	  
activation.	  
2.	  To	  investigate	  whether	  manipulation	  of	  the	  tumour	  microenvironment	  using	  CsA	  is	  a	  
safe	   and	   effective	   method	   of	   inhibiting	   proliferation	   in	   patients	   with	   early-­‐stage,	  
adverse-­‐risk	  disease:-­‐	  
• To	   investigate	   the	   safety	   and	   efficacy	   of	   CsA	   therapy	   in	   patients	   with	   poor-­‐
prognosis	   (defined	   by	   CD38	   expression)	   that	   does	   not	   meet	   conventional	  
criteria	  for	  treatment.	  
• To	  use	  in-­‐vivo	  deuterium	  labelling	  as	  a	  novel	  method	  of	  measuring	  the	  effect	  of	  
drug	  on	  tumour	  proliferation.	  
• To	  apply	  in-­‐vitro	  assays	  to	  further	  define	  the	  effect	  of	  CsA	  in-­‐vivo.	  	  
3.	   To	  use	   in-­‐vivo	   labelling	  of	   CLL	   cells	   to	   investigate	   the	   kinetics	   of	   proliferation	   and	  
trafficking	  of	  CLL	  cells:-­‐	  
• To	  measure	  in-­‐vivo	  proliferation	  rates	  and	  to	  investigate	  intra-­‐patient	  variation	  
in	  proliferation	  rates.	  
• To	  investigate	  release	  and	  disappearance	  rates	  of	  recently	  proliferated	  cells.	  
• To	   investigate	   the	   relationship	   between	   sIgM	   expression,	   BCR	   internalisation	  
and	  proliferation	  and	  kinetics	  of	  release	  and	  disappearance.	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 .	  General	  Materials	  and	  Methods	  Chapter	  2
2.1	  Primary	  Patient	  Material	  
2.1.1	  Ethical	  Approval	  
Peripheral	   blood	  mononuclear	   cells	   (PBMCs)	  were	   collected	   from	   randomly	   selected	  
patients	  with	  a	  confirmed	  diagnosis	  of	  CLL.	  Ethical	  approval	  was	  provided	  by	  a	  National	  
Research	  Ethics	  Service	  (NRES	  reference	  08/H0906/94)	  and	  informed	  written	  consent	  
was	  obtained	  according	  to	  the	  Declaration	  of	  Helsinki.	  Blood	  was	  donated	  by	  healthy	  
donors	  for	  use	  as	  ‘normal	  controls’.	  	  
	  
2.1.2	  Isolation	  of	  peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  
PBMCs	   were	   isolated	   by	   density-­‐gradient	   separation	   using	   Histopaque	   1077	   (Sigma	  
Aldrich).	   The	   cells	   were	   centrifuged	   for	   25	   minutes	   at	   400	   g	   with	   no	   brake.	   The	  
monolayer	  was	  harvested	  and	  washed	  in	  phosphate	  buffered	  saline	  (PBS)	  before	  being	  
pelleted	  for	  10	  minutes	  at	  300	  g.	  Platelets	  were	  removed	  by	  resuspending	  the	  pellet	  in	  
PBS	   and	   centrifuging	   at	   300	   g	   for	   10	   minutes	   twice.	   Manual	   cell	   counting	   was	  
performed	   using	   a	   counting	   chamber	   (Hawksley),	   with	   trypan	   blue	   solution	   as	   a	  
viability	  stain.	  
	  
2.1.3	  CLL	  cell	  culture	  
CLL	   cells	   were	   cultured	   in	   Roswell	   Park	   Memorial	   Institute	   Medium	   (RPMI	   1640,	  
Sigma),	   10	   %	   (v/v)	   Foetal	   Bovine	   Serum	   (FBS,	   Sigma),	   L-­‐Glutamine	   (2mM	   final),	  
penicillin	  (2000	  units	  per	  mL)	  and	  streptomycin	  (2mg/mL)	  Complete	  medium	  (CM).	  All	  
cell	  culture	  was	  performed	  at	  37°C,	  100	  %	  humidity	  and	  5	  %	  CO2.	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2.1.4	  Fibroblast	  culture	  
Untransfected	  fibroblasts	  and	  fibroblasts	  transfected	  with	  CD40L	  were	  used	  (gift	  from	  
Prof	   Pepper,	   Cardiff	   University).	   Fibroblasts	   were	   cultured	   in	   Dulbecco’s	   Modified	  
Eagle’s	  Medium	  (DMEM)	  with	  glucose	  (4500	  ng/l),	  L-­‐Glutamine,	  sodium	  pyruvate	  and	  
sodium	  bicarbonate	  supplemented	  with	  10	  %	  (v/v)	  FBS,	  penicillin	  (2000	  units	  per	  mL)	  
and	  streptomycin	  (2mg/mL).	  Fibroblasts	  were	  cultured	  at	  an	  initial	  concentration	  of	  2	  x	  
105/ml	   in	  24	  well	  plates	  and	  left	  for	  12	  hours	  to	  adhere	  to	  the	  plastic	  and	  to	  achieve	  
confluence.	   Cells	   were	   passaged	   by	   washing	   twice	   with	   PBS	   and	   incubating	   with	  
trypsin-­‐EDTA	   for	  2	  minutes	   to	   allow	  cell	   detachment	  before	  washing	  with	  50mL	  PBS	  
containing	  10	  %	  (v/v)	  FBS.	  
	  
2.1.5	  Freezing	  cells	  
PBMCs	  were	   frozen	  at	  106	  -­‐	  107	   cells	  per	  mL	   in	  50	  %	  CM	  and	  50	  %	   freezing	  medium	  
(containing	   80%	   (v/v)	   FBS	   and	   20	   %	   (v/v)	   dimethyl	   sulphoxide	   (DMSO)).	   Cells	   were	  
aliquoted	   into	   cryovials	   (Nalgene)	   and	   immediately	   transferred	   to	   a	   Mr.	   Frosty™	  
freezing	   container	   that	   contained	  70	  %	   (v/v)	   isopropanol.	   This	  was	  placed	   in	  a	   -­‐80°C	  
freezer	   and	   left	   over	   night	   to	   allow	   controlled	   freezing.	   The	   following	   day,	   cryovials	  
were	  transferred	  to	  a	   liquid	  nitrogen	  containing	  storage	  facility	  for	   long-­‐term	  storage	  
within	   King’s	   College	   London	   Human	   Tissue	   Authority	   Approved	   (HTA)	   Tissue	   Bank	  
(licence	  12223,	  September	  2006,	  unconditional	  status).	  
	  
2.1.6	  Reviving	  cells	  
On	  collection	  from	  the	  cryostore,	  cryovials	  were	  rapidly	  thawed	  in	  a	  37°C	  water	  bath	  
and	   washed	   in	   PBS	   to	   remove	   the	   DMSO-­‐containing	   freezing	   medium	   before	   re-­‐
suspending	  in	  pre-­‐warmed	  complete	  media.	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2.1.7	  T	  cell	  isolation	  
T	  cells	  were	  negatively	   selected	   from	  PBMCs	  using	  an	  EasySep™	  T	  cell	   separation	  kit	  
(Stem	  Cell)	  as	  per	  the	  manufacturer’s	  instructions.	  PBMCs	  were	  resuspended	  at	  5	  x	  107	  
in	   PBS	   containing	   2	   %	   (v/v)	   FBS	   and	   labelled	   with	   tetrameric	   antibody	   complexes	  
recognizing	  CD14,	  CD16,	  CD19,	  CD20,	  CD36,	  CD56,	  CD66b,	  CD123,	  glycophorin	  A	  and	  
dextran-­‐coated	   magnetic	   particles.	   The	   labelled	   cells	   were	   separated	   using	   an	  
EasySep™	  magnet	  and	  the	  unbound	  T	  cells	  poured	  off	  into	  a	  new	  tube.	  
CD4+	  T	  cells	  were	  selected	  using	  the	  same	  EasySep™	  technology	  but	  with	  a	  kit	  (Stem	  
Cell)	   using	   tetrameric	   antibody	   complexes	   that	   additionally	   recognised	   CD8	   and	  
TCRγ/δ.	  
	  
2.1.8	  CLL	  cell	  isolation	  –	  negative	  selection	  
CLL	   cells	   were	   negatively	   selected	   using	   an	   EasySep™	   B	   cell	   separation	   kit	   without	  
CD43	  (Stem	  Cell)	  as	  per	  manufacturer’s	  instructions.	  Unwanted	  cells	  were	  targeted	  for	  
removal	  with	  tetrameric	  antibody	  complexes	  recognizing	  CD2,	  CD3,	  CD14,	  CD16,	  CD56,	  
glycophorin	   A	   and	   dextran-­‐coated	   magnetic	   particles.	   The	   labelled	   cells	   were	  
separated	  using	  the	  EasySep™	  magnet	  and	  the	  unbound	  CLL	  B	  cells	  harvested.	  
	  
2.2	  Activation	  Methods	  
2.2.1	  T	  cell	  activation	  using	  Phorbol	  12-­‐Myristate	  13-­‐Acetate	  (PMA)	  and	  Ionomycin	  
T	   Cells	   were	   activated	   using	   PMA	   (Sigma)	   at	   10	   ng/mL	   and	   Ionomycin	   (Sigma)	   at	   1	  
μ/mL	  at	  a	  concentration	  of	  1	  x	  106	  cells/mL	   in	  CM	   in	  24	  well	  plates	  at	  37°C	   in	  a	   fully	  
humidified	  atmosphere	  of	  5	  %	  CO2.	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2.2.2	  T	  cell	  activation	  using	  anti-­‐CD3/CD28	  
24	   well	   plates	   were	   coated	   with	   500	   μL	   of	   agonistic	   anti-­‐CD3	   (ebiosciences)	   at	  
2.5μL/mL	  in	  PBS	  (Sigma).	  The	  antibody	  was	  allowed	  to	  bind	  to	  the	  plastic	  at	  4oC	  for	  24	  
hours.	  The	  unbound	  antibody-­‐containing	  solution	  was	  completely	  aspirated	  and	  wells	  
were	  gently	  washed	  with	  PBS	  before	  addition	  of	  the	  T	  cell	  suspension	  (1	  x	  106	  cells/ml	  
in	  CM).	  Anti-­‐CD28	  (ebiosciences)	  was	  added	  to	  the	  suspension	  at	  1	  μL/mL).	  Cells	  were	  
activated	  at	  37°C	  in	  a	  fully	  humidified	  atmosphere	  of	  5	  %	  CO2.	  
	  
2.2.3	  B	  cell	  stimulation	  using	  anti-­‐IgM	  
Normal	  and	  CLL	  B	  cells	  were	  stimulated	  through	  the	  B	  Cell	  Receptor	  (BCR)	  using	  goat	  F	  
(ab’)2	   anti-­‐human	   IgM	   (μ	   chain	   specific)	   (Southern	  Biotech)	   at	   a	   concentration	  of	   10	  
μg/mL.	   B	   cells	  were	   activated	   at	   1	   -­‐2	   x	   106	  /	  mL	   in	   CM	  at	   37°C	   in	   a	   fully	   humidified	  
atmosphere	  of	  5	  %	  CO2.	  
	  
2.2.4	  B	  cell	  stimulation	  using	  CD40L	  transfected	  fibroblasts	  
CD40L	   transfected	   fibroblasts	  were	   allowed	   to	   adhere	   to	   plastic	   (24	  well	   plate)	   and	  
were	   confirmed	  by	   light	  microscopy	   to	  be	   confluent	  before	   the	  extraction	  of	  DMEM	  
and	  addition	  of	  purified	  CLL	  cells	  at	  a	  concentration	  of	  1	  x	  106	  /	  mL	  in	  CM.	  Cells	  were	  
co-­‐cultured	  at	  37°C	   in	  a	   fully	  humidified	  atmosphere	  of	  5	  %	  CO2	   for	  24	  hours	  before	  
mechanical	  detachment	  of	  CLL	  cells.	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2.3.	  Reagents	  
2.3.1	  Ciclosporin	  for	  in-­‐vitro	  use.	  
Ciclosporin	  (Sigma)	  was	  dissolved	  in	  ethanol	  to	  make	  a	  stock	  concentration	  of	  1	  mg/mL	  
and	  stored	  in	  aliquots	  at	  -­‐20°C.	  A	  working	  concentration	  of	  10	  μg/mL	  was	  prepared	  for	  
same-­‐day	  use.	  A	  final	  concentration	  of	  200	  ng/mL	  was	  applied	  to	  all	  experiments.	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Table	  2.1	  General	  Consumables	  
Consumable	  	   Manufacturer	  
7-­‐	  Amino-­‐Actinomycin	  (7-­‐AAD)	   BD	  Biosciences	  
Annexin	  V	   BD	  Biosciences	  
Annexin	  V	  Binding	  Buffer	   BD	  Biosciences	  
Anti	  Human	  CD3	  	   eBioscience	  
Anti	  Human	  CD28	   eBioscience	  
BD	  Cytofix/Cytoperm™	   BD	  Biosciences	  
Bovine	  Serum	  Albumin	   Sigma	  Aldrich	  
Brefeldin	   BD	  Biosciences	  
Bromophenol	  Blue	   Sigma	  Aldrich	  
BD	  Perm/Wash	  Buffer™	   BD	  Biosciences	  
BD	  CompBeads	  anti-­‐mouse	  Igκ	   BD	  Biosciences	  
4’,5-­‐diamidino-­‐2-­‐phenylindole	  (DAPI)	   Sigma	  
Dimethyl	  Sulphoxide	  (DMSO)	   Sigma	  
Dithiothreitol	  (DTT)	   Sigma	  
Dulbecco’s	  Modified	  Eagle	  Medium	   Sigma	  
ECL	  Western	  Blotting	  Detection	  Reagent	   GElifesciences	  
EasySep	  Negative	  Human	  CD3	  Kit	   Stemcell	  
EasySep	  Negative	  Human	  CD4	  Kit	   Stemcell	  
EasySep	  Negative	  Human	  CD19	  Kit	  (without	  CD43)	   Stemcell	  
Ethanol	   Fischer	  Scientific	  
Ethylenediaminetetraaceticacid	  (EDTA)	   ThermoFischer	  	  
EZ-­‐Run™	  Pre-­‐stained	  Rec	  Protein	  Ladder	   ThermoFischer	  
Fixable	  Viability	  Dye	  eFluor®	  780	   eBiosciences	  
Foetal	  Calf	  Serum	   Sigma	  
Glycerol	   Sigma	  
Goat	  F(ab’)2	  Anti-­‐Human	  IgM	  (μ	  chain	  specific)	   SouthernBiotech	  
Histopaque	  1077	   Sigma	  Aldrich	  
Human	  HT-­‐12	  v4.0	  Expression	  BeadChip	  Kit	   Illumina	  
Ionomycin	   Sigma	  Aldrich	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L-­‐glutamine	   Sigma	  Aldrich	  
Methanol	   ThermoFischer	  
1	  %	  NP-­‐40	   Sigma	  Aldrich	  
Paraformaldehyde	  16	  %	  w/v	  aq	  sol	   VWR	  
Phorbol	  12-­‐myristate	  13-­‐acetate	   Sigma	  Aldrich	  
Phosphate	  buffered	  saline	   Sigma	  Aldrich	  
Phosphatase	  Inhibitor	  Cocktail	  II,	  III	   Sigma	  Aldrich	  
Protease	  Inhibitor	  Cocktail	   Sigma	  Aldrich	  
R6K	  screen	  tapes	   Agilent	  technologies	  
R6K	  reagents	   Agilent	  technologies	  
Red	  cell	  lysis	  buffer	   eBioscience	  
RNAeasy®	  mini	  kit	   Qiagen	  
Roswell	  Park	  Memorial	  Institute	  (RPMI)	  1640	   Sigma	  Aldrich	  
0.1%	  Sodium	  Azide	   Severn	  Biotech	  
0.1%	  sodium	  deoxycholate	   Sigma	  Aldrich	  
Sodium	  dodecyl	  sulfate	  (SDS)	   Sigma	  Aldrich	  
SuperScript®	  III	  Reverse	  Transcriptase	   Life	  Technologies	  
TargetAmp™Nano-­‐g™	  Biotin-­‐aRNA	  Labelling	  Kit	   Cambio/Epicentre	  
Tris	  HCl	  	   Sigma	  
0.1	  %	  Triton	  X-­‐100	   Sigma	  Aldrich	  
Trypan	  Blue	   Fluka	  Analytical	  
Trypsin	   Sigma	  Aldrich	  
Tween-­‐20	   Sigma	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2.4	  Flow	  Cytometry	  
2.4.1	  Preparation	  of	  cells	  for	  assessment	  of	  surface	  antigens	  
Cells	   were	  washed	   twice	   in	   PBS	   and	   re-­‐suspended	   at	   1-­‐2	   x	   105	   in	   1	  mL	   PBS	   before	  
adding	  1	  μL	  fixable	  viability	  dye	  (Ebiosciences).	  Cells	  were	  incubated	  with	  the	  dye	  for	  
10	  mins	  at	  room	  temperature	  in	  the	  dark	  before	  washing	  twice	  with	  PBS.	   	  Cells	  were	  
then	  re-­‐suspended	  at	  1-­‐2	  x	  105	  in	  100	  μL	  PBS	  incubating	  with	  saturating	  concentrations	  
of	  the	  relevant	  antibodies	  for	  20	  minutes	  at	  4°C	  in	  the	  dark.	  Cells	  were	  washed	  twice	  in	  
PBS	  before	  analysis	  on	  the	  flow	  cytometer	  (BD,	  FACSCanto	  II).	  	  
	  
2.4.2	  Preparation	  of	  cells	  for	  analysis	  of	  intracellular	  cytokines	  
Brefeldin	   (Sigma)	   1	   μL	   /mL	   was	   added	   to	   the	   activation	   wells	   6	   hours	   before	  
termination	  of	  the	  activation	  period.	  Brefeldin	  is	  a	  fungal	  metabolite	  that	  disrupts	  the	  
golgi	   apparatus	   and	   prevents	   the	   secretion	   of	   cytokines	   so	   that	   they	   are	   retained	  
within	   the	   cytoplasm.	   Cells	  were	   then	  washed	   and	   stained	  with	   fixable	   viability	   dye	  
and	  for	  cell	  surface	  antigens	  as	  above.	  Fixation	  was	  subsequently	  performed	  using	  400	  
μL	   Cytofix	   per	   test	   (BD	   Cytofix™)	   for	   10	   minutes.	   Cells	   were	   then	   washed	   and	  
resuspended	   in	  1	  mL	  permeabilisation	  buffer	   (BD	  Perm/Wash	  Buffer™)	  for	  15	  mintes	  
at	  room	  temperature.	  The	  cells	  were	  pelleted	  at	  300	  g	  for	  5	  minutes	  and	  supernatant	  
was	   aspirated.	   Cells	   were	   resuspended	   in	   100	   μL	   permeabilisation	   buffer	   and	  
incubated	   with	   the	   antibody	   to	   the	   intracellular	   cytokine	   for	   20	   minutes	   at	   room	  
temperature.	   Cells	  were	  washed	   twice	   in	   permeabilisation	   buffer	   before	   analysis	   on	  
the	  flow	  cytometer	  (BD,	  FACSCanto	  II).	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2.4.3	  Apoptosis	  Assay	  
Viability	   assays	  were	   performed	   using	   Annexin	   V-­‐conjugated	   to	   FITC	   and	   7-­‐AAD	   (BD	  
Biosciences).	  Annexin	  V	  binds	  to	  phosphatidyl	  serine,	  which	  is	  present	  on	  the	  external	  
cellular	  surface	  early	  in	  the	  process	  of	  apoptosis.	  7-­‐AAD	  is	  a	  cell-­‐impermeant	  dye	  that	  
is	  able	  to	  bind	  ds-­‐DNA	  in	  cells	  where	  the	  cellular	  membrane	  has	  been	  compromised	  (as	  
in	  fully	  apoptotic	  cells).	   	  100	  μL	  Annexin	  V	  binding	  buffer	  (BD	  Biosciences)	  was	  added	  
to	  the	  experimental	  sample	  with	  2.5	  μL	  Annexin-­‐V	  antibody	  +	  1	  μL	  7-­‐AAD	  and	  allowed	  
to	  incubate	  for	  15	  minute	  in	  the	  dark	  at	  room	  temperature.	  400	  μL	  Annexin	  V	  binding	  
buffer	  was	  then	  added	  prior	  to	  sample	  analysis	  by	  flow	  cytometry.	  
	  
2.4.4	  Compensation	  Matrix	  for	  Flow	  Cytometry	  
Compensation	  beads	   (BD	  Biosciences)	  were	  used	   to	   create	   the	   compensation	  matrix	  
for	   fluorochromes	   conjugated	   to	   surface	   antigens.	   Positive	   and	  negative	  beads	  were	  
vortexed	   for	  30	  s	  before	  adding	  one	  droplet	   to	  100	  μL	  PBS	  and	   incubating	  with	  5	  μL	  
fluorochrome-­‐conjugated	   antibody	   for	   20	   minutes	   in	   the	   dark	   at	   4°C.	   Beads	   were	  
washed	   twice	   before	   re-­‐suspending	   in	   100	   μL	   PBS	   for	   acquisition	   on	   the	   flow	  
cytometer.	  
Live/	  Dead	  cells	  were	  used	  to	  create	  the	  viability	  compensation	  control.	  Fresh	  PBMCs	  
were	   prepared	   at	   a	   concentration	   of	   1	   x	   106/mL	   and	   equally	   divided	   into	   2	   round-­‐
bottomed	  FACS	   tubes.	  One	   tube	  was	  placed	   in	  a	  65°C	  water	  bath	   for	  4	  minutes	  and	  
then	  on	  ice	  for	  5	  minutes.	  Live	  and	  dead	  cells	  were	  then	  recombined	  and	  stained	  with	  
the	   fixable	   viability	   dye	   as	   above	   before	   washing	   twice	   for	   acquisition	   on	   the	   flow	  
cytometer.	  
20,000	   events	   were	   acquired	   for	   each	   compensation	   control	   and	   the	   matrix	   was	  
calculated	  using	  BD	  FacsDIVA	  software.	  	  
2.4.5	  Controls	  
Fluoresence	   minus	   one	   controls	   were	   prepared	   for	   fluorescence	   gating	   of	   surface	  
antigens.	  Isotype	  matched	  controls	  were	  used	  for	  intracellular	  fluorescence	  gating.	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2.4.6	  BD	  FACSCanto	  II	  (BD	  Biosciences)	  Lasers	  and	  Fluorochromes	  
Data	  was	  acquired	  using	  the	  BD	  Biosciences	  FACSCanto	  II,	  configured	  as	   in	  Table	  2.2.	  
Flow	  cytometry	  antibodies	  and	  their	  fluorochromes	  are	  listed	  in	  Table	  2.3.	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Table	  2.3	  Flow	  Cytometry	  Antibodies	  
Antibody	   Clone	   Supplier	  
CD3	  -­‐	  V500	   UCHT1	   BD	  
CD3	  –	  PB	  	   HIT39	   Biolegend	  
CD4	  –	  ef450	   OKT4	   Biolegend	  
CD4	  –	  PercP-­‐Cy5.5	   OKT4	   Biolegend	  
CD5	  –	  FITC	   UCHT2	   Biolegend	  
CD5	  –	  PE-­‐Cy7	   UCHT2	   Biolegend	  
CD8	  –	  PercP-­‐Cy5.5	   SK1	   Biolegend	  
CD8	  –	  APC	   SK1	   Biolegend	  
CD5	  –	  PE-­‐Cy7	   UCHT2	   Biolegend	  
CD19	  –	  PE	   HIB19	   Biolegend	  
CD19	  –	  APC	   HIB19	   Biolegend	  
CD25	  –	  APC	   BC96	   Biolegend	  
CD38	  –	  PE	   HIT2	   Biolegend	  
CD45-­‐RA	   HI100	   Biolegend	  
CD69	  –	  AF488	   FN50	   Biolegend	  
CD69	  –	  PE	   FN50	   Biolegend	  
CD154	  (CD40L)	  –	  PE	   24-­‐31	   Biolegend	  
CD279	  (PD1)	  –	  APC	   EH12.2H7	   Biolegend	  
IFNγ	  –	  BV421	   4S.3B	   Biolegend	  
CXCR4	  –	  PE	   12GS	   Biolegend	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2.5	  Image	  Flow-­‐Cytometry	  -­‐	  Amnis	  ImageStream	  X®	  (Merck)	  
Image	   flow	   cytometry	   was	   performed	   using	   the	   Amnis	   ImageStream	   X®	   which	  
combines	   cellular	   microscopy	   (40	   x	   magnification	   lens)	   with	   flow-­‐cytometry.	   By	  
collecting	   large	   numbers	   of	   digital	   images	   per	   sample	   and	   by	   providing	   numerical	  
representation	  of	   image-­‐based	   features,	   individual	   cell	   information	   is	   combined	  with	  
statistical	  significance	  afforded	  by	  large	  sample	  sizes.	  	  
2.5.1	  Configuration	  
The	   ImageStream	  X®	  has	   six	   co-­‐linear	   lasers	   and	  a	  40	   x	  magnification	   lens	  allowing	  6	  
images	   (bright	   field	  plus	  5	  x	   fluorescent	  channels)	   to	  be	  collected	   for	  each	  cell	   to	  be	  
collected	  simultaneously	  with	  a	  high	  resolution	  camera.	  Figure	  2.1	  demonstrates	  how	  











Figure	  2.1	  	  ImageStream	  X®	  	  Configuration	  
Hydrodynamically	  focused	  cells	  are	  trans-­‐illuminated	  by	  a	  brightfield	   light	  source	  and	  
orthogonally	  by	  lasers.	  An	  objective	  lens	  collects	  fluorescence	  emissions,	  scattered	  and	  
transmitted	   light	   from	   the	   cells.	   The	   collected	   light	   intersects	   with	   the	   spectral	  
decomposition	   element.	   Light	   of	   different	   spectral	   bands	   leaves	   the	   decomposition	  
element	  at	  different	  angles	   such	   that	  each	  band	   is	   focused	  onto	  6	  different	  physical	  
locations	   of	   the	   camera.	   The	   camera	   operates	   in	   TDI	   (time	   delay	   integration)	  mode	  
that	  electronically	  tracks	  moving	  objects.	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Table	  2.4	  ImageStream	  X®	  Fluorochromes	  and	  Detection	  Channels	  
	  
2.5.2	  Preparation	  of	  cells	  for	  Image	  Flow	  Cytometry	  
1-­‐3	   x	  106	   cells	  were	   collected,	  washed	   in	   ice-­‐cold	  PBS/2	  %	  v/v	   FBS	  and	  pelleted	   in	  a	  
pre-­‐cooled	   centrifuge	   for	   5	  minutes	   at	   300	   g.	   Cells	  were	   surface-­‐stained	   on	   ice	   and	  
washed	  in	  ice-­‐cold	  PBS	  2	  %	  v/v	  FBS	  containing	  1mM	  EDTA.	  Cells	  were	  then	  fixed	  in	  400	  
μL	  4	  %	  paraformaldehyde	  (VWR)	  for	  10	  minutes.	  The	  fixed	  cells	  were	  then	  washed	  in	  
PBS	  and	  re-­‐suspended	  in	  100	  μL	  permeabilisation	  buffer	  (containing	  2	  %	  FBS,	  0.1	  %	  v/v	  
Triton	  X-­‐100	   (Sigma),	  0.1	  %	  v/v	  sodium	  azide	   (Severn	  Biotech).	  The	  primary	  antibody	  
was	   added	   to	   the	   permeabilisation	   buffer	   at	   a	   concentration	   of	   10	   μg/mL	   and	   was	  
allowed	  to	   incubate	  at	  room	  temperature	  for	  20	  minutes.	  Cells	  were	  washed	  once	  in	  
permeabilisation	  buffer	  and	  resuspended	  at	  100	  μL	  with	  the	  secondary	  antibody	  at	  a	  
concentration	  of	  15	  μg/mL.	   	  This	  was	  allowed	  to	   incubate	   for	  15	  minutes	  before	   the	  
cells	  were	  washed	  twice	  with	  PBS/2	  %	  v/v	  FBS.	  A	  minimum	  sample	  size	  of	  60	  μL	  at	  a	  
cellular	  concentration	  of	  1	  x	  106/mL	  was	  prepared.	  DAPI	  (1:10	  	  v/v)	  (Sigma)	  was	  added	  
immediately	  before	  analysis.	  
Antibodies	  used	  in	  this	  investigation	  are	  listed	  in	  Table	  2.5.	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Table	  2.5	  Image	  Flow	  Cytometry	  Antibodies	  
Antibody	   Dilution	   Source	  
CD4	  –	  PercpCy5.5	   5:100	   Biolegend	  
CD19	  –	  PE	   5:100	   Biolegend	  
Rabbit	  anti-­‐NFAT-­‐C2	   1:20	   Santa	  Cruz	  
Rabbit	  anti-­‐NFκB-­‐p65	   1:20	   Santa	  Cruz	  
F(ab’)2	  Donkey	   anti-­‐rabbit	  
IgG-­‐FITC	  
1:200	   Jackson	  Immunoresearch	  
	  
2.5.3	  Compensation	  and	  controls	  
The	   compensation	   matrix	   was	   produced	   using	   fresh	   primary	   cells	   that	   had	   been	  
prepared	   as	   single	   stained	   controls.	   Fluorescence	  minus	   one	   controls	  were	   used	   for	  
fluorescence	   gating.	   Imaging	   controls	   were	   prepared	   using	   an	   unstimulated	   sample	  
(untranslocated).	   A	   sample	   stained	   for	   the	   secondary	   antibody	   only	   was	   used	   as	   a	  
further	  staining	  control.	  
2.5.4	  Image	  Analysis	  using	  IDEAS®	  software	  
ImageStream	  Data	  Exploration	  and	  Analysis	   Software	   (IDEAS®)	  was	  used	   to	   calculate	  
the	  percentage	  translocation	  of	  the	  transcription	  NFAT	  and	  NFκB-­‐p65	  in	  CLL	  and	  CD4	  T	  
cells.	   	  After	   compensation,	   similarity	   analysis	  was	  performed	  on	   single,	   focused	   cells	  
based	   on	   their	   width	   to	   height	   ratio	   and	   high	   nuclear	   contrast	   (measured	   by	   the	  
gradient	   max	   feature).	   The	   degree	   of	   nuclear	   translocation	   was	   measured	   by	  
comparing	  the	  nuclear	  fluorescence	  image	  with	  the	  pattern	  of	  fluorescence	  produced	  
by	  the	  nuclear	  label.	  Nuclear	  translocation	  is	  considered	  to	  have	  occurred	  when	  there	  
is	   an	  overlap	  between	  nucleus	   and	   transcription	   factor	   signal.	   The	   similarity	   score	   is	  
calculated	   from	   the	   Pearson’s	   correlation	   coefficient	   based	   on	   a	   linear	   regression	  
analysis	  of	  pairs	  of	  values	  taken	  from	  different	  data	  sources.	  
Nuclear	  to	  cytoplasmic	  ratio	  of	  transcription	  factor	  signal	  was	  calculated	  by	  creating	  a	  
‘mask’	   around	   the	   nucleus,	   defined	   by	   the	   DAPI	   signal	   followed	   by	   a	   single	   pixel	  
erosion	  to	  ensure	  that	  no	  cytoplasmic	  signal	  was	  included.	  The	  cytoplasmic	  mask	  was	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created	  by	  subtracting	  the	  nuclear	  mask	  from	  the	  transcription	  factor	  mask.	  The	  ratio	  
of	   the	   transcription	   factor	   integral	   in	   the	   nucleus	   compared	   to	   that	   integral	   in	   the	  
cytoplasmic	  mask	  was	  used	  to	  create	  this	  feature.	  
An	  example	  of	  the	  gating	  strategy	  is	  shown	  in	  Figure	  2.2.	  
	  
	  
Figure	   2.2	   (a-­‐e)	   Example	   of	   gating	   strategy	   using	   IDEAS®	   to	   assess	   NFκB-­‐p65	  
translocation	  	  
Single,	  focused	  cells	  expressing	  CD4	  were	  gated	  on,	  followed	  by	  cells	  that	  co-­‐expressed	  
of	   NFκB-­‐p65	   and	   DAPI.	   The	   degree	   of	   nuclear	   translocation	   was	   calculated	   by	  
measuring	  the	  similarity	  between	  the	  nuclear	  (DAPI)	  and	  NFκB-­‐p65	  signal.	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2.6	  Western	  Blotting	  for	  ERK	  and	  Phosho-­‐ERK	  
2.6.1	  Solutions	  and	  Reagents	  
Lysis	  buffer	  
• 125mM	  Tris	  HCl	  pH	  6.8	  
• 4	  %	  w/v	  SDS	  
• 40	  %	  v/v	  glycerol	  
• 200mM	  DTT	  
• 0.002	  %	  w/v	  bromophenol	  blue	  
	  2.6.2	  Cell	  Lysis	  
Cell	   lystates	  were	  prepared	  by	  adding	  50	  μL	   ice-­‐cold	   lysis	  buffer	   to	  1	  x	  106	  cells	   (dry	  
pellets).	   Following	  mechanical	  disaggregation,	   lysates	  were	  heated	   to	  95-­‐100°C	   for	  5	  
minutes	  and	  then	  briefly	  centrifuged	  (30	  s,	  1000x	  Gmax).	  The	  tube	  was	  flicked	  to	  ensure	  
complete	  mixing.	  	  
2.6.3	  Protein	  Electrophoresis	  and	  Western	  Blotting	  
Whole	  cell	  lysates	  were	  separated	  by	  Polyacrylamide	  Gel	  Electrophoresis	  (PAGE)	  using	  
the	  NuPAGE	  system	  (Invitrogen).	  Protein	  lystates	  of	  between	  1	  x	  105	  and	  3	  x	  105	  were	  
loaded	  per	  lane	  on	  a	  4-­‐1	  %	  (w/v)	  bis-­‐Tris	  polyacrylamide	  gel.	  EZ-­‐Run™	  pre-­‐stained	  Rec	  
protein	   ladder	   (Thermo	  Fischer)	  was	  used	   to	  determine	   the	  molecular	  weight	  of	   the	  
bands.	   Gels	   were	   assembled	   in	   a	   NuPAGE	   gel	   apparatus	   and	   run	   for	   1	   hour	   in	   1	   x	  
Running	  Buffer	   (Invitrogen:	   50mM	  MES,	   50mM	  Tris,	   0.1	  %	  w/v	   SDS,	   1	   nM	  EDTA,	   pH	  
7.3)	   at	   200V.	   After	   electrophoresis,	   the	   separated	   proteins	   were	   transferred	   to	   a	  
nitrocellulose-­‐coated	   nylon	   membrane	   (Hybond	   c-­‐Extra,	   GE	   healthcare)	   using	   the	  
NuPAGE	   semi-­‐dry	   gel	   blotting	  module	   according	   to	   the	  manufacturer’s	   instructions.	  
Transfer	  was	  for	  1.5	  hours	  in	  NuPAGE	  Transfer	  buffer	  (Invitrogen:	  25mM	  Bicine,	  25mM	  
Bis-­‐Tris,	  1	  mM	  EDTA,	  pH	  7.2)	  with	  20	  %	  v/v	  methanol	  at	  25V.	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2.6.4	  Antibody	  Staining	  
Membranes	  were	  washed	   x	   2	   in	   PBS-­‐	   0.05	  %	   Tween	   and	   blocked	   for	   one	   hour	  with	  
BSA-­‐	  PBS	  0.05	  %	  Tween	  (3	  %	  w/v)	  or	  non-­‐fat	  dried	  milk-­‐PBS	  Tween	  (10	  %	  w/v)	  prior	  to	  
washing	  x	  3	  with	  PBS-­‐0.05	  %	  Tween	  and	  overnight	  incubation	  at	  4°C	  with	  primary	  goat-­‐
anti	   human	  antibodies	   to	   phospho-­‐ERK	   (in	  BSA-­‐	   PBS	   0.05	  %	  Tween,	   1:1000	   v/v)	   and	  
total	   ERK	   (in	   non-­‐fat	   dried	   milk-­‐PBS	   0.05	   %	   Tween,	   1:1000	   v/v)	   (Cell	   Signalling).	  
Following	  washing	  x	  3	  in	  PBS-­‐	  0.05	  %	  Tween,	  horseradish	  peroxidase	  (HRP)-­‐conjugated	  
rabbit-­‐anti-­‐goat	  antibody	  1:2000	  v/v	  (Dako)	  was	  incubated	  for	  1	  hour	  before	  washing	  x	  
3	  in	  PBS-­‐	  0.05	  %	  Tween.	  
Enhanced	   chemo-­‐luminescence	   (ECL™,	   GE	   lifesciences),	   consisting	   of	   luminol	   and	  
hydrogen	  peroxide	  solution	  was	  used	  to	  visualize	  the	  bands	  (HRP	  cleaves	  the	  luminol	  
agent	  to	  produce	  light).	  Detection	  was	  performed	  using	  photographic	  film	  (Hyperfilm	  
ECL,	  GE	  Healthcare),	  which	  was	  developed	  using	  a	  Compact	  X4	  X-­‐ray	  developer	  (Konica	  
Minolta).	  
Densitometric	  analysis	  of	  ERK-­‐specific	  bands	  was	  performed	  with	  ImageJ	  Software	  (GE	  
Healthcare).	   The	   values	   of	   individual	   patients	   were	   calculated	   as	   percentage	   of	   the	  
positive	  control	  and	  determined	  as	  the	  ratio	  of	  the	  optical	  density	  of	  phospho-­‐ERK	  and	  
optical	  density	  of	  total	  ERK.	  	  
	  
2.7	  Gene	  Expression	  Studies	  
RNA	  was	  prepared	  from	  purified	  CD4	  and	  CD8	  T	  cells.	  Purification	  was	  performed	  using	  
fluorescence	   activated	   cell	   sorting	   and	   purity	  was	   confirmed	   to	   be	   ≥	   95	   	   %	   by	   flow	  
cytometry.	  Cells	  were	   temporarily	   stored	  at	   -­‐80°C	  and	  RNA	  was	  prepared	   in	  batches	  
using	   the	   RNAEasy®	   Mini	   kit	   (Qiagen)	   as	   per	   manufacturer’s	   instructions.	   The	  
concentration	   and	   quality	   of	   the	   RNA	   was	   assessed	   using	   the	   NanoDrop	   2000	  
spectrophotometer	  (ThermoFischer	  Scientific)	  before	  being	  transferred	  on	  dry	   ice	  for	  
analysis	  of	  gene	  expression	  at	  the	  Biomedical	  Research	  Centre,	  Guy’s	  Hospital.	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Gene	   expression	   studies	   were	   performed	   using	   Illumina®	   iScan	   technology.	   Briefly,	  
cDNA	  was	  generated	  from	  mRNA	  in	  the	  sample	  using	  reverse	  transcription.	  The	  cDNA	  
was	  the	  transcribed	   into	  cRNA,	  which	  was	  biotin-­‐labelled,	  amplified	  and	  purified	  and	  
quantified.	  The	  cRNA	  was	   then	  allowed	   to	  hybridise	   to	   the	  bead	  chip	   (Human	  HT-­‐12	  
v4.0	  Expression	  BeadChip,	   Illumina®)	  and	  was	  washed	  and	   stained	  with	   streptavidin-­‐
Cy3.	   The	   bead	   chip	   was	   then	   scanned	   using	   the	   Illumina®	   iScan	   and	   data	   analysed	  
using	  Genome	  Studio	  to	  assess	  the	  genes	  expressed	  in	  the	  samples.	  
2.8	  Data	  Analysis	  
Data	   was	   analysed	   using	   GraphPad	   v.	   7.0	   (Prism).	   Significance	   was	   assessed	   using	  
either	  a	  Student’s	  paired	  t	  test	  or	  a	  Wilcoxon	  matched-­‐pairs	  signed	  rank	  test	  according	  
to	  whether	  the	  data	  passed	  the	  D'Agostino	  &	  Pearson	  normality	  test.	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 .	   In-­‐Vitro	   Studies	   of	   the	   Effect	   of	   Ciclosporin	   A	   on	  Chapter	  3
Healthy	  Donor	  and	  CLL	  T	  and	  B	  Cells	  
3.1	  Background	  and	  Rationale	  
The	   main	   objective	   of	   this	   study	   was	   to	   determine	   whether	   manipulation	   of	   the	  
tumour	  microenvironment	  using	  ciclosporin	  A	   (CsA)	   to	   inhibit	  T	   cell	   activation,	   could	  
be	  applied	  as	  a	  therapeutic	  strategy	   in	  early	  stage,	  adverse	  risk	  CLL.	   It	  has	  previously	  
been	  shown	  that	  CLL	  cells	  become	  activated	  and	  undergo	  proliferation	   in	  the	   lymph-­‐
node	  compartment	  where	  interaction	  with	  activated	  CD4	  T	  cells	  is	  thought	  to	  promote	  
tumourigenesis	   (Herishanu	   et	   al.,	   2011;	   O.	   Jaksic,	   Kardum	   Skelin,	   &	   Jaksic,	   2010;	  
Pascutti	   et	   al.,	   2013;	   Patten,	   Buggins,	   Richards,	   Wotherspoon,	   Salisbury,	   Mufti,	  
Hamblin,	  &	  Devereux,	  2008b).	  Patten	  et	  al	  demonstrated	   that	  within	   the	  CLL	   lymph-­‐
node,	  recently	  proliferated	  CLL	  cells	  were	  closely	  associated	  with	  activated	  CD4	  T	  cells	  
and	   that	   co-­‐culture	   of	   CLL	   cells	   with	   CD4	   T	   cells	   induced	   the	   activation	   and	  
proliferation	   of	   CLL	   cells	   (Patten,	   Buggins,	   Richards,	   Wotherspoon,	   Salisbury,	   Mufti,	  
Hamblin,	  &	  Devereux,	  2008b).	  Furthermore,	  Bagnara	  et	  al	  demonstrated	  that	  activated	  
CD4	  T	  cells	  were	  necessary	  for	  the	  engraftment,	  survival,	  and	  proliferation	  of	  CLL	  cells	  
in	   the	   non-­‐obese	   diabetes/severe	   combined	   immunodeficiency/γcnull	   (NSG)	   mouse	  
model	  (Bagnara	  et	  al.,	  2011).	  These	  studies	  suggest	  that	  targeting	  CD4	  T	  cell	  activation	  
could	  indirectly	  suppress	  CLL	  cell	  activation	  and	  proliferation.	  
	  In	  preparation	  for	  the	  clinical	  trial	  investigating	  the	  effect	  of	  CsA	  on	  CLL	  proliferation	  
in-­‐vivo,	  the	  effect	  of	  CsA	  on	  healthy	  donor	  and	  CLL	  T	  cells	  was	  studied.	  As	  CsA	  is	  known	  
to	   inhibit	   NFAT	   and	   NFκB	   activation,	   and	   in	   view	   of	   the	   role	   of	   these	   transcription	  
factors	  in	  mediating	  B	  Cell	  Receptor	  (BCR)	  signalling	  in	  CLL,	  the	  direct	  effect	  of	  CsA	  on	  
CLL	  cells	  was	  also	  investigated.	  Finally,	  an	  in-­‐vitro	  co-­‐culture	  system	  was	  developed	  to	  
simulate	   the	   effect	   of	   CsA	   on	   CLL	   cell:	   CD4	   T	   cell	   interactions	   in	   the	   tumour-­‐
microenvironment.	  	  
Early	   in-­‐vitro	   studies	   into	   the	  mechanism	   of	   action	   of	   CsA	   suggested	   that	   it	   has	   a	   T	  
lymphocyte	   specific	   effect.	   Borel	   et	   al	   demonstrated	   that	   CsA	   suppressed	   the	  
proliferation	  of	  concanavalin	  (ConA)	  stimulated	  splenic	  T	  lymphocytes	  (ConA	  is	  a	  lectin	  
that	   cross	   links	   the	   T	   cell	   receptor)	   but	   that	   it	   did	   not	   inhibit	   proliferation	   of	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lipopolysaccharide	  (LPS)	  stimulated	  B	  lymphocytes	  in	  nude	  mice	  (Borel	  et	  al.,	  1977).	  In	  
agreement	  with	  this	  theory,	  White	  et	  al	  demonstrated	  that	  a	  dose	  of	  0.08-­‐1	  μg/mL	  CsA	  
was	  sufficient	  to	  inhibit	  phytohaemagluttinin	  stimulated	  T	  lymphocytes	  (PHA,	  another	  
lectin	   that	   activates	   T	   cells	   by	   cross-­‐linking	   the	  T	   cell	   receptor),	  whereas	  doses	  of	   at	  
least	  5	  μg/mL	  CsA	  were	  required	  to	  inhibit	  proliferation	  of	  B	  lymphocytes	  induced	  by	  
sheep	  anti-­‐porcine	  IgM	  (White	  et	  al.,	  1979).	  	  
Subsequent	  investigations	  into	  the	  mechanism	  of	  action	  of	  CsA	  revealed	  that	  in	  T	  cells	  
stimulated	  using	  ConA	  or	  anti-­‐CD3,	  interleukin	  2	  (IL2)	  production/	  responsiveness	  and	  
cellular	  proliferation	  were	  strongly	  inhibited	  in	  the	  presence	  of	  the	  drug	  (Bunjes	  et	  al.,	  
1981).	  However,	  T	  cells	  stimulated	  with	  anti-­‐CD28	  (co-­‐stimulation)	  in	  addition	  to	  anti-­‐
CD3	  were	  found	  to	  be	   less	  sensitive	  to	  the	  effect	  of	  CsA,	  whilst	  cells	  stimulated	  with	  
anti-­‐CD28	  alone	  were	  found	  to	  be	  resistant	  (June	  et	  al.,	  1987).	  As	  anti-­‐CD28	  activation	  
differs	   from	   anti-­‐CD3	   activation	   by	   stimulating	   cyclic	   guanosine	   monophosphate	  
(cGMP)	  signalling	  rather	  than	  calcium	  signalling,	  these	  observations	  suggested	  that	  CsA	  
targeted	  the	  calcium-­‐dependent	  pathway.	  
The	  effect	  of	  CsA	  on	  B	   lymphocytes	  was	  also	   found	  to	  depend	  on	   the	  mechanism	  of	  
stimulation.	  B	  cell	  proliferation	  induced	  by	  anti-­‐IgM,	  which	  activates	  calcium	  signalling,	  
has	  been	  shown	  to	  be	  sensitive	  to	  CsA	  whilst	  LPS,	  which	  stimulates	  cells	  via	  a	  calcium-­‐
independent	  mechanism,	  has	  been	  demonstrated	   to	  be	   resistant	   to	  CsA	   (Choi	  et	   al.,	  
1994;	   Fuleihan	   et	   al.,	   1994;	   Klaus,	   1988).	   The	   observation	   that	   B	   cell	   proliferation	  
induced	  by	  CD40L,	  either	  alone	  or	  expressed	  by	  activated	  T	  cells	  is	  relatively	  resistant	  
to	   the	  effect	   of	   CsA,	   suggests	   that	   there	   are	   further	  qualitative	  differences	  between	  
methods	   of	   activation	   that	   determine	   drug	   sensitivity	   (Kim	   et	   al.,	   2005;	   K.	   Schuh,	  
Avots,	  Tony,	  Serfling,	  &	  Kneitz,	  1996;	  Wortis	  et	  al.,	  1995).	  	  
In	  1991,	  Flanagan	  et	  al	  reported	  that	  CsA	  inhibits	  calcium-­‐dependent	  T	  cell	  activation	  
by	  forming	  a	  complex	  with	  a	  prolyl	  isomerase,	  preventing	  the	  nuclear	  translocation	  of	  
NFAT	   (Flanagan	  et	  al.,	  1991;	  Le	  Roy	  et	  al.,	  2012;	  K.	  Schuh	  et	  al.,	  1996).	   Later	   studies	  
confirmed	  that	  CsA	  binds	  with	  high	  affinity	  to	  the	  cyclophilins	  which	  possess	  peptidyl-­‐
proline-­‐cis-­‐trans	   isomerase	  activity	   (Schreiber,	  1991),	   forming	  a	  complex	  that	   inhibits	  
the	   calcium	   and	   calmodulin	   dependent	   activity	   of	   calcineurin	   (J.	   Liu	   et	   al.,	   1991).	  
Inhibition	   of	   calcineurin	   inhibits	   its	   phosphatase	   activity,	   which	   is	   required	   for	   the	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dephosphorylation	  of	  NFAT	  -­‐	  a	  process	  that,	  on	  TCR	  ligation,	  enables	  its	  translocation	  
from	   the	   cytoplasm	   to	   the	   nucleus.	   Within	   the	   nucleus,	   NFAT	   proteins	   initiate	   the	  
transcription	  of	  a	  number	  of	  genes	  including	  IL2,	  IL4,	  IL6,	  IL21	  and	  CD40L	  (Fuleihan	  et	  
al.,	  1994;	  Kim	  et	  al.,	  2005)	  .	  	  
In	   addition	   to	   its	   effects	   on	   NFAT	   in	   T	   cells,	   CsA	   has	   been	   demonstrated	   to	   inhibit	  
members	  of	  the	  NFκB	  transcription	  factor	  family	  including	  NFκB-­‐p65,	  -­‐p50	  and	  c-­‐rel	  in	  
T	   cells	   by	   inhibiting	   the	   degradation	   of	   IκB,	   a	   necessary	   step	   for	   NFκB	   nuclear	  
translocation	  (Marienfeld	  et	  al.,	  1997).	  CsA	  has	  also	  been	  found	  to	  inhibit	  the	  JNK	  and	  
p38	  mitogen-­‐activated	  protein	  kinase	  (MAPK)	  pathways	  that	  are	  further	  upstream	  and	  
essential	  for	  T	  cell	  activation	  (Hewamana	  et	  al.,	  2009;	  Su	  et	  al.,	  1994).	  	  
Although	  CsA	  has	  been	  found	  to	  inhibit	  NFAT	  translocation	  in	  B	  lymphocytes	  activated	  
by	  anti-­‐IgM,	  phorbol	  12-­‐myristate	  13-­‐acetate	  (PMA)	  and	  Ionomycin	  (Venkataraman	  et	  
al.,	  1994)	  and	  CD40L	  /IL4	  (Choi	  et	  al.,	  1994;	  Flanagan	  et	  al.,	  1991;	  K.	  Schuh	  et	  al.,	  1996),	  
there	   is	   no	   evidence	   in	   the	   literature	   that	   CsA	   inhibits	   NFκB	   translocation	   in	   B	  
lymphocytes	  activated	  by	  any	  of	  these	  mechanisms.	  
NFAT	  and	  NFκB	  have	  been	  shown	  to	  play	  a	  key	  role	  in	  CLL	  pathogenesis	  but	  the	  effect	  
of	  CsA	  on	  these	  transcription	  factors	  has	  not	  previously	  been	  investigated	  in	  CLL.	  In	  all	  
cases	  studied,	  levels	  of	  NFAT-­‐C1	  and	  NFAT-­‐C2	  are	  increased	  in	  CLL	  cells	  compared	  with	  
healthy	  B	  lymphocytes	  (Le	  Roy	  et	  al.,	  2012;	  K.	  Schuh	  et	  al.,	  1996).	  NFAT-­‐C2	  levels	  have	  
been	   found	   to	   be	   comparable	   with	   those	   of	   T	   lymphocytes	   and	   furthermore,	   have	  
been	  found	  to	  be	  highest	   in	  those	  patients	  that	  do	  not	  respond	  to	  signalling	  through	  
the	  BCR	  (Le	  Roy	  et	  al.,	  2012).	  	  	  
NFAT-­‐C1	  levels	  are	  under	  the	  transcriptional	  control	  of	  NFAT-­‐C2	  (Zhou	  et	  al.,	  2002)	  and	  
as	  NFAT-­‐C1	  has	  been	   shown	   to	  play	  a	   key	   role	   in	  B	   lymphocyte	   survival,	   has	  been	  a	  
greater	   focus	   of	   studies	   of	   BCR	   signalling	   in	   CLL.	   Apollonio	   et	   al	   have	   reported	   that	  
constitutive	  NFAT-­‐C1	  nuclear	   localisation	   is	  a	  key	  characteristic	  of	  CLL	  cells	   that	  have	  
an	   ‘anergic’	   phenotype	   i.e.	   express	   low	   levels	   of	   sIgM,	   do	   not	   mobilise	   calcium	   in	  
response	   to	   sIgM	   ligation	   and	  exhibit	   constitutive	   ERK	  phosphorylation.	   Inhibition	  of	  
NFAT-­‐C1	  nuclear	   translocation	  using	   the	  cell-­‐permeable	  VIVIT	  peptide	   that	  competes	  
with	   calcineurin	   for	   NFAT	   binding	   restores	   BCR	   signalling	   capacity	   and	   in	   doing	   so,	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impairs	  CLL	  cell	  survival	  (Apollonio	  et	  al.,	  2013).	  Although	  Le	  Roy	  et	  al	  found	  that	  NFAT-­‐
C1	  was	  constitutively	  activated	  in	  CLL	  regardless	  of	  BCR	  signalling	  capacity;	  they	  found	  
that	  nuclear	  localisation	  could	  be	  induced	  upon	  BCR	  ligation	  in	  those	  cases	  considered	  
to	   be	   ‘responders’.	   They	   found	   that	   NFAT-­‐C1	   translocation	   in	   ‘responders’	   could	   be	  
blocked	  by	  the	  VIVIT	  peptide	  and	  that	   this	   inhibited	  metabolic	  activity	   (Le	  Roy	  et	  al.,	  
2012).	   In	   the	   MEC1-­‐transplanted	   mouse	   model	   of	   CLL	   (characterised	   by	   an	   anergic	  
phenotype),	   injection	   of	   the	   VIVIT	   peptide	   reduced	   tumour	   volume	   and	   increased	  
survival	  providing	  further	  evidence	  for	  the	  role	  of	  NFAT	  in	  CLL	  pathogenesis	  (Apollonio	  
et	  al.,	  2013).	  The	  cause	  of	  NFAT	  up-­‐regulation	  in	  CLL	  remains	  unknown,	  however	  it	   is	  
possible	  that	  it	  is	  driven	  by	  antigen	  ligation	  of	  the	  BCR	  in-­‐vivo.	  	  
The	  NFκB	  family	  of	  transcription	  factors	  has	  also	  been	  demonstrated	  to	  play	  a	  major	  
role	  in	  CLL	  pathogenesis.	  The	  NFκB	  family	  is	  comprised	  of	  p50,	  p52,	  p65	  (Rel-­‐A),	  c-­‐Rel,	  
and	  Rel-­‐B	  components,	  which,	  in	  the	  inactive	  state,	  exist	  as	  cytoplasmic	  homodimeric	  
or	   heterodimeric	   complexes,	   bound	   to	   IκB	   proteins.	   Upon	   stimulation,	   IκB	   is	  
phosphorylated	   by	   IκB	   Kinase	   (IKK)	   and	   subsequently	   ubiquitinated	   and	   degraded,	  
allowing	  translocation	  of	  NFκB	  to	  the	  nucleus	  and	  transcription	  of	  NFκB	  target	  genes	  
(Huxford,	   Huang,	  Malek,	   &	   Ghosh,	   1998).	   Pro-­‐survival,	   anti-­‐apoptotic	   gene	   products	  
related	   to	   NFκB	   activation	   include	   BCL-­‐2,	   Bcl-­‐XL,	   and	   Survivin	   and	   FLICE	   inhibitory	  
protein	  (FLIP)	  (Cuní	  et	  al.,	  2004;	  Granziero	  et	  al.,	  2001).	  	  
	  In	  CLL,	  it	  has	  been	  found	  that	  there	  is	  constitutive	  activation	  of	  NFκB	  and	  furthermore,	  
that	   increased	   basal	   NFκB-­‐p65	   -­‐	   DNA	   binding	   is	   predictive	   of	   advanced	   stage,	   high	  
tumour	  burden	  and	  short	  time	  to	  first	  treatment	  (Furman	  et	  al.,	  2000;	  Hewamana	  et	  
al.,	   2009).	   Nuclear	   translocation	   of	   NFκB-­‐p65	   in	   CLL	   cells	   can	   be	   induced	   by	   CD40	  
ligation,	   by	   sIgM	   ligation	   and	   as	   a	   consequence	   of	   BAFF	   and	   APRIL	   signalling	   in	   the	  
tumour	  microenvironment	   (Endo	  et	  al.,	  2007;	  Furman	  et	  al.,	  2000;	  Hewamana	  et	  al.,	  
2008).	   NFκB-­‐p65	   translocation	   is	   disrupted	   by	   LC-­‐1,	   a	   parthenolide	   derivative	   that	  
inhibits	   IKK	   and	   this	   leads	   to	   reduced	   viability	   of	   CLL	   cells	   (Hewamana	   et	   al.,	   2008).	  
Although	  the	  effect	  of	  CsA	  on	  NFκB-­‐p65	  activation	  has	  not	  been	  studied	   in	  CLL	  cells,	  
the	  observation	   that	  CsA	  disrupts	  NFκB-­‐p65	  activation	   in	  T	  cells	   suggests	   that	   it	  may	  
have	  a	  direct	  effect	  on	  CLL	  cell	  survival	  (Marienfeld	  et	  al.,	  1997;	  Meyer	  et	  al.,	  1997).	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  In-­‐vitro	   studies	   into	   the	   effect	   of	   CsA	   in	   CLL	   are	   limited	   in	   number.	   Schmid	   et	   al	  
demonstrated	   that	   IL2	   and	  TNFα	  driven	  proliferation	  of	   highly	  purified	  CLL	   cells	  was	  
sensitive	   to	   CsA	   in	   a	   dose-­‐dependent	   manner	   (Schmid	   et	   al.,	   1994).	   However,	   the	  
effect	   of	   CsA	   on	   transcription	   factor	   activation	   in	   CLL	   cells	   warrants	   further	  
investigation.	  
The	   observation	   that	   in	   20	   %	   of	   patients	   treated	   with	   CsA	   for	   autoimmune-­‐
complications	  of	  CLL,	  there	  is	  an	  anti-­‐leukaemia	  effect,	  reflects	  that	  CsA	  is	  active	  in	  a	  
proportion	  of	  patients	  with	  this	  disease	  (Cortes	  et	  al.,	  2001).	  However,	   the	  nature	  of	  
the	  in-­‐vivo	  effect	  may	  be	  a	  direct	  effect	  on	  CLL	  cells,	  an	  indirect	  T	  cell	  dependent	  effect	  
or	  a	  combination	  of	  the	  two.	  
To	  address	   this,	  a	   series	  of	   in-­‐vitro	  assays	  was	  developed	  to	   investigate	   the	  effect	  of	  
CsA	   on	   CLL	   cells,	   CD4	   T	   cells	   and	   the	   interaction	   between	   the	   CLL	   and	   activated	  
autologous	  CD4	  T	  cells.	  
We	  started	  by	  investigating	  the	  effect	  of	  CsA	  on	  CLL	  derived	  T	  cells;	  although	  the	  effect	  
of	  CsA	  on	  healthy	  donor	  T	  cells	   is	  well	  documented,	  the	  effect	  on	  CLL	  T	  cells	  has	  not	  
been	  reported.	  Secondly,	   the	  effect	  of	  CsA	  on	  the	  ability	  of	  CLL	  cells	   to	  respond	  to	  T	  
cell	   activation	   was	   investigated.	   Activation	   was	   designed	   to	   reproduce	   lymph-­‐node	  
based	  events	  and	  therefore	  included	  CD40L	  activation	  to	  simulate	  CD4-­‐	  T	  cell	  mediated	  
activation	  of	  CLL	  cells.	  	  
We	   then	   simultaneously	   investigated	   both	   the	   direct	   and	   indirect,	   T	   cell	   dependent	  
effects	  of	  CsA	  on	  CLL	   cells	   by	   co-­‐culturing	  CLL	   cells	  with	   activated	  autologous	  CD4	  T	  
cells.	  	  
As	  BCR	  mediated	  signalling	  in	  CLL	  has	  been	  shown	  to	  be	  sensitive	  to	  the	  VIVIT	  peptide	  
that	  inhibits	  NFAT	  activation	  (Apollonio	  et	  al.,	  2013;	  Le	  Roy	  et	  al.,	  2012),	  the	  effect	  of	  
CsA	   on	  BCR	   signalling	  was	   investigated.	   Finally,	   in	   view	  of	   the	   fact	   that	   inhibition	   of	  
NFAT	  signalling	  has	  been	  shown	  to	  reverse	  anergy	  and	  to	  induce	  apoptosis	  (Apollonio	  
et	  al.,	  2013),	  the	  effect	  of	  CsA	  on	  the	  viability	  of	  CLL	  cells	  was	  investigated.	  
To	   more	   precisely	   define	   the	   effect	   of	   CsA	   in	   CLL,	   the	   effect	   of	   the	   drug	   on	   the	  
transcription	  factors	  NFAT-­‐C2	  and	  NFκB-­‐p65	  in	  CD4	  T	  cells	  and	  CLL	  cells	  was	  assessed.	  
	   81	  
Although	  NFAT-­‐C1	  activation	  is	  classically	  associated	  with	  B	  cell	  malignancies,	  NFAT-­‐C2	  
was	  measured	  in	  CLL	  cells	  as	  there	  was	  no	  suitable	  NFAT-­‐C1	  antibody	  available	  for	  flow	  
cytometry.	  
We	   planned	   to	   apply	   the	   in	   vitro	   assays	   developed	   in	   this	   investigation	   to	   further	  
explore	  the	  in-­‐vivo	  effect	  of	  CsA	  in	  the	  CyCLLe	  study.	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3.2	  Methods	  
Comprehensive	  general	  methods	  are	  detailed	  in	  Chapter	  2.	  
T	   cells	   were	   stimulated	   with	   anti-­‐CD3	   and	   anti-­‐CD28	   to	   achieve	   physiological	  
activation.	  A	  strong	  proliferative	  signal	  is	  afforded	  by	  anti-­‐CD3	  stimulation	  whilst	  anti-­‐
CD28	  provides	  ‘signal	  2’	  to	  reduce	  the	  number	  of	  cells	  becoming	  anergic	  or	  undergoing	  
apoptosis.	   Activation	   was	   achieved	   using	   anti-­‐CD3	   coated	   plates	   and	   unbound	   anti-­‐
CD28	   rather	   than	   using	   bead-­‐bound	   antibodies	   to	   avoid	   potential	   difficulties	  
interpreting	  flow-­‐cytometry	  data	  in	  the	  presence	  of	  beads.	  
T	   cell	   activation	   was	   measured	   using	   a	   combination	   of	   CD69,	   a	   surface	   marker	   of	  
activation	  and	   IFNγ,	  a	  Th1	   intracellular	  cytokine	   released	  upon	  T	  cell	  activation.	   IFNγ	  
was	  measured	  as	  it	  has	  been	  reported	  to	  be	  produced	  by	  CLL-­‐specific	  Th1	  cells	  which	  
have	  been	  shown	  to	  activate	  CLL	  cells	  via	  the	  induction	  of	  CD38	  in	  a	  T-­‐bet	  dependent	  
fashion	  (Bürgler	  et	  al.,	  2015;	  Gitelson	  et	  al.,	  2003;	  Os	  et	  al.,	  2013).	  
The	   direct	   effect	   of	   CsA	  was	  measured	   on	   CLL	   cells	   activated	   through	   CD40	   (CD40L	  
transfected	   fibroblasts),	   activated	   autologous	   CD4	   T	   cells	   and	   via	   BCR	   ligation.	  
Activation	   was	   measured	   by	   flow-­‐cytometric	   assessment	   of	   CD25	   and	   CD69	  
expression.	  CD25	  is	  the	  alpha	  unit	  of	  the	  IL2	  receptor,	  and	  CD69	  is	  a	  membrane	  protein	  
expressed	  with	  four	  hours	  of	  lymphocyte	  activation	  (Simms	  &	  Ellis,	  1996).	  
The	  effect	  of	  CsA	  on	  the	   interaction	  between	  activated	  CD4	  T	  cells	  and	  CLL	  cells	  was	  
assessed	  by	  co-­‐culturing	   these	  cells	  at	  a	   ratio	  of	  1:4,	   similar	   to	   that	   found	   in	   the	  CLL	  
lymph-­‐node	  compartment.	  
The	  effect	   of	   CsA	  on	   cell	   viability	  was	  measured	   flow-­‐cytometrically	   using	   annexin-­‐V	  
and	   7-­‐AAD	   staining.	   Annexin-­‐V	   binds	   to	   phosphatidylserine	   that	   translocates	   to	   the	  
extra-­‐cellular	   membrane	   at	   early	   stages	   of	   apoptosis	   and	   7-­‐AAD	   passages	   through	  
disrupted	  cell	  membranes	  of	  cell	  at	  later	  stages	  of	  apoptosis	  to	  bind	  with	  high	  affinity	  
to	  DNA.	  
The	   effect	   of	   CsA	   on	   NFAT	   and	   NFκB	   activation	   in	   CLL	   cells	   and	   CD4	   T	   cells	   was	  
measured	   using	   image	   flow-­‐cytometry	   (Amnis	   ImageStream	   X®),	   which	   combines	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microscopy	  with	  flow-­‐cytometry	  (Chapter	  2.5).	  There	  are	  many	  established	  methods	  of	  
assessing	   the	   subcellular	   localization	   of	   NFAT	   and	   NFκB	   including	  Western	   blotting,	  
Electrophoretic	  Mobility	   Shift	   Assays	   (EMSA),	   Enzyme	   Linked	   Immunosorbent	   Assays	  
(ELISA)	   and	   immunohistochemistry.	   However,	   image	   flow-­‐cytometry	   allows	   rapid	  
quantitative	   assessment	   of	   subcellular	   localisation	   of	   transcription	   factors	   in	   large	  
numbers	   of	   cells.	   Furthermore,	   surface	   staining	   allows	   distinction	   of	   transcription	  
factor	   localisation	   in	   different	   cell	   populations	   within	   a	   sample.	   The	   IDEAS®	   image	  
analysis	   software	   applies	   features	   (algorithms)	   and	   masking	   operations	   (region-­‐	  
finders),	   to	   perform	   image-­‐based	   analysis.	   To	   assess	   events	   of	   translocation,	   a	  
similarity	  score	  algorithm	  is	  used.	  This	  is	  calculated	  by	  log	  transforming	  the	  Pearson’s	  
correlation	   coefficient	   for	   pixel	   values	   of	   the	   DAPI	   (nuclear)	   and	   FITC	   (NFκB/	   NFAT)	  
signals.	  Examples	  of	  non-­‐translocated	  and	   translocated	  NFκB	  are	   illustrated	   in	  Figure	  
3.1.	  	  
Assessment	  of	  nuclear	   translocation	  was	   initially	  challenging;	  difficulties	   involved	   the	  
preparation	  of	  concentrated	  activated	  cells	  in	  a	  single-­‐cell	  suspension,	  optimisation	  of	  
the	   fixation	  and	  permeabilisation	  protocol,	  maintenance	  of	   a	   central	   fluidics	   stream,	  
camera-­‐focus,	   laser	   function	  and	  software	   issues.	  The	  design	  of	   the	  activation	  assays	  
required	  a	  significant	  amout	  of	  preparation	  including	  testing	  different	  fluorochromes,	  
and	   analysing	   the	   time-­‐course	   of	   transcription	   factor	   translocation	   in	   response	   to	  
various	  stimuli.	  	  
	  
	   	  







Figure	  3.1	  a	  Examples	  of	  non-­‐translocated	  and	  translocated	  NFκB-­‐p65	   in	  CLL	  CD4+	  T	  
cells	  
Each	  cell	   is	  imaged	  (x40)	  shown	  in	  “Brightfield’.	  DAPI	  is	  used	  to	  stain	  the	  nucleus	  and	  
NFκB-­‐p65	   is	   stained	  with	   FITC.	   Nuclear	   translocation	   is	   calculated	   by	  measuring	   the	  
similarity	   between	   the	   nuclear	   and	   transcription	   factor	   stains.	   Upper	   row	   illustrates	  
non-­‐translocated	  NFκB-­‐p65	  and	  lower	  row	  illustrates	  translocated	  NFκB-­‐p65.	  	  
b	   Exemplary	   histogram	   demonstrating	   degree	   of	   similarity	   between	   nucleus	   and	  
NFκB-­‐p65	  	  
The	  similarity	  between	  NFκB-­‐p65	  and	  nuclear	  stain	  is	  illustrated	  pre-­‐activation,	  in	  blue,	  
and	  post	  activation,	  in	  red.	  
NFkB/DAPI , NFkB/DAPI , NFkB/DAPI  
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3.3	  Results	  
3.3.1	  Ciclosporin	  A	  inhibits	  healthy	  donor	  and	  CLL	  CD4	  T	  cell	  activation	  stimulated	  by	  
anti-­‐CD3/anti-­‐CD28	  in	  a	  dose-­‐dependent	  manner	  
The	  optimum	  CsA	  concentration	  for	   in-­‐vitro	   studies	  was	  determined	  by	  performing	  a	  
series	  of	  dose-­‐response	  assays,	  where	  the	  inhibition	  of	  expression	  of	  T	  cell	  activation	  
markers	   was	   determined	   over	   a	   range	   of	   CsA	   concentrations.	   As	   plasma	  
concentrations	  of	  greater	  than	  200	  ng/mL	  are	  associated	  with	  in-­‐vivo	  toxicity,	  this	  was	  
the	  maximum	  concentration	  investigated	  in-­‐vitro.	  PBMCs	  from	  healthy	  donors	  and	  CLL	  
patients	  were	  activated	   in	  the	  presence	  of	   increasing	  concentrations	  of	  CsA,	   from	  10	  
ng/mL	  to	  200	  ng/mL.	  Activation	  status	  at	  24	  hours	  was	  determined	  by	  CD69	  and	  IFNγ	  
co-­‐expression	   by	   flow-­‐cytometry.	   Figure	   3.2	   illustrates	   the	   gating	   strategy	   applied.	  
Figure	  3.3	  demonstrates	  that	  CsA	  inhibits	  healthy	  donor	  and	  CLL	  CD4	  T	  cell	  activation	  
in	  a	  dose-­‐dependent	  manner	  with	  maximum	  inhibition	  occurring	  at	  100-­‐200	  ng/mL.	  
	  
Figure	  3.2	  Gating	  strategy	  applied	  to	  assess	  activation	  of	  T	  cells	  
Flow	  cytometry	  data	  was	  acquired	  using	   the	  BD	  Canto	  2.	  Compensation	  was	  applied	  
and	  data	  analysed	  using	   FlowJo	  v10.6.	  Gates	  were	   set	  using	   fluorescence-­‐minus	  one	  
controls.	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Figure	  3.3	   	   (a&b)	  CsA	   inhibits	  activation	  of	  healthy	  donor	  and	  CLL	  T	  cells	   in	  a	  dose-­‐
dependent	  manner	  
PBMCs	  were	   activated	  using	   anti-­‐CD3	   coated	  plates	   and	  unbound	  anti-­‐CD28.	   PBMCs	  
from	   healthy	   donors	   and	   CLL	   patients	   were	   activated	   in	   the	   presence	   of	   increasing	  
concentrations	  of	  CsA.	  CD69	  and	  IFNγ	  co-­‐expression	  was	  measured	  at	  24	  hours	  using	  
flow	  cytometry.	  Viable	  CD3+/CD4+	   cells	  were	  gated	  on.	  Results	   are	  plotted	  as	  mean	  
with	  standard	  deviation.	  
	  
3.3.2	   Ciclosporin	   inhibits	   healthy	   donor	   and	   CLL	   CD4	   and	   CD8	   T	   cell	   activation	  
stimulated	  by	  anti-­‐CD3/anti-­‐CD28	  
To	  investigate	  whether	  CsA	  could	  significantly	  overcome	  T	  cell	  stimulation	  induced	  by	  
anti-­‐CD3/anti-­‐CD28,	   PBMCS	   from	  healthy	   donors	   and	   CLL	   patients	  were	   activated	   in	  
the	  presence	  of	  CsA	  or	  a	  vehicle	  control	  (VC).	  A	  concentration	  of	  200	  ng/mL	  CsA	  was	  
used	  as	  this	  was	  demonstrated	  to	  have	  the	  greatest	  suppressive	  effect	   in	  the	   limited	  
dose-­‐response	   assays.	   Activation	   status	   at	   24	   hours	   was	   determined	   by	   flow	  
cytometric	  assessment	  of	  CD69	  and	  IFNγ	  co-­‐expression.	  Figure	  3.4	  demonstrates	  that	  
in	  healthy	  donor	  activated	  CD4	  and	  CD8	  T	  cells,	  200	  ng/ml	  CsA	  inhibits	  co-­‐expression	  of	  
CD69	  and	   IFNγ	   from	  a	  mean	  of	  23.7	  %	   to	  a	  mean	  of	  8.7	  %	   (Wilcoxon	  matched-­‐pairs	  
signed	   rank	   test	   p=0.06)	   and	   from	   a	  mean	   of	   19.3	  %	   to	   a	  mean	   of	   6.3	  %	   (Wilcoxon	  
matched-­‐pairs	  signed	  rank	  test,	  p=0.06)	  respectively.	  Co-­‐expression	  of	  CD69	  and	  IFNγ	  
by	   activated	  CLL	  CD4	  T	   cells	  was	   reduced	   from	  a	  mean	  of	   19.8%	   to	   a	  mean	  of	   6.7%	  
(paired	  t-­‐test,	  p=0.003)	  and	  by	  activated	  CLL	  CD8	  T	  cells	  from	  a	  mean	  of	  20%	  to	  a	  mean	  
of	  6.6%	  (paired	  t-­‐test,	  p=0.03)	  in	  the	  presence	  of	  200	  ng/ml	  CsA.	  	  
Percent healthy donor CD4 T Cells Co-expressing CD69 and IFNγ
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Having	   found	   that	  CsA	   significantly	   reduces	  activation	  of	  healthy	  donor	  and	  CLL	  CD4	  
and	  CD8	  T	  cell	  activation,	  it	  was	  then	  necessary	  to	  investigate	  whether	  CsA	  disrupts	  the	  
mechanism	  whereby	  CD4	  T	   cells	  activate	  CLL	   cells.	  As	   the	  evidence	   for	  T	   cells	   in	  CLL	  
pathogenesis	  is	  limited	  to	  CD4	  T	  cells,	  further	  experiments	  focused	  entirely	  on	  CLL	  CD4	  
T	  cells.	  	  
	  
a.	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  b.	  
	   	   	  
c.	   	   	   	   	   	   	   d.	  
	   	  	  
	  	  
Figure	  3.4	  (a-­‐d)	  Ciclosporin	  inhibits	  activation	  of	  normal	  and	  CLL	  CD4	  and	  CD8	  T	  Cells	  	  
PBMCs	  from	  normal	  donors	  (NC)	  and	  CLL	  patients	  (CLL)	  were	  activated	  using	  anti-­‐CD3	  
coated	  plates	  and	  unbound	  anti-­‐CD28	   in	  the	  presence	  of	  CsA	  or	  vehicle	  control	   (VC).	  
CD69/	   IFNγ	   co-­‐expression	   was	   measured	   at	   24	   hours	   using	   flow	   cytometry.	   Viable	  
CD3+/CD4+	   and	   viable	   CD3+/CD8+	   cells	   were	   gated	   on	   (gates	   were	   set	   using	  
fluorescence	  minus	  one	  controls).	  ‘Percent	  parent’	  denotes	  the	  percent	  of	  T	  cells	  that	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3.3.4	  Ciclosporin	  inhibits	  CD40L	  expression	  in	  activated	  CLL	  CD4	  T	  cells	  
Within	   the	   tumour	   microenvironment,	   CD40L	   expression	   and	   IL21	   secretion	   are	  
considered	  to	  form	  major	  components	  in	  the	  process	  of	  activation	  of	  CLL	  cells	  by	  CD4	  T	  
cells.	  IL21	  is	  a	  type	  1	  cytokine;	  it	  is	  strongly	  induced	  upon	  TCR	  ligation	  and	  stimulates	  
STAT	  1	  and	  STAT	  3	  signalling.	  The	  IL21	  5’	  regulatory	  region	  contains	  three	  NFAT	  binding	  
sites	  and	   induction	  of	   IL-­‐21	  promoter	  activity	  has	  been	   found	   to	  be	   impaired	  by	  CsA	  
treatment	  (Kim	  et	  al.,	  2005).	  CD40L	  expression	  by	  activated	  T	  cells	  has	  previously	  been	  
found	  to	  be	  NFAT	  dependent	  and	  sensitive	   to	  CsA	   (Fuleihan	  et	  al.,	  1994;	  Tsytsykova,	  
Tsitsikov,	  &	  Geha,	  1996).	  
CD40L	  and	  IL21	  expression	  was	  measured	  after	  12	  and	  24	  hours	  respectively	  in	  viable	  
CLL	   CD4	   T	   cells	   activated	   with	   anti-­‐CD3	   and	   anti-­‐CD28	   in	   the	   presence	   of	   CsA	   200	  
ng/ml	  (CsA)	  or	  vehicle	  control	  (VC).	  	  
Figure	  3.5.a	  demonstrates	   that	   there	  was	  a	  22	  %	   reduction	   (paired	   t-­‐test,	  p=0.03)	   in	  
CD40L	  Median	  Fluorescence	   Intensity	  (MFI)	   in	  CLL	  CD4	  T	  cells	   in	  the	  presence	  of	  200	  
ng/ml	   CsA.	   Figure	   3.5.b	   demonstrates	   that	   CsA	   did	   not	   inhibit	   expression	   of	   IL21	   by	  
activated	  CLL	  CD4	  T	  cells	  at	  24	  hours.	  
The	   strong	   inhibition	   of	   CD40L	   expression	   by	   CD4	   T	   cells	   suggests	   that	   this	   would	  
disarm	   their	   potential	   to	   activate	   CLL	   cells	   in	   the	   lymph-­‐node	   compartment.	   The	  
absence	   of	   inhibition	   of	   IL21	   secretion	   may	   be	   due	   to	   the	   high	   level	   of	   IL21	  
fluorescence	   in	   the	  unstimulated	   state	   (Figure	  3.5c).	  A	  blocking	   antibody	   could	  have	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Figure	  3.5	  (a-­‐b)	  CsA	  inhibits	  CLL	  CD4	  T	  cell	  expression	  of	  CD40L	  but	  does	  not	  inhibit	  
IL21	  secretion	  	  
a.	  CLL	  CD4	  T	  cells	  were	  activated	  using	  anti-­‐CD3	  coated	  plates	  and	  unbound	  anti-­‐CD28	  
in	   the	   presence	   of	   CsA	   200	   ng/ml	   or	   vehicle	   control	   (VC).	   CD40L	   expression	   was	  
measured	  at	  12	  hours	  using	  flow	  cytometry.	  b.	  IL21	  expression	  was	  measured	  after	  24	  
hours	  using	  intracellular	  flow-­‐cytometry.	  Brefeldin	  was	  added	  12	  hours	  before	  the	  end	  
of	   incubation.	   Viable	   CD3+/CD4+	   cells	   were	   gated	   on	   (gates	   were	   set	   using	  
fluorescence	  minus	  one	  controls).	  	  
	  
Figure	  3.5	  c.	  Gating	  strategy	  illustrating	  expression	  of	  IL21	  by	  resting,	  stimulated	  and	  
CsA-­‐treated	  CLL	  CD4	  T	  cells	  
CLL	  CD4	  T	  cells	  were	  activated	  using	  anti-­‐CD3	  coated	  plates	  and	  unbound	  anti-­‐CD28	  in	  
the	  presence	  of	  CsA	  200	  ng/ml	  or	  vehicle	  control	  (VC).	  IL21	  expression	  was	  measured	  
after	  24	  hours	  using	  intracellular	  flow-­‐cytometry.	  Brefeldin	  was	  added	  12	  hours	  before	  
the	   end	   of	   incubation.	   Viable	   CD3+/CD4+	   cells	  were	   gated	   on	   (gates	  were	   set	   using	  
fluorescence	  minus	  one	  controls).	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3.3.5	  Ciclosporin	  does	  not	   inhibit	  healthy	  donor	  or	  CLL	  B	  cell	  activation	   induced	  by	  
CD40L	  
Having	  demonstrated	  that	  CsA	  has	  a	  suppressive	  effect	  on	  CLL	  T	  cells,	  the	  direct	  effect	  
of	  CsA	  on	  healthy	  donor	  and	  CLL	  B	  cells	  was	  investigated.	  CD40L	  was	  used	  to	  activate	  
CLL	   cells	   as	   this	   molecule	   is	   transiently	   expressed	   by	   activated	   T	   cells	   in	   CLL	  
proliferation	  centres	  and	  is	  thought	  to	  play	  a	  role	  in	  CLL	  survival	  and	  proliferation	  via	  
CD40	  engagement	  and	  NFκB	  activation	  (Furman	  et	  al.,	  2000;	  Ghia	  et	  al.,	  2002).	  CD40	  is	  
a	   member	   of	   the	   tumour	   necrosis	   factor	   receptor	   family	   expressed	   by	   B	   cells.	   Co-­‐
culture	  of	  CLL	  B	  cells	  with	  CD40L	  transfected	  fibroblasts	  has	  been	  shown	  to	  stimulate	  
proliferation	  (Hamilton	  et	  al.,	  2012).	  
To	   investigate	   whether	   CsA	   can	   overcome	   CD40L	   induced	   activation	   of	   CLL	   cells,	  
negatively	   selected	   healthy	   donor	   and	   CLL	   B	   cells	   were	   co-­‐cultured	   with	   CD40L	  
transfected	   fibroblasts	   in	   the	  presence	  of	  CsA	  200	  ng/ml	   (CsA)	  or	  VC.	  Activation	  was	  
assessed	   after	   24	   hours	   by	   measuring	   CD25	   and	   CD69	   expression.	   Figure	   3.6	  
demonstrates	   that	   CsA	   does	   not	   inhibit	   the	   expression	   of	   CD25	   or	   CD69	   by	   healthy	  
donor	   B	   cells	   (n=4)	   or	   CLL	   cells	   (n=8)	   activated	   with	   CD40L.	   In	   contrast	   to	   CD69	  
expression	  downstream	  of	  BCR	  signalling,	  CD69	   induced	  by	  CD40L	  was	   insensitive	   to	  
CsA	  suggesting	   that	   there	  are	  significant	  differences	   in	   transcription	   factor	  activation	  
according	   to	   the	   mechanism	   of	   CLL	   cell	   stimulation.	   In	   addition	   to	   a	   qualitative	  
difference	   in	  the	  mechanism	  of	  stimulation,	   it	   is	  also	  possible	  that	  CD40L	  stimulation	  
using	   CD40L	   transfected	   fibroblasts	   provides	   a	   greater	   intensity	   of	   stimulation	   that	  
cannot	  be	  overcome	  by	  CsA.	  
Additionally	   CsA	   does	   not	   inhibit	   the	   expression	   of	   CD25	   or	   CD69	   by	   CLL	   cells	   co-­‐
cultured	  with	  untransfected	  fibroblasts	  (n=8)	  demonstrating	  that	  CsA	  does	  not	  directly	  
inhibit	  expression	  of	  these	  activation	  markers	  in	  the	  resting	  state.	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Figure	   3.6	   (a-­‐f)	   Activation	   status	   of	   healthy	   donor	   (NC)	   and	  CLL	   B	   cells	   co-­‐cultured	  
with	   CD40L	   transfected	   and	   untransfected	   fibroblasts	   in	   the	   presence	   of	   CsA	   or	  
vehicle	  control	  	  
Negatively	  selected	  B	  cells/CLL	  cells	  were	  co-­‐cultured	  with	  fibroblasts	  in	  the	  presence	  
of	  CsA.	  Expression	  of	  CD25	  and	  CD69	  was	  measured	  after	  24	  hours	  by	  flow	  cytometry.	  
Viable	  cells	  expressing	  CD19	  and	  co-­‐expressing	  CD5/	  CD19	  were	  gated	  on	   to	   identify	  
healthy	  donor	  and	  CLL	  cells	  respectively	  (gates	  were	  set	  using	  fluorescence	  minus	  one	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3.3.6	  Ciclosporin	  has	  a	  major	  CD4	  T	  cell	  dependent	  effect	  and	  a	  minor	  direct	  effect	  on	  
CLL	  cells	  co-­‐cultured	  with	  autologous	  CD4	  T	  cells	  
In	   view	   of	   the	   observation	   that	   activated	   autologous	   CD4	   T	   cells	   stimulate	   the	  
activation	  and	  proliferation	  of	  the	  tumour-­‐cells	  in-­‐vivo	  (Bagnara	  et	  al.,	  2011;	  Patten	  et	  
al.,	  2005),	  and	   in	   light	  of	   the	  effect	  of	  CsA	  on	  CLL	  T	   cells,	  we	  went	  on	   to	   investigate	  
whether	   CsA	   can	   inhibit	   CD4	   T	   cell	   dependent	   activation	   of	   CLL	   cells.	   A	   system	  was	  
developed	  whereby	  CLL	   cells	  were	   co-­‐cultured	  with	   autologous	  CD4	  T	   cells	   that	   had	  
been	  activated	  using	  anti-­‐CD3/anti-­‐CD28	  in	  the	  presence	  of	  CsA	  or	  a	  VC	  for	  12	  hours.	  
To	  assess	  for	  any	  direct	  effect	  of	  CsA,	  CLL	  cells	  were	  negatively	  selected	  using	  immune-­‐
magnetic	   beads,	   conditioned	   with	   200	   ng/mL	   CsA	   /	   VC	   for	   one	   hour	   and	   washed,	  
before	  being	  combined	  with	  the	  CD4	  T	  cells	  for	  co-­‐culture,	  as	  illustrated	  in	  Figure	  3.7.	  
Activation	   of	   CLL	   B	   and	   T	   cells	   was	   assessed	   daily	   for	   3	   days	   by	   flow	   cytometric	  
assessment	  of	   CD25	   and	  CD69	  expression	  by	   viable	  CLL	  B	   cells	   and	  CD25,	   CD69	   and	  
CD40L	  expression	  by	  viable	  CD4	  T	  cells.	  	  
Figure	  3.8	  is	  a	  representative	  plot	  demonstrating	  the	  time-­‐course	  of	  activation	  of	  CD4	  
T	  cells	  and	  CLL	  cells	  from	  a	  single	  patient	  following	  co-­‐culture.	  This	  was	  repeated	  using	  
cells	  from	  six	  different	  patients	  (summarised	  in	  Figure	  3.10).	  The	  results	  demonstrate	  
that	   after	   activation	   with	   anti-­‐CD3/CD28	   in	   the	   presence	   of	   CsA,	   there	   is	   marked	  
inhibition	  of	  T	  cell	  expression	  of	  CD25,	  CD69	  and	  CD40L	  that	  is	  evident	  throughout	  the	  
co-­‐culture	  period.	  After	  48	  hours,	  in	  the	  presence	  of	  CsA,	  CD40L	  MFI	  was	  reduced	  by	  a	  
mean	   of	   23.5	   %	   (Wilcoxon	   test,	   p=0.03).	   At	   72	   hours,	   there	   was	   a	   trend	   towards	  
inhibition	  of	  CD25	  expression	   (MFI	  was	   inhibited	  by	  a	  mean	  of	   64	  %	   (Wilcoxon	   test,	  
p=0.56)),	  CD69	  was	  reduced	  by	  a	  mean	  of	  39	  %	  (Wilcoxon	  test,	  p=0.03)	  and	  CD40L	  by	  a	  
mean	  of	  40	  %	  (Wilcoxon	  test,	  p=0.06)	  (Figure	  3.9	  a-­‐c).	  The	  lack	  of	  statistical	  significance	  
of	   change	   in	   CD25	   expression	   appears	   to	   be	   due	   to	   the	   heterogeneity	   within	   our	  
sample	  of	  cases	  rather	  than	  absence	  of	  effect.	  A	  larger	  sample	  size	  would	  be	  necessary	  
to	  investigate	  this	  further.	  
Treatment	   of	   CD4	   T	   cells	  with	   CsA	   significantly	   impaired	   their	   ability	   to	   activate	   CLL	  
cells;	  CD25	  MFI	  was	  reduced	  by	  a	  mean	  of	  64	  %	  (Wilcoxon	  test,	  p=0.03)	  and	  CD69	  by	  a	  
mean	  of	  63	  %	  (Wilcoxon	  test,	  p=0.03)	  in	  CLL	  cells	  co-­‐cultured	  with	  CsA-­‐treated	  CD4	  T	  
cells.	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In	   addition	   to	   the	   T	   cell	   dependent	   effect	   of	   CsA	  on	  CLL	   cell	   activation,	   there	  was	   a	  
smaller	   direct	   effect;	  MFI	   of	   CD25	  was	   reduced	   by	   a	  mean	   of	   41	  %	   (Wilcoxon	   test,	  
p=0.06)	  and	  CD69	  by	  a	  mean	  of	  29	  %	  (Wilcoxon	  test,	  p=0.03)	  at	  72	  hours	  in	  CsA	  pre-­‐
conditioned	   CLL	   cells	   activated	   with	   untreated	   autologous	   CD4	   T	   cells.	   Inhibition	   of	  
CD25	  expression	  did	  not	  reach	  statistical	  significance.	  	  
There	  was	  a	  reciprocal	  reduction	  in	  the	  activation	  status	  of	  CD4	  T	  cells	  co-­‐cultured	  with	  
CsA	  pre-­‐conditioned	  CLL	  cells;	  expressed	  lower	  levels	  of	  CD40L	  (mean	  reduction	  of	  7	  %	  
(Wilcoxon	  test,	  p=0.03))	  and	  CD69	  (mean	  reduction	  of	  12	  %	  (Wilcoxon	  test,	  p=0.03)),	  
further	   emphasising	   the	   bi-­‐directional	   nature	   of	   signalling	   between	   CLL	   and	   CD4-­‐T	  
Cells.	  
	  
Figure	  3.7	  Co-­‐Culture	  system	  to	  investigate	  the	  direct/indirect	  effect	  of	  CsA	  on	  CLL	  B	  
cells	  
	  Autologous	  CD4+	  T	  Cells	  were	  activated	  using	  anti-­‐CD3/anti-­‐CD28	  for	  12	  hours	  in	  the	  
presence	   of	   VC	   or	   CsA.	   After	   12	   hours,	   the	   activated	   cells	   were	   recombined	   with	  
selected	  CLL	  B	  cells	   that	  had	  been	  pre-­‐conditioned	  with	  CsA	  or	  VC	  and	  washed,	  at	  a	  
ratio	  of	  1:4.	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Figure	  3.8	  CsA	  has	  a	  major	  CD4	  T	  cell	  dependent	  effect	  and	  a	  minor	  direct	  effect	  on	  
activation	  of	  CLL	  cells	  in	  co-­‐culture	  system	  
A	   representative	   plot	   of	   time-­‐dependent	   activation	   of	   CD4	   T	   Cells	   and	   CLL	   cells	   co-­‐
cultured	  as	  illustrated	  in	  Figure	  3.7.	  The	  activation-­‐status	  of	  CD4	  T	  Cells	  and	  CLL	  B	  cells	  
was	  assessed	  by	   flow	  cytometry	  daily	   for	  3	  days.	  Viable	  cells	  were	  gated	  on	  and	   the	  









































































































































	   95	  
	  
	  
Figure	  3.9	  (a-­‐e)	  CsA	  has	  a	  major	  T	  cell	  dependent	  effect	  and	  a	  minor	  direct	  effect	  on	  
CLL	  cells	  activated	  with	  autologous	  CD4+	  T	  Cells	  	  
(a-­‐c)	  CD4	  T	   cells	  were	  activated	  with	  anti-­‐CD3/CD28	   for	  12	  hours	   in	   the	  presence	  of	  
CsA	  (T-­‐CsA)	  or	  VC.	  They	  were	  then	  co-­‐cultured	  with	  autologous	  CLL	  cells	  that	  had	  been	  
pre-­‐conditioned	  with	  CsA	  (CLL-­‐CsA)	  or	  VC,	  for	  72	  hours.	  a-­‐c	  illustrates	  activation	  status	  
of	  CD4	  T	  cells	  treated	  with	  CsA	  and	  VC	  and	  co-­‐cultured	  with	  CLL	  cells	  for	  72	  hours.	  d-­‐e	  
illustrates	  activation	  status	  of	  CLL	  cells	  pre-­‐conditioned	  with	  CsA/	  VC	  and	  co-­‐cultured	  
with	  autologous	  CD4	  T	  cells	  treated	  with	  CsA/	  VC	  for	  72	  hours.	  Viable	  cells	  were	  gated	  
on	  and	  the	  expression	  of	  surface	  markers	  is	  presented	  as	  Median	  Fluorescent	  Intensity	  
(MFI).	  This	  figure	  summarises	  results	  of	  six	  experiments	  using	  six	  different	  patients.	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3.3.7	  Ciclosporin	  inhibits	  CD69	  expression	  in	  healthy	  donor	  B	  cells	  and	  CLL	  cells	  
activated	  through	  the	  B	  cell	  receptor	  
BCR	   signalling	   is	   considered	   to	   play	   a	   major	   role	   in	   CLL	   pathogenesis.	   CLL	   cells	   are	  
variably	  responsive	  to	  BCR	  signalling;	   those	  that	  are	  unresponsive	  display	   features	  of	  
anergy,	   with	   constitutive	   activation	   of	   NFAT	   and	   ERK,	   and	   are	   protected	   from	  
apoptosis	   via	   expression	   of	   BCL2	   and	  MCL1	   (Muzio	   et	   al.,	   2008).	   Inhibition	   of	   NFAT	  
signalling	  using	  the	  cell	  permeable	  VIVIT	  peptide	  has	  been	  shown	  to	  reduce	  metabolic	  
activity	  of	  CLL	   cells	   in	   ‘responders’	   and	   to	   reverse	  anergy	  and	   stimulate	  apoptosis	   in	  
‘non-­‐responders’(Apollonio	  et	  al.,	  2013;	  Le	  Roy	  et	  al.,	  2012)	  .	  
In	  view	  of	  the	  known	  effect	  of	  CsA	  on	  NFAT	  signalling	  we	  investigated	  the	  effect	  of	  CsA	  
on	  healthy	  donor	  and	  CLL	  cells	  stimulated	  with	  agonistic	  anti-­‐IgM.	  
Negatively	   selected	  healthy	  donor	  and	  CLL	  B	  cells	  were	  stimulated	  with	  goat	  F	   (ab’)2	  
anti	   human	   IgM	   for	   24	   hours	   in	   the	   presence	   and	   absence	   of	   CsA	   (200	   ng/ml).	  
Activation	   was	   flow-­‐cytometrically	   assessed	   by	   measuring	   the	   proportion	   of	   cells	  
expressing	  CD25	  and	  CD69	  after	  24	  hours.	  Figure	  3.10	  demonstrates	  that	  in	  anti-­‐IgM-­‐
stimulated	  healthy	  donor	  B	  cells	  treated	  with	  CsA,	  CD69	  expression	  was	  reduced	  from	  
a	  mean	  of	  66.5	  %	  to	  a	  mean	  of	  55.2	  %	  (paired	  t-­‐test,	  p=0.0018).	  	  
CLL	  cells	  were	  variably	  responsive	  to	  IgM	  stimulation,	  in	  our	  sample,	  6/7	  responded	  to	  
sIgM	   ligation	   by	   upregulating	   CD25	   and	   CD69	   expression.	   Amongst	   the	   ‘responders’	  
CsA	  reduced	  CD69	  expression	  from	  a	  mean	  of	  70	  %	  to	  a	  mean	  of	  61.98	  %	  (Wilcoxon	  
matched	  pairs	  signed	  rank	  p	  =	  0.03).	  There	  was	  no	  statistically	  significant	  effect	  of	  CsA	  
on	   CD25	   expression	   in	   healthy	   donor	   or	   CLL	   B	   cells	   activated	   through	   the	   BCR,	  
suggesting	  that	  in	  contrast	  to	  CD69	  expression,	  CD25	  expression	  is	  regulated	  by	  a	  CsA	  
insensitive	  mechanism.	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Figure	   3.10	   (a-­‐d)	   Activation	   status	   of	   healthy	   donor	   B/	   CLL	   cells	   stimulated	   in	   the	  
presence	  of	  CsA	  or	  vehicle	  control	  
Selected	  healthy	  donor	  and	  CLL	  B	   cells	  were	   stimulated	  with	   IgM	   in	   the	  presence	  of	  
CsA	   or	   VC.	   Expression	   of	   CD25	   and	   CD69	   was	   measured	   after	   24	   hours	   by	   flow	  
cytometry.	  Viable	  cells	  co-­‐expressing	  CD19	  (healthy	  donor)	  or	  co-­‐expressing	  CD5	  and	  
CD19	   (CLL)	   were	   gated	   on	   (gates	   were	   set	   using	   fluorescence	   minus	   one	   controls).	  
Percent	  parent	  denotes	  the	  percentage	  of	  B/	  CLL	  cells	  expressing	  CD25	  and	  CD69.	  

















































































































	   98	  
3.3.8	   There	   is	   a	   trend	   towards	   reduced	   viability	   of	   CLL	   cells	   in	   the	   presence	   of	  
ciclosporin	  
Having	   demonstrated	   that	   CsA	   inhibits	   both	   the	   activation	   of	   CLL	   cells	   stimulated	  
through	  the	  BCR	  and	  CLL	  cells	  stimulated	  by	  autologous	  CD4	  T	  cells,	  it	  was	  necessary	  to	  
investigate	  the	  effect	  of	  CsA	  on	  CLL	  cell	  viability.	  NFAT	  and	  NFκB	  signalling	  play	  a	  role	  
in	  maintaining	   the	   viability	   of	   CLL	   cells	   and	   it	   is	   possible	   that	  CsA	  may	  disrupt	   these	  
signalling	  pathways.	  	  
To	  investigate	  whether	  any	  effect	  of	  CsA	  on	  the	  viability	  of	  CLL	  cells	  was	  direct,	  or	  T	  cell	  
dependent,	  cells	  were	  cultured	  as	  unselected	  PBMCs	  or	  as	  selected	  CLL	  cells.	  CLL	  cell	  
selection	   was	   performed	   using	   immunomagnetic	   beads	   (Materials	   and	   Methods:	  
Section	   2.8)	   and	   the	   purity	   was	   confirmed	   to	   be	   ≥	   95	   %	   CD5+/CD19+	   by	   flow	  
cytometry.	  Cells	  were	  cultured	  at	  a	  density	  of	  3	  x	  106	   for	  96	  hours	   in	  complete	  RPMI	  
with	  CsA	  200	  ng/mL	  or	  VC.	  After	  96	  hours,	  viability	  was	  assessed	  by	  measuring	  non-­‐
viable	   cells	   with	   Annexin	   V	   and	   7-­‐Aminoactinomycin	   D	   (7-­‐AAD).	   Annexin	   V	   is	   a	  
phospholipid	   binding	   protein	   that	   binds	   to	   phosphatidylserine	   exposed	   on	   apoptotic	  
cells	  and	  7-­‐AAD	  is	  a	  DNA	  intercalating	  dye	  that	  can	  only	  enter	  cells	  with	  disrupted	  cell	  
membranes,	  indicating	  necrosis.	  An	  example	  of	  a	  flow-­‐cytometry	  plot	  pre	  and	  post	  cell	  
culture	  with	  and	  without	  CsA	  is	  shown	  Figure	  3.11.	  
After	   96	   hours,	   there	   was	   a	   trend	   towards	   greater	   viability	   when	   CLL	   cells	   were	  
cultured	  as	  PBMCs	  than	  when	  cultured	  as	  purified	  CLL	  cells	  (mean	  of	  differences	  =	  10	  
%,	  paired	  t-­‐test	  p=0.059),	  suggesting	  a	  protective	  effect	  of	  T	  cells.	  There	  was	  a	  trend	  
towards	  reduced	  CLL	  cell	  viability	   in	  the	  presence	  of	  CsA	  in	  both	  CLL	  cells	  cultured	  as	  
PBMCs	  (mean	  viability	  =	  26.68	  %	  vs	  31.2	  %	  (paired	  t-­‐test,	  p	  =	  0.06))	  and	  as	  selected	  CLL	  
cells	   (mean	   viability	   =	   15.57	   vs	   21.08	  %	   (paired	   t-­‐test,	   p	   =	   0.07))	   as	   shown	   in	   Figure	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Figure	  3.11	  (a-­‐h)	  Flow	  cytometry	  plots	  demonstrating	  viability	  of	  PBMCs	  pre-­‐and	  post	  
96-­‐hour	  culture	  with	  CsA	  or	  VC	  
(a-­‐d)	  CLL	  cells	  were	  cultured	  as	  PBMCs	  with	  CsA	  200	  ng/mL	  or	  vehicle	  control	  (VC)	  for	  
96	  hours.	  Viability	  was	  assessed	  flow-­‐	  cytometrically	  by	  excluding	  cells	  staining	  positive	  
for	  annexin	  V	  or	  7-­‐AAD.	  (e-­‐h).	  Flow	  cytometry	  plots	  demonstrating	  viability	  of	  purified	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Figure	  3.12	  Viability	  of	  CLL	  cells	   cultured	  as	  PBMCs	  and	  as	   selected	  CLL	  cells	   in	   the	  
presence	  of	  CsA	  
	  CLL	  cells	  were	  cultured	  as	  PBMCs	  or	  as	   selected	  CLL	  cells	  with	  and	  without	  CsA	  200	  
ng/mL	  for	  96	  hours.	  Viability	  was	  assessed	  at	  baseline	  and	  after	  96	  hours	  by	  excluding	  
cells	  staining	  positive	  for	  annexin	  V	  or	  7-­‐AAD.	  


















a. Day 4 Viability CLL PBMCs +/- CsA





















b. Day 4 Viability Pure CLL cells +/- CsA
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3.3.9	  Time-­‐course	  of	  NFκB	  and	  NFAT-­‐C2	  activation	  in	  normal	  CD4+	  T	  cells	  stimulated	  
in	  presence	  and	  absence	  of	  ciclosporin	  
The	  time-­‐course	  of	  nuclear	  translocation	  of	  NFκB-­‐p65	  and	  NFAT-­‐C2	  of	  CD4+	  T	  cells	  was	  
investigated	  by	  activating	  healthy	  donor	  PBMCs	  with	  PMA	  and	   Ionomycin.	  PMA	  plus	  
Ionomycin	  was	  selected	  as	  the	  mechanism	  of	  as	  the	  combination	  has	  been	  shown	  to	  
induce	   rapid	   and	   robust	   T	   cell	   activation.	   Ionomycin	   activates	   calcium/calmodulin-­‐
dependent	   signaling	   pathways,	   and	   induces	   the	   hydrolysis	   of	   phosphoinositides	   and	  
the	   activation	   of	   protein	   kinase	   C	   (PKC)	   in	   human	   T	   cells.	   PMA	   is	   thought	   to	   act	   in	  
synergy	  with	  Ionomycin	  to	  enhance	  activation	  of	  PKC.	  
Translocation	  was	  assessed	  at	  10,	  20,	  30	  and	  60	  minutes	  post	  stimulation.	  CD4+	  T	  cells	  
were	  gated	  on	  and	  the	  degree	  of	  nuclear	  translocation	  of	  NFκB-­‐p65	  and	  NFAT-­‐C2	  was	  
calculated	   using	   a	   similarity	   score	   between	   the	   nucleus	   (DAPI)	   and	   the	   transcription	  
factor	  (FITC).	  The	  effect	  of	  CsA	  was	  investigated	  by	  simultaneously	  incubating	  the	  cells	  
with	   VC	   or	   CsA	   for	   one	   hour	   pre-­‐activation.	   Figure	   3.13	   demonstrates	   that	   nuclear	  
NFκB-­‐p65	  peaked	  at	  30	  minutes	  and	  nuclear	  NFAT-­‐C2	  peaked	  at	  10-­‐20	  minutes	  post	  
stimulation.	  In	  this	  example,	  nuclear	  translocation	  of	  NFκB-­‐p65	  was	  reduced	  by	  28.7	  %	  
at	   30	   minutes	   and	   nuclear	   translocation	   of	   NFAT-­‐C2	   was	   reduced	   by	   57	   %	   at	   10	  
minutes	   in	   the	   presence	   of	   CsA.	   Therefore	   the	   time	   chosen	   for	   future	   experiments	  
involving	  T	  cell	  activation	  was	  30	  minutes	  for	  NFκB-­‐p65	  and	  10	  minutes	  for	  NFAT-­‐C2.	  
	  
Figure	  3.13	  (a&b)	  Exemplary	  plots	  of	  time-­‐course	  of	  nuclear	  translocation	  of	  NFAT-­‐C2	  
and	  NFκB-­‐p65	  in	  normal	  CD4+	  T	  cells	  in	  presence	  of	  VC	  and	  CsA	  
PBMCs	  were	  activated	  with	  PMA	  and	  Ionomycin	  in	  the	  presence	  of	  VC	  or	  CsA.	  Percent	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3.3.10	   Time-­‐course	   of	   NFκB-­‐p65	   and	  NFAT-­‐C2	   activation	   in	   CLL	   cells	   stimulated	   by	  
CD40L	  in	  presence	  and	  absence	  of	  ciclosporin	  
The	   time-­‐course	   of	   nuclear	   translocation	   of	   NFκB-­‐p65	   and	   NFAT-­‐C2	   in	   CLL	   cells	   in	  
response	   to	  CD40L	   stimulation	  was	   investigated	  using	  CD40L	   transfected	   fibroblasts.	  
Again,	   CD40L	   mediated	   activation	   was	   considered	   necessary	   to	   re-­‐capitulate	   T	   cell	  
activation	   of	   CLL	   cells.	   Figure	   3.14	   illustrates	   that	   nuclear	   translocation	   of	  NFκB-­‐p65	  
peaked	   at	   3	   hours	   post	   activation	   and	   was	   not	   inhibited	   in	   the	   presence	   of	   CsA.	  
Nuclear	   translocation	   of	   NFAT-­‐C2	   peaked	   at	   10-­‐20	  minutes	   and	   was	   transient,	   with	  
nuclear	   translocation	   falling	   by	   30	  minutes.	   In	   the	   illustrated	   example,	   there	   was	   a	  
reduction	  in	  NFAT-­‐C2	  translocation	  in	  the	  presence	  of	  CsA;	  it	  was	  reduced	  by	  13	  %	  at	  
10	  minutes	  and	  by	  43	  %	  at	  20	  minutes.	  
	  	  
	  
Figure	  3.14	  (a&b)	  Exemplary	  plot	  of	  time-­‐course	  of	  nuclear	  translocation	  of	  NFκB-­‐
p65	  and	  NFAT-­‐C2	  in	  CLL	  cells	  in	  presence	  of	  VC	  and	  CsA	  
CLL	  PBMCs	  were	  co-­‐cultured	  with	  CD40L	  transfected	  fibroblasts	  in	  the	  presence	  of	  VC	  
or	   CsA	   for	   the	   times	   shown.	   CLL	   B	   cells	   were	   gated	   on	   and	   the	   degree	   of	   nuclear	  
translocation	   of	   NFκB-­‐p65	   and	   NFAT-­‐C2	   was	   calculated	   using	   a	   similarity	   score	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3.3.11	  Ciclosporin	  significantly	  inhibits	  NFκB-­‐p65	  and	  NFAT-­‐C2	  nuclear	  translocation	  
in	  CLL	  CD4+	  T	  Cells	  
Having	  established	  that	  NFκB-­‐p65	  nuclear	  translocation	  peaks	  at	  30	  minutes	  and	  NFAT-­‐
C2	  translocation	  peaks	  at	  10	  minutes	  following	  PMA	  and	  Ionomycin	  stimulation	  of	  CD4	  
T	   cells,	   the	   effect	   of	   CsA	   on	   CLL	   CD4	   T	   cells	   at	   these	   time-­‐points	   was	   investigated.	  
Translocation	   of	   NFκB-­‐p65/NFAT-­‐C2	   was	   assessed	   in	   selected	   CD4	   T	   cells	   from	  
eight/nine	  CLL	  patients	  respectively.	  Figure	  3.15	  demonstrates	  that	  in	  the	  presence	  of	  
CsA,	  NFκB-­‐p65	  translocation	  was	  reduced	  from	  a	  mean	  of	  59.53	  %	  to	  a	  mean	  of	  35.63	  
%	  	  (paired	  t-­‐test,	  p<0.0001)	  and	  NFAT-­‐C2	  was	  reduced	  from	  a	  mean	  of	  53	  %	  to	  a	  mean	  
of	  36.5	  %	  (paired	  t-­‐test,	  p=0.005).	  
	  
	  
Figure	   3.15	   (a&b)	   CsA	   inhibits	   nuclear	   translocation	   of	   NFκB-­‐p65	   and	   NFAT-­‐C2	  
translocation	  in	  activated	  CLL	  CD4+	  T	  cells	  
Selected	   CD4+	   T	   cells	   were	   activated	   with	   PMA	   and	   Ionomycin	   for	   ten	   minutes	  
following	  incubation	  with	  VC	  or	  CsA	  for	  one	  hour.	  CD4+	  T	  cells	  were	  gated	  on	  and	  the	  
degree	   of	   nuclear	   translocation	   of	   NFκB-­‐p65	   and	   NFAT-­‐C2	   was	   calculated	   using	   a	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3.3.12	  Effect	  of	  ciclosporin	  on	  NFκB-­‐p65	  and	  NFAT-­‐C2	  translocation	  in	  CLL	  cells	  
Having	  demonstrated	  that	  nuclear	  translocation	  of	  NFκB-­‐p65	  peaks	  at	  three	  hours	  and	  
nuclear	   NFAT-­‐C2	   peaks	   at	   10	   minutes	   after	   activation	   of	   CLL	   B	   cells	   with	   CD40L	  
transfected	   fibroblasts,	   CsA	   inhibition	   of	   translocation	   was	   measured	   at	   these	   time	  
points.	   Figure	   3.16	   demonstrates	   that	   CsA	   does	   not	   significantly	   inhibit	   nuclear	  
translocation	   of	   NFκB-­‐p65	   or	   NFAT-­‐C2	   in	   CD40L	   activated	   CLL	   cells	   at	   these	   time	  
points.	   This	   is	   in	   agreement	   with	   the	   observation	   that	   CsA	   does	   not	   inhibit	   CD40L	  
mediated	   activation	   of	   CLL	   cells	   as	   assessed	   by	   CD25	   and	   CD69	   expression.	   This	  
observation	  is	  at	  odds	  with	  the	  well-­‐documented	  effect	  of	  CsA	  on	  NFAT	  activation	  and	  
potentially	  relates	  to	  the	  supra-­‐physiological	  mechanism	  of	  CLL	  cell	  activation.	  
	  
	  
	  Figure	  3.16	  (a&b)	  Effect	  of	  CsA	  on	  NFκB-­‐p65	  and	  NFAT-­‐C2	  translocation	  in	  CLL	  cells	  
	  Selected	   CLL	   cells	   were	   pre-­‐incubated	   with	   VC	   or	   CsA	   for	   60	  minutes	   before	   being	  
activated	  with	  CD40L	  transfected	  fibroblasts	  for	  the	  above	  times.	  CLL	  cells	  were	  gated	  
on	  and	  the	  degree	  of	  nuclear	  translocation	  of	  NFκB-­‐p65	  and	  NFAT-­‐C2	  was	  calculated	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3.4	  Discussion	  
The	   in-­‐vitro	  assays	  presented	  here	  were	  designed	  to	  dissect	  the	  mechanism	  of	  action	  
of	  CsA	  in	  patients	  with	  CLL;	   looking	  at	  the	  direct	  effect	  of	  CsA	  on	  CD4	  T	  cells	  and	  CLL	  
cells	  and	  on	  the	  interaction	  between	  them,	  as	  would	  be	  expected	  to	  occur	  in	  the	  CLL	  
lymph-­‐node.	  
We	  found	  that	  both	  healthy	  donor	  and	  CLL	  CD4	  T	  cell	  activation,	  assessed	  by	  CD69	  and	  
IFNγ	  expression,	  was	   significantly	   inhibited	   in	   the	  presence	  of	  CsA	   (200	  ng/ml).	  As	   it	  
has	   previously	   been	   reported	   that	   IFNγ	   is	   a	  major	  mechanism	   by	  which	   CLL-­‐specific	  
Th1	  cells	  drive	   the	  expression	  of	  CD38	  by	  CLL	  cells	   (Bürgler	  et	  al.,	  2015),	   this	   finding	  
suggests	  that	  CsA-­‐treated	  CD4	  T	  cells	  may	  have	  an	  impaired	  ability	  to	  activate	  CLL	  cells.	  
Previous	   investigations	   into	  the	  nature	  of	  CD4	  T	  cell-­‐mediated	  survival	  and	  activation	  
of	   CLL	   cells	   in	   the	   lymph-­‐node	   microenvironment	   have	   demonstrated	   that	   CD40L	  
expression	  and	  IL21	  secretion	  play	  a	  key	  role	  in	  this	  process	  (Ghia	  et	  al.,	  2002;	  Pascutti	  
et	   al.,	   2013).	   As	   CsA	   has	   been	   demonstrated	   to	   inhibit	   CD40L	   expression	   and	   IL21	  
secretion	   in	   healthy	   T	   cells	   (Fuleihan	   et	   al.,	   1994;	   Kim	   et	   al.,	   2005),	   we	  went	   on	   to	  
investigate	   the	   effect	   of	   CsA	   on	   CLL	   CD4	   T	   cells.	   Importantly,	   we	   found	   that	   in	   the	  
presence	  of	  CsA,	  there	  was	  marked	  inhibition	  of	  CD40L	  expression.	  In	  view	  of	  the	  fact	  
that	   CD40L	   signalling	   has	   been	   shown	   to	   play	   a	   key	   role	   in	   CLL	   cell	   survival	   via	   the	  
induction	  of	  BCL-­‐2	  and	  MCL-­‐1	  (Scielzo	  et	  al.,	  2011)	  and	  that	  blocking	  this	  axis	  using	  a	  
monoclonal	  antibody	  to	  CD40L	  induces	  apoptosis	  (Furman	  et	  al.,	  2000),	  this	  would	  be	  
predicted	  to	  reduce	  CLL	  cell	  survival.	  However,	  IL21	  secretion	  was	  not	  reduced	  in	  the	  
presence	   CsA,	   which	   goes	   against	   the	   known	   NFAT-­‐dependent	   mechanism	   of	  
transcription	  of	  the	  IL21	  gene.	  One	  explanation	  for	  this	  observation	  is	  the	  high	  level	  of	  
baseline	   fluorescence	   for	   IL21	   and	   a	   blocking	   antibody	  may	   have	   been	   employed	   to	  
establish	  a	  true-­‐negative	  control.	  
We	  further	  interrogated	  the	  effect	  of	  CsA	  on	  healthy	  and	  CLL	  CD4	  cells	  by	  measuring	  
nuclear	  translocation	  of	  NFAT-­‐C2	  and	  NFκB-­‐p65	  using	  image	  flow	  cytometry.	  We	  found	  
that	  CsA	  had	  a	  significant	  effect	  on	  nuclear	  translocation	  of	  both	  NFAT-­‐C2	  and	  NFκB-­‐
p65,	  reducing	  nuclear	  localisation	  by	  30	  %	  and	  40	  %,	  respectively.	  NFAT-­‐C2	  and	  NFκB-­‐
p65	  are	  key	  regulators	  of	  the	  transcription	  of	  IL2,	  IL4,	  IL6,	  IL21,	  TNFα,	  IFNγ	  and	  CD40L,	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inhibition	  of	  which	  would	  be	  predicted	   to	  have	  a	  detrimental	  effect	  on	   the	  ability	  of	  
CD4	  T	  cells	  to	  activate	  CLL	  cells.	  
CD40L	   mediated	   activation	   of	   CLL	   cells	   by	   CD4	   T	   cells	   in	   the	   lymph-­‐node	  
microenvironment	  is	  considered	  to	  play	  a	  key	  role	  in	  the	  survival	  and	  proliferation	  of	  
CLL	  cells.	  We	  found	  that	  CD40L	  was	  a	  potent	  method	  of	  activating	  expression	  of	  CD25	  
and	  CD69	  by	  CLL	  B	  cells	  and	  that	  this	  activation	  was	  not	  sensitive	  to	  the	  effect	  of	  CsA.	  
Furthermore,	  NFκB-­‐p65	  and	  NFAT-­‐C2	  translocation	  was	  induced	  in	  CD40L	  activated	  CLL	  
cells,	   and	  was	   insensitive	   to	   CsA.	   This	   finding	   is	   in-­‐keeping	  with	   in-­‐vitro	   studies	   that	  
have	   demonstrated	   that	   CD40L-­‐induced	   proliferation	   of	   healthy	   B	   lymphocytes	   is	  
resistant	   to	   the	   effect	   of	   CsA	   (Wortis	   et	   al.,	   1995).	   However,	   it	   is	   at	   odds	   with	   the	  
finding	   that	   in	  B	   lymphocytes,	  NFAT	  signalling	   induced	  by	  CD40L	  +	   IL4	   is	   sensitive	   to	  
the	   effect	   of	   CsA	   (Choi	   et	   al.,	   1994).	   IL4	   signalling	   is	   mediated	   by	   STAT6	  
phosphorylation	   and	   this	   mechanism	   of	   activation	   has	   recently	   been	   shown	   to	   be	  
upregulated	  in	  CLL	  cells	  compared	  to	  healthy	  B	  lymphocytes;	  however	  sensitivity	  of	  IL4	  
signalling	  to	  CsA	  has	  not	  been	  investigated	  (Bhattacharya	  et	  al.,	  2015).	  	  
Investigation	   into	   the	  effect	  of	  CsA	  on	   the	   interaction	  between	  activated	  CD4	  T	  cells	  
and	   CLL	   cells	   in	   the	   co-­‐culture	   system	  was	   designed	   to	   re-­‐capitulate	   the	   CLL:	   T	   cell	  
interactions	   in	   the	   lymph-­‐node	   compartment.	   Pascutti	   et	   al	   have	  demonstrated	   that	  
compared	  to	   isolated	  CD40L	  mediated	  activation,	  CD4	  T	  cells	   induce	  a	  different	  gene	  
expression	  profile	  and	  that	  chemokine	  signalling	  molecules	  account	  for	  this	  difference	  
(Pascutti	   et	   al.,	   2013).	   Co-­‐culture	   experiments	   demonstrated	   that	   CsA	   had	   a	   major	  
inhibitory	   effect	   on	   CD4	   T	   cells,	  which	   impaired	   their	   ability	   to	   activate	   CLL	   cells.	   In	  
addition	  to	  the	  indirect,	  CD4	  T	  cell	  dependent	  effect	  of	  CsA	  on	  CLL	  cells,	  the	  drug	  had	  
an	  additional	  direct	  effect	  on	  CLL	  cells,	  as	  evidenced	  by	  reduced	  expression	  of	  CD69	  by	  
CsA	   pre-­‐conditioned	   CLL	   cells	   co-­‐cultured	   with	   untreated	   activated	   CD4	   T	   cells.	  
Furthermore,	   CsA-­‐treated	   CLL	   cells	   provided	   less	   reciprocal	   CD4	   T	   cell	   activation,	  
further	  emphasising	  the	  role	  of	  bi-­‐directional	  signalling	  between	  CLL	  and	  CD4	  T	  cells.	  
The	  effect	  of	  CsA	  on	  BCR	  mediated	  activation	  was	  an	  important	  line	  of	  investigation	  in	  
view	  of	  the	  profound	  effect	  that	   ibrutinib	  and	  idelalisib	  that	   inhibit	  BCR	  signalling	  via	  
targeted	  inhibition	  of	  BTK	  and	  PI3Kδ	  respectively	  (Herman	  et	  al.,	  2010)	  (Herman	  et	  al.,	  
2011).	  CsA	  is	  known	  to	  inhibit	  NFAT	  that	  plays	  a	  key	  role	  in	  BCR	  mediated	  signalling	  in	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CLL	   cells	   and	   furthermore,	   inhibition	   of	   NFAT	   signalling	   using	   the	   VIVIT	   peptide	   has	  
been	  shown	  to	  reduce	  metabolic	  activity	  in	  both	  anergic	  and	  signalling-­‐competent	  CLL	  
cells	  and	  to	  reduce	  tumour	  volume	  in	  the	  MEC-­‐1	  mouse	  model	  of	  CLL	  (Apollonio	  et	  al.,	  
2013;	  Le	  Roy	  et	  al.,	  2012).	  Secondly,	  NFκB-­‐p65	  plays	  an	  important	  role	  in	  BCR	  signalling	  
and	  the	  survival	  and	  proliferation	  of	  CLL	  cells,	  and	  has	  been	  shown	  to	  be	  sensitive	  to	  
CsA	  in	  T	  cells.	  	  
Healthy	   donor	   and	   CLL	   cells	   activated	   through	   the	   BCR	   showed	   reduced	   CD69	  
expression	   on	   the	   presence	   of	   CsA,	   consistent	   with	   reports	   that	   CsA	   inhibits	   IgM	  
induced	  NFAT	  activation	  and	  B	  cell	  proliferation	  (Venkataraman	  et	  al.,	  1994)	  (Wortis	  et	  
al.,	   1995).	  However,	   CD25	  expression	  was	  not	   suppressed	   in	   either	  healthy	  or	  CLL	  B	  
cells	   in	   the	   presence	   of	   CsA,	   suggesting	   that	   a	   CsA-­‐insensitive	   pathway	   in	   CLL	   cells	  
regulates	  expression	  of	   this	  molecule.	  Owing	   to	   technical	  difficulties	  with	   the	   Image-­‐
Stream™,	  the	  effect	  of	  CsA	  on	  NFAT-­‐C2	  and	  NFκB-­‐p65	  activation	  in	  CLL	  cells	  activated	  
through	   the	  BCR	  was	  not	   investigated	   in	   this	   study	  but	   remains	  an	   important	   line	  of	  
investigation.	  
Finally,	  in	  view	  of	  the	  effect	  of	  CsA	  on	  BCR	  signalling	  and	  in	  view	  of	  the	  effect	  of	  CsA	  on	  
CLL	  T	  cells	  that	  protect	  CLL	  cells	  against	  apoptosis,	  the	  effect	  of	  CsA	  on	  the	  viability	  of	  
CLL	  cells	  cultured	  in	  isolation	  or	  as	  PBMCs	  was	  investigated.	  There	  was	  a	  trend	  towards	  
increased	   viability	   when	   CLL	   cells	   were	   cultured	   as	   PBMCs	   and	   there	   was	   a	   similar	  
trend	  towards	  reduced	  viability	  in	  the	  presence	  of	  CsA	  regardless	  of	  the	  presence	  of	  T	  
cells.	  Any	  effect	  of	  CsA	  on	  CLL	  viability	  would	  therefore	  appear	  to	  be	  an	  independent	  
of	  T	  cells.	  
In	   summary,	   CsA	   has	   a	   complex	   and	   heterogeneous	   effect	   on	   CLL:	   CD4	   T	   cell	  
interaction.	  Although	  CsA	  primarily	  reduced	  CD4	  T	  cell	  mediated	  activation	  of	  CLL	  cells	  
through	   inhibition	  of	   IFNγ	  and	  CD40L	  expression,	   there	  was	  a	  direct	  effect	  of	  CsA	  on	  
CLL	   cells,	  notably	   reducing	   the	  ability	  of	  CLL	   cells	   to	   respond	   to	  CD4	  T	   cell-­‐mediated	  
activation.	  The	  fact	  that	  CD4	  T	  cell-­‐induced	  activation	  of	  CLL	  cells	  was	  sensitive	  to	  CsA	  
whilst	  CD40L	  mediated	  activation	  was	  resistant	  to	  CsA	  may	  by	  due	  to	  both	  qualitative	  
and	  quantitative	  differences	  in	  the	  mode	  of	  activation	  including	  cytokine	  signalling.	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There	  was	  a	  direct	   effect	  of	  CsA	  on	  CLL	   cells	   activated	   through	   the	  BCR	   in	   signalling	  
competent	  cases,	  suggesting	  that	  CsA	  has	  a	   further,	  CD4	  T	  cell-­‐independent	  effect	   in	  
these	  cases.	  Additionally,	  the	  trend	  towards	  reduced	  viability	  seen	  in	  CsA-­‐treated	  CLL	  
cells	  is	  consistent	  with	  the	  effect	  of	  the	  cell	  permeable	  VIVIT	  peptide	  that	  inhibits	  NFAT	  
translocation	   and	   reduces	   viability	   in	   both	   anergic	   and	   signalling-­‐competent	   cases	  
(Apollonio	  et	  al.,	  2013;	  Le	  Roy	  et	  al.,	  2012).	  	  
The	   in-­‐vitro	  studies	  provide	  evidence	  of	  a	  two-­‐pronged	  anti-­‐leukaemia	  mechanism	  of	  
action	  of	  CsA,	   involving	  both	  CD4	  T	   cell-­‐dependent	   and	  direct	  mechanisms	  of	   action	  
that	   explains	   why	   a	   proportion	   of	   patients	   with	   CLL	   treated	   with	   CsA	   experience	  
tumour-­‐regression.	  However,	   the	   fact	   that	   there	  was	  evidence	  of	  CsA-­‐insensitive	  CLL	  
cell	   activation	   in	   cells	   activated	   through	   the	   BCR	   emphasises	   the	   complexity	   of	  
signalling	   that	   is	   likely	   to	   be	   further	   complicated	   by	   interactions	   between	   CLL	   cells,	  
endothelial	  cells	  and	  nurse-­‐like	  cells	  in	  the	  lymph-­‐node	  compartment.	  	  
	  Based	   on	   the	   positive	   findings	   of	   the	   effect	   of	   CsA	   in-­‐vitro,	   a	   clinical	   trial	   was	  
performed	   to	   investigate	   the	   in-­‐vivo	   effect	   of	   CsA	   in	   patients	  with	   poor	   risk	   disease	  
who	   do	   not	  meet	   conventional	   criteria	   for	   treatment	   and	   in	   whom	   investigation	   of	  
novel	  treatment	  strategies	  is	  warranted.	  The	  in-­‐vitro	  studies	  of	  CsA	  in	  CLL	  were	  applied	  
to	  investigate	  the	  in-­‐vivo	  effect	  of	  CsA	  in	  patients	  recruited	  to	  the	  clinical	  trial.	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 .	  Manipulation	  of	  the	  Tumour	  Microenvironment:	  	  An	  Chapter	  4
In-­‐vivo	  Study	  of	  Ciclosporin	  in	  Chronic	  Lymphocytic	  Leukaemia	  
4.1	  Introduction	  
4.1.1	  Background	  and	  Rationale	  
CLL	   is	   a	   highly	   heterogeneous	   disease	   with	   clinical	   outcomes	   reflecting	   significant	  
differences	   in	   disease	   biology.	   Determination	   of	   the	   biological	   characteristics	   of	   the	  
disease,	  for	  example	  IgVH	  gene	  mutational	  status	  and	  expression	  of	  CD38	  and	  CD49d,	  
are	   useful	   in	   predicting	   time	   to	   first	   treatment	   and	   overall	   survival	   and	   therefore	  
provide	  relevant	  information	  to	  both	  the	  patient	  and	  clinician	  at	  the	  time	  of	  diagnosis	  
(Hamblin	  et	   al.,	   1999)	   (Bulian	  et	   al.,	   2014;	  Damle	  et	   al.,	   1999;	  Hamblin	  et	   al.,	   2002).	  
Median	   survival	   was	   reported	   to	   be	   109	  months	   in	   patients	   with	   either	   unmutated	  
IgVH	  genes	   (IgVH	  -­‐UM),	   or	   CD38	   positive	   expression	   (>30	  %)	   and	  was	   293	  months	   in	  
patients	  who	  lacked	  either	  of	  these	  inferior	  prognostic	  markers.	  Although	  there	  was	  a	  
correlation	   between	   CD38	   expression	   and	   unmutated	   IgVH	   genes,	   there	   was	  
discordant	   expression	   in	   28	   %	   patients,	   in	   whom	   progression	   free	   survival	   was	  
intermediate	  (Hamblin	  et	  al.,	  2002).	  	  
Investigators	  have	  since	  established	  that	  a	  threshold	  of	  7	  %	  CD38	  expression	  is	  a	  more	  
stringent	  discriminator	  of	  prognosis;	  with	  median	  overall	  survival	  estimated	  to	  be	  114	  
months	  in	  patients	  with	  <7	  %	  CD38	  compared	  to	  79	  months	  in	  those	  with	  >7	  %	  CD38	  
expression	  (Kröber	  et	  al.,	  2002;	  Thornton	  et	  al.,	  2004).	  
Identification	  of	  poor-­‐risk	  characteristics	  does	  not,	  however,	  influence	  the	  decision	  to	  
commence	   treatment	   and	   can	   therefore	   be	   psychologically	   damaging	   to	   patients.	  
Treatment	   is	   reserved	   for	   patients	   with	   symptomatic,	   progressive	   disease	   based	   on	  
evidence	  that	  early	  intervention	  with	  Chlorambucil	  does	  not	  improve	  survival	  (Dighiero	  
et	  al.,	  1998).	  The	  cohort	  of	  patients	  with	  poor	  risk	  characteristics,	  destined	  to	  have	  a	  
short	  time	  to	  first	  treatment	  represents	  an	  area	  of	  unmet	  medical	  need.	  Identification	  
of	   a	   strategy	   that	   can	   be	   applied	   to	   slow	   the	   rate	   of	   disease	   progression	   before	  
patients	  meet	  the	  conventional	  criteria	  to	  start	  treatment	  (Hallek	  et	  al.,	  2008)	  is	  highly	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desirable.	   A	   treatment	   strategy	   applied	   in	   this	   setting	   should	   be	   non-­‐toxic,	   effective	  
and	  should	  inhibit	  rather	  than	  contribute	  to	  the	  genetic	  evolution	  of	  the	  tumour.	  
For	  many	  years,	  CLL	  was	  considered	  to	  be	  a	  disease	  of	  failed	  apoptosis	  (Kitada	  et	  al.,	  
1998)	  but	  a	   landmark	  study	  using	   in-­‐vivo	  deuterium	  labelling	   in	  CLL	   identified	  that	   in	  
patients	  with	  progressive	  disease,	  proliferation	  rates	  can	  reach	  2	  %	  per	  day	  (Messmer	  
et	   al.,	   2005).	   Although	   neither	   CD38	   expression	   or	   IgVH	  mutational	   status	   identified	  
patients	   with	   high	   proliferation	   rates,	   it	   was	   subsequently	   reported	   that	   within	   a	  
patient,	  CD38+	  CLL	  cells	  proliferated	  at	  twice	  the	  rate	  of	  CD38-­‐	  CLL	  cells	  (Calissano	  et	  
al.,	   2009).	   This	   study	   therefore	   provided	   a	   key	   link	   between	   CLL	   proliferation	   and	  
inferior	  prognosis	  in	  patients	  with	  CD38+	  CLL.	  
	  
Proliferation	  of	  CLL	  cells	  occurs	  in	  secondary	  lymphoid	  tissue,	  where	  there	  is	  evidence	  
of	  active	  signalling	  through	  the	  B	  cell	  receptor	  (BCR)	  (Herishanu	  et	  al.,	  2011).	  However,	  
the	  survival	  and	  proliferation	  of	   tumour	  cells	   is	  also	   thought	   to	  depend	  on	  signalling	  
from	   components	   of	   the	  microenvironment	   including	   activated	   CD4	   T	   cells,	   stromal	  
cells,	  endothelial	  cells	  and	  nurse-­‐like	  cells	  (Buggins	  et	  al.,	  2010;	  J.	  A.	  Burger	  et	  al.,	  2000;	  
Panayiotidis	   et	   al.,	   1996).	   As	   noted	   in	   chapter	   1,	   our	   group	   and	   others	   have	  
investigated	   the	   role	   of	   activated	   CD4	   T	   cells	   in	   the	   lymph-­‐node	  microenvironment	  
(Ghia	  et	  al.,	  2002;	  Patten,	  Buggins,	  Richards,	  Wotherspoon,	  Salisbury,	  Mufti,	  Hamblin,	  
&	  Devereux,	  2008b;	  Willimott	  et	  al.,	  2007)	  (Bagnara	  et	  al.,	  2011)	  (Pascutti	  et	  al.,	  2013).	  
In	   light	   of	   the	   evidence	   for	   the	   role	   of	   CD4	   T	   cells	   in	   promoting	   CLL	   survival	   and	  
proliferation,	   we	   hypothesised	   that	   CD4	   T	   cell	   suppression	   may	   inhibit	   CLL	   cell	  
activation	  and	  proliferation.	   Furthermore,	   since	   signals	   from	  CD4+	  T-­‐cells	   induce	   the	  
DNA	   modifying	   enzyme	   activation	   induced	   cytidine	   deaminase	   (AID),	   which	   has	  
previously	  been	   implicated	   in	   the	   induction	  of	  mutations	   in	  CLL,	   targeting	  these	  cells	  
might	  also	  reduce	  the	  genomic	  evolution	  of	  the	  disease.	  Manipulation	  of	  the	  tumour	  
microenvironment	  in	  this	  way	  could	  be	  a	  relatively	  non-­‐toxic	  mechanism	  of	  inhibiting	  
disease	  progression	  in	  patients	  destined	  to	  have	  a	  poor	  outcome.	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4.1.2	  Ciclosporin	  
There	  are	  a	  number	  of	  agents	  that	  are	  applied	  in	  clinical	  medicine	  that	  have	  an	  anti-­‐T	  
cell	   effect;	   these	   include	   polyclonal	   antibodies	   e.g	   antithymocyte	   globulin	   (ATG),	  
monoclonal	  antibodies	  e.g.	  muromonomab-­‐CD3,	  drugs	  that	  inhibit	  the	  immunophilins	  
e.g.	   ciclosporin	   (CsA),	   tacromilus	   and	   sirolimus,	   and	   small	   biological	   agents	   including	  
fingolimod.	  CsA	  was	  selected	  as	  the	  investigational	  agent	  to	  suppress	  T	  cell	  activation	  
as	  most	  clinical	  experience	  has	  been	  gained	  with	  this	  agent,	  including	  in	  the	  context	  of	  
CLL,	   where	   it	   has	   been	   shown	   to	   lead	   to	   tumour	   regression	   in	   approximately	   20	   %	  
cases	  treated	  for	  autoimmune	  complications	  (Cortes	  et	  al.,	  2001).	  	  
CsA	   is	  a	  fungal	  derived	  polypeptide	  that	  was	  discovered	  to	  have	  anti-­‐T	  cell	  activity	   in	  
1976	   (Borel	   et	   al.,	   1976).	   CsA	   inhibits	   T	   cell	   activation	   by	   forming	   a	   complex	   with	  
cyclophilin;	  the	  complex	  binds	  to	  calcineurin	  and	  blocks	  its	  phosphatase	  activity,	  which	  
is	   required	   for	   the	   nuclear	   translocation	   of	   cNFAT.	   This,	   in	   turn,	   inhibits	   the	   nuclear	  
transcription	   of	   IL2,	   IL4	   and	   CD40L	   required	   for	   the	   growth	   and	   differentiation	   of	   T	  
cells.	   CsA	   was	   first	   applied	   to	   the	   field	   of	   organ	   transplantation	   in	   the	   early	   1980s	  
where	   it	   now	   represents	   the	   standard	  of	   care	   in	  preventing	   graft	   rejection.	  CsA	  was	  
subsequently	   applied	   to	   autoimmune	   conditions	   where	   it	   has	   been	   shown	   to	   be	   a	  
relatively	   safe	   and	   effective	   method	   of	   treating	   a	   variety	   of	   conditions	   including	  
rheumatoid	  arthritis,	  psoriasis	  and	  bullous	  pemphygoid.	  In	  the	  setting	  of	  CLL,	  CsA	  has	  
been	  used	  to	  treat	  autoimmune	  haemolytic	  anaemia	  (AIHA)	  and	  pure	  red	  cell	  aplasia	  
(PRCA)	  and	  has	  been	  reported	  to	  have	  anti-­‐tumour	  efficacy	  (Cortes	  et	  al.,	  2001).	  	  
CsA	   is	  an	  orally	  available	  drug	  with	  minimal	  metabolism	   in	   the	  gastrointestinal	   tract.	  
The	  drug	  is	  predominantly	  absorbed	  from	  the	  small	  bowel	  after	  which	  it	  enters	  cells	  by	  
diffusion.	  Metabolism	   takes	  place	   in	   the	   liver	  by	   the	   cytochrome	  CYP3A	  system.	  The	  
recommended	   dose	   in	   autoimmune	   conditions	   is	   5	   mg/kg/day,	   targeting	   a	   trough	  
concentration	   of	   150-­‐200	   ng/ml	   to	  minimize	   renal	   toxicity	   (Moyer,	   Post,	   Sterioff,	   &	  
Anderson,	  1988).	  Toxicity	  related	  to	  CsA	  therapy	  can	  be	  separated	  into	  those	  related	  
to	  the	  chemical	  effect	  of	  the	  drug	  and	  those	  related	  to	  immune	  suppression.	  Toxicities	  
are	  listed	  in	  Table	  4.1	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Table	  4.1	  Ciclosporin	  	  Toxicities	  
System	   Toxicity	  
Renal	   Hypertension,	  haemolytic	  uraemic	  
syndrome	  
Liver	   Hepatic	  dysfunction	  
Gastrointestinal	   Gastrointestinal	  disturbance,	  pancreatitis	  
Haematological	   Anaemia,	  thrombocytopenia,	  
microangiopathic	  haemolytic	  anaemia	  
Neurological	   Tremor,	  headache,	  paraesthesia,	  
encephalopathy,	  demyelination,	  motor	  
polyneuropathy,	  benign	  intracranial	  
hypertension	  
Endocrine	   Menstrual	  disturbance,	  hyperglycaemia	  
Musculoskeletal	   Myalgia	  
Immunological	   CMV	  reactivation,	  EBV	  reactivation	  
Electrolyte	  disturbance	   Hyperkalaemia,	  hypomagnesaemia,	  
hyperuricaemia	  
Other	   Anorexia,	  gingival	  hyperplasia,	  fatigue,	  
hyperlipidaemia,	  hypertrichosis	  
	  
Before	  embarking	  on	  the	  clinical	  trial,	  a	  series	  of	  assays	  was	  developed	  to	  investigate	  
the	   in-­‐vitro	   effect	   of	   CsA	   and	   to	   subsequently	   be	   applied	   to	   the	   clinical	   trial	   to	  
investigate	  the	  in-­‐vivo	  effect	  of	  CsA	  in	  patients	  with	  CLL.	  	  
The	  in-­‐vitro	  studies,	  discussed	  in	  depth	  in	  Chapter	  3,	  demonstrated	  that	  CsA	  inhibited	  
nuclear	   translocation	   of	   NFAT-­‐C2	   and	   NFκB-­‐p65	   in	   activated	   CLL	   CD4	   T	   cells.	  
Furthermore,	  there	  was	  reduced	  expression	  of	  IFNγ	  and	  CD40L	  in	  CD4	  T	  cells	  activated	  
in	   the	   presence	   of	   CsA;	   IFNγ	   and	   CD40L	   are	   thought	   to	   play	   a	   key	   role	   in	   T-­‐cell	  
activation	   of	   CLL	   cells	   in	   the	   lymph-­‐node	   compartment.	   In	   the	   co-­‐culture	   system	  
designed	   to	   replicate	   CD4	   T	   cell:	   CLL	   interaction	   in	   the	   lymph-­‐node	   compartment,	  
treatment	  of	  CD4	  T	  cells	  with	  CsA	  appeared	  to	  indirectly	  reduce	  CLL	  cell	  activation.	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In	  addition	  to	  the	  CD4	  T	  cell-­‐dependent	  effect	  of	  the	  drug,	  CsA	  had	  a	  direct	  effect	  on	  
CLL	   cells.	  Not	  only	  did	  CsA	   inhibit	   the	  ability	  of	  CLL	   cells	   to	   respond	   to	  activation	  by	  
autologous	  CD4	  T	  cells,	  it	  inhibited	  activation	  of	  CLL	  cells	  stimulated	  through	  the	  BCR.	  
Finally,	  there	  was	  a	  trend	  towards	  reduced	  viability	  of	  CLL	  cells	  in	  the	  presence	  of	  CsA,	  
consistent	  with	  the	  fact	  that	  CsA	  inhibits	  NFAT	  and	  NFκB-­‐p65	  which	  are	  known	  to	  play	  
a	  role	  in	  maintaining	  viability.	   In	  summary,	  the	   in-­‐vitro	  studies	  demonstrated	  a	  major	  
CD4	   T	   cell	   dependent	   effect	   and	   a	   smaller	   direct	   effect	   of	   CsA	   on	   CLL	   cells.	   These	  
studies	   concluded	   that	   CsA	   has	   in-­‐vitro	   activity	   in	   CLL	   and	   provided	   an	   important	  
foundation	  for	  developing	  a	  clinical	  study.	  
4.1.3	  Study	  Design	  and	  Endpoints	  
The	  clinical	   trial	  was	  designed	  to	   investigate	  the	  effect	  of	  CsA	  on	  proliferation	  of	  CLL	  
cells	  in	  ten	  patients	  with	  early	  stage,	  adverse	  risk	  (defined	  by	  CD38	  expression	  >	  7	  %)	  
disease.	  The	  ‘Ciclosporin	  in	  Early	  Stage,	  Adverse	  Risk	  Chronic	  Lymphocytic	  Leukaemia’	  
Trial	   (CyCLLe)	   was	   a	   Phase	   2	   Study	   set-­‐up	   and	   co-­‐ordinated	   by	   Bloodwise	   Trials	  
Acceleration	  Program	  and	  sponsored	  by	  the	  University	  of	  Birmingham.	  
The	  primary	  end-­‐point	  of	  the	  study	  was	  change	  in	  proliferation	  after	  four	  weeks	  of	  CsA	  
treatment.	   As	   proliferation	   takes	   place	   in	   the	   lymph-­‐node	   compartment,	   a	   ‘whole-­‐
body	  method’	   of	  measuring	   proliferation	  was	   necessary.	   Deuterium	   labelling,	   which	  
has	  previously	  been	  applied	  to	  measure	  the	  proliferation	  of	  CLL	  cells	  (Defoiche	  et	  al.,	  
2008;	   Messmer	   et	   al.,	   2005)	   was	   considered	   as	   the	   best	   method	   for	   measuring	  
proliferation.	  
Deuterium	  is	  a	  stable,	  non-­‐radioactive	  isotope	  of	  hydrogen	  that	  can	  be	  delivered	  orally	  
as	   either	   deuterated	   water	   or	   deuterated	   glucose.	   In-­‐vivo	   measurement	   of	  
proliferation	  using	  deuterated	  glucose	  was	  first	  described	  by	  Prof.	  D.	  Macallan	  and	  has	  
been	   used	   to	   study	   highly	   proliferative	   cell	   populations,	   particularly	   lymphocyte	  
populations	  (Macallan	  et	  al.,	  1998).	  The	  advantage	  of	  using	  deuterated	  glucose	  is	  that	  
the	  body	  glucose	  pool	  is	  small	  (approximately	  15g)	  and	  that	  it	  turns-­‐over	  rapidly,	  such	  
that	  a	  well-­‐defined	  pulse	  of	  cells	  can	  be	  labelled	  in	  a	  single	  day	  and	  tracked	  over	  time.	  
In	  comparison,	  the	  body	  water	  pool	  is	  large,	  labelling	  requires	  ingestion	  of	  deuterated	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water	   daily	   for	   84	   days	   and	   there	   is	   slow	   turnover,	   leading	   ongoing	   uptake	   of	   label	  
during	  the	  wash-­‐out	  phase.	  	  
Deuterated	   glucose	   labelling	   is	   performed	   in	   semi-­‐fasting	   state.	   Enrichment	   of	   the	  
plasma-­‐glucose	   compartment	   is	   rapidly	   achieved	   following	   a	   priming	   dose	   of	  
deuterated	  glucose.	  Enrichment	  is	  sustained	  for	  a	  ten-­‐hour	  period	  by	  administration	  of	  
aliquots	  of	  labelled	  glucose	  every	  30	  minutes	  and	  by	  limiting	  oral	  intake	  of	  un-­‐labelled	  
glucose/	   carbohydrate.	   After	   entering	   cells,	   glucose-­‐6-­‐phosphate	   is	   converted	   non-­‐
oxidatively	   to	   ribose-­‐5-­‐phosphate,	   then	   further	   phosphorylated	   to	   phosphoribose	  
pyrophosphate	   (PRPP),	   which	   is	   the	   basis	   for	   de	   novo	   synthesis	   of	   both	   purine	   and	  
pyrimidine	  nucleotides.	  	   	   	  
Following	  cessation	  of	  labelling,	  the	  cell	  population	  of	  interest	  can	  be	  serially	  sampled	  
over	  time	  to	  assess	  rates	  of	  appearance/	  disappearance	  and	  proliferation.	  The	  cells	  are	  
isolated,	   purified	   and	   DNA	   is	   extracted.	   DNA	   is	   hydrolysed,	   derivatised	   (using	  
pentafluoro	   tri-­‐acetate	   (PTFA))	   and	   the	   degree	   of	   deuterium	   enrichment	   measured	  
using	   gas	   chromatography	   mass-­‐spectrometry	   (GC-­‐MS).	   In	   this	   study,	   aliquots	   of	  
100,000	  cells	  were	  transferred	  to	  Prof	  Macallan’s	  lab	  where	  Dr.	  Zhang	  performed	  DNA	  
extraction,	  hydrolysis,	  derivatisation	  and	  GC-­‐MS.	  Deuterium	  enrichment	  of	  adenosine	  
is	   preferentially	   measured	   as	   purines	   are	   synthesized	   via	   the	   de	   novo	   nucleotide	  
pathway	  rather	  than	  by	  the	  nucleoside	  salvage	  pathway	  (Macallan	  et	  al.,	  2009).	  	  
As	  proliferation	  occurs	  in	  the	  lymph-­‐node	  compartment,	  it	  was	  assumed	  that	  cells	  are	  
initially	   labelled	   there	  and	   then	   traffic	   to	   the	  peripheral	  blood.	  Therefore,	   secondary	  
trial	   endpoints	   included	   rates	   of	   appearance	   of	   labelled	   cells	   from	   the	   lymph-­‐node	  
compartment	   into	   the	   peripheral	   blood,	   followed	   by	   their	   later	   disappearance.	  
Measurement	   of	   release	   rates	   of	   labelled	   cells	   into	   the	   peripheral	   blood	   was	  
considered	  to	  be	  an	  important	  line	  of	  investigation	  in	  view	  of	  the	  in-­‐vitro	  observation	  
that	  CsA	   inhibits	  expression	  of	  CD69	  by	  CLL	   cells,	  which	  would	  promote	   their	   egress	  
into	   the	   peripheral	   circulation.	   CD69	   has	   been	   shown	   to	   promote	   the	   retention	   of	  
lymphocytes	   in	   lymphoid	   organs	   by	   acting	   downstream	   of	   INF	   α/β	   and	   to	   down-­‐
modulate	   sphingosine	   1-­‐phosphate	   receptor-­‐1	   (S1P1)	   expression	   that	   is	   required	   for	  
lymphocyte	   egress	   (Shiow	   et	   al.,	   2006).	   Disappearance	   rates	   of	   CLL	   cells	   were	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measured	  in	  view	  of	  the	  trend	  towards	  increased	  apoptosis	  of	  CLL	  cells	  in	  the	  presence	  
of	  CsA.	  	  
The	  clinical	  response	  to	  CsA	  therapy	  at	  three	  months	  post	  treatment	  and	  the	  toxicity	  
of	  therapy	  were	  additionally	  collected	  as	  secondary	  outcome	  measures.	  
Translational	   studies	   developed	   during	   the	   in-­‐vitro	   phase	   of	   this	   investigation	   were	  
applied	   to	   further	   dissect	   the	   mechanism	   of	   action	   of	   CsA	   in-­‐vivo.	   Although	   it	   is	  
recognised	  that	  CLL:	  CD4	  T	  cell	  interaction	  and	  CLL	  proliferation	  takes	  place	  within	  the	  
lymph-­‐node,	   all	   studies	   were	   performed	   on	   peripheral	   blood	   CLL	   cells.	   Studies	   on	  
lymph-­‐node	   derived	   cells	   were	   not	   feasible	   within	   the	   clinical	   trial.	   Translational	  
studies	  included	  flow	  cytometry	  assessment	  of	  the	  activation	  status	  of	  CD4	  T	  cells	  and	  
CLL	   cells,	   image-­‐flow	   cytometry	   assessment	   of	   NFAT-­‐C2	   and	   NFκB-­‐p65	   translocation	  
and	   the	   gene	   expression	   profile	   of	   CD4+	   T	   cell	   and	   CLL	   cells	   pre	   and	   during	   CsA	  
treatment.	  	  
It	   has	   previously	   been	   demonstrated	   that	   the	   T	   cell	   compartment	   in	   CLL	   is	   skewed	  
towards	  an	  effector	  memory	  phenotype	   that	  correlates	  with	   increased	  expression	  of	  
the	  exhaustion	  markers	  CD244,	  CD160,	  PD-­‐1	  and	  Blimp1,	   consistent	  with	  an	  antigen	  
experienced	   phenotype	   (Riches	   et	   al.,	   2013).	   We	   therefore	   assessed	   whether	   CsA	  
treatment	  impacted	  on	  this	  phenotype	  by	  assessment	  of	  T	  cell	  subsets	  and	  expression	  
of	  PD-­‐1	  pre-­‐and	  after	  four	  weeks’	  in-­‐vivo	  exposure	  to	  CsA.	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4.2	  Materials	  and	  Methods	  
4.2.1	  Trial	  Set-­‐Up	  and	  Management	  
The	  trial	  was	  designed	  by	  Prof	  Stephen	  Devereux	  (Chief	   Investigator)	   in	  collaboration	  
with	   co-­‐investigators	   Prof	   Macallan,	   Prof	   Fegan,	   Prof	   Pepper,	   Dr	   Stocken	   and	   Dr	  
Cuthill.	  The	  trial	  was	  funded	  by	  and	  performed	  with	  support	  from	  the	  Bloodwise	  Trials	  
Acceleration	  Program	   (TAP)	   and	   co-­‐ordinated	  by	   Sonia	   Fox	   (Cancer	  Research	  Clinical	  
Trials	  Unit,	  Birmingham).	  The	  trial	  was	  granted	  ethical	  approval	  (REC:12/EE/0485)	  and	  
local	   approval	   from	   the	   Department	   of	   Research	   and	   Development.	   The	   trial	   was	  
registered	   on	   the	   EudraCT	   database	   (2012-­‐002795-­‐13).	   The	   trial	  was	   opened	   at	   two	  
centres;	  King’s	  College	  Hospital	  and	  University	  Hospital	  Wales,	  Cardiff	  (UHW).	  The	  trial	  
was	   compliant	   with	   the	   principles	   of	   Good	   Clinical	   Practice	   and	   all	   laboratory	   work	  
complied	  with	  the	  principles	  of	  Good	  Laboratory	  Practice.	  
4.2.2	  Trial	  Overview	  
CyCLLe	  was	  a	  Phase	  II	  Single	  Arm	  study	  with	  the	  objective	  of	  investigating	  the	  effect	  of	  
CsA	  on	  tumour	  kinetics	   in	  CLL	  (for	  Protocol,	  see	  Appendix	  1).	  Outcome	  measures	  are	  
listed	  below:-­‐	  
Primary	  Outcome	  Measures:	  
• Change	   in	   proliferation	   rate	   after	   four	   weeks	   of	   CsA	   therapy,	   measured	   by	  
deuterated	  glucose	  incorporation	  
Secondary	  Outcome	  Measures:	  
• Toxicity	  of	  CsA	  in	  patients	  with	  CLL	  	  
• Spontaneous	   intra-­‐patient	   variation	   in	   proliferation,	   release	   and	   loss	   of	   CLL	  
cells	  from	  the	  circulation	  
• Time	   to	  maximum	   release	   of	   labelled	   CLL	   cells	   from	   the	   circulation	  with	   CsA	  
therapy	  
• Complete	  response	  rate	  
• Overall	  response	  rate	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Translational	  Outcome	  Measures:	  	  
• Effect	  of	  CsA	  on	  phenotype	  of	  CLL	  and	  T	  cells	  	  
• Effect	  of	  CsA	  on	  transcription	  factors	  NFκB-­‐p65	  and	  NFAT	  
• Gene	  expression	  profile	  of	  selected	  CLL	  and	  CD4	  T	  cells	  
4.2.3	  Eligibility	  Criteria	  
Inclusion	  Criteria	  
• Binet	  Stage	  A	  or	  B	  CLL	  not	  requiring	  treatment	  by	  conventional	  criteria	  
• Age	  ≥	  18	  
• ECOG	  performance	  status	  ≤	  2	  
• Life	  expectancy	  	  >	  12	  months	  
• No	  therapy	  for	  CLL	  in	  previous	  3	  months	  (including	  glucocorticoids)	  
• CD38+	  ≥	  7	  %	  
• Normal	  renal	  function	  
• Normal	  liver	  function	  
• Negative	  serology	  for	  Hepatitis	  C,	  HIV	  and	  active	  Hepatitis	  B	  infection	  
• Valid	  informed	  consent	  
Exclusion	  Criteria	  
• Active	  infection	  
• Active	  autoimmune	  disease	  requiring	  therapy	  
• Diabetes	  Mellitus	  
• Previous	  myocardial	  infarction	  or	  clinically	  significant	  cardiac	  dysrhythmia	  
• Uncontrolled	  hypertension	  
• Taking	   medication	   known	   to	   have	   serious	   interaction	   with	   CsA	   where	  
interaction	  cannot	  be	  managed	  by	  adjusting	  CsA	  dose	  
• Fludarabine	  refractory	  disease	  
• Previous	  bone	  marrow	  transplant	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• History	  of	  prior	  malignancy,	  with	  the	  exception	  of	  certain	  malignancies	  treated	  
with	  curative	  intent	  and	  with	  no	  evidence	  of	  active	  disease	  for	  more	  than	  three	  
years	  
• Pregnant	  and	  lactating	  patients	  (patients	  of	  childbearing	  potential	  should	  have	  
a	  negative	  pregnancy	  test)	  
• Patients	   and	   partners	   of	   childbearing	   potential	   not	   willing	   to	   use	   effective	  
contraception	  during	  and	  for	  three	  months	  after	  the	  study	  
	  
4.2.4	  Outline	  of	  the	  CyCLLe	  study	  
The	  study	  was	  initially	  designed	  to	  include	  three	  labelling	  days,	  enabling	  assessment	  of	  
proliferation	   on	   two	   occasions	   to	   investigate	   intra-­‐patient	   variation	   in	   proliferation	  
before	   the	   commencement	   of	   CsA.	   Due	   to	   the	   difficulty	   in	   recruiting	   patients,	   the	  
protocol	  was	  amended	  to	  make	  the	   first	  cycle	  optional,	   followed	  by	   two	  compulsory	  
cycles,	  as	  illustrated	  in	  Figure	  4.1.	  Labelling	  with	  deuterated	  glucose	  was	  performed	  on	  
D0	   and	   compulsory	   blood	   tests	   were	   drawn	   on	   days	   4,	   7,	   14,	   21,	   28	   and	   56-­‐	   post	  
labelling.	  Assessment	  of	  release	  rate	  of	  labelled	  cells	  into	  the	  peripheral	  blood	  was	  an	  
optional	   extra	   and	   involved	   blood	   tests	   on	   days	   1,	   2,	   3	   post	   labelling.	   CsA	   was	  
administered	  for	  56	  days	  and	  there	  was	  an	  option	  to	  continue	  treatment	  for	  up	  to	  six	  
months	  in	  responding	  patients.	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Figure	  4.1	  Outline	  of	  CyCLLe	  
The	   study	   included	   two	   compulsory	   cycles	   and	   one	   optional	   cycle.	   CsA	   therapy	  was	  
commenced	  on	  D28	  of	  the	  second	  cycle.	  Bloods	  for	  deuterium	  assessment	  were	  drawn	  
at	  baseline,	  on	  day	  4,	  weekly	  for	  four	  weeks	  and	  then	  after	  8	  weeks.	  
	  
4.2.5	  Trial	  Recruitment	  
Patients	   were	   provided	   with	   a	   Patient	   Information	   Sheet	   and	   were	   given	   adequate	  
time	   to	   make	   a	   decision	   regarding	   participation.	   After	   the	   patient	   agreed	   to	  
participate,	   they	   signed	   an	   informed	   consent	   form,	   following	   which	   they	   were	  
screened	   for	   eligibility.	   Full	   screening	   evaluation	   included	   medical	   history,	   physical	  
examination,	  blood	  tests	  and	  ECG.	  Once	  the	  patient	  was	  confirmed	  to	  be	  eligible	   for	  
trial	   entry,	   they	   were	   registered	   via	   the	   Cancer	   Research	   UK	   Clinical	   Trials	   Unit.	   Dr	  
Cuthill	  approached	  all	  patients	  and	  arranged	  all	  consent	  and	  screening	  visits.	   In	  total,	  
fourteen	   patients	   were	   approached,	   seven	   consented	   to	   screening	   and	   five	   were	  
eligible	   for	   trial	   entry.	   Four	  patients	  were	   recruited	   form	  King’s	  College	  Hospital	   and	  
one	  from	  UHW.	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4.2.6	  Deuterium	  Labelling	  
Deuterated	   Glucose	   (Cambridge	   Isotope	   Laboratories),	   60	   g,	   was	   reconstituted	   with	  
200ml	   water	   and	   left	   to	   dissolve	   over-­‐night.	   Patients	   were	   advised	   to	   eat	   a	   light	  
breakfast	   and	   to	   attend	   early	   on	   the	   labelling	   day	   (Day	   0).	   On	   arrival,	   patients	  
underwent	   a	   physical	   examination	   for	   fitness	   to	   proceed.	   Baseline	  blood	  was	  drawn	  
(1ml	  EDTA)	  and	   frozen	  at	   -­‐20	   °C.	  Three	  drops	  of	  blood	  were	  placed	  on	  a	   filter	  paper	  
and	   allowed	   to	   air-­‐dry.	   36	  ml	  D2-­‐glucose	  was	   given	   at	   baseline	   and	   10	  ml	   at	   thirty-­‐
minute	  intervals	  for	  ten	  hours.	  Finger-­‐prick	  blood	  tests	  were	  performed	  at	  one,	  three,	  
five	  eight	   and	   ten	  hours,	  with	  blood	   spots	   allowed	   to	   air-­‐dry	  on	   filter	  papers	  before	  
storing	  at	  -­‐20	  °C	  and	  shipping	  to	  St	  George’s	  Hospital.	  During	  the	  day,	  the	  patient	  was	  
allowed	  to	  eat	  three	  half-­‐portions	  of	  low	  carbohydrate,	  low-­‐sugar	  food,	  specifically	  at	  
three	   hours,	   five	   hours	   thirty	  minutes	   and	   eight	   hours	   thirty	  minutes.	   Labelling	  was	  
repeated	   after	   eight	   weeks.	   Dr.	   Cuthill	   arranged	   and	   co-­‐ordinated	   all	   labelling	  
appointments	   and	   King’s	   College	   Hospital	   and	   trained	   staff	   at	   Cardiff	   University	  
Hospital.	  
	  
4.2.7	  Blood	  Sampling	  
5ml	   EDTA	   blood	   samples	   were	   drawn	   on	   days	   4,	   7,	   14,	   21	   and	   28.	   If	   the	   patient	  
consented	   to	   the	   optional	   release-­‐rates	   study,	   5	   ml	   EDTA	   blood	   samples	   were	  
additionally	  drawn	  on	  days	  1,	  2,	  3	  post	  labelling.	  Blood	  sampling	  at	  KCH	  was	  performed	  
by	  Dr.	  Cuthill	  with	  the	  occasional	  help	  of	  Clinical	  Trials	  nurses.	  
	  
4.2.8	  CLL	  cell	  isolation	  –	  for	  assessment	  of	  deuterium	  incorporation	  
CLL	   cells	   were	   positively	   selected	   using	   CD19	   microbeads	   (Miltenyi)	   as	   per	   the	  
manufacturer’s	   instructions.	  Positive	   selection	  was	  used	  as	   this	  provided	  an	  efficient	  
yield	  of	  CD19	   cells	  with	  a	  purity	  of	   >95	  %.	  107	  PBMCs	  were	  pelleted	  at	  300	  g	   for	  10	  
minutes	  and	  the	  supernatant	  removed	  by	  aspiration.	  Cells	  were	  resuspended	  in	  80	  μL	  
running	  buffer	  (containing	  PBS,	  0.5	  %	  (w/v)	  bovine	  serum	  albumin	  and	  2nM	  EDTA,	  pH	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7.2)	  and	  20	  μL	  CD19	  microbeads.	  Cells	  were	  incubated	  at	  4°C	  	  for	  15	  minutes	  to	  enable	  
labeling,	   following	   which,	   cells	   were	   washed	   with	   1	   mL	   running	   buffer	   and	   re-­‐
suspended	  in	  500	  μL	  running	  buffer	  for	  selection	  using	  the	  Automacs™	  cell	  separator.	  
Selected	   CD19	   cells	   were	   aliquoted	   at	   1	   x	   106	   cells	   into	   Eppendorf	   microtubes	   and	  
pelleted	   at	   12000	   g	   for	   3	   minutes.	   The	   supernatant	   was	   aspirated	   and	   cell	   pellets	  
stored	  at	  -­‐80°C	  until	  they	  were	  shipped	  to	  St	  George’s	  Hospital	  for	  gas	  chromatography	  
mass	   spectrometry	   assessment	   of	   deuterium	   incorporation	   in	   Prof	   Macallan’s	  
laboratory.	  CLL	  purity	  was	  measured	  at	   least	  once	   for	  each	  patient	  and	  when	  a	  new	  
positive	   selection	  kit	  was	   introduced	  using	   flow	  cytometry;	  an	  example	  of	   the	  purity	  
check	  is	  illustrated	  in	  Figure	  4.2	  
	  
Figure	  4.2	  Example	  of	  CLL	  purity	  check	  by	  flow	  cytometry	  
The	   purity	   of	   CLL	   cells	   was	   measured	   pre	   and	   post	   positive-­‐selection.	   Purity	   was	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4.2.9	  Assessment	  of	  deuterium	  incorporation	  
Aliquots	  of	  purified	  cells	  and	  filter	  papers	  (whole	  blood	  glucose)	  were	  transferred	  to	  Dr	  
Yan	  Zhang	  (Prof	  D.	  Macallan,	  Institute	  of	  Infection	  and	  Immunity,	  St	  George’s	  Hospital,	  
University	  of	  London)	  where	  analysis	  of	  deuterium	  enrichment	  was	  performed.	  Dr.	  Yan	  
Zhang	   performed	   all	   sample	   preparation	   and	   deuterium	   enrichment	   analysis;	   Prof	  
Macallan	  reviewed	  and	  modeled	  data.	  Calculation	  of	  whole	  blood	  glucose	  deuterium	  
enrichment	   over	   the	   ten-­‐hour	   labelling	   period	   was	   necessary	   for	   calculation	   of	   the	  
fraction	  of	  new	  DNA.	  An	  example	  of	  whole	  blood	  glucose	  enrichment	  from	  a	  subject	  
labelled	  in	  the	  CyCLLe	  study	  is	  illustrated	  in	  Figure	  4.3.	  
a. Assessment	  of	  blood	  glucose	  enrichment:	  
i. Glucose	  extracted	  from	  filter	  papers.	  
ii. Glucose	  derivatised	  and	  transferred	  to	  vials.	  
iii. Gas-­‐chromatography	   mass	   spectrometry	   (GC-­‐MS)	   analysis	   using	  
selective	  monitoring	  for	  ions	  of	  328	  and	  330.	  
iv. Enrichment	   determined	   from	   ratios	   of	   ions	   M+2/[M+0+M+2],	  
calibrating	  against	  standard	  glucose	  samples	  of	  known	  enrichment.	  
v. Area	  under	  curve	  for	  glucose	  enrichment	  vs	  time	  calculated.	  
	  
Figure	  4.3	  Example	  of	  deuterium	  enrichment	  of	  plasma	  glucose	  during	  labelling	  	  
Whole	   blood	   glucose	   deuterium	   enrichment	   following	   oral	   deuterated	   glucose	  
labelling.	  The	  study	  participant	  received	  a	  priming	  dose	  of	  deuterated	  glucose	  at	  t=0,	  
followed	  by	  aliquots	  at	  30	  minute	  intervals	  for	  10	  hours.	  Blood	  was	  sampled	  by	  finger-­‐
prick	   tests	   at	   pre-­‐specified	   intervals	   post	   labelling.	   Deuterium	   enrichment	   was	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b. Assessment	  of	  DNA	  deuterium	  enrichment.	  
i. DNA	  was	  extracted	  using	  Qiagen	  Kit.	  
ii. DNA	  digested	  to	  deoxydenosine.	  
iii. Digested	  DNA	  derivatised	  to	  PTFE	  derivative.	  
iv. Deuterium	  enrichment	  analysed	  by	  GC-­‐MS	  using	  selective	  monitoring	  of	  
ions	  of	  M/Z	  435,	  437	  (corresponding	  to	  M+0	  and	  M+2).	  
v. Ratio	   of	   M+2/[M+0+M+2]	   of	   abundance	   matched	   samples	   used	   to	  
calculate	   the	  enrichment	  of	  deuterated	  adenosine.	   Standard	  curves	  of	  
known	  enrichment	  were	  used	  for	  calibration.	  
vi. Analysis	  of	  ratios	  was	  repeated	  in	  triplicate.	  
vii. The	  fraction	  of	  new	  DNA	  (f)	  was	  calculated	  by	  dividing	  DNA	  enrichment	  
by	  the	  mean	  precursor	  enrichment	  
	  
4.2.10	  Ciclosporin	  Therapy	  
Ciclosporin	   (Neoral™)	   was	   commenced	   on	   Day	   28	   after	   labelling	   at	   a	   dose	   of	  
5mg/kg/day	   by	   mouth	   (PO),	   in	   a	   twice-­‐daily	   (bd)	   dosing	   regime.	   Patients	   were	  
reviewed	   twice	   weekly	   until	   CsA	   levels	   were	   stable	   (no	   dose	   adjustment	   for	   three	  
consecutive	   doses)	   and	   weekly	   thereafter.	   Clinical	   reviews	   included	   physical	  
examination	   and	   blood	   tests	   for	   full	   blood	   count,	   blood	   film,	   urea	   and	   electrolytes,	  
liver	   function	   tests	   and	   CsA	   levels.	   EBV	   and	   CMV	   viral	   loads	   were	   measured	   on	   a	  
weekly	  basis.	  CsA	  doses	  were	  adjusted	  to	  target	  levels	  of	  150-­‐200	  ng/ml.	  CsA	  therapy	  
was	  continued	   for	  a	  minimum	  of	  eight	  weeks;	  patients	  who	  responded	  to	   treatment	  
had	   the	   option	   to	   continue	   therapy	   for	   a	   further	   four	   months.	   Stopping	   criteria	  
included	   unacceptable	   toxicity,	   serious	   adverse	   events,	   a	   rise	   in	   creatinine	   >	   100%	  
from	  baseline,	  an	  increase	  in	  CMV/EBV	  levels	  to	  >100,000	  copies	  per	  ml	  or	  the	  patient	  
becoming	   pregnant.	   A	   final	   clinical	   review	   was	   performed	   two	   months	   after	  
completion	  of	  treatment.	  Dr.	  Cuthill	  peformed	  all	  clinical	  reviews,	  reviewed	  all	  results	  
and	  advised	  patients	  on	  CsA	  dosing	  for	  patients	  recruited	  at	  King’s	  College	  Hospital.	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4.2.11	  Translational	  Studies	  
Fifty	   milliliters	   of	   blood	   was	   drawn	   on	   day	   14	   post	   labelling	   and	   was	   processed	   at	  
King’s	  College	  London	  for	  further	   investigations	   into	  the	  mechanism	  of	  action	  of	  CsA.	  
These	  studies	   included	   immunophenotyping	  of	  resting	  and	  stimulated	  CLL	  and	  CD4	  T	  
cells,	  assessment	  of	  resting	  and	  stimulated	  NFκB-­‐p65	  and	  NFAT-­‐C2	  translocation	  using	  
image	   flow	   cytometry,	   analysis	   of	   T	   cell	   subsets	   and	  Gene	  Expression	  Profiling	  using	  
the	  Illumina	  Bead	  Array	  platform.	  Methods	  were	  developed	  during	  the	  investigation	  of	  
the	  in-­‐vitro	  effect	  of	  CsA	  in	  CLL.	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4.3	  Results	  
4.3.1	  Patient	  Characteristics	  
Five	   patients	  were	   enrolled	   across	   the	   two	   sites,	   four	   at	   King’s	   College	  Hospital	   and	  
one	  at	  University	  Hospital	  of	  Wales.	  All	  patients	  were	  men	  and	  the	  median	  age	  was	  62	  
years.	  All	  patients	  had	  Binet	  Stage	  A	  CLL	  and	  only	  one	  patient	  had	  previously	  received	  
treatment	   (Table	   4.2).	   Patients	   all	   had	   normal	   cytogenetics	   except	   patient	   004,	  who	  
had	  a	  complex	  karyotype;	  this	  patient	  was	  also	  the	  only	  patient	  to	  have	  received	  prior	  
therapy	  (Fludarabine,	  Cyclophosphamide	  and	  Rituximab).	  Patient	  001	  was	  withdrawn	  
during	  Cycle	  2	  following	  the	  development	  of	  grade	  2	  atrial	  fibrillation.	  Patients	  001-­‐004	  
consented	  to	  the	  optional	  extra	  cycle	  of	  labelling	  to	  enable	  assessment	  of	  intra-­‐patient	  
variation	  in	  proliferation.	  	  	  
Table	  4.2	  Patient	  Characteristics	  
	  
	  
	   	  
Trial	  
Number	  
Age	   Sex	   Binet	  
Stage	  
CD	  38	  	   IgVH	   FISH/cytogenetics	   Previous	  
Rx	  
001	   69	   M	   A	   7%	   Mutated	   No	  abnormality	   Nil	  
	  
002	   53	   M	   A	   66%	   Mutated	   No	  abnormality	   Nil	  
	  
003	   65	   M	   A	   >7%	   Not	  
assessed	  
Awaited	   Nil	  
	  




005	   62	   M	   A	   9%	   Mutated	   Biallelic	  13q	  del	   Nil	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4.3.2	  Primary	  End-­‐point	  
The	   primary	   outcome	   measure,	   change	   in	   proliferation	   rate	   of	   CLL	   cells	   after	   four	  
weeks	   was	   assessable	   in	   four	   patients.	   	   Modelled	   labelling	   curves,	   illustrating	   the	  
fraction	  of	  deuterium	  labelled	  cells	  per	  day	  are	  shown	  in	  Figure	  4.4	  a-­‐e.	  The	  turnover	  
rates	   of	   CLL	   cells	   in	   the	   five	   subjects	   studied	   were	   generally	   very	   low	   and	   labelling	  
curves	  tended	  to	  be	  flat	  indicating	  that	  the	  massive	  pool	  of	  leukaemic	  cells	  in	  the	  body	  
has	   a	   very	   slow	   turnover	   rate.	   Nine	   studies	   were	   performed	   before	   CsA	   and	   the	  
modelled	  mean	  proliferation	   rate	  of	   leukaemic	  cells	  was	  0.353	  ±	  0.253	  %/day	   (Table	  
4.3),	   equivalent	   to	   a	   doubling	   time	   of	   about	   200	   days.	   This	   is	   consistent	   with	  
proliferation	   rates	  measured	   in	  deuterated	  water	   studies	  where	  overall	   proliferation	  
rates	   were	   0.1-­‐1.76	   %/day,	   and	   proliferation	   rates	   greater	   than	   0.35	   %/day	   were	  
associated	  with	   progressive	   disease	   (Messmer	   et	   al.,	   2005).	   There	  was	   intra-­‐subject	  
variability	  in	  repeated	  pre-­‐treatment	  data,	  mainly	  attributable	  to	  subjects	  001	  and	  003.	  
In	  the	  four	  studies	  performed	  after	  CsA	  treatment,	  proliferation	  rates	  were	  very	  similar	  
to	  pre-­‐treatment	  values,	  0.254	  ±	  0.157	  %/day,	  equivalent	  to	  a	  doubling	  time	  of	  about	  
270	  days	  (Figure	  4.4f).	  	  
There	   was	   no	   difference	   in	   proliferation	   rate	   after	   four	   weeks’	   therapeutic	   CsA.	  
Furthermore,	  there	  was	  evidence	  of	  background	  intra-­‐patient	  variation	  in	  proliferation	  
rates	  (Table	  4.3,	  Figure	  4.4).	  
In	   Patient	   005,	   the	   proliferation	   rate	   appeared	   to	   increase	   in	   the	   presence	   of	   CsA.	  
However,	   there	  was	  a	   slight	   reduction	   in	   the	   total	   lymphocyte	   count	  whilst	  CsA	  was	  
being	  administered	  to	  this	  patient.	  One	  explanation	  for	  this	  observation	  may	  be	  that	  
anergy	  was	  reversed	  in	  the	  presence	  of	  CsA	  i.e.	  BCR	  signalling	  was	  restored,	  allowing	  
increased	   proliferation	   but	   a	   co-­‐incidental	   increase	   in	   apoptosis.	   To	   interrogate	   this	  
further,	   calcium-­‐signalling	   capacity	   in	   response	   to	   BCR	   ligation	   pre-­‐	   and	   during	   CsA	  
therapy	  could	  be	  measured.	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Figure	   4.4	   (a-­‐e)	   Modelled	   deuterium	   labelling	   in	   CLL	   cells	   in	   patients	   recruited	   to	  
CyCLLe	  
Patients	   2-­‐5	   underwent	   2	   cycles	   of	   labelling.	   Cycle	   1	   was	   immediately	   pre-­‐CsA	   and	  
Cycle	   2	  was	  performed	  after	   4	  weeks	   therapeutic	  CsA.	   Patients	   1-­‐4	   consented	   to	   an	  
optional	  cycle	  of	  labelling	  to	  assess	   intra-­‐patient	  variation	  in	  proliferation	  rates	  in	  the	  
absence	   of	   CsA.	  Deuterium	  enrichment	  was	  measured	  by	   gas	   chromatography	  mass	  
spectrometry	  and	  data	  was	  modelled	  by	  Prof.	  Macallan.	  
	  
	  
Figure	  4.4	  f	  Summary	  of	  proliferation	  rates	  for	  all	  patients	  
Each	   line	  represents	  a	  different	  patient.	  Patients	  2-­‐5	  were	   labelled	  pre	  and	  post	  CsA.	  
Patients	  1-­‐4	  underwent	  an	  optional	  cycle	  of	   labelling	  to	  assess	   intra-­‐patient	  variation	  
in	  the	  absence	  of	  CsA.	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Table	   4.3	   Proliferation	   Rate	   (%	   /day)	   as	   calculated	   by	   deuterium	   enrichment	   in	  
purified	  CLL	  cells	  
Proliferation	  rate	  was	  measure	  by	  in-­‐vivo	  labelling	  with	  deuterated	  glucose	  pre	  (C1)	  
and	  post	  CsA	  (C2).	  An	  optional	  extra	  labelling	  cycle	  was	  performed	  in	  4/5	  patients.	  
	  
Patient	   Optional	   –
P%/Day	  
C1-­‐	  P%/Day	   C2-­‐	  P%/Day	   Intra-­‐patient	  
variation	  
P%/day	  
(Optional	  vs	  C1)	  
Effect	  of	  CsA	  
on	   P%/day	  
(C1	  v	  C2)	  
001	   0.836	   0.401	   	   -­‐0.435%	   	  
002	   0.243	   0.358	   0.364	   +0.115%	   +0.006%	  
003	   0.691	   0.113	   0.063	   -­‐0.578%	   -­‐0.05%	  
004	   0.192	   0.201	   0.190	   +0.009%	   -­‐0.01%	  
005	   	   0.147	   0.399	   	   +0.25%	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4.3.3	  Release	  and	  loss	  rates	  of	  CLL	  cells	  from	  circulation	  
Release	  and	  loss	  rates	  were	  calculated	  by	  measuring	  the	  fraction	  of	  labelled	  CLL	  cells	  at	  
sequential	   time	   points	   post	   labelling	   (Table	   4.4).	   As	   measurement	   of	   release	   rates	  
required	  daily	  blood	   tests	   for	   the	   first	  week	  post	   labelling,	   it	  was	  an	   ‘optional	   extra’	  
procedure	  in	  the	  trial	  protocol.	  Measurement	  of	  time	  to	  maximum	  release	  of	  labelled	  
cells	  into	  the	  circulation	  was	  measured	  in	  three	  patients	  at	  baseline	  and	  in	  one	  patient	  
during	   CsA	   treatment.	   Time	   to	   maximum	   release	   rates	   was	   variable	   both	   between	  
patients	   and	   within	   patients,	   with	   a	   range	   of	   3-­‐21	   days	   pre-­‐treatment.	   Time	   to	  
maximum	   release	   was	   reduced	   from	   21	   to	   14	   days	   in	   the	   one	   patient	   assessed	   on	  
treatment.	   Although	   no	   conclusions	   can	   be	   drawn	   from	   this	   isolated	   observation,	  
shorter	   time	   to	   release	   in	   the	   presence	   of	   CsA	   is	   consistent	   with	   the	   in-­‐vitro	  
observation	   that	   CD69	   expression	   is	   inhibited	   in	   the	   presence	   of	   the	   drug.	   CD69	  
expression	  has	  been	  shown	  to	  play	  a	  role	  in	  tissue	  retention	  of	  B-­‐lymphocytes	  through	  
down-­‐modulation	  of	  S1P1	  expression	  (Shiow	  et	  al.,	  2006).	  
Disappearance	   rates	   were	   difficult	   to	   estimate	   as	   enrichments	   were	   so	   low;	   in	   four	  
measurements	  pre-­‐CsA	  and	  one	  post-­‐CsA	  no	  discernible	  loss	  of	  labelled	  cells	  occurred	  
during	  the	  28	  day	  follow-­‐up	  period.	  
Table	  4.4	  Release	  and	  Loss	  Rates	  of	  Labelled	  CLL	  cells	  
Mean	  time	  to	  maximum	  release	  of	  labelled	  CLL	  cells	  was	  assessed	  by	  drawing	  blood	  on	  
a	  daily	  basis	  for	  the	  first	  week	  post	  labelling.	  	  
	  
Cycle	  	   Mean	   (95%	   CI)	   Time	   to	  
Maximum	  release	  in	  days	  
Mean	  (95%	  CI)	  Loss	  rate	  of	  
CLL	  cells	  	  
0	   16.5	  	  	  (95%	  CI	  2.17,	  30.82)	   2.02	  	  (95%	  CI	  -­‐4.42,	  8.46)	  
1	   9.2	  	  	  	  	  (95%	  CI	  -­‐3.98,	  22.38)	   2.16	  	  	  (95%	  CI	  -­‐1.62,	  5.93)	  
2	   7.25	  (95%	  CI	  -­‐0.256,	  14.76)	   0.36	  	  (95%	  CI	  -­‐0.38,	  1.10)	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4.3.4	  Toxicity	  of	  ciclosporin	  
Patients	  were	  subject	   to	   twice	  weekly	  assessments	  until	   the	  CsA	  dose	  had	   remained	  
unchanged	   for	   three	   consecutive	   doses.	   Trough	   levels	   were	   targeted	   between	   150-­‐
200ng/ml.	  The	  median	  time	  in	  range	  was	  46.5	  %	  (30-­‐50	  %).	  A	  median	  of	  83.5	  %	  (66-­‐86	  
%)	   of	   all	   readings	  were	  within	   a	   25	  %	  margin	   of	   the	   therapeutic	   range	   (Figure	   4.5).	  
Toxicity	  assessments	   included	  physical	  examination,	  biochemical	  assessment	  of	   renal	  
function,	   liver	  function,	  electrolytes	  and	  glucose.	  Patients	  were	  screened	  for	  EBV	  and	  
CMV	  reactivation	  with	  weekly	  viral	  load	  monitoring.	  	  
Adverse	   Events	   listed	   in	   (Table	   4.5)	   were	  mainly	   grade	   1-­‐2	   and	   included	   headache,	  
myalgia,	  nausea,	  paraesthesia,	  tremor.	  In	  one	  patient,	  headache	  was	  considered	  to	  be	  
severe	  (grade	  3).	  There	  were	  three	  episodes	  of	  infection	  (grade	  1-­‐2).	  One	  patient	  (001)	  
was	  withdrawn	  from	  the	  study	  when	  he	  developed	  atrial	  fibrillation	  whilst	  taking	  CsA.	  
Two	  days	  later,	  he	  was	  admitted	  to	  hospital	  with	  a	  myocardial	  infarction	  (grade	  3)	  and	  
underwent	   coronary	   artery	   bypass	   grafting.	   The	   atrial	   fibrillation	   and	   myocardial	  
infarction	   were	   considered	   to	   be	   serious	   adverse	   events	   unrelated	   to	   the	   study	  
medication;	  there	  were	  no	  electrolyte	  abnormalities	  at	  the	  onset	  of	  atrial	  fibrillation.	  	  
Laboratory	   abnormalties	   were	   mostly	   grade	   1	   and	   included	   rise	   in	   alkaline	  
phosphatase	   in	  3	  /5	  patients,	   rise	   in	  bilirubin	   in	  2/5	  patients,	   rise	   in	  creatinine	   in	  5	   (	  
grade	   1	   x	   4,	   grade	   2	   x	   1	   )	   and	   grade	   1	   hypomagnasemia	   in	   4	   patients.	   These	  were	  
predictable	  toxicities	  of	  CsA.	  
One	  patient	  was	  found	  to	  have	  reactivated	  EBV	  (grade	  1)	  but	  remained	  asymptomatic	  
and	  the	  viraemia	  resolved	  spontaneously.	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Figure	  4.5	  CsA	  trough	  levels	  in	  CyCLLe	  subjects	  
CsA	   levels	   were	   measured	   in	   the	   Clinical	   Pathology	   Accredited	   (CPA)	   accredited	  
laboratories	  at	  KCH	  and	  UHW.	  CsA	  levels	  were	  titrated	  to	  a	  therapeutic	  range	  of	  150-­‐
200	  ng/ml	  by	  Dr.	  Cuthill.	  
	  
Table	  4.5	  Adverse	  Events	  
Adverse	  Event	   Grade	  1	  N	  (%)	   Grade	  2	  N	  (%)	   Grade	  3	  N	  (%)	  
Nausea	   5	  (100	  %)	   0	   0	  
Infection	   0	   2	  (40	  %)	   0	  
Myalgia	   4	  (80	  %)	   0	  	   0	  
Headache	   4	  (80	  %)	   0	   1	  (20	  %)	  
Tremor	   2	  (40	  %)	   0	   0	  
Paraesthesia	   3	  (60	  %)	   0	   0	  




3	  (60	  %)	   0	   0	  
Laboratory:	  	  
Bilirubin	  
1	  (20	  %)	   0	   0	  
Laboratory:	  
Creatinine	  
4	  (80	  %)	   1	  (20	  %)	   0	  
Laboratory:	  
Magnesium	  
4	  (80	  %)	   0	   0	  
Laboratory:	  
EBV	  VL	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4.3.5	  Clinical	  response	  to	  ciclosporin	  	  
Response	  rate	  to	  CsA	  was	  measured	  on	  D56	  in	  four	  patients	  using	  the	  Hallek	  Criteria	  
for	   Response	   Assessment	   (Hallek	   et	   al.,	   2008).	   All	   patients	   had	   stable	   disease	   after	  
eight	  weeks	  of	   CsA	   therapy.	  On	   review	  of	   serial	   lymphocyte	   counts	   (Figure	  4.6),	   4/5	  
patients	  were	  observed	  to	  develop	  an	  increase	  in	  peripheral	  blood	  lymphocyte	  count	  
immediately	  after	  initiation	  of	  CsA	  therapy	  that	  resolved	  over	  subsequent	  weeks.	  This	  	  
finding	   suggests	   that	   there	   is	   enhanced	   release	   of	  malignant	   cells	   from	   the	   tumour	  
microenvironment	  into	  the	  peripheral	  circulation	  in	  the	  presence	  of	  CsA.	  
	  
Figure	  4.6	  Serial	  lymphocyte	  counts	  during	  CsA	  therapy	  	  
Peripheral	  blood	   lymphocyte	  counts	  were	  monitored	   in	  all	  patients	   from	  the	   time	  of	  
baseline	  assessment	  and	  throughout	  CsA	  therapy.	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4.3.6	   Translational	   Studies	   	   -­‐	   Peripheral	   blood	   derived	   CD4	   T	   cells	   show	   trend	  
towards	  reduced	  activation	  following	  four	  weeks	  of	  ciclosporin	  therapy	  
The	  CyCLLe	  study	  was	  based	  on	   the	  hypothesis	   that	   inhibition	  of	  activation	  of	  CD4	  T	  
cells	  in	  CLL	  may	  reduce	  CLL	  activation	  and	  proliferation	  in-­‐vivo.	  It	  was	  therefore	  critical	  
to	  investigate	  whether	  the	  T	  cell	  suppressive	  effect	  of	  CsA	  seen	  in-­‐vitro	  is	  relevant	  in-­‐
vivo.	  The	  activation	  status	  of	  CD4	  T	  cells	  was	  measured	  in	  fresh	  CD4	  T	  cells	  negatively	  
selected	  from	  PBMCs	  pre	  treatment	  with	  CsA	  and	  after	  4	  weeks	  of	  CsA	  therapy	  (blood	  
drawn	  12	  hours	  after	  last	  dose).	  The	  activation	  of	  CD4	  T	  cells	  was	  assessed	  at	  rest	  and	  
following	  activation	  with	  anti-­‐CD3	  and	  anti-­‐CD28	  to	   investigate	   if	  CsA	  therapy	  affects	  
the	   potential	   of	   peripheral	   blood	   CD4	   T	   cells	   to	   be	   activated	   in	   the	   appropriate	  
environment.	   Activation	   status	   was	   assessed	   by	   flow	   cytometric	   measurement	   of	  
CD25,	  CD69,	  and	  CD40L	  expression.	  In-­‐vitro	  investigation	  into	  the	  effect	  of	  CsA	  on	  CD4	  
T	   cell	   activation	   by	   anti-­‐CD3	   and	   anti-­‐CD28	   had	   shown	   that	   CD69	   and	   CD40L	   are	  
inhibited	   in	   the	   presence	   of	   CsA	   and	   that	   there	   is	   a	   trend	   towards	   reduced	   CD25	  
expression.	   	   Although	   expression	   of	   activation-­‐markers	   in	   the	   resting-­‐state	   was	  
unchanged	   during	   CsA	   therapy,	   there	   was	   a	   trend	   towards	   reduced	   capacity	   to	   be	  
activated	   by	   CD3/28	   ligation.	   In	   all	   three	   patients,	   expression	   of	   CD25	   and	   CD69	   by	  
activated	   CD4	   T	   cells	   was	   reduced	   on	   treatment,	   and	   this	   pattern	   held	   for	   CD40L	  
expression	  in	  two	  of	  three	  patients.	  As	  in-­‐vivo	  assessment	  of	  T	  cell	  activation	  was	  only	  
possible	  in	  three	  patients,	  the	  results	  did	  not	  reach	  statistical	  significance	  (Figure	  4.7).	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Figure	  4.7	  Resting	  and	  activated	  CD4	  T	  Cell	  expression	  of	  CD25,	  CD69	  and	  CD40L	  pre	  
and	  post	  CsA	  therapy	  
Expression	   of	   CD25,	   CD69	   and	   CD40L	   was	   flow	   cytometrically	   measured	   on	   fresh,	  
viable	  CD4	  T	  cells	  before	  and	  after	  4	  weeks	  therapeutic	  CsA.	  Expression	  was	  measured	  
in	  both	  the	  resting	  and	  activated	  state.	  Activation	  was	  achieved	  using	  anti-­‐CD3	  coated	  
plates	  and	  un-­‐bound	  anti-­‐CD28.	  
	  
	  	  	  
4.3.7	  Translational	  Studies	  –	  Peripheral	  blood	  derived	  CLL	  cells	  show	  mixed	  response	  
to	  four	  weeks	  of	  in-­‐vivo	  ciclosporin	  therapy	  
Having	   shown	   that	  CD4	  T	   cell	   activation	   is	   suppressed	   following	   in-­‐vivo	   CsA	   therapy,	  
and	  on	  the	  basis	  that	   in-­‐vitro,	  this	   lead	  to	  reduced	  CLL	  cell	  activation,	  we	  went	  on	  to	  
measure	  CLL	  cell	  activation	  status	  in	  both	  the	  resting	  and	  CD40L-­‐stimulated	  state	  pre	  
and	  post	  CsA	  treatment.	  Expression	  of	  CD25,	  CD38	  and	  CD69	  was	  measured	  in	  freshly	  
collected,	   viable	   CLL	   cells.	   CD38	   is	   a	   Type	   II	   transmembrane	   glycoprotein	   that	  
participates	   in	   signal	   transduction	   necessary	   for	   activation	   and	   proliferation	   of	   B	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To	   test	   the	   effect	   of	   in-­‐vivo	   CsA	   on	   the	   ability	   of	   CLL	   cells	   to	   respond	   to	   CD40L	  
activation,	   negatively	   selected	   CLL	   cells	   were	   stimulated	   with	   CD40L	   transfected	  
fibroblast-­‐coated	   plates.	   Expression	   of	   CD25	   and	   CD38	   showed	   a	   mixed	   response;	  
however,	   expression	   of	   CD69	   by	   stimulated	   CLL	   cells	   was	   consistently	   suppressed	  
following	  CsA	  treatment.	  Again,	  this	  result	  did	  not	  reach	  statistical	  significance	  due	  to	  
the	  small	  number	  patients	   investigated	  (Figure	  4.8).	  This	  observation	  is	   in	  contrast	  to	  
the	   finding	   that	   CD69	   expression	   by	   CLL	   cells	   activated	  with	   CD40L	   in-­‐vitro	   was	   not	  
inhibited	  by	  CsA.	  The	  difference	  between	  in-­‐vitro	  and	  in-­‐vivo	  findings	  may	  relate	  to	  the	  
fact	   that	  CsA	  was	  administered	  for	   four	  weeks	  pre-­‐activation	  with	  CD40L	  transfected	  
fibroblasts	   in	   the	   in-­‐vivo	   study	  whilst	   CLL	   cells	  were	   preconditioned	  with	   CsA	   for	   60	  
minutes	  in	  the	   in-­‐vitro	  assay,	  allowing	  time	  for	  the	  gene	  expression	  of	  CLL	  cells	  to	  be	  
altered.	  
	  
Figure	  4.8	  Resting	  and	  activated	  CLL	  cell	  expression	  of	  CD25,	  CD38	  and	  CD69	  pre	  and	  
post	  CsA	  Therapy	  
Expression	  of	  CD25,	  CD38	  and	  CD69	  was	  flow	  cytometrically	  measured	  on	  fresh,	  viable	  
CLL	  cells	  before	  and	  after	  4	  weeks	  therapeutic	  CsA.	  Expression	  was	  measured	  in	  both	  
the	   resting	   and	   activated	   state.	   Activation	   was	   achieved	   using	   CD40L	   transfected	  
fibroblasts.	  The	  sample	  size	  eliminated	  the	  potential	  for	  statistical	  analysis.	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4.3.8	  In-­‐vivo	  ciclosporin	  suppresses	  CLL	  cell	  activation	  by	  autologous	  CD4	  T	  cells	  
Having	  demonstrated	  a	  trend	  towards	  suppression	  of	  CD4	  T	  cell	  activation	  following	  in-­‐
vivo	  CsA	  therapy,	  the	  effect	  of	  in-­‐vivo	  CsA	  on	  the	  ability	  of	  CD4	  T	  cells	  to	  activate	  CLL	  
cells	  was	  next	   investigated.	  PBMCs	  were	  harvested	  pre	  and	  post	  treatment	  with	  CsA.	  
CD4	   T	   cells	   were	   isolated	   and	   activated	   with	   anti-­‐CD3	   and	   anti-­‐CD28	   for	   12	   hours	  
before	  re-­‐combining	  with	  purified	  CLL	  cells	  for	  24	  hours.	  No	  additional	  CsA	  was	  added	  
to	  the	  culture	  medium.	  In	  the	  post	  in-­‐vivo	  CsA	  co-­‐culture,	  CD25	  expression	  at	  24	  hours	  
was	  reduced	  by	  a	  mean	  of	  37	  %,	  CD38	  expression	  was	  reduced	  by	  a	  mean	  of	  36	  %	  and	  
CD69	  expression	  was	   reduced	  by	   a	  mean	  of	   16.4	  %.	   The	   sample	   size	   eliminated	   the	  
potential	  for	  statistical	  analysis.	  These	  findings	  suggest	  that	  following	  in-­‐vivo	  CsA,	  CD4	  
T	  cells	  may	  be	  less	  able	  to	  activate	  CLL	  cells.	  	  
	  
	  
Figure	   4.9	   CLL	   cell	   activation	   pre	   and	   post	   in-­‐vivo	   CsA	   following	   co-­‐culture	   with	  
activated	  autologous	  CD4	  T	  cells	  	  
CLL	  cells	  from	  patients	  pre	  and	  post	  CsA	  treatment	  were	  co-­‐cultured	  for	  24	  hours	  with	  
CD4	  T	  cells	  that	  had	  been	  activated	  with	  anti-­‐CD3	  /	  anti-­‐CD28.	  Activation	  was	  assessed	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4.3.9	   Effect	   of	   in-­‐vivo	   ciclosporin	   on	   baseline	   transcription	   factor	   activation	   in	   CLL	  
and	  CD4	  T	  cells	  
In-­‐vitro	  studies	  that	  utililised	  image	  flow	  cytometry	  to	  assess	  the	  effect	  of	  CsA	  on	  CD4	  T	  
cell	   and	   CLL	   cell	   transcription	   factor	   activation	   demonstrated	   that	   CsA	   inhibited	  
nuclear	  translocation	  of	  NFAT-­‐C2	  and	  NFκB-­‐p65	  in	  CD4	  T	  cells	  activated	  with	  PMA	  and	  
Ionomycin.	   Furthermore,	   NFAT-­‐C2	   and	   NFκB-­‐p65	   nuclear	   translocation	   in	   CD40L	  
activated	  CLL	  cells	  could	  not	  be	  overcome	  by	  CsA.	  To	   investigate	  the	  effect	  of	   in-­‐vivo	  
CsA	  therapy	  on	  transcription	  factor	  activation,	  NFAT-­‐C2	  and	  NFκB-­‐p65	  localisation	  was	  
assessed	   in	   freshly	   collected	   CD4	   T	   cells	   and	   CLL	   cells.	   There	   was	   no	   significant	  
difference	  between	  pre-­‐	  and	  post-­‐treatment	  transcription	  factor	  localisation	  in	  resting	  
CLL	  and	  CD4	  T	  cells.	  
	  
Figure	   4.10	  Nuclear	  NFAT-­‐C2	   and	  NFκB-­‐p65	   in	   resting	   CLL	   and	   CD4	   T	   cells	   pre	   and	  
after	  4	  weeks	  CsA	  therapy	  
CLL/	  CD4+	  T	  cells	  were	  gated	  on	  and	  the	  degree	  of	  nuclear	  translocation	  of	  NFκB-­‐p65	  
and	  NFAT-­‐C2	  was	  calculated	  using	  a	  similarity	  score	  between	  the	  nucleus	   (DAPI)	  and	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4.3.10	   There	   is	   a	   trend	   towards	   reduced	   transcription	   factor	   activation	   in	   CLL	   and	  
CD4	  T	  cells	  following	  in-­‐vivo	  ciclosporin	  therapy	  
In	  view	  of	  the	  observation	  that	  CsA	  inhibits	  nuclear	  translocation	  of	  NFAT-­‐C2	  and	  NFκB	  
-­‐p65	   in	   activated	   CLL	   CD4	   T	   cells	   in-­‐vitro,	   the	   effect	   of	   in-­‐vivo	   CsA	   on	   transcription	  
factor	  activation	  was	  measured.	  Following	  4	  weeks	  of	  in-­‐vivo	  CsA	  therapy,	  CD4	  T	  cells	  
were	   isolated	  and	  activated	   for	  30	  minutes	  with	  PMA	  and	   Ionomycin.	  Figure	  4.11a-­‐b	  
shows	   that	   there	   is	   a	   trend	   towards	   reduced	   nuclear	   translocation	   of	   NFAT-­‐C2	   and	  
NFκB-­‐p65,	  consistent	  with	  the	  in-­‐vitro	  findings.	  	  	  
We	  then	  went	  on	  to	  investigate	  the	  effect	  of	  in-­‐vivo	  CsA	  on	  NFAT-­‐C2	  and	  NFκB-­‐p65	  in	  
CLL	   cells	   activated	   with	   CD40L	   transfected	   fibroblasts.	   Although	   the	   in-­‐vitro	   studies	  
demonstrated	   no-­‐effect	   of	   CsA	   on	   CD40L	  mediated	   transcription	   factor	   activation	   in	  
CLL	  cells,	  and	  although	  there	  was	  no	  discernible	  effect	  on	  resting	  CLL	  cells,	  there	  was	  a	  
reduction	  in	  nuclear	  NFAT-­‐C2	  and	  NFκB-­‐p65	  in	  2/3	  patients	  assessed	  (Figure	  4.11c-­‐d).	  
Assessment	  of	   transcription	   factor	   activation	  was	  only	  measureable	   in	   3	   patients	   on	  
the	  CyCLLe	  study,	  therefore	  findings	  did	  not	  reach	  statistical	  significance.	  	  	  
	   	  
Figure	  4.11	  Nuclear	  NFAT-­‐C2	  and	  NFκB-­‐p65	  in	  activated	  CLL	  and	  CD4	  T	  cells	  pre	  and	  
after	  4	  weeks	  CsA	  therapy	  
CD4	  T	  cells	  were	  activated	  using	  PMA	  and	  Ionomycin	  and	  CLL	  cells	  were	  activated	  using	  
CD40	   L	   transfected	   fibroblasts.	   CLL/	   CD4+	   T	   cells	   were	   gated	   on	   and	   the	   degree	   of	  
nuclear	  translocation	  of	  NFκB-­‐p65	  and	  NFAT-­‐C2	  was	  calculated	  using	  a	  similarity	  score	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4.3.11	  Ciclosporin	  has	  no	  effect	  on	  T	  cell	  subsets	  following	  in-­‐vivo	  therapy	  
A	  number	  of	  abnormalities	  of	  T	  cell	  number	  and	  function	  have	  been	  reported	  in	  CLL;	  it	  
has	  been	  shown	  that	  there	  is	  skewing	  of	  the	  normal	  CD4:	  CD8	  ratio	  with	  expansion	  of	  
CD8	  T	  cells	  and	  accumulation	  of	  terminally	  differentiated	  effector	  memory	  T	  cells	  with	  
a	  relative	  paucity	  of	  naïve	  precursors	  (Nunes	  et	  al.,	  2012).	  We	  therefore	   investigated	  
whether	   4	  weeks	   CsA	   therapy	   had	   an	   impact	   on	   these	   subsets	   in	   patients	  with	   CLL.	  
PBMCs	  were	  collected	  pre-­‐	  and	  after	  4	  weeks	  CsA	  therapy.	  Subsets	  were	  assessed	  by	  
flow	  cytometry,	  gating	  on	  single,	  viable	  T	  cells	  according	  to	  the	  expression	  of	  CCR7	  and	  
CD45RA,	   classifying	   T	   cells	   as	   Naïve,	   CM	   (central	   memory),	   EM	   (effector	   memory)	  
EMRA	   (terminally	   differentiated	   effector).	   Gates	   were	   set	   using	   ‘fluoresence	   minus	  
one’	  controls,	  as	  illustrated	  in	  Figure	  4.12	  a.	  Figure	  4.12	  b	  illustrates	  pie-­‐charts	  of	  CD4	  
and	  CD8	  subsets	  pre	  and	  post	  CsA	  for	  each	  patient	  that	  are	  summarized	  in	  Figure	  4.11	  
c-­‐d.	  CD8	  T	  cells	  were	  particularly	  skewed	  towards	  a	  terminally	  differentiated	  effector	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Figure	  4.12	  (a-­‐d)	  T	  cell	  subsets	  assessed	  pre	  and	  post	  4	  weeks	  of	  in-­‐vivo	  CsA	  therapy	  
T	  cell	  subsets	  were	  assessed	  in	  4	  patients	  pre	  and	  after	  4	  weeks	  CsA	  therapy.	  	  
a.	  Sub-­‐sets	  were	  measured	  by	  flow	  cytometry,	  gating	  on	  single,	  viable	  CD4/	  CD8	  T	  cells	  
according	  to	  the	  expression	  of	  CCR7	  and	  CD45	  RA	  and	  classifying	  T	  cells	  as	  Naïve,	  CM	  
(central	   memory),	   EM	   (effector	   memory)	   EMRA	   (terminally	   differentiated	   effector).	  
Gates	  were	  set	  using	  FMO	  controls.	  
b.	  Pie	  charts	  illustrating	  CD4	  and	  CD8	  T	  cell	  sub-­‐sets	  in	  each	  participant	  pre	  and	  post	  4	  
weeks	  in-­‐vivo	  CsA	  therapy.	  
c.	  Summary	  of	  CD4	  and	  CD8	  T	  cell	  sub-­‐sets	  pre	  and	  post	  4	  weeks	  in-­‐vivo	  CsA	  therapy.	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4.3.12	   Translational	   Studies	   –	   PD-­‐1	   Expression	   by	   CLL	   CD4	   and	   CD8	   T	   cells	   is	   not	  
sensitive	  to	  4	  weeks	  in-­‐vivo	  ciclosporin	  therapy	  
CLL	   CD4	   and	   CD8	   T	   cells	   have	   been	   shown	   to	   have	   increased	   expression	   of	   PD-­‐1,	   a	  
marker	   of	   T	   cell	   exhaustion,	   compared	   to	   age-­‐matched	   controls	   (Brusa	   et	   al.,	   2013)	  
and	  it	  has	  been	  proposed	  that	  PD-­‐1	  ligation	  by	  CLL	  cells	  plays	  a	  role	  in	  immune-­‐evasion	  
(Brusa	  et	  al.,	  2013;	  Riches	  et	  al.,	  2013).	  Furthermore,	  PD-­‐1	  expression	  has	  been	  shown	  
to	  be	  under	  transcriptional	  control	  of	  NFAT-­‐C1	  and	  sensitive	  to	  CsA	  (Oestreich,	  Yoon,	  
Ahmed,	  &	  Boss,	  2008).	  We	  therefore	  measure	  PD-­‐1	  expression	  on	  peripheral	  blood	  T	  
cells	   before	   and	   after	   4	   weeks	   CsA	   therapy	   (Figure	   4.13).	   PD-­‐1	   expression	   was	   not	  
significantly	  affected	  by	  the	  presence	  of	  CsA	  (n=4).	  
	  
	  	  
Figure	  4.13	  PD-­‐1	  Expression	  before	  and	  after	  4	  weeks	  of	  in-­‐vivo	  CsA	  therapy	  
PD-­‐1	  expression	  by	  viable,	  peripheral	  blood	  CD4	  and	  CD8	  T	  cells	  was	  measured	  by	  flow	  
cytometry	  per	  and	  after	  4	  weeks	  therapeutic	  CsA	  in	  5	  patients	  with	  CLL.	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4.3.13	  Translational	  Studies	  –	  Effect	  of	  in-­‐vivo	  ciclosporin	  on	  gene	  expression	  profile	  
of	  CLL	  and	  CD4	  T	  cells	  
Gene	  expression	  profiling	  using	  microarray	  technology	  was	  employed	  to	  compare	  gene	  
expression	  in	  purified	  CD4	  T	  cells	  and	  CLL	  cells	  pre	  and	  after	  four	  weeks	  of	  CsA	  therapy.	  
It	   was	   crucial	   to	   assess	   gene	   expression	   in-­‐vivo	   in	   view	   of	   the	   complex	   interactions	  
between	  CLL	  and	  CD4	  T	  cells	  that	  cannot	  be	  accurately	  replicated	  in-­‐vitro.	  
Briefly,	  cells	  were	  purified	  by	  fluorescence	  activated	  cell	  sorting	  (FACS)	  ensuring	  purity	  
>	  95	  %.	  RNA	  was	  extracted	  using	  Qiagen	  RNAeasy	  mini-­‐kit.	  The	  quantity	  and	  quality	  of	  
RNA	  was	  assessed	  using	  the	  NanoDrop	  2000	  (Thermo	  Scientific)	  spectrophotometer.	  A	  
minimum	  of	  150ng/mcl	  was	  required	  for	  hybridization;	  this	  was	  achieved	  with	  purified	  
CLL	   cells	   pre	   and	   post	   treatment	   from	   all	   5	   patients	   but	   from	   CD4	   T	   cells	   in	   only	   3	  
patients.	  Aliquots	  of	  RNA	  were	   transferred	   to	   the	  Genomics	   core	   at	   the	  BRC,	  where	  
gene	   expression	   was	   assessed	   using	   Illumina®	   Microarray	   Bead	   Chip	   technology	  
(Chapter	   2.7).	   	   RNA	   hybridization	   to	   the	   BeadChip	   microarray	   was	   assessed	   using	  
Illumina®	   iScan	   technology.	   Comparison	   of	   gene	   expression	   was	   performed	   using	  
Genome	   Studio	   Software.	   Bonferroni	   correction	   and	   false	   discovery	   rate	   adjustment	  
were	  applied	  to	  correct	  for	  multiple	  hypothesis	  testing.	  
Following	  Bonferroni	  correction,	  there	  was	  reduced	  transcription	  of	  two	  genes	  in	  CD4	  
T	   cells	   post	   CsA	   therapy;	  DDIT4	   (DNA	  damage	   inducible	   transcript	   4)	   (p=	   3.30-­‐7)	   and	  
PTGER4	  	  (Prostaglandin	  E	  receptor	  4)	  (p	  =	  9.57-­‐7).	  Using	  the	  less	  stringent	  test	  of	  False	  
Discovery	  Rate,	  SNORA12	  (small	  nucleolar	  RNA)	  was	  also	  suppressed	  in	  CD4	  T	  cells	   in	  
the	  presence	  of	  CsA.	  	  
DDIT4	  encodes	  DDIT4,	  which	  acts	  as	  a	  negative	  regulator	  of	  mTOR,	  a	  serine/threonine	  
kinase	   that	   regulates	  a	  variety	  of	  cellular	   functions	  such	  as	  growth,	  proliferation	  and	  
autophagy.	  It	  has	  not	  previously	  been	  implicated	  in	  the	  mechanism	  of	  action	  of	  CsA.	  
	  PTGER4	  encodes	  prostaglandin	  E	  receptor	  4	  (EP4),	  a	  g-­‐protein	  coupled	  receptor	  that	  
has	  a	  pro-­‐inflammatory	  mechanism	  of	  action	  in	  T	  cells,	  implicated	  in	  cancer	  and	  auto-­‐
immunity	  (Sreeramkumar,	  Fresno,	  &	  Cuesta,	  2011).	  EP4	  leads	  to	  Th1	  and	  Th17	  skewing	  
that	  can	  be	  blocked	  by	  EP4-­‐specific	  antagonism,	  suppressing	  Th1	  and	  Th17	  expansion	  
in	   the	   lymph-­‐node	   of	   an	   animal	   model	   of	   inflammation	   (Yao	   et	   al.,	   2009).	   Little	   is	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understood	   about	   the	   regulation	   of	   PTGER4	   transcription	   in	   T	   cells	   and	   again,	   its	  
inhibition	   has	   not	   previously	   been	   implicated	   in	   the	   mechanism	   of	   action	   of	   CsA.	  
SNORA12	  encodes	  a	  small	  nucleolar	  RNA	  that	  is	  involved	  in	  RNA	  processing	  and	  its	  role	  
has	  not	  previously	  been	  reported	  to	  be	  a	  target	  of	  CsA	  therapy.	  	  
The	   results	   of	   the	   gene	   expression	   studies	   should	   be	   tested	   by	   performing	   reverse	  
transcription	  quantitative	  polymerase	  chain	  reaction	  (RT-­‐qPCR)	  of	  DDIT4,	  PTGER4	  and	  
SNORA12	  genes.	  However,	  there	  was	  an	  insufficient	  quantity	  of	  CD4	  T	  cells	  to	  extract	  
additional	  RNA	  so	  it	  was	  not	  possible	  to	  further	  validate	  microarray	  results.	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4.4	  Discussion	  
The	   purpose	   of	   the	   CyCLLe	   study	   was	   to	   investigate	   whether	   manipulation	   of	   the	  
tumour	  microenvironment,	  using	   the	  calcineurin	   inhibitor	  CsA	  to	  suppress	  CD4	  T	  cell	  
activation,	   inhibits	   the	   proliferation	   rate	   of	   CLL	   cells	   in-­‐vivo.	   In-­‐vitro	   studies	  
demonstrated	  that	  in	  CLL,	  CsA	  inhibits	  the	  activation	  of	  CD4	  T	  cells	  and	  that	  when	  co-­‐
cultured	  with	  CLL	  cells,	  CsA-­‐treated	  autologous	  CD4	  T	  cells	  were	   less	  able	  to	  activate	  
CLL	  cells.	  There	  was	  an	  additional	  direct	  effect	  of	  CsA	  on	  CLL	  cells,	  notably	   inhibiting	  
CD69	   expression	   which	   plays	   a	   role	   in	   retention	   of	   CLL	   cells	   in	   the	   lymph-­‐node	  
compartment	  (Shiow	  et	  al.,	  2006;	  Sic	  et	  al.,	  2014).	  
The	  study	  aimed	  to	  investigate	  the	  effect	  of	  CsA	  in	  patients	  with	  early	  stage	  adverse-­‐
risk	   CLL	   in	   whom,	   despite	   the	   more	   progressive	   nature	   of	   the	   disease,	   there	   is	  
currently	  no	  known	  intervention	  that	  improves	  clinical	  outcome.	  	  
The	   initial	  study	  was	  designed	  to	   intensively	   investigate	  the	   in-­‐vivo	  effect	  of	  CsA	   in	  a	  
small	   cohort	  of	  patients,	  with	  a	  plan	   to	  expand	   to	  a	   larger	   cohort	   study	  with	   clinical	  
end-­‐points	   if	   there	  was	  a	  measurable	   reduction	   in	   the	  proliferation	   rate	  of	  CLL	   cells.	  
Unfortunately,	  despite	   the	  convincing	  effect	  of	  CsA	   in-­‐vitro,	   the	   trial	   failed	   to	   recruit	  
fully,	  making	   it	   difficult	   to	   draw	   conclusions	   and	   a	   larger	   cohort	   study	   could	   not	   be	  
justified.	  
The	  proliferation	  rate	  of	  CLL	  cells	  was	  measured	  using	  in-­‐vivo	  labelling	  with	  deuterated	  
glucose,	   the	   first	   time	  that	   this	   technique	  has	  been	  employed	  to	  assess	   the	  effect	  of	  
drug	   treatment.	   Pre-­‐treatment	   proliferation	   rates	   were	   low	   (mean	   =	   0.35	   %/day),	  
similar	   to	   proliferation	   rates	   in	   patients	   with	   no	   indication	   for	   treatment,	   reported	  
using	  deuterated	  water	  (Messmer	  et	  al.,	  2005).	  Spontaneous	  intra-­‐patient	  variation	  in	  
proliferation	  was	  observed	  in	  4	  patients	  who	  consented	  to	  the	  optional	  extra	  labelling	  
cycle;	  this	  was	  considered	  to	  be	  attributable	  to	  low	  enrichment	  rates	  resulting	  from	  a	  
large	   pool	   of	   non-­‐proliferating	   CLL	   cells.	   There	   was	   no	   measurable	   reduction	   in	  
proliferation	   of	   CLL	   cells	   after	   4	   weeks	   of	   CsA	   therapy	   and	   there	   was	   no	   clinical	  
response	  observed	  after	  8	  weeks	  of	  treatment;	  all	  patients	  had	  stable	  disease.	  
Four	  of	  five	  patients	  were	  observed	  to	  develop	  a	  lymphocytosis	  upon	  commencement	  
of	  CsA	  therapy,	  suggestive	  of	  an	  effect	  of	  CsA	  on	  CLL-­‐cell	  interaction	  with	  the	  tumour	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microenvironment.	  This	  may	  be	  explained	  by	  the	  observation	  that	  in-­‐vitro,	  CsA	  inhibits	  
CD69	  expression	  by	  CLL	  cells	  activated	  by	  both	  autologous	  CD4	  T	  cells	  and	  through	  the	  
BCR.	  CD69	  expression	  by	  CLL	  cells	  plays	  a	  role	   in	  tissue-­‐retention	  by	  down-­‐regulating	  
S1P1	   expression	   that	   is	   required	   for	   egress	   of	   tumour	   cells	   from	   the	   lymph-­‐node	  
compartment	   (Sic	   et	   al.,	   2014).	   Furthermore,	   the	   expression	   of	   CD69	   by	   CD40L-­‐
activated	  CLL	  cells	  appeared	  to	  be	  inhibited	  following	  in-­‐vivo	  CsA,	  however	  it	  was	  not	  
possible	   to	   analyse	   for	   statistical	   significance	   due	   to	   the	   small	   number	   of	   patients	  
assessed.	   An	   acute	   lymphocytosis	   related	   to	   the	   redistribution	   of	   CLL	   cells	   from	   the	  
lymph-­‐node	  compartment	  into	  the	  peripheral	  blood	  is	  a	  recognised	  feature	  in	  patients	  
treated	   with	   drugs	   that	   inhibit	   BCR	   signalling	   (Herman,	   Niemann,	   et	   al.,	   2014b).	  
Notably,	   BTK	   inhibition	  with	   ibrutinib	   leads	   to	   a	   rapid	   reduction	   in	   CD69	   expression	  
and	   a	   reduction	   in	   proliferation	   of	   peripheral	   blood	   CLL	   cells	   (measured	   by	   Ki67	  
expression)	   in-­‐vivo	   (Herman,	   Mustafa,	   et	   al.,	   2014a).	   However,	   down-­‐regulation	   of	  
CXCR4	  signalling	  is	  thought	  to	  contribute	  to	  the	  egress	  of	  CLL	  cells	  in	  patients	  treated	  
with	  ibrutinib	  (Herman,	  Niemann,	  et	  al.,	  2014b).	  Expression	  of	  this	  chemokine	  receptor	  
should	   be	   measured	   in	   the	   context	   of	   CsA	   therapy,	   particularly	   as	   it	   is	   under	   the	  
transcriptional	  control	  of	  NFAT3	  and	  has	  been	  shown	  to	  be	  sensitive	  to	  CsA	   in	  an	   in-­‐
vitro	  model	  (Y.	  H.	  Huang,	  Sojka,	  &	  Fowell,	  2012).	  
Patients	  tolerated	  CsA	  treatment	  well,	  with	  the	  commonest	  side	  effects	  being	  grade	  1	  
headache,	  nausea	  and	  myalgia.	   Importantly,	   there	  were	  no	  severe	   infections.	  Patient	  
001	   was	   withdrawn	   from	   the	   study	   after	   one	   week	   of	   CsA	   therapy,	   following	   the	  
development	  of	  atrial	  fibrillation.	  Two	  days	  after	  discontinuing	  treatment,	  he	  went	  on	  
to	   sustain	   a	   myocardial	   infarction.	   These	   events	   were	   deemed	   to	   have	   been	  
independent	  of	  the	  treatment.	  	  
Translational	   studies	   revealed	   no	   significant	   difference	   in	   the	   activation	   status	   of	  
unstimulated	   CD4	   and	   CLL	   cells	   following	   in-­‐vivo	   CsA	   therapy.	   However,	   post-­‐
treatment,	   there	   was	   a	   trend	   towards	   reduced	   responsiveness	   of	   CD4	   T	   cells	   to	  
stimulation	  with	  anti-­‐CD3/	  anti-­‐CD28.	  In	  order	  to	  replicate	  CD4	  T	  cell:	  CLL	  interactions	  
in	  the	  tumour	  microenvironment,	  CLL	  cells	  were	  co-­‐cultured	  with	  activated	  autologous	  
CD4	  T	  cells	  before	  and	  during	  CsA	  treatment.	   In	  the	  co-­‐cultures	  performed	  during	   in-­‐
vivo	   CsA	   treatment,	   there	   was	   a	   trend	   towards	   inhibition	   of	   CLL	   cell	   activation,	  
suggesting	   that	   inhibition	   of	   CD4	   T	   cell	   activation	   translates	   into	   reduced	   CLL	   cell	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activation.	   Additionally,	   there	  was	   a	   trend	   towards	   reduced	   CD69	   expression	   by	   CLL	  
cells	  activated	  with	  CD40L	  during	  in-­‐vivo	  therapy,	  suggesting	  that	  CsA	  may	  reduce	  the	  
response	  of	  CLL	  cells	  to	  T	  cell	  activation.	  	  
In	   view	   of	   the	   previously	   described	   mechanism	   of	   action	   of	   CsA,	   activation	   of	  
transcription	  factors	  NFκB-­‐p65	  and	  NFAT-­‐C2	  was	  assessed	  using	  image	  flow	  cytometry	  
to	  measure	   nuclear	   translocation	   in	   CD4	   T	   cells	   and	   CLL	   cells	   pre	   and	   during	   in-­‐vivo	  
CsA.	   Although	   there	   was	   no	   overall	   difference	   in	   transcription	   factor	   activation	   in	  
unstimulated	  CD4	  T	  cells,	  there	  was	  a	  trend	  towards	  reduced	  NFκB-­‐p65	  and	  NFAT-­‐C2	  
nuclear	  translocation	  following	  PMA	  and	  Ionomycin	  activation.	  Furthermore,	  although	  
CsA	  did	  not	  inhibit	  NFκB-­‐p65	  and	  NFAT-­‐C2	  nuclear	  translocation	  in	  CD40L	  activated	  CLL	  
cells	   in-­‐vitro,	   there	  was	   a	   reduction	   in	   transcription	   factor	   activation	   in	   response	   to	  
CD40L	   stimulation	   in	   two	  of	   three	  patients	   assessed	  during	   in-­‐vivo	  CsA	   therapy.	   	   An	  
explanation	   for	   this	   finding	   is	   that	   CLL	   cells	   may	   have	   altered	   gene	   expression	   and	  
therefore	   altered	   sensitivity	   to	   CD40L	   activation	   following	   four	   weeks	   of	   CsA	  
treatment.	  
One	  patient	  (005)	  exhibited	  reduced	  nuclear	  translocation	  of	  NFκB-­‐p65	  in	  CD4	  T	  cells	  
and	   reduced	  NFκB-­‐p65	  and	  NFAT-­‐C2	  nuclear	   translocation	   in	   resting	  CLL	   cells	   during	  
CsA	  therapy.	  Furthermore,	  expression	  of	  CD25	  and	  CD69	  by	  activated	  CD4	  T	  cells	  and	  
expression	  of	  CD38	  and	  CD69	  by	  activated	  CLL	  cells	  was	  reduced	  in	  this	  case.	  Counter-­‐
intuitively,	  there	  appeared	  to	  be	  an	  increase	   in	  the	  proliferation	  rate	  of	  CLL	  cells	  and	  
an	  overall	  small	  reduction	  in	  the	  total	  lymphocyte	  count	  following	  commencement	  of	  
CsA.	  One	  explanation	  for	  these	  findings	   is	  that	  there	  may	  have	  been	  a	  component	  of	  
anergy	   that	   was	   reversed	   in	   the	   presence	   of	   CsA,	   leading	   to	   an	   increased	   rate	   of	  
apoptosis	   of	   CLL	   cells.	   To	   investigate	   this	   further,	   signalling-­‐response	   to	  BCR-­‐ligation	  
should	  have	  been	  measured	  before	  and	  during	  CsA	  therapy.	  
PD-­‐1	  expression	  by	  CD4	  T	  cells	  has	  been	   reported	   to	  be	  CsA-­‐	   sensitive,	  and	  as	  a	  key	  
component	   in	   immune	  evasion	   in	  CLL,	  was	  an	   important	   line	  of	   investigation	  on	   this	  
study.	  However,	  we	   found	   that	   PD-­‐1	  expression	  was	  not	   reduced	  after	   4	  weeks	  CsA	  
therapy.	   Furthermore,	   T	   cell	   phenotype	   remained	   remarkably	   stable	   post	   CsA,	   with	  
preservation	  of	  expanded	  CD8	  effector	  memory	  and	  effector	  compartments.	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Comparison	  of	  gene	  expression	  on	  CLL	  and	  CD4	  T	  cells	  pre	  and	  post	  in-­‐vivo	  CsA	  therapy	  
was	   performed	   to	   further	   investigate	   the	   effect	   of	   CsA	   on	   CD4	   T	   cell:	   CLL	   cell	  
interactions	  in-­‐vivo.	  Comparison	  of	  CD4	  T	  cell	  gene	  expression	  pre	  and	  post	  treatment	  
was	  only	  possible	  in	  three	  patients	  due	  to	  insufficient	  mRNA	  from	  the	  fourth	  patient.	  
However,	  amongst	  the	  three	  genes	  down-­‐regulated	  on	  treatment,	  was	  PTGER4,	  which	  
encodes	  prostaglandin	  E	  receptor	  4	  (EP4).	  This	  g-­‐protein	  coupled	  receptor	  is	  reported	  
to	  transmit	  pro-­‐inflammatory	  signalling,	  leading	  to	  Th1/Th17	  skewing	  in-­‐vivo.	  Although	  
not	   previously	   reported	   to	   contribute	   to	   the	   mechanism	   of	   action	   of	   CsA,	   down-­‐
regulation	  is	  consistent	  with	  in-­‐vitro	  and	  in-­‐vivo	  effects	  of	  the	  drug.	  
There	  are	  a	  number	  of	  limitations	  to	  this	  study;	  the	  major	  challenge	  being	  recruitment.	  
Firstly,	   the	   trial	   protocol	   defined	   ‘poor	   risk’	   as	   expression	  of	  CD38	   in	   >	  7%	  CLL	   cells.	  
Many	  of	  the	  patients	  found	  to	  meet	  this	  criterion	  had	  evidence	  of	  disease	  progression	  
that	   warranted	   conventional	   therapy	   at	   the	   time	   of	   diagnosis.	   Secondly,	   the	   trial	  
protocol	   involved	   24	   weeks	   of	   continuous	   patient	   commitment	   with	   a	   minimum	   of	  
weekly	   hospital	   visits	   during	   the	   eight	   weeks	   of	   CsA	   therapy.	   This	   degree	   of	  
commitment	   was	   prohibitive	   for	   most	   patients	   approached	   regarding	   the	   study,	  
meaning	  that	  only	  four	  patients	  (of	  fourteen	  approached)	  were	  recruited	  in	  the	  initial	  
phase.	  Following	  a	  protocol	  amendment	  to	  reduce	  the	  protocol	  duration	  to	  16	  weeks,	  
one	  further	  patient	  was	  recruited.	  Despite	  major	  efforts	  to	  recruit	  patients,	   including	  
an	  attempt	  to	  open	  the	  study	  at	  Southampton	  General	  Hospital,	  the	  small	  number	  of	  
patients	  recruited	  meant	  that	  this	  study	  lacked	  statistical	  significance.	  
Secondly,	  there	  is	  a	  large	  pool	  of	  non-­‐proliferating	  cells	  in	  patients	  with	  CLL	  leading	  to	  
‘dilution’	  of	  the	  activated/	  proliferating	  sub-­‐population.	  Measurement	  of	  proliferation	  
in	   the	   lymph-­‐node	   compartment	   may	   have	   been	   a	   valuable	   method	   of	   targeting	  
proliferating	  CLL	   cells,	   but	   serial	   lymph-­‐node	   sampling	  was	  beyond	   the	   scope	  of	   this	  
investigation.	  
Finally,	   four	  weeks	  was	  a	  relatively	  short	  duration	  of	  exposure	  to	  CsA.	   In	  view	  of	  the	  
kinetics	   of	   proliferation,	   release	   and	   disappearance	   of	   cells	   explored	   in	   detail	   in	  
Chapter	   5,	   a	   longer	   treatment	   interval	   before	   measuring	   the	   impact	   of	   CsA	   on	  
proliferation	  may	  have	  been	  more	  informative.	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If	  this	  investigation	  were	  to	  be	  repeated,	  simplification	  of	  the	  research	  protocol	  would	  
be	  the	  greatest	  priority.	  The	  protocol	  would	  involve	  baseline	  labelling	  with	  deuterated	  
glucose	  before	  commencement	  of	  CsA	  after	  two	  weeks.	  Following	  eight	  weeks	  of	  CsA	  
therapy,	  labelling	  would	  be	  performed	  for	  a	  second	  time.	  Serial	  blood	  samples	  would	  
be	  taken	  for	  two	  weeks	  after	  the	  second	  labelling,	  doubling	  the	  exposure	  time	  to	  CsA	  
but	  reducing	  patient	  commitment	  to	  twelve	  weeks.	  
In	  summary,	  despite	  the	  promising	   in-­‐vitro	  effect	  of	  CsA	   in	  CLL,	   the	  CyCLLe	  study	  did	  
not	  demonstrate	  a	  significant	  biological	  or	  clinical	  effect	  of	  CsA	  in	  patients	  with	  early	  
stage,	   adverse-­‐risk	   disease.	   It	   does	   however	   highlight	   the	   importance	   of	   clinical-­‐trial	  
design	  in	  both	  answering	  clinical	  questions	  whilst	  ensuring	  that	  the	  degree	  of	  patient	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 .	  In-­‐Vivo	  Studies	  of	  Tumour	  Kinetics	  in	  CLL	  Chapter	  5
5.1	  Introduction	  
Chronic	  lymphocytic	  leukaemia	  is	  characterised	  by	  considerable	  clinical	  heterogeneity	  
that	  reflects	  major	  differences	  in	  the	  capacity	  of	  tumour	  cells	  to	  proliferate.	  It	  is	  widely	  
accepted	   that	   CLL	   cells	   are	   dependent	   upon	   signalling	   from	   the	   tumour	  
microenvironment	  for	  survival	  and	  proliferation.	  Furthermore,	  there	  is	  robust	  evidence	  
for	  the	  role	  of	  BCR	  signalling	   in	  driving	  the	  proliferation	  of	  CLL	  cells	  within	  the	  tissue	  
compartment.	   In	  a	  comparative	  gene	  expression	  study	  of	   lymph-­‐node	  and	  peripheral	  
blood	  derived	  CLL	  cells,	  Herishanu	  et	  al	  demonstrated	  that	  BCR	  signalling	  is	  the	  most	  
prominent	   pathway	   up-­‐regulated	   in	   lymph-­‐node	   resident	   CLL	   cells,	   and	   that	  
proliferation	  measured	   by	   Ki67	  was	   four-­‐fold	   greater	   in	   the	   LN	   compared	   to	   the	   PB	  
(Herishanu	   et	   al.,	   2011).	   Detailed	   characterisation	   of	   the	   relationship	   between	  
migration	  of	  tumour	  cells	  into	  the	  tissue-­‐compartment,	  BCR	  signalling	  and	  proliferation	  
is	   fundamental	   to	   understanding	   the	   disease	   biology	   that	   underpins	   the	   clinical	  
heterogeneity	  in	  CLL.	  
A	  major	  contributing	  factor	  to	  whether	  patients	  experience	  early	  disease	  progression	  is	  
the	   IgVH	  mutational	   status.	  On	   a	   clinical	   level,	   patients	  with	   unmutated	   IgVH	   	   genes	  
(UM-­‐CLL)	   demonstrate	   a	   short	   time	   to	   first	   treatment	   and	   reduced	   progression-­‐free	  
and	   overall	   survival	   (Damle	   et	   al.,	   1999;	   Hamblin	   et	   al.,	   1999).	   In-­‐vitro	   studies	   have	  
elegantly	   demonstrated	   that	   in	   UM-­‐CLL,	   there	   is	   increased	   sIgM	   expression	   and	  
enhanced	   calcium-­‐flux,	   SYK	   phosphorylation	   and	   proliferation	   in	   response	   to	   BCR	  
ligation	   (Guarini	   et	   al.,	   2008;	   Mockridge	   et	   al.,	   2007).	   In	   contrast,	   in	   patients	   with	  
mutated	   IgVH	  genes	  (M-­‐CLL),	  CLL	  cells	  are	  programmed	  towards	  ‘anergy’	  ie	  a	  state	  of	  
unresponsiveness	  to	  sIgM	  stimulation,	  characterised	  by	  constitutive	  activation	  of	  ERK	  
and	   NFAT	   (Muzio	   et	   al.,	   2008).	   In	   health,	   anergy	   acts	   to	   silence	   auto-­‐reactive	   B	  
lymphocytes	   following	   low-­‐affinity	   antigen	   binding,	   leading	   to	   their	   elimination	   by	  
apoptosis	   (Goodnow,	   1997).	   However,	   CLL	   cells	   are	   protected	   from	   apoptosis,	  
permitting	  the	  survival	  of	  anergic	  cells.	  
The	   distinction	   between	  UM-­‐CLL	   and	  M-­‐CLL	   is	   not	   absolute,	   Apollonio	   et	   al	   did	   not	  
demonstrate	   a	   statistically	   significant	   relationship	   between	   IgM-­‐induced	   ERK	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phosphorylation	   and	   IgVH	   mutational	   status	   (Apollonio	   et	   al.,	   2013).	   An	   important	  
discriminator	   in	   patients	   with	   M-­‐CLL	   is	   the	   degree	   of	   sIgM	   expression,	   with	   high	  
expression	  significantly	  associated	  with	  ability	  to	  signal	  through	  the	  BCR	  (Mockridge	  et	  
al.,	  2007).	  Furthermore,	  there	  is	  heterogeneous	  signalling	  within	  the	  cohort	  of	  M-­‐CLL	  
patients	   in	   which	   there	   is	   uniform	   sIgM	   expression,	   suggesting	   that	   there	   are	  
additional	  influences	  on	  BCR	  signalling	  that	  are	  likely	  to	  be	  environmental	  (Apollonio	  et	  
al.,	  2013).	  	  
The	  clinical	  outcomes	  of	  patients	  with	  M-­‐CLL	  are	  highly	  variable.	  Expression	  of	  the	  cell	  
surface	   molecules	   CD49d	   and	   CXCR4	   that	   are	   functionally	   related	   to	   the	   migratory	  
potential	  of	  tumour	  cells	  has	  recently	  been	  shown	  to	  be	  predictive	  of	  overall	  survival	  
within	   this	   cohort	   of	   patients	   (Pepper	   et	   al.,	   2015).	   High	   expression	   of	   CXCR4	   and	  
CD49d	  identified	  a	  cohort	  of	  patients	  with	  a	  prognosis	  similar	  to	  that	  of	  patients	  with	  
UM-­‐CLL,	  further	  emphasising	  the	  importance	  of	  migration	  in	  the	  pathogenesis	  of	  CLL.	  
In	   view	   of	   the	   role	   of	   the	   tumour	   microenvironment	   in	   the	   pathogenesis	   of	   CLL,	  	  
characterisation	  of	  trafficking	  of	  proliferating	  CLL	  cells	  between	  peripheral	  blood	  and	  
tissue	  compartments	  is	  an	  important	  line	  of	  investigation.	  Calissano	  et	  al	  investigated	  
this	  relationship	  using	  in-­‐vivo	  labelling	  with	  deuterated	  water;	  all	  proliferating	  CLL	  cells	  
incorporate	  deuterium	   into	  DNA	  and	   ‘enrichment’	   can	  be	  measured	  by	  GC-­‐MS.	  They	  
went	   on	   to	   sort	   deuterium	   labelled	   peripheral	   blood	   CLL	   cells	   according	   to	   co-­‐
expression	   of	   CD5	   (a	   marker	   of	   recent	   BCR	   signalling)	   and	   the	   chemokine	   receptor	  
CXCR4	  (required	  for	  tissue-­‐migration	  via	  binding	  with	  SDF-­‐1),	  taking	  the	  10	  %	  of	  cells	  at	  
each	   extreme	   and	   the	   intermediate	   10	  %	   cells.	   They	   found	   that	   the	   sub-­‐population	  
with	   the	   lowest	   CXCR4	   and	   highest	   CD5	   (CXCR4low/	   CD5hi)	   expression	   had	   11	   x	  
greater	  deuterium	  enrichment	  than	  the	  subpopulation	  with	  the	  reciprocal	  phenotype,	  
demonstrating	   that	   this	   represented	   the	   most	   recently	   proliferated	   sub-­‐population.	  
Global	   gene	   expression	   studies	   found	   that	   CXCR4low/	   CD5	   hi	   cells	   expressed	   pro-­‐
proliferation	  and	  anti-­‐apoptosis	  genes,	  whereas	  CXCR4hi/	  CD5low	  cells	  preferentially	  
expressed	  anti-­‐proliferative	  genes	  and	  genes	  associated	  with	   lymph-­‐node	  homing	  e.g	  
CCR7	  (Calissano	  &	  Damle,	  2011).	  They	  went	  on	  to	  propose	  that	  there	   is	  a	  continuum	  
between	  proliferating	   and	   resting	   sub-­‐populations,	  whereby	   following	  migration	   and	  
proliferation	   in	  the	   lymph-­‐node,	  CXCR4	   is	  down-­‐regulated	  and	  cells	  are	  released	   into	  
the	  peripheral	  blood.	  Recently	  proliferated	  CLL	  cells	  subsequently	  enter	  a	  resting	  state,	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characterised	   by	   loss	   of	   CD5	   and	   re-­‐expression	   of	   CXCR4,	   after	   which	   they	   either	  
undergo	   apoptosis	   or	   re-­‐enter	   the	   lymph-­‐node	   to	   undergo	   a	   further	   round	   of	  
proliferation.	  
This	  model	   is	   supported	  by	   in-­‐vitro	   studies	   that	   have	  utilised	   a	   circulation	   system	   in	  
CLL;	   it	   was	   reported	   that	   circulating	   CLL	   cells	   re-­‐express	   CXCR4	   and	   that	   following	  
migration	   across	   an	   endothelial	   layer,	   CXCR4	   is	   down-­‐regulated	   (Pasikowska	   et	   al.,	  
2016;	  Walsby	  et	  al.,	  2014).	  Additionally,	   it	  has	  been	  reported	  that	  ligation	  of	  the	  BCR	  
leads	  to	  a	  phenotypic	  change	  that	  includes	  down-­‐regulation	  of	  CXCR4	  (Quiroga	  et	  al.,	  
2009),	  leading	  to	  dissociation	  from	  SDF-­‐1	  expressed	  by	  stromal	  cells.	  However,	  lymph-­‐
node	  re-­‐entry	  by	  circulating	  CLL	  cells	  has	  not	  been	  demonstrated	  in-­‐vivo.	  
	  
(Calissano	  &	  Damle,	  2011)	  
Figure	  5.1	  Hypothetical	  Model	  of	  CLL	  Trafficking	  	  
This	  model	  of	  trafficking	  illustrates	  the	  hypothesis	  that	  CLL	  cells	  undergo	  proliferation	  
in	   the	   lymph-­‐node	   compartment.	   Proliferating	   cells	   characterised	   by	   high	   CD5/	   high	  
CD38	   and	   low	   CXCR4	   expression	   are	   then	   released	   into	   the	   peripheral	   blood	  
compartment	   where	   CXCR4	   is	   re-­‐expressed	   and	   CD5	   is	   down	   regulated.	   Recently	  
proliferated	   cells	   subsequently	   undergo	   apoptosis	   or	   re-­‐enter	   the	   lymph-­‐node	  
compartment	  to	  under-­‐go	  a	  further	  round	  of	  proliferation.	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In	  view	  of	  the	  sub-­‐clonal	  heterogeneity	  observed	  by	  Calissano	  et	  al	  and	  in	  light	  of	  the	  
major	   role	   that	   BCR	   signalling	   plays	   in	   CLL	   proliferation,	   Coelho	   et	   al	   went	   on	   to	  
investigate	  the	  intra-­‐clonal	  relationship	  between	  sIgM	  expression	  and	  phenotypic	  and	  
functional	   characteristics	   including	   CXCR4	   expression,	   BCR	   signalling	   capacity	   and	  
proliferation.	  CLL	  sub-­‐groups	  were	  defined	  by	  the	  degree	  of	  sIgM	  expression	  (based	  on	  
bead-­‐bound	   anti-­‐IgM	   (sub-­‐groups	   1-­‐4:	   subgroup	   1	   with	   the	   lowest	   degree	   of	   bead	  
binding	   to	   subgroup	   4	   with	   the	   highest	   bead	   binding	   visualised	   by	   image	   flow	  
cytometry)).	  They	  found	  that	  highest	  proportion	  of	  cells	  was	  in	  subgroup	  1,	  which	  was	  
enriched	  with	   cells	   expressing	   the	   activation	  markers	   CD25	   and	   CD38	   and	   cells	   that	  
had	  recently	  proliferated	  (Ki67	  positive).	  Cells	  in	  the	  highest	  sub-­‐group	  expressed	  high	  
CD5,	   high	   CXCR4	   and	   had	   the	   greatest	   increase	   in	   pERK	   upon	   sIgM	   ligation.	   It	   was	  
concluded	   that	   the	   subgroup	   1	   represented	   a	   post-­‐proliferative	   fraction	   whilst	  
subgroup	   4	   represented	   a	   potentially	   dangerous	   cohort	   of	   cells,	   primed	   for	   lymph-­‐
node	  entry,	  BCR	  signalling	  and	  proliferation	  (Coelho	  et	  al.,	  2013).	  
These	   findings	   are	   at	   odds	   with	   the	   in-­‐vivo	   labelling	   studies	   that	   report	   that	   the	  
recently	  proliferated	  fraction	  is	  characterised	  by	  CXCR4low/CD5hi.	  This	  may	  be	  due	  to	  
the	   fact	   that	   recently	   proliferated	   CLL	   cells	   have	   undergo	   complex	   and	   dynamic	  
phenotypic	  changes	  that	  may	  be	  poorly	  represented	  in	  static	  in-­‐vitro	  systems.	  
In-­‐vivo	   labelling	  studies	  provide	   the	  most	  accurate	   representation	  of	   tumour	  kinetics	  
but	   are	   challenging	   to	   perform	   in	   an	   observational	   setting	   where	   long-­‐term	   patient	  
commitment	   is	  essential.	   In-­‐vivo	   labelling	  of	  proliferating	  cells	   can	  be	  achieved	  using	  
deuterium,	   a	   non-­‐radioactive	   isotope	   of	   hydrogen,	   delivered	   either	   as	   deuterated	  
water	   or	   deuterated	   glucose.	   Deuterated	  water	   is	  more	   suitable	   for	   labelling	   slowly	  
proliferating	   cells;	   as	   the	   body	   water	   pool	   is	   large,	   daily	   administration	   of	   60ml	   of	  
deuterated	  water	  is	  required	  to	  achieve	  1-­‐5	  %	  labelling	  and	  must	  be	  maintained	  for	  84	  
days	   to	   study	  proliferation	   (Messmer	   et	   al.,	   2005).	   The	  wash-­‐out	  period	   is	   also	   slow	  
(104	  days),	   thus	   this	  method	   isn’t	   suitable	   for	   sequential	   labelling	  e.g.	   to	   investigate	  
the	  effect	  of	  a	  drug	  on	  proliferation.	  In	  view	  of	  the	  slow	  on-­‐set	  /off-­‐set	  of	  labelling,	  this	  
method	   is	  also	  unsuitable	   for	   labelling	  populations	  of	  cells	   that	   rapidly	  proliferate	  or	  
disappear	   (due	   to	   apoptosis	   or	   change	   in	   phenotype).	   In	   comparison,	   deuterated	  
glucose	   is	   more	   appropriate	   for	   labelling	   rapidly	   proliferating	   and	   transient	  
populations.	  The	  body	  glucose	  pool	  is	  small	  (15g),	  with	  a	  half-­‐life	  of	  two	  hours	  allowing	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rapid	  achievement	  of	  labelling	  (40	  %	  deuterium	  enrichment)	  that	  can	  be	  maintained	  by	  
regular	   oral	   administration	   of	   10ml	   of	   deuterated	   glucose	   every	   30	   minutes.	   Rapid	  
disappearance	  of	  deuterated	  glucose	  on	  cessation	  on	  intake	  produces	  a	  clearly	  defined	  
pulse	  of	  labelled	  cells	  that	  can	  be	  tracked	  over	  time	  in	  the	  peripheral	  blood	  and	  tissue	  
compartments.	  
Orally	   administered	   deuterated	   glucose	   has	   previously	   been	   used	   to	   compare	  
proliferation	  rates	  of	  CLL	  cells	  with	  healthy	  B	  lymphocytes.	  Seven	  patients	  with	  CLL	  and	  
seven	  healthy	  controls	  were	  studied;	  deuterium	  enrichment	  was	  measured	  in	  purified	  
populations	   from	   peripheral	   blood	   samples	   that	   were	   drawn	   from	   3-­‐21	   days	   post	  
labelling.	   The	   proliferation	   rate	   of	   CLL	   cells	   was	   lower	   than	   that	   of	   healthy	   B	  
lymphocytes	   (0.47	   %/d	   vs	   1.31	   %/day	   p=0.007)	   but	   combined	   with	   a	   reduced	  
disappearance	  rate,	  appeared	  to	  result	  in	  reduced	  cell	  turnover	  and	  net	  accumulation	  
of	   cells	   (Defoiche	   et	   al.,	   2008).	   The	  mean	   proliferation	   rate	   in	   this	   small	   study	   was	  
remarkably	   similar	   to	   that	   reported	   from	   the	  deuterated	  water	   studies	   (0.44	  %/day)	  
(Messmer	  et	  al.,	  2005)	  and	  there	  was	  considerable	  heterogeneity	  between	  patients.	  
We	   sought	   to	   investigate	   in-­‐vivo	   tumour	   kinetics	   in	   CLL	   using	   orally	   delivered	  
deuterated	  glucose	  in	  a	  cohort	  of	  ten	  patients	  with	  non-­‐progressive	  disease.	  	  
We	  started	  by	  measuring	  the	  proliferation	  rate	  of	  the	  entire	  clone	  of	  CLL	  cells	  in	  each	  
individual	   and	   then	   went	   on	   to	   assess	   intra-­‐patient	   variation	   in	   proliferation	   by	  
repeating	  deuterium	  labelling	  after	  eight	  weeks.	  The	  degree	  of	  spontaneous	  variation	  
in	   proliferation	   is	   important	   to	   assess	  whether	   ‘in-­‐vivo	   proliferation’	   can	   be	   used	   to	  
measure	  the	  effect	  of	  an	  intervention	  in	  clinical	  trials.	  	  
The	   relationship	   between	   clonal	   proliferation	   rates	   and	   phenotypic	   and	   functional	  
parameters	   associated	   with	   proliferation	   was	   then	   investigated	   by	   measuring	   CD38	  
expression	   and	   BCR-­‐ligation	   induced	   ERK	   phosphorylation.	   Finally,	   clonal	   CLL	  
proliferation	   rates	   were	   correlated	   with	   telomere	   length	   to	   investigate	   if	   point	  
proliferation	   rates	   were	   reflective	   the	   tumour’s	   replicative	   history.	   Telomere	   length	  
has	   previously	   been	   shown	   to	   be	   a	   highly	   predictive	   prognostic	  marker	   in	   CLL,	  with	  
shortened	  telomeres	  being	  predictive	  of	  shortened	  time	  to	  first	  treatment	  and	  inferior	  
overall	  survival	  (T.	  T.	  Lin	  et	  al.,	  2010;	  Ricca	  et	  al.,	  2007;	  Rossi	  et	  al.,	  2009).	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We	   then	   went	   on	   to	   investigate	   trafficking	   of	   CLL	   cells	   between	   the	   lymph-­‐node	  
compartment	  and	  the	  peripheral	  blood.	  The	  kinetics	  of	  release	  and	  disappearance	  of	  
recently	   proliferated	   CLL	   cells	   were	   previously	   studied	   in	   1960s	   using	   intraveneous	  
tritiated	   thymidine,	   followed	   by	   measurement	   of	   radioactivity	   in	   leukocyte	   smears	  
(Zimmerman,	  Godwin,	  &	  Perry,	  1968).	  These	  studies	  reported	  that	  the	  there	  were	  two	  
patterns	   of	   labelling,	   the	   first	   pattern	   indicating	   a	   small	   population	   of	   rapidly	  
proliferating	   cells	   that	   was	   relatively	   short	   lived.	   The	   second	   pattern,	   observed	   in	  
patients	   with	   splenomegaly,	   indicated	   a	   population	   of	   long-­‐lived	   cells	   that	   were	  
detectable	  at	  eight	  weeks	  after	  labelling.	  	  
We	   aimed	   to	   accurately	   establish	   rates	   of	   release	   and	   disappearance	   of	   recently	  
proliferated	   CLL	   cells	   in	   the	   peripheral	   blood	   compartment	   by	   sampling	   peripheral	  
blood	   at	   regular	   intervals	   over	   an	   eight-­‐week	  period.	   There	   are	   a	   number	  of	   factors	  
that	  contribute	  to	  tissue	  homing	  and	  retention	  including	  CXCR4	  and	  CCR7	  expression,	  
whilst	   egress	   is	   determined	   by	   expression	   of	   the	   sphingosine-­‐1-­‐phosphate	   receptor	  
(S1P1).	   It	   has	   previously	   been	   reported	   that	   in	   CLL,	   defective	   S1P1	   expression	  
contributes	  to	  extended	  survival	  by	  prolonging	  the	  residency	  of	  the	  tumour	  cells	  in	  the	  
pro-­‐survival	  niche	  (Capitani	  et	  al.,	  2012).	  
Disappearance	  of	  CLL	  cells	  from	  the	  circulation	  can	  occur	  due	  to	  cell	  death,	  homing	  to	  
tissue-­‐sites	  or	  by	  a	  change	  in	  phenotype.	  Disappearance	  rates	  of	  recently	  proliferated	  
CLL	  cells	  have	  previously	  been	  investigated	  by	  Defoiche	  et	  al	  who	  measured	  deuterium	  
enrichment	   in	  CLL	  cells	   for	  up	   to	  21	  days	  and	  concluded	  that	   rates	  of	  disappearance	  
were	   reduced	   compared	   to	   healthy	   B	   lymphocytes.	   We	   went	   on	   to	   measure	  
enrichment	  for	  a	  minimum	  of	  56	  days	  and	  for	  84	  days	  in	  a	  sub-­‐set	  of	  patients	  to	  fully	  
characterise	  the	  kinetics	  of	  disappearance	  of	  CLL	  cells	  in	  our	  cohort	  of	  patients.	  
As	   a	   sub-­‐study	   to	   further	   investigate	   trafficking	   between	   the	   peripheral	   blood	   and	  
lymph-­‐node	  compartments,	  we	  went	  on	  to	   investigate	   if	  a	  proportion	  of	   labelled	  CLL	  
cells	   re-­‐enter	   the	   lymph-­‐node.	   Although	   in-­‐vitro	   studies	   have	   shown	   that	   the	  
chemokine	  receptor	  CXCR4	  is	  re-­‐expressed	  in	  circulating	  CLL	  cells	  (Walsby	  et	  al.,	  2014),	  
and	   that	   this	   is	   thought	   to	   enable	   lymph-­‐node	   re-­‐entry,	   this	   has	   not	   been	  
demonstrated	   in-­‐vivo.	   Establishment	   of	   tissue	   homing	   in-­‐vivo	   is	   fundamental	   to	   the	  
characterisation	  of	  CLL	  pathogenesis.	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We	   further	   investigated	   the	   relationship	   between	   trafficking	   and	   proliferation	   using	  
the	   strategy	   described	   by	   Calissano	   et	   al,	   measuring	   deuterium	   enrichment	   in	  
peripheral	  blood	  sub-­‐populations	  defined	  by	  CXCR4	  and	  CD5	  expression.	  In	  doing	  this,	  
we	   took	   advantage	   of	   the	   ‘pulse’	   labelling,	   achievable	   only	  with	   deuterated	   glucose	  
labelling,	   to	   further	   investigate	   changes	   in	   labelling	   in	   the	   sub-­‐populations	   over	   an	  
extended	  period	  of	  time.	  
The	   sub-­‐populations	   described	   by	   Calissano	   et	   al	   have	   only	   been	   demonstrated	   in	  
peripheral	  blood	  CLL	  cells,	  with	  the	  hypothesis	  that	  following	  release	  from	  the	  lymph-­‐
node,	   there	   is	   dynamic	   expression	   of	   CXCR4	   and	   CD5	   in	   circulating	   CLL	   cells	   that	  
enables	   lymph-­‐node	   re-­‐entry.	   We	   therefore	   measured	   deuterium	   enrichment	   in	  
lymph-­‐node	  derived	  CLL	   cells	   according	   to	  expression	  of	  CXCR4	  and	  CD5	   to	  assess	   if	  
sub-­‐populations	  with	  distinct	  proliferative	  characteristics	  exist	  outside	   the	  peripheral	  
blood	  compartment.	  	  
In	  view	  of	  the	  role	  that	  BCR	  signalling	  plays	   in	  driving	  CLL	  proliferation,	  we	  sought	  to	  
investigate	   the	   relationship	   between	   BCR	   expression,	   function,	   trafficking	   and	  
proliferation.	   It	   has	   been	   reported	   that	   sIgM	   expression	   and	   BCR	   signalling	   is	   up-­‐
regulated	   in	   lymph-­‐node	   derived	   CLL	   cells	   (Coulter	   et	   al	   (manuscript	   submitted))	  
(Herishanu	  et	  al.,	  2011).	  Furthermore,	  it	  has	  recently	  been	  reported	  that	  IL4,	  possibly	  
derived	  from	  CLL	  T	  cells,	  augments	  CD79b	  and	  sIgM	  expression	  and	  BCR	  signalling	   in	  
the	  CLL	   lymph-­‐node	  (Aguilar-­‐Hernandez	  et	  al.,	  2016;	  Guo	  et	  al.,	  2016).	  However,	   it	   is	  
unclear	  what	  happens	  to	  BCR	  expression	  in	  the	  wake	  of	  proliferation.	  One	  hypothesis	  
is	  that	  the	  BCR	  is	  internalised	  upon	  antigen	  engagement	  and	  that	  re-­‐expression	  occurs	  
slowly.	   In-­‐vitro	   studies	   have	   shown	   that	  maximum	   recovery	   of	   sIgM	   expression	   and	  
signalling	  capacity	  occurs	  after	  48-­‐72	  hours’	   incubation	  (Mockridge	  et	  al.,	  2007).	  This	  
would	  suggest	  a	  model	  where	  the	  BCR	  is	  internalised	  following	  antigen	  engagement	  in	  
the	  lymph-­‐node	  and	  is	  slowly	  re-­‐expressed	  following	  release	  into	  the	  peripheral	  blood	  
compartment.	  It	  is	  clear	  that	  the	  microenvironment	  plays	  a	  key	  role	  in	  BCR	  expression	  
in	   CLL	   and	   as	   such,	   investigations	   into	   the	   dynamics	   of	   BCR	   expression	   are	   best-­‐
performed	   in-­‐vivo.	   We	   therefore	   measured	   deuterium	   enrichment	   in	   CLL	   sub-­‐
populations	  according	  to	  sIgM	  expression,	  taking	  the	  highest,	  intermediate	  and	  lowest	  
decade	  of	  cells.	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The	   relationship	   between	   sIgM	   expression,	   BCR	   internalisation	   and	   BCR	   signalling-­‐
capacity	  has	  recently	  been	  investigated	  by	  Coulter	  et	  al	  (manuscript	  submitted).	  It	  was	  
found	  that	  although	  CLL	  cells	  express	  low	  levels	  of	  sIgM,	  the	  capacity	  to	  internalise	  the	  
BCR	  is	  increased	  in	  leukaemic	  cells	  and	  that	  sIgM	  expression	  is	  the	  principal	  factor	  that	  
affects	   internalisation.	   They	   found	   that	   lymph-­‐node	   derived	   CLL	   cells	   exhibited	  
increased	   sIgM	   expression	   and	   BCR	   internalisation	   compared	   to	   peripheral	   blood	  
derived	  CLL	  cells	  and	  that	  capacity	  to	  internalise	  the	  BCR	  positively	  correlated	  with	  CD5	  
expression.	  	  	  
To	   further	   investigate	   the	   relationship	   between	   BCR	   expression,	   BCR	   internalisation	  
and	   proliferation,	   we	  went	   on	   to	  measure	   deuterium	   enrichment	   in	   subpopulations	  
defined	  high,	  intermediate	  and	  low	  BCR	  internalisation,	  using	  a	  pH	  sensitive	  dye	  linked	  
to	  agonistic	  IgM.	  	  
In	   summary,	  we	   performed	   a	   detailed	   investigation	   into	   the	   kinetics	   of	   proliferation	  
and	   trafficking	   between	   peripheral	   blood	   and	   lymph-­‐node	   compartments	   using	   the	  
novel	   approach	   in-­‐vivo	   labelling	  with	   deuterated	   glucose.	  We	   sought	   to	   characterise	  
the	  relationship	  between	  BCR	  expression,	   internalisation,	  proliferation	  and	  trafficking	  
between	   the	   tumour	   microenvironment	   and	   peripheral	   blood	   in	   a	   small	   cohort	   of	  
patients	  with	  non-­‐progressive	  CLL.	  This	   investigation	   is	  particularly	   relevant	   in	  an	  era	  
where	   we	   are	   increasingly	   using	   drugs	   that	   inhibit	   BCR	   signalling	   and	   that	   have	  
consequential	   effects	   on	   proliferation	   and	   trafficking	   to	   treat	   patients	   with	  
symptomatic	   CLL.	   Improved	   characterisation	   of	   the	   underlying	   pathophysiology	   will	  
enable	  us	  to	  better	  understand	  the	  heterogeneous	  effects	  of	  BCR	  antagonists	  in-­‐vivo.	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5.2	  Aims	  and	  Objectives	  
	  
1. To	  determine	   the	  proliferation	   rate	  of	  CLL	  cells	   in	  a	  cohort	  of	  patients	   (n=10)	  
with	   non-­‐progressive	   disease	   using	   in-­‐vivo	   labelling	   with	   deuterated	   glucose	  
and	  to	  determine	  the	  degree	  of	  intra-­‐patient	  variation	  in	  proliferation	  rate	  over	  
a	  eight	  week	  period.	  
	  
2. To	   investigate	   the	   relationship	   between	   point-­‐proliferation	   rate	   and	   CLL	  
telomere	  length	  in	  a	  cohort	  of	  patients	  with	  non-­‐progressive	  disease.	  
	  
3. To	   investigate	   the	   relationship	   between	   phenotypic	   and	   functional	  
characteristics	  and	  CLL	  proliferation	  rate.	  
	  
4. To	  investigate	  the	  rate	  of	  release	  of	  proliferated	  CLL	  cells	  from	  the	  lymph-­‐node	  
compartment	   into	   the	   peripheral	   blood	   compartment	   and	   the	   subsequent	  
disappearance	  rate	  of	  proliferated	  cells	  from	  the	  peripheral	  blood.	  
	  
5. To	   investigate	   the	   relationship	   between	   BCR	   expression,	   BCR	   function	  
(internalisation),	  proliferation	  and	  trafficking	  using	  deuterium	  labelling	  to	  track	  





	   160	  
5.3	  Materials	  and	  Methods	  
5.3.1	  Trial	  Design	  
A	   single-­‐centre,	   observational	   cohort	   study	   was	   designed	   to	   investigate	   tumour	  
kinetics	  in	  ten	  patients	  with	  non-­‐progressive	  Binet	  Stage	  A/B	  CLL	  who	  had	  not	  received	  
treatment	   in	   the	  previous	   three	  months.	   The	   study	   consisted	  of	   two	  cycles	  whereby	  
labelling	  with	  deuterated	  glucose	  was	  performed	  on	  Day	  0	  of	  each	  cycle.	  Release	  rates	  
were	   investigated	   by	   performing	   daily	   blood	   tests	   for	   the	   first	   week	   of	   Cycle	   1,	  
following	   which	   blood	   was	   drawn	   weekly	   for	   the	   subsequent	   four	   weeks	   and	   after	  
eight	   weeks	   to	   investigate	   disappearance	   of	   labelled	   cells	   (Figure	   5.2).	   Intra-­‐patient	  
variation	  in	  proliferation	  was	  measured	  by	  comparing	  proliferation	  rates	  from	  Cycles	  1	  
and	  2.	  Patients	  with	  palpable	  lymph-­‐nodes	  were	  offered	  the	  opportunity	  to	  participate	  
in	   a	   sub-­‐study	   where	   lymph-­‐node	   sampling	   was	   performed	   to	   further	   investigate	  
trafficking	  between	  the	  peripheral	  blood	  and	  lymph-­‐node	  compartments.	  
	  
Primary	  End-­‐points:-­‐	  i.	  Rate	  of	  release	  of	  recently	  proliferated	  CLL	  cells	  
	  	  	  	  	  	  	  	  	  	  	  ii.	  Correlation	  of	  CLL	  proliferation	  rate	  with	  telomere	  length	  
	  	  	  	  	  	  	  	  	  	  iii.	  Intra-­‐patient	  variation	  in	  tumour	  proliferation	  
Figure	  5.2	  Schema	  for	  In-­‐Vivo	  Studies	  of	  Tumour	  Kinetics	  In	  CLL	  
	  Deuterated	  glucose	  labelling	  was	  performed	  in	  two	  occasions,	  separated	  by	  8	  weeks.	  
In	   Cycle	   1,	   blood	   sampling	   took	   place	   daily	   for	   the	   first	   week,	   weekly	   for	   the	   first	  
month	  and	  then	  after	  two	  months.	  In	  Cycle	  2,	  blood	  sampling	  took	  place	  on	  days	  4,	  7,	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5.3.2	  Eligibility	  
Patients	   with	   non-­‐progressive	   Binet	   Stage	   A	   or	   B	   CLL	   who	   had	   not	   have	   received	  
therapy	  for	  at	  least	  3	  months	  and	  had	  no	  current	  indication	  for	  therapy,	  were	  eligible.	  
Exclusion	   criteria	   included	   diabetes	   mellitus	   (due	   to	   the	   risk	   of	   deranged	   glycaemic	  
control	   on	   labelling	   days),	   active	   autoimmune	   disease	   requiring	   immunosuppressive	  
therapy,	  pregnancy/lactation,	  positive	  serology	  for	  HIV,	  Hepatitis	  C	  or	  active	  infection	  
with	  Hepatitis	  B	  and	  other	  active	  malignancy.	  
Patients	  were	   identified	  by	  clinicians	  working	  within	  the	  CLL	  service	  at	  King’s	  College	  
Hospital	   (Denmark	  Hill	  and	  Princess	  Royal	  University	  Hospital	  Sites)	  and	  were	  given	  a	  
Patient	  Information	  Sheet	  to	  consider	  for	  a	  minimum	  of	  24	  hours	  before	  the	  consent	  
visit.	   The	   patient	   provided	   written,	   informed	   consent	   before	   undergoing	   screening	  
investigations.	  Consent	  and	  screening	  was	  performed	  by	  Dr.	  Cuthill.	  
	  
5.3.3	  Deuterium	  Labelling	  
Labelling	   was	   performed	   as	   described	   for	   the	   CyCLLe	   Study	   (described	   in	   4.2.2).	   All	  
labelling	  was	  performed	  by	  Dr	  Cuthill	  with	  the	  support	  of	  trained	  Clinical	  Trials	  Nurses	  
in	  the	  Clinical	  Trials	  Facility	  at	  King’s	  College	  Hospital.	  
	  
5.3.4	  Blood	  Sampling	  
6ml	  peripheral	  blood	  was	  drawn	  in	  Lithium	  heparin	  tubes	  at	  the	  specified	  time	  points.	  
	  
5.3.5	  PBMC	  isolation	  and	  storage	  
Peripheral	  blood	  mononuclear	   cells	  were	   immediately	   isolated	  using	  Ficoll	  Hypacque	  
Density	  Centrifugation	  as	  described	  in	  2.2.	  PBMCs	  were	  rapidly	  frozen	  as	  described	  in	  
2.5.	  Four	  aliquots	  of	  PBMCs	  were	  stored	  at	  each	  time-­‐point	  for	  each	  patient.	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5.3.6	  Lymph-­‐node	  Sampling	  
Patients	  who	  agreed	  to	  participate	  in	  this	  sub-­‐study	  (Ethics)	  provided	  written	  consent	  
at	   the	   time	   of	   each	   fine-­‐	   needle	   aspirate.	   The	   skin	   was	   cleaned	   with	   chlorhexidine	  
impregnated	   sponge	   and	   allowed	   to	   dry.	   A	   12	   gauge	   needle	   was	   passed	   into	   the	  
lymph-­‐node	   and	   tissue	   was	   multiply	   aspirated	   into	   a	   10	   ml	   syringe.	   Suction	   was	  
released	   before	   withdrawing	   the	   needle.	   The	   tissue	   was	   expelled	   into	   a	   specimen	  
container	  containing	  2ml	  RPMI.	  
The	   specimen	  was	   transferred	   to	   the	   laboratory	   and	  was	   centrifuged	   at	   300	  g	   for	   5	  
minutes.	  The	  supernatant	  was	  discarded	  and	  cells	   re-­‐suspended	   in	  2	  ml	   red	  cell	   lysis	  
buffer	  at	  37°C	  for	  15	  minutes.	  The	  buffer	  was	  then	  removed	  by	  centrifugation	  at	  300	  g	  
for	  5	  minutes	  and	  cells	  were	  washed	  x	  2	   in	  PBS/	  5mM	  EDTA	  and	  incubated	  with	  CD5	  
(FITC),	   CD19	   (APC)	   and	  CXCR4	   (PE).	   Cells	  were	  washed	   x	   2	   in	   PBS/	   10mM	  EDTA	   and	  
passed	  through	  a	  nylon	  mesh	  to	  remove	  clumps.	  DAPI	  (1:1000)	  was	  added	  5	  minutes	  
before	  flow	  sorting.	  Cells	  were	  flow-­‐sorted	  using	  the	  BD	  FACS	  Aria™	  II	  Cell	  Sorter	  at	  the	  
core	  flow	  facility,	  Biomedical	  Research	  Centre,	  Guy’s	  Hospital.	  	  Cells	  were	  collected	  in	  
1.5	  ml	  Eppendorf	   tubes	  and	  were	   stored	  as	  dry	  pellets	   in	   a	  monitored	   -­‐80°C	   freezer	  
before	  they	  were	  transported	  to	  St	  George’s	  Hospital	  on	  dry	  ice.	  
	  
5.3.7	  PBMC	  recovery	  and	  fluorescence	  activated	  cell	  sorting	  
PBMCs	  from	  all	  time-­‐points	  within	  a	  cycle	  were	  recovered	  simultaneously,	  as	  described	  
in	  2.6.	  Cells	  were	  rested	  at	  37°C	  in	  RPMI	  for	  one	  hour	  before	  labelling	  with	  antibodies	  
for	  cell	  sorting.	  Labelling	  was	  performed	  on	  ice	  and	  CLL	  cells	  were	  washed	  twice	  with	  
PBS.	  DAPI	  was	  used	  to	  label	  non-­‐viable	  CLL	  cells.	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5.3.8	  CXCR4/	  CD5	  sub-­‐population	  sorting	  
107	  PBMCs	  were	  rapidly	  thawed	  and	  recovered	  at	  37°C	   in	  RPMI	  for	  60	  minutes.	  They	  
were	  then	  washed	  with	  PBS	  and	  labelled	  with	  CD5	  (FITC),	  CD19	  (APC)	  and	  CXCR4	  (PE).	  
Antibodies	  were	  incubated	  with	  cells	  on	  ice	  for	  15	  minutes	  before	  being	  washed	  twice	  
with	   ice-­‐cold	  PBS.	  Cells	  were	  re-­‐suspended	  in	  2	  ml	  PBS	  containing	  2	  %	  FBS	  and	  5mM	  
EDTA.	   1mcl	   DAPI	   (1:100)	   was	   added	   5	   minutes	   before	   acquisition.	   Cells	   were	   flow-­‐
sorted	  using	  the	  BD	  FACSAria™	  II	  Cell	  Sorter	  as	  above.	  The	  gating	  strategy	  is	  illustrated	  
below.	  Three	  sub-­‐populations	  of	  CLL	  cells	  were	  collected,	  defined	  by	  CXCR4hi/	  CD5low,	  	  	  
CXCR4int/CD5int	   and	   CXCR4low/	   CD5	   hi.	   5	   x	   105-­‐1	   x	   106	  cells	   from	   each	   population	  
were	  collected	  in	  1.5ml	  Eppendorf	  tubes.	  Dry	  pellets	  were	  made	  and	  stored	  at	  -­‐80	   °C	  
before	  they	  were	  transported	  to	  St	  George’s	  Hospital	  on	  dry	  ice.	  	  
	  
Figure	  5.3	  Gating	  strategy	  for	  FACS	  sorting	  of	  CLL	  cells	  and	  sub-­‐populations	  
Single,	  viable	  CLL	  cells	  (CD5+/CD19+)	  were	  FACS	  sorted	  into	  cohorts	  according	  to	  
expression	  of	  CXCR4	  and	  CD5,	  the	  highest,	  intermediate	  and	  lowest	  15	  %	  cells.	  A	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5.3.9	  Surface	  IgM	  Sorting	  
107	  PBMCs	  were	  rapidly	   thawed	  and	  recovered	  at	  37°C	   in	  RPMI	   for	  60	  minutes.	  Cells	  
were	  washed	  and	  labelled	  with	  CD5	  (PECy7)	  and	  CD19	  (PB).	  Antibodies	  were	  incubated	  
with	   cells	   at	   4°C	   for	   15	   minutes	   before	   being	   washed	   twice	   with	   PBS.	   Immediately	  
before	  sorting,	  cells	  were	   incubated	  with	  anti-­‐IgM	  (FITC)	  on	   ice	   for	  15	  minutes.	  Cells	  
were	  washed	  twice	  with	   ice-­‐cold	  PBS	  containing	  2	  %	  FBS	  and	  5mM	  EDTA.	  1mcl	  DAPI	  
(1:100)	  was	  added	  5	  minutes	  before	  acquisition	  and	  was	  incubated	  on	  ice.	  Cells	  were	  
flow-­‐sorted	   using	   the	   BD	   FACSAria™	   II	   Cell	   Sorter.	   The	   gating	   strategy	   is	   illustrated	  
below	   (Figure	   5.4).	   Three	   sub-­‐populations	   of	   CLL	   cells	  were	   collected,	   defined	   by	   1)	  
IgM	  low	  (lowest	  10	  %),	  2)	  IgM	  intermediate	  (middle	  10	  %)	  and	  IgM	  high	  (top	  10	  %).	  5	  x	  
105-­‐	  1	  x	  106	  cells	   from	  each	  population	  were	  collected	   in	  1.5ml	  Eppendorf	  tubes.	  Dry	  
pellets	  were	  made	  and	  stored	  at	  -­‐80°C	  before	  transporting	  to	  St	  George’s	  Hospital	  on	  
dry	  ice.	  
	  
Figure	  5.4.	  Gating	  Strategy	  for	  sIgM	  FACS	  sorting	  	  
Aliquots	  of	  cryopreserved	  CLL	  cells	  were	  recovered	  and	  labelled	  with	  FITC-­‐conjugated	  
anti-­‐	   sIgM	   antibody.	   Single,	   viable	   CLL	   cells	   expressing	   low,	   intermediate	   and	   high	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5.3.10	  BCR	  Internalisation	  Assay	  
BCR	  internalisation	  assays	  were	  performed	  by	  Dr	  Eve	  Coulter	  using	  a	  locally	  developed	  
assay	   (Dr	   Eve	   Coulter,	  manuscript	   submitted)	   that	   use	   a	   pH	   sensitive	   dye	   (pHrodo™	  
Red	   avidin	   (Life	   Technologies,	   Paisley,	  UK))	   conjugated	   to	   anti-­‐IgM.	  Outside	   the	   cell,	  
where	  pH	  is	  neutral,	  there	  is	  no	  fluorescence	  whereas	  within	  the	  cell,	  pH	  =	  5	  and	  the	  
dye	   fluoresces.	   Therefore,	   following	   BCR	   ligation	   and	   receptor	   internalisation,	   a	  
fluorescent	  signal	  is	  emitted	  and	  is	  measurable	  by	  flow	  cytometry	  (Figure	  5.5).	  
	  Briefly,	   one	   microgram	   of	   pHrodo™	   Red	   Avidin	   was	   incubated	   with	   or	   without	   an	  
equimolar	  amount	  of	  biotinylated	  goat	  F(ab’)2	  anti-­‐human	   Immunoglobulin	  M	  (αIgM;	  
Cambridge	   Biosciences,	   Cambridge,	   UK)	   for	   one	   hour	   at	   room	   temperature	   to	   allow	  
formation	   of	   labelled	   complexes.	   Target	   cells	   (5x105)	   were	   incubated	   with	   pHrodo-­‐
avidin-­‐αIgM	   (pHrodo-­‐αIgM)	   for	   30	   minutes	   at	   4⁰C	   to	   allow	   initial	   receptor	   binding,	  
then	  at	  37⁰C	   for	  a	   further	  one	  hour	   to	  allow	  for	   internalisation.	  All	   incubations	  were	  
performed	   in	   PBS	   pH	   7.4,	   so	   that	   any	   observed	   fluorescence	   was	   due	   to	   BCR	  
internalisation	   and	   trafficking	   of	   the	   pHrodo-­‐αIgM	   to	   acidified	   endosomes.	   BCR	  
internalisation	  was	  expressed	  as	  the	  percentage	  of	  cells	  with	  fluorescence	  above	  that	  
of	  the	  pHrodo-­‐avidin	  negative	  control.	  
	  
Figure	  5.5	  pHrodo™	  application	  to	  measure	  BCR	  internalisation	  	  
pHrodo	  is	  a	  fluorogenic	  dye	  that	  increases	  in	  fluorescence	  as	  the	  pH	  of	  its	  surrounding	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5.3.11	  BCR	  Internalisation	  Sorting	  
107	  PBMCs	  were	  rapidly	  thawed	  and	  recovered	  at	  37°C	  in	  RPMI	  for	  60	  minutes.	  PBMCs	  
were	  washed	  with	  PBS	  and	  incubated	  with	  100mcl	  of	  the	  pHrodo	  cocktail	  at	  4°C	  for	  30	  
minutes.	  PBMCs+	  cocktail	  were	   then	   transferred	   to	  a	  37°C	   incubator	   for	  60	  minutes.	  
PBMCs	  were	  washed	   in	   ice-­‐	   cold	   PBS	   and	  were	   surface-­‐stained	  with	   CD5	   (APC)	   and	  
CD19	   (PB)	   on	   ice	   for	   15	   minutes.	   PBMCs	   were	   washed	   twice	   in	   PBS.	   DAPI	   was	  
incubated	  with	  the	  cells	  or	  five	  minutes	  on	  ice	  immediately	  before	  sorting.	  The	  gating	  
strategy	  below	  was	  used;	  we	  collected	  the	  top,	  middle	  and	  lowest	  10	  %	  viable	  CLL	  cells	  
according	  to	  ability	  to	  internalise	  the	  BCR.	  Gates	  were	  manipulated	  during	  the	  sort	  to	  
maintain	  10	  %	  cells	  in	  each	  gate.	  
	  
	  
Figure	  5.6	  Gating	  Strategy	  for	  BCR	  internalisation	  FACS	  sorting	  
	  Aliquots	   of	   cryopreserved	   CLL	   cells	   were	   recovered,	   labelled	   with	   avidin-­‐αIgM	  
(pHrodo-­‐αIgM)	  and	  incubated	  to	  allow	  internalisation.	  Single,	  viable	  CLL	  cells	  with	  low,	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5.3.12	  Gas	  Chromatography	  Mass	  Spectrometry	  
Gas	  chromatography	  mass	  spectrometry	  (GC	  MS)	  was	  performed	  by	  Dr.	  Yan	  Zhang	  in	  
Prof.	   Macallan’s	   laboratory	   at	   St.	   George’s	   Hospital,	   as	   per	   the	   method	   detailed	   in	  
4.2.8.	  
5.3.13	  Single	  Telomere	  Length	  Analysis	  
Telomere	   length	  was	   analysed	   by	   our	   collaborator,	   Prof.	   Baird,	   at	   Cardiff	  University.	  
DNA	   was	   extracted,	   solubilized,	   quantified	   and	   diluted.	   Multiple	   polymerase	   chain	  
reactions	  (PCRs;	  typically	  6	  reactions	  per	  sample)	  were	  carried	  out	  for	  each	  test	  DNA	  
with	  telomere-­‐adjacent	  and	  Teltail	  primers.	  The	  reactions	  were	  cycled	  with	  an	  MJ	  PTC-­‐
225	   thermocycler.	   The	   DNA	   fragments	   were	   resolved	   by	   0.5	   %	   Tris	   acetate	  
ethylenediaminetetraacetic	   acid	   agarose	   gel	   electrophoresis,	   and	   detected	   by	   2	  
separate	   Southern	   blot	   hybridizations	   with	   random-­‐primed	   α-­‐33P–	   labeled	   TTAGGG	  
repeat	  probe	  and	  a	  telomere-­‐adjacent	  probe,	  together	  with	  a	  probe	  to	  detect	  the	  1-­‐kb	  
and	   2.5-­‐kb	   molecular	   weight	   markers.	   The	   hybridized	   fragments	   were	   detected	   by	  
phosphorimaging	   with	   a	   Molecular	   Dynamics	   Storm	   860	   phosphorimager.	   The	  
molecular	   weights	   of	   the	   DNA	   fragments	   were	   calculated	   using	   the	   Phoretix	   1D	  
quantifier.	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5.3.14	  Trial	  Administration	  
The	   study	  was	   sponsored	   by	   King’s	   College	   Hospital	   NHS	   Foundation	   Trust	   and	  was	  
included	  in	  the	  National	  Institute	  for	  Health	  Research	  Clinical	  Research	  Network	  (NIHR	  
CRN)	   portfolio.	   The	   trial	   received	   peer-­‐reviewed	   funding	   from	   Leukaemia	   and	  
Lymphoma	  Research	  (now	  called	  ‘Bloodwise’).	  
Ethical	   approval	   was	   granted	   by	   the	   National	   Research	   Ethics	   Committee	  
(13/LO/0434).	  
Two	  substantial	  amendments	  were	  approved.	  Amendment	  1	   (August	  2013)	   removed	  
the	   requirement	   for	  patients	   to	  express	  >	  7	  %	  CD38	   from	   the	   inclusion	   criteria.	   This	  
was	   because	   the	   initial	   inclusion	   criteria	   were	   deemed	   to	   be	   too	   restrictive	   and	   a	  
barrier	   to	   recruitment.	   Amendment	   2	   (April	   2015)	   was	   submitted	   to	   enable	   the	  
recruitment	   for	   six	   further	   patients	   with	   unmutated	   IgVH	   genes.	   This	   protocol	   was	  
amended	  to	  a	  single	  cycle	  (one	  labelling	  day)	  with	  extended	  peripheral	  blood	  sampling,	  
up	  to	  12	  weeks.	  
Dr	   Cuthill	   performed	   all	   trial	   administration	   including	   application	   through	   the	  
Integrated	  Research	  Application	  System,	  amendment	  submission	  and	  maintenance	  of	  
recruitment	  data	  for	  the	  NIHR	  CRN	  portfolio.	  The	  study	  was	  reviewed	  monthly	  at	  the	  
King’s	  College	  Hospital	  CLL	  Clinical	  Trials	  Meeting.	  
	  
	   	  
	   169	  
5.4	  Results	  
5.4.1	  Patient	  Characteristics	  
Ten	   patients	   were	   recruited	   to	   the	   study	   (Table	   5.1).	   By	   chance,	   all	   patients	   were	  
found	  to	  have	  mutated	   IgVH	  	  genes	  (M-­‐CLL).	  A	  study	  amendment	  has	  been	  submitted	  
to	  enable	  the	  recruitment	  of	  a	   further	  cohort	  of	  patients	  with	  unmutated	   IgVH	  genes	  
(UM-­‐CLL).	  Notably,	  three	  patients	  expressed	  CD38	  at	  a	  level	  of	  ≥	  7	  %.	  
	  


















K1	   66	   F	   7	   A	   Nil	   M	   7	  %	   Normal	  
K2	   55	   F	   200	   B	   Nil	   M	   0	  %	   13q-­‐	  
K3	   38	   F	   20	   A	   Nil	   M	   1	  %	   Normal	  
K4	   67	   F	   60	   A	   Nil	   M	   0	  %	   Normal	  
K5	   62	   M	   30	   A	   Nil	   M	   0	  %	   Normal	  
K6	   68	   F	   200	   B	   Nil	   M	   3	  %	   13q-­‐	  
K7	   65	   M	   90	   B	   Nil	   M	   0	  %	   13q-­‐	  
K8	   69	   M	   39	   B	   Nil	   M	   12	  %	   Trisomy	  12	  
K9	   54	   M	   100	   B	   Nil	   M	   0	  %	   Normal	  
K10	   53	   M	   20	   A	   Nil	   M	   51	  %	   Trisomy	  12	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5.4.2	   Assessment	   of	   proliferation	   rate	   and	   of	   intra-­‐patient	   variation	   in	   peripheral	  
blood	  CLL	  cells	  
The	  proliferation	  rate	  of	  CLL	  cells	  was	  calculated	  by	  dividing	  the	  maximum	  deuterium	  
enrichment	  in	  CLL	  cell	  DNA	  by	  the	  plasma	  glucose	  deuterium	  enrichment	  corrected	  for	  
intracellular	   dilution.	   Proliferation	   rates	   were	   heterogeneous	   and	   varied	   from	   0.08	  
%/day	   to	  0.95	  %/day.	  The	  mean	  proliferation	  rate	   in	  our	  population	  of	  patients	  with	  
non-­‐progressive	   M-­‐CLL	   was	   0.36	   %/day.	   As	   expected,	   this	   is	   lower	   than	   the	   mean	  
proliferation	  rate	  of	  0.44	  %/day	  reported	  by	  Messmer	  et	  al	  in	  a	  cohort	  of	  18	  patients,	  
half	  of	  whom	  had	  UM-­‐CLL	  and	  half	  of	  whom	  had	  progressive	  disease	  (Messmer	  et	  al.,	  
2005).	  
We	   sought	   to	   investigate	   the	   degree	   of	   spontaneous	   intra-­‐patient	   variation	   in	  
proliferation	  by	  repeating	   in-­‐vivo	   labelling	  with	  deuterated	  glucose	  after	  eight	  weeks.	  
Measurement	  of	  spontaneous	  variation	  in	  proliferation	  is	  essential	  if	  this	  method	  is	  to	  
be	  applied	  to	  assess	  the	  effect	  of	  an	  intervention	  on	  proliferation.	  
There	  was	  significant	  positive	  correlation	  between	  cycles	  1	  and	  2	  (r=0.6331	  p=0.049),	  
as	   illustrated	   in	   Figure	   5.7.	   In	   one	   patient,	   there	   was	   a	   doubling	   of	   proliferation	  







Figure	  5.7	  Correlation	  between	  proliferation	  rates	  of	  peripheral	  blood	  CLL	  cells	  	  
Proliferation	  rates	  were	  measured	  on	   two	  occasions,	   spaced	  by	  eight-­‐weeks,	   in	   ten	  patients.	  
Proliferation	  rate	  was	  calculated	  using	  maximum	  deuterium	  enrichment	  in	  purified	  peripheral	  
blood	  CLL	  cells.	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5.4.3	   Relationship	   between	   sIgM	   expression,	   BCR	   signalling,	   CD38	   expression	   and	  
proliferation	  
The	  proliferation	  of	  CLL	  cells	  is	  thought	  to	  result,	  at	  least	  in	  part,	  from	  antigen	  ligation	  
and	   signalling	   through	   the	   BCR.	   However,	   BCR	   responses	   are	   heterogeneous	   both	  
between	  patients	  and	  within	  a	  patient.	  In	  patients	  with	  UM-­‐CLL,	  sIgM	  expression	  and	  
BCR	  signalling	  responses	  are	  stronger	  and	  are	  associated	  with	  proliferation	  whereas	  in	  
patients	   with	  M-­‐CLL,	   sIgM	   expression	   is	   lower,	   there	   is	   a	   lack	   of	   BCR	   signalling	   and	  
these	  cells	  are	  programed	  towards	  anergy	  (Apollonio	  et	  al.,	  2013;	  Guarini	  et	  al.,	  2008;	  
Mockridge	   et	   al.,	   2007).	   However,	   within	   the	   M-­‐CLL	   group,	   there	   is	   considerable	  
heterogeneity;	  some	  patients	  have	  high	  sIgM	  expression,	  similar	  to	  the	  UM-­‐CLL	  group,	  
and	  these	  patients	  signal	  through	  the	  BCR.	  	  
The	  proliferation	  of	  CLL	  cells	  has	  previously	  been	   linked	  to	  the	  expression	  of	  CD38,	  a	  
molecule	   that	   serves	   both	   as	   an	   ectoenzyme	   and	   receptor	   (Deaglio	   et	   al.,	   2003;	  
Morabito	  et	  al.,	  2006).	  Within	  a	  CLL	  clone,	  it	  has	  been	  shown	  that	  the	  CD38+	  fraction	  is	  
enriched	   for	   recently	   proliferated	   cells	   (Calissano	   et	   al.,	   2009;	   Damle	   et	   al.,	   2007).	  
CD38	  expression	  is	  upregulated	  in	  the	  lymph-­‐node	  compared	  to	  the	  peripheral	  blood	  
in	   a	   process	   that	   has	   been	   shown	   to	   be	   dependent	   on	   signals	   from	   the	   tumour	  
microenvironment,	   specifically	   activated	   CD4	   T	   cells	   (O.	   Jaksic	   et	   al.,	   2004;	   Patten,	  
Buggins,	   Richards,	   Wotherspoon,	   Salisbury,	   Mufti,	   Hamblin,	   &	   Devereux,	   2008b;	  
Willimott	   et	   al.,	   2007).	   Investigations	   into	   the	   impact	   of	   CD38	   expression	   on	   BCR	  
signalling	   have	   yielded	   conflicting	   results;	   most	   recently,	   it	   has	   been	   shown	   that	   in	  
patients	   with	   UM-­‐CLL,	   ‘signallers’	   generally	   expressed	   CD38	   whilst	   there	   this	  
relationship	  did	  not	  hold	   for	  patients	  with	  M-­‐CLL	   (Lanham	  et	  al.,	  2003;	  Mockridge	  et	  
al.,	   2007;	   Zupo	   et	   al.,	   1996).	   This	   reinforces	   the	   hypothesis	   that	   CD38	   expression	  
influences	  CLL	  activation	  and	  proliferation	  through	  mechanisms	  that	  are	  independent	  
of	  the	  BCR.	  
To	   investigate	   the	   association	   between	   sIgM	   expression,	   CD38	   expression,	   BCR	  
signalling	   and	   proliferation	   in	   our	   cohort	   of	   patients	   with	  M-­‐CLL,	   we	  measured	   the	  
phenotypic	  and	   functional	  parameters	   in	   relation	   to	   in-­‐vivo	  proliferation	   rates	   (Table	  
5.2).	   The	   expression	   of	   sIgM	   and	   CD38	   was	   measured	   by	   flow	   cytometry	   (Median	  
fluorescent	   intensity	   (MFI)	   and	   percentage	   expression,	   respectively),	   and	   pERK	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activation	   in	   response	   to	   agonistic	   sIgM	   ligation	   was	   assessed	   by	   Western	   Blotting	  
(Figure	  5.8).	  Total	  and	  phospho-­‐ERK	  was	  measured	  before	  and	  after	  sIgM	  stimulation,	  
using	   Western	   Blotting	   (Chapter	   2.6).	   Signal	   strength	   was	   quantified	   using	  
densitometric	  analysis	   (Image	   J	  Software).	  Activation	  ratio	  was	  calculated	  by	  dividing	  
the	   ratio	   of	   stimulated	   pERK	   by	   the	   ratio	   of	   stimulated	   ERK.	   In	   patients	   K2	   and	   K9,	  
there	  was	  activation	  of	  ERK	  phosphorylation	  following	  IgM	  stimulation.	  
We	  did	  not	  observe	  a	  direct	  association	  between	  sIgM	  expression	  and	  proliferation	  in	  
our	  small	  cohort	  of	  patients.	  In	  the	  two	  patients	  in	  whom	  there	  was	  evidence	  of	  active	  
signalling	   through	   the	   BCR,	   proliferation	   rates	   were	   at	   the	   higher	   end	   of	   the	   range	  
(>0.3	  %/day);	   however,	   the	   two	  patients	  with	   the	  highest	  proliferation	   rates	  did	  not	  
exhibit	  active	  BCR	  signalling.	  	  
Strikingly	  the	  patients	  with	  the	  highest	  proliferation	  rates	  (K8	  and	  K10)	  harboured	  the	  
cytogenetic	  abnormality	  Trisomy	  12	  and	  expressed	  CD38	  (12	  %	  and	  51	  %	  respectively).	  
It	  has	  recently	  been	  reported	  that	  in	  addition	  to	  increased	  expression	  of	  CD11a,	  CD49d	  
and	  CD38	  (D'Arena	  et	  al.,	  2001;	  Su'ut	  et	  al.,	  1998;	  Zucchetto	  et	  al.,	  2013),	  Trisomy	  12	  
cells	   have	   increased	   expression	   of	   CD11b,	   CD18,	   CD29	   and	   ITGB7;	   they	   exhibit	  
upregulated	   integrin	   signalling	   and	   enhanced	   VLA-­‐4	   directed	   adhesion	   and	   motility	  
(Riches	  et	   al.,	   2014).	   The	  heterodimeric	   integrins	  CD11a/	  CD18	   (LFA-­‐1),	   CD11b/CD18	  
(Mac-­‐1)	  and	  CD49d/CD29	  (VLA-­‐4)	  are	  transmembrane	  proteins	  that	  are	  involved	  in	  the	  
transendothelial	   migration	   of	   leukocytes	   from	   the	   peripheral	   blood	   into	   the	   lymph-­‐
node	  compartment.	  In	  an	  in-­‐vitro	  circulation	  model	  of	  CLL,	  it	  was	  found	  that	  cells	  that	  
underwent	   transendothelial	   migration	   expressed	   CD38	   and	   CD49d	   (Walsby	   et	   al.,	  
2014).	   Furthermore,	   Pasikowska	   et	   al	   have	   recently	   reported	   that	   in	   addition	   to	  
identifying	  CLL	  cells	  with	  the	  greatest	  potential	  to	  undergo	  transendothelial	  migration,	  
CD49d	  expression	  identifies	  CLL	  cells	  with	  enhanced	  capacity	  to	  activate	  CD4	  and	  CD8	  
T	  cells	  (Pasikowska	  et	  al.,	  2016).	  	  
Our	   finding	   that	   the	   patients	  with	   the	   highest	   proliferation	   rates	   expressed	   CD38	   is	  	  
consistent	  with	   that	   of	   Calissano	   et	   al	  who	   found	   that	   the	   fraction	   of	   CD38	  positive	  
cells	   is	  enriched	  for	  proliferating	  cells	   (Calissano	  et	  al.,	  2009).	   It	   is	   therefore	   feasible,	  
that	  enhanced	  migration	  into	  the	  tumour	  microenvironment,	  in	  addition	  to	  enhanced	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capacity	  to	  activate	  CD4	  T	  cells,	  contributed	  to	  the	  increased	  CLL	  proliferation	  rates	  in	  
these	  patients.	  
	  
Figure	  5.8	  Representative	  Western	  Blot	  illustrating	  pERK	  activation	  
Phospho-­‐ERK	  and	  total-­‐ERK	  were	  measured	  by	  Western	  Blotting	  at	  baseline,	  following	  
at	  baseline	  and	  	  following	  10	  minutes	  stimulation	  with	  agonistic	  anti-­‐IgM	  in	  patients	  K9	  
and	  K10.	  PMA	  was	  used	  as	  a	  positive	  control	  for	  activation.	  Histones	  (H3)	  were	  probed	  
as	  a	  loading	  control.	  
	  
Table	   5.2	   Summary	   of	   sIgM	  expression,	   ERK	   phosphorylation	   and	   CD38	   expression	  
and	  CLL	  proliferation	  rate	  in	  patients	  with	  mutated	  IgVH	  genes	  
	  



















K1# 924# 1.02# 0.83# 1.22# 7%# 0.08#
K2# 1047# 2.86# 0.99# 2.86' 0%# 0.33'
K3# 242# 0.21# 0.71# 0.3# 1%# 0.125#
K4# 2534# 0.16# 0.82# 0.21# 0%# 0.215#
K5# 410# 1.63# 1.71# 0.95# 0%# 0.190#
K6# 507# 0.56# 0.97# 0.58# 3%# 0.230#
K7# 183# 1.14# 0.95# 1.2# 0%# 0.280#
K8# 152# 0.59# 0.7# 0.84# 12%' 0.95'
K9# 512# 4.73# 1.01# 4.69' 0%# 0.32'
K10# 139# 1.14# 0.81# 1.4# 51%' 0.72'
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  5.4.4	  Correlation	  of	  prolifetion	  rate	  with	  telomere	  length	  
Telomere	   length	   has	   been	   reported	   to	   correlate	  with	   clinical	   stage,	   IgVH	  mutational	  
status,	  CD38	  expression,	  poor	  risk	  cytogenetics	  and	  β2-­‐microglobulin	  levels	  in	  CLL	  (T.	  T.	  
Lin	   et	   al.,	   2010;	   Roos	   et	   al.,	   2008).	   Furthermore,	   although	   in-­‐vivo	   deuterated	  water	  
studies	  did	  not	  demonstrate	  a	  statistically	  significant	  correlation	  between	  proliferation	  
rates	  and	  biomarkers	  of	  poor-­‐risk	  disease,	  they	  reported	  correlation	  with	  progressive	  
CLL.	  We	   therefore	   explored	  whether	   there	   is	   a	   direct	   correlation	   between	   telomere	  
length	  and	  in-­‐vivo	  proliferation	  rate	  (Figure	  5.9).	  Telomere	  length	  was	  measured	  using	  
the	  STELA	  assay	   (5.3.13),	   the	  assay	  was	  performed	  by	  Prof	  Baird,	  our	  collaborator	  at	  
Cardiff	  University.	  Mean	  telomere	   length	   in	  our	  cohort	  of	  patients	  was	  equal	   to	   that	  
reported	  by	  Lin	  et	  al	  in	  patients	  with	  Binet	  Stage	  A	  CLL	  (T.	  T.	  Lin	  et	  al.,	  2010).	  Notably,	  
K9	  had	  the	  greatest	  BCR	  signalling	  capacity	  (pERK	  activation),	  a	  proliferation	  rate	  above	  
the	  median	  of	  0.255	  %/day	  and	  the	  shortest	  telomere	  length.	  
However,	   there	   was	   no	   significant	   correlation	   between	   telomere	   length	   and	  
proliferation	   rate	   in	   our	   cohort	   of	   patients.	   Although	   telomere	   length	   has	   been	  
reported	  to	  be	  strongly	  predictive	  of	  clinical	  outcome	  in	  CLL,	  it	  has	  since	  been	  reported	  
that	   there	   is	  no	  significant	   telomere	  attrition	  over	   time	   in	  CLL	  cells	   (CH	  Jones,	  verbal	  
communication)	  suggesting	  that	  proliferation	  rate	  and	  telomere	  length	  are	  not	  directly	  
related	  to	  each	  other.	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Figure	  5.9	  CLL	  Telomere	  length	  of	  patients	  recruited	  to	  the	  In-­‐Vivo	  Study	  of	  Tumour	  
Kinetics	  in	  CLL	  (K1-­‐K10)	  using	  STELA	  	  
XpYp	  gels	  displaying	  the	  telomere	  profiles	  in	  CLL	  cells.	  Mean	  telomere	  length	  (kb)	  and	  
proliferation	  rate	  (Fmax)	  are	  detailed	  above.	  STELA	  was	  performed	  by	  Prof.	  Baird.	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5.4.5	  Release	  rate	  of	  deuterium	  labelled	  CLL	  cells	  into	  the	  peripheral	  blood	  
The	   time	   taken	   for	   recently	   proliferated	   CLL	   cells	   to	   be	   released	   into	   the	   peripheral	  
blood	  from	  the	  lymph-­‐node	  compartment	  reflects	  the	  duration	  of	  time	  that	  leukaemic	  
cells	   receive	  survival	  and	  proliferation	  signalling	   from	  the	  tumour	  microenvironment.	  
Disruption	   of	   this	   interplay	   is	   potentially	   a	   desirable	   approach	   to	   inhibit	   disease	  
progression.	  	  
To	  investigate	  the	  time	  taken	  for	  proliferated	  CLL	  cells	  to	  be	  released	  from	  the	  lymph-­‐
node	   compartment	   (LN)	   into	   the	   peripheral	   blood	   (PB),	   phlebotomy	  was	   performed	  
daily	  for	  the	  first	  week	  and	  then	  weekly	  for	  four	  weeks	  after	  labelling.	  	  
PBMCs	  were	  harvested	  and	  stored	  at	  -­‐180°C	   for	  future	  use.	  Cryopreserved	  cells	  were	  
recovered	  in	  RPMI	  for	  60	  minutes	  at	  37°C	  before	  being	  surface-­‐stained.	  Viable	  CLL	  cells	  
were	   flow-­‐cytometrically	   sorted	   on	   co-­‐expression	   of	   CD5	   and	   CD19.	   CLL	   cells	   were	  
stored	   as	   dry	   pellets	   and	   transferred	   to	   St	   George’s	   Hospital	   in	   batches	   for	   GC	  MS	  
analysis	  of	  deuterium	  incorporation.	  Figure	  5.10	  illustrates	  the	  Cycle	  1	  labelling	  profile	  
of	   CLL	   cells	   in	   all	   ten	   participants	   over	   the	   eight-­‐week	   period.	   Median	   time	   to	  
maximum	  release	  was	  10.5	  days	  (range	  =	  2-­‐56	  days).	  Time	  to	  maximum	  release	  of	  ≥	  14	  
days	  was	  associated	  with	   splenomegaly	   in	  4/5	   cases.	   This	   finding	   is	   concordant	  with	  
observations	  made	  using	  both	  deuterated	  water,	  in	  which	  slow	  release	  was	  associated	  
with	  high	  CXCR4	  expression	   and	  progressive	  disease,	   and	   tritiated	   thymidine	   studies	  
that	  showed	  a	  distinct	  profile	  of	  labelling	  in	  patients	  with	  organomegaly	  (Calissano	  et	  
al.,	   2009;	   Zimmerman	   et	   al.,	   1968).	   The	   patient	   with	   the	   longest	   time	   to	  maximum	  
release	  (K4)	  had	  the	  greatest	  degree	  of	  splenomegaly	  and	  the	  highest	  sIgM	  expression	  
(18x	  higher	   than	   the	   lowest	   sIgM	  expression),	  possibly	   suggesting	   that	  greater	   tissue	  
retention	  time	  leads	  to	  greater	  sIgM	  expression.	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Figure	  5.10	  Release	  rates	  of	  recently	  proliferated	  CLL	  cells	  into	  the	  peripheral	  blood.	  
The	   fraction	  of	  deuterium	   labelled	  CLL	  cells	   in	   the	  peripheral	  blood	  during	  Cycle	  1	   is	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5.4.6	  Recently	  proliferated	  CLL	  cells	  can	  be	  detected	  12	  weeks	  post	  labelling	  
An	   investigation	   into	   the	   rate	   of	   disappearance	   of	   labelled	   cells	   from	   the	   peripheral	  
blood,	  reflecting	  the	  loss	  of	  cells	  by	  apoptosis	  or	  migration,	  was	  necessary	  to	  establish	  
the	   longevity	   of	   recently	   proliferated	   CLL	   cells.	   Deuterated	   water	   studies	  
demonstrated	  that	  proliferation	  is	  significant	  in	  the	  pathogenesis	  of	  CLL	  but	  it	  was	  not	  
possible	   to	   determine	   disappearance	   rates	   due	   to	   the	   ongoing	   uptake	   of	   deuterium	  
into	  proliferating	   cells	  during	   the	   ‘wash-­‐out’	  phase.	  Deuterated	  glucose	   studies	  have	  
the	   advantage	   of	   providing	   a	   ‘pulse’	   of	   clearly	   defined	   labelling,	   allowing	   the	  
disappearance	  of	  labelled	  cells	  to	  be	  studied.	  
Rate	   of	   disappearance	   of	   labelled	   cells	   was	   initially	   investigated	   by	   measuring	   the	  
fraction	  of	  labelled	  CLL	  cells	  in	  the	  peripheral	  circulation	  weekly	  for	  the	  first	  four	  weeks	  
and	  then	  after	  eight	  weeks.	  Having	  observed	  that	  the	  rate	  of	  disappearance	  was	  very	  
slow,	   with	   labelled	   cells	   detectable	   after	   8	   weeks	   in	   half	   of	   patients,	   sampling	   was	  
extended	  to	  twelve	  weeks.	  Figure	  5.11	   illustrates	  that	   labelled	  cells	  were	  detected	   in	  
all	   3	   patients	   assessed	   after	   12	   weeks.	   This	   rate	   of	   disappearance	   is	   profoundly	  
reduced	  compared	  to	  B	  lymphocytes,	  reported	  to	  have	  a	  half-­‐life	  of	  12	  days	  (Defoiche	  
et	  al.,	  2008).	  Secondly,	  in	  patients	  K8	  and	  K10,	  there	  is	  a	  rapid	  loss	  of	  labelled	  cells	  over	  
the	   first	   4	   weeks	   and	   then	   a	   plateau	   over	   the	   subsequent	   8	   weeks,	   suggestive	   of	  
heterogeneous	  disappearance	   rates	  within	   the	  CLL	   clone.	   Remarkably,	   these	   are	   the	  
two	   patients	   with	   the	   highest	   proliferation	   rates,	   CD38	   expression	   and	   presence	   of	  
Trisomy	  12.	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Figure	  5.11	  Disappearance	  rates	  of	  labelled	  CLL	  cells	  over	  a	  12	  week	  period	  
Deuterium	  enrichment	  in	  CLL	  cells	  was	  measured	  on	  day	  4	  and	  day	  7	  and	  then	  weekly	  
for	   4	   weeks.	   Late	   measurements	   were	   performed	   on	   days	   56	   and	   84	   to	   assess	  
disappearance	   over	   an	   extended	   time-­‐period	   in	   three	   patients.	   The	   fraction	   of	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5.4.7	   Investigation	   into	  whether	   recently	  proliferated	  CLL	   cells	   re-­‐enter	   the	   lymph-­‐
node	  compartment	  
CLL	  is	  considered	  to	  be	  a	  two	  compartment	  disease,	  where	  proliferation	  takes	  place	  in	  
the	  lymph-­‐node	  compartment,	  after	  which	  cells	  are	  released	  into	  the	  circulation	  where	  
they	   remain	   quiescent	   and	   a	   proportion	   of	   cells	   die	   by	   apoptosis	   (Herishanu	   et	   al.,	  
2011).	  Deuterium	  labelling	  studies	  have	  demonstrated	  that	  expression	  of	  CXCR4/	  CD5	  
identifies	  CLL	  cells	  at	  varying	  stages	  of	  proliferation.	  Cells	  expressing	  CD5hi/	  CXCR4	  low	  
represent	   the	   most	   recently	   proliferated	   population	   and	   it	   is	   hypothesised	   that	   re-­‐
expression	  of	  CXCR4	   in	  circulating	  cells	  enables	  them	  to	  re-­‐enter	  the	   lymph-­‐node	  via	  
SDF-­‐1	   ligation,	   to	   under-­‐go	   a	   further	   round	   of	   proliferation	   (Calissano	   et	   al.,	   2009).	  
However,	  lymph-­‐node	  re-­‐entry	  has	  not	  been	  proven.	  
We	   sought	   to	   investigate	   the	   hypothesis	   that	   recently-­‐proliferated	   CLL	   cells	   can	   re-­‐
enter	   the	   lymph-­‐node	   by	   performing	   serial	   FNAs	   in	   three	   patients	   with	   palpable	  
cervical	   lymph-­‐nodes.	   Samples	  were	   collected	   under	   a	   previously	   ethically	   approved	  
study	   (REC	  09/H0805/5).	   Lymph-­‐node	   sampling	  was	   initially	  performed	  on	  days	  1,	  7,	  
and	  21	  post	  labelling	  to	  capture	  peak	  labelling	  in	  proliferating	  cells,	  maximum	  release	  
from	   the	   lymph-­‐node	   and	   possible	   re-­‐entry	   back	   to	   the	   lymph-­‐node	   compartment.	  
Sampling	   time	   was	   informed	   by	   peripheral	   blood	   CLL	   labelling	   (Cycle1)	   and	   was	  
adjusted	  for	  each	  participant	  in	  the	  study.	  	  
Paired	   peripheral	   blood	   (PB)	   and	   lymph-­‐node	   (LN)	   labelling	   for	   the	   entire	   CLL	  
population	  for	  the	  three	  participants	  is	  illustrated	  in	  Figure	  5.9.	  	  Deuterium	  labelling	  in	  
LN	  derived	  CLL	   cells	  was	   significantly	   greater	   than	   labelling	   in	  PB	  CLL	   cells	  drawn	  on	  
Day	   7	   in	   patients	   K2	   and	   K6,	   reflecting	   that	   CLL	   cells	   proliferate	   in	   the	   LN	   in	   these	  
patients.	   Comparison	   of	   PB	   in	   LN	   labelling	   in	   K6	   confirmed	   the	   slow	   release	   rate,	  
demonstrating	   that	   it	   took	   28	   days	   for	   labelling	   to	   equilibrate	   between	   the	   two	  
compartments.	   In	   Patient	   K4,	   who	   had	   significant	   splenomegaly,	   there	   was	   no	  
deuterium	   labelling	   detected	   on	   Day	   7	   but	   labelled	   cells	   were	   detected	   on	   Day	   28,	  
suggesting	   that	   recently	   proliferated	   cells	   had	   entered	   the	   lymph-­‐node	   from	   the	  
peripheral	  blood.	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Figure	  5.12	  Paired	  lymph-­‐node	  and	  peripheral	  blood	  deuterium	  labelling	  
Paired	   lymph-­‐node	  and	  peripheral	  blood	   sampling	  was	  performed	  on	   three	  patients.	  
Viable	  CLL	  cells	  were	  FACS	  sorted	  and	  deuterium	  enrichment	  measured	  by	  GC	  MS.	  
	  
5.4.8	  Sub-­‐populations	  of	  different	  proliferative	  capacity	  exist	  in	  the	  CLL	  lymph-­‐node	  
Deuterated	   water	   studies	   performed	   by	   Calissano	   et	   al	   demonstrated	   that	   the	  
CXCR4lo/	   CD5	   hi	   sub-­‐population	   in	   peripheral	   blood	   was	   enriched	   for	   recently	  
proliferated	  CLL	  cells	   (Calissano	  et	  al.,	  2009).	   It	   is	   thought	   that	   these	  cells	  undergo	  a	  
dynamic	   phenotypic	   change	   in	   the	   circulation	   that	   enables	   their	   recirculation	   to	   the	  
lymph-­‐node.	   We	   therefore	   investigated	   whether	   CLL	   cells	   of	   distinct	   proliferative	  
capacities	  exist	  in	  the	  lymph-­‐node.	  Analysis	  of	  sub-­‐populations	  defined	  by	  CXCR4	  and	  
CD5	  expression	  in	  paired	  samples	  from	  peripheral	  blood	  and	  lymph-­‐node	  was	  possible	  
in	   one	   patient.	   Deuterium	   enrichment	   in	   the	   entire	   CLL	   population	   (black)	   was	  
measured	   in	   relation	   to	   that	   in	   sub-­‐populations	   that	   were	   flow	   sorted	   according	   to	  
CXCR4	  and	  CD5	  expression.	  Figure	  5.13a	  and	  b	  demonstrate	  that	  although	  not	  directly	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proliferative	   characteristics	  exist	   in	   the	   lymph-­‐node.	  The	  observation	   that	  deuterium	  
enrichment	   is	  similar	   in	  the	  sub-­‐population	  defined	  by	  CXCR4	  low/CD5	  high	   is	  similar	  
to	  that	  of	  the	  entire	  CLL	  population	  suggests	  that	  this	  sub-­‐population	  accounts	  for	  the	  
bulk	  of	  CLL	  cells	   in	   the	   lymph-­‐node	  and	  that	   the	  unlabelled	  population	  characterised	  
by	   CXCR4hi/	   CD5low	   is	   a	   minor	   population.	   On	   day	   28,	   labelling	   was	   lost	   from	   the	  
lymph-­‐node	   population	   of	   cells	   with	   CXCR4low/	   CD5hi,	   and	   was	   gained	   in	   the	  




Figure	  5.13a	  FACS	  scatter	  plot	  of	  lymph-­‐node	  and	  peripheral	  blood	  derived	  CLL	  cells	  
Viable	  CLL	  cells	  were	  FACS	  sorted	  according	  to	  co-­‐expression	  of	  CD19	  and	  CD5.	  Expression	  of	  
CXCR4	  and	  CD5	  were	  measured	  to	  ensure	  that	  populations	  were	  phenotypically	  distinct.	  	  
Figure	   5.13b	   Deuterium	   enrichment	   in	   peripheral	   blood	   and	   lymph-­‐node	   CLL	  
populations	  	  
Deuterium	   enrichment	   in	   the	   entire	   CLL	   population	   (black)	   and	   sub-­‐populations	  
defined	  by	  CXCR4	  and	  CD5	  on	  days	  0,	  7	  and	  28	  post	  labelling.	  Deuterium	  enrichment	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5.4.9	   Subclonal	   heterogeneity	   identified	   by	   CXCR4/	   CD5	   expression	   reveals	   a	  
quiescent	   sub-­‐population	   that	   does	   not	   appear	   to	   be	   derived	   from	   a	   recently	  
proliferated	  population	  
Calissano	  et	  al	  have	  previously	  reported	  that	  expression	  of	  CXCR4	  and	  CD5	   identifies	  
the	   most	   recently	   proliferated	   sub-­‐population	   in	   CLL,	   a	   critical	   finding	   that	  
demonstrates	   a	   relationship	   between	   trafficking	   and	   proliferation.	   They	   proposed	   a	  
model	  whereby	  CXCR4	   is	   re-­‐expressed	  and	  CD5	   is	   reciprocally	   lost	  by	   circulating	  CLL	  
cells,	   which	   subsequently	   migrate	   to	   the	   lymph-­‐node	   compartment	   to	   undergo	   a	  
further	   round	   of	   proliferation.	   Using	   the	   ‘pulse-­‐chase’	   labelling,	   possible	   only	   with	  
deuterated	  glucose,	  we	  were	  able	  to	  investigate	  the	  kinetics	  of	  CXCR4/	  CD5	  expression	  
and	  the	  relationship	  between	  sub-­‐populations	  of	  CLL	  cells.	  
Our	   aim	   was	   to	   establish	   whether	   the	   peripheral	   blood	   compartment	   in	   CLL	   is	  
homogenous,	   with	   all	   cells	   having	   an	   equal	   potential	   to	   undergo	   proliferation	  
determined	  by	  migration	  into	  tissue	  sites	  or	  whether	  sub-­‐populations	  are	  functionally	  
distinct.	  	  
Deuterium	   labelled	   peripheral	   blood	   CLL	   cells	   from	   participants	   K2,	   K3	   and	   K4	  were	  
flow-­‐cytometrically	   sorted	   according	   to	   expression	   of	   CXCR4	   and	   CD5	   at	   ten	   time-­‐
points	   over	   eight	   weeks.	   Deuterium	   labelling	   was	   analysed	   by	   GC	   MS.	   In	   all	   three	  
patients,	   the	   sub-­‐population	   with	   CXCR4hi/CD5low	   remained	   unlabelled/minimally	  
labelled	  throughout	  the	  eight-­‐week	  period	  post	   labelling.	  This	  suggests	   that	   this	  sub-­‐
population	  is	  quiescent	  and	  independent	  of	  the	  other	  populations.	  
As	  previously	   reported,	   the	  sub-­‐population	  with	  CXCR4low/	  CD5hi	  demonstrated	   the	  
greatest	  degree	  of	  labelling	  (3.5-­‐	  6	  x	  that	  of	  the	  CLL	  population	  as	  a	  whole)	  (Calissano	  
et	  al.,	  2009).	  Furthermore,	  as	  labelling	  was	  lost	  from	  this	  population,	  it	  was	  reciprocally	  
gained	   in	   the	   population	   of	   CLL	   cells	   with	   intermediate	   expression	   of	   CXCR4/CD5,	  
suggesting	  that	  that	  these	  populations	  are	  in	  continuity	  with	  each	  other	  (Figure	  5.14).	  	  
	   184	  
	  
	  
Figure	   5.14	   Deuterium	   labelling	   in	   CLL	   sub-­‐populations	   defined	   by	   CXCR4/	   CD5	  
expression	  over	  56	  days	  
Labelled	  CLL	  cells	  were	  FACS	  sorted	  according	  to	  CXCR4/	  CD5	  expression	  over	  an	  eight	  
week	   period	   post	   in-­‐vivo	   labelling	   and	   deuterium	   enrichment	   measured	   by	   GC	  MS.	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5.4.10	  Recently	  proliferated	  CLL	  cells	  are	  characterised	  by	  high	  sIgM	  expression	  that	  
is	  subsequently	  down-­‐regulated	  in	  circulating	  CLL	  cells	  
Having	   confirmed	   the	   relationship	   between	   trafficking	   and	   proliferation	   in	   CLL	   and	  
having	  identified	  that	  there	  is	  a	  quiescent	  sub-­‐population	  defined	  by	  CXCR4hi/	  CD5low	  
expression,	   we	   went	   on	   to	   investigate	   the	   relationship	   between	   sIgM	   expression,	  
proliferation	   and	   trafficking.	   Expression	   of	   sIgM	   has	   previously	   been	   linked	   to	   BCR	  
signalling	   in	   patients	   with	   mutated	   IgVH	   genes	   (Mockridge	   et	   al.,	   2007)	   but	   the	  
relationship	   with	   proliferation,	   fundamental	   to	   pathogenesis,	   has	   not	   been	  
investigated.	  
A	   previous	   investigation	   into	   functional	   sub-­‐clonal	   heterogeneity	   in	   CLL	   used	   sIgM	  
expression	   to	   define	   sub-­‐populations.	   The	   authors	   reported	   that	   the	   sub-­‐population	  
with	  the	  lowest	  sIgM	  expression	  was	  enriched	  with	  markers	  of	  recent	  activation	  (CD25,	  
CD38)	  and	  that	  there	  was	  a	  trend	  towards	  increased	  Ki67	  expression	  (n=2)	  suggesting	  
evidence	  of	  recent	  proliferation	  (Coelho	  et	  al.,	  2013).	  However,	  at	  odds	  with	  this	  was	  
their	   observation	   that	   CD5	   expression,	   a	   marker	   of	   recent	   BCR	   signalling,	   was	  
increased	  in	  the	  sub-­‐population	  with	  the	  highest	  sIgM	  expression.	  Characterisation	  of	  
the	   relationship	  between	  sIgM	  expression,	  proliferation	  and	   trafficking	   is	  essential	   in	  
view	  of	  the	  role	  of	  BCR	  signalling	  in	  CLL.	  
We	   flow-­‐sorted	   labelled	   CLL	   cells	   from	   three	   patients	   according	   to	   sIgM	   expression,	  
taking	  the	   lowest,	   intermediate	  and	  highest	  10	  %	  cells	  at	  pre-­‐specified	   intervals	  over	  
an	   eight	   week	   period	   post	   labelling.	   Figure	   5.15	   illustrates	   that	   CLL	   cells	   with	   the	  
highest	   sIgM	   expression	   have	   the	   greatest	   deuterium	   labelling,	   ie	   have	   recently	  
proliferated.	   This	   is	  most	   profound	   in	   Patient	   K8,	  where	   the	   sIgM	  Hi	   population	   has	  
>30	   x	  deuterium	   labelling	  of	   the	   sIgM	  Low	  population.	   This	  patient	  had	   that	  highest	  
proliferation	   rate	   overall	   but	   a	   low	  median	   fluorescent	   intensity	   of	   sIgM	  expression,	  
further	  emphasising	  the	  subclonal	  nature	  of	  the	  disease.	  
Labelling	  is	  rapidly	  lost	  from	  the	  population	  with	  the	  highest	  sIgM	  expression	  relative	  
to	  the	  CLL	  population	  as	  a	  whole,	  possibly	  due	  to	  rapid	  dilution	  of	  this	  compartment	  
with	  unlabeled	  CLL	  cells.	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Cells	  with	  the	  lowest	  sIgM	  expression	  exhibit	  minimal	  deuterium	  labelling,	  suggesting	  
that	  this	  population	  is	  quiescent	  and	  not	  derived	  from	  sIgM	  Hi	  population	  i.e	  similar	  to	  
the	  CXCR4hi/	  CD5	  lo	  sub-­‐population.	  
	  
	  
Figure	   5.15	   Deuterium	   enrichment	   in	   entire	   CLL	   population	   and	   sub-­‐populations	  
defined	  according	  to	  sIgM	  expression	  	  
CLL	  cells	  were	  labelled	  in-­‐vivo	  (n=3)	  and	  viable	  CLL	  cells	  were	  sorted	  according	  to	  sIgM	  
expression,	   taking	   top	   (sIgM	  Hi),	  middle	   (sIgM	   Int)	   and	  bottom	   (sIgM	  Lo)	  10	  %	  cells.	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5.4.11	   BCR	   internalisation	   identifies	   CLL	   sub-­‐populations	  with	   distinct	   proliferative	  
capacities	  
In	  view	  of	  the	  observation	  that	  sub-­‐population	  of	  CLL	  cells	  with	  the	  highest	  degree	  of	  
sIgM	  expression	  represented	  the	  most	  recently	  proliferated	  population,	  and	  that	  it	  has	  
been	   found	   that	   sIgM	   expression	   is	   the	   principal	   factor	   that	   determines	   BCR	  
internalisation	   following	  agonistic	   sIgM	   ligation	   (Coulter	  et	  al	  manuscript	   submitted),	  
we	   went	   on	   to	   investigate	   the	   relationship	   between	   BCR	   internalisation	   and	  
proliferation.	   Deuterium	   labelled	   CLL	   cells	   were	   FACS	   sorted	   according	   to	   BCR	  
internalisation,	   taking	   the	   highest,	   intermediate	   and	   lowest	   10	   %	   cells.	   BCR	  
internalisation	   was	   measured	   using	   the	   pHrodo™	   assay	   described	   in	   5.3.11.	   	   Figure	  
5.16	  illustrates	  that	  the	  10	  %	  CLL	  cells	  with	  the	  highest	  BCR	  internalisation	  is	  enriched	  
with	  proliferated	  cells	  whilst	  the	  10	  %	  cells	  with	  the	  lowest	  BCR	  internalisation	  remain	  
unlabeled/	   minimally	   labelled.	   This	   pattern	   mirrors	   the	   relationship	   between	   sIgM	  
expression	   and	   proliferation	   and	   suggests	   a	   pathway	  whereby	   sIgM	   expression,	   BCR	  
internalisation	   and	   proliferation	   are	   linked.	   This	   is	   consistent	   with	   the	   finding	   that	  
lymph-­‐node	  derived	  CLL	  cells	  and	  those	  expressing	  high	  levels	  of	  CD5	  have	  the	  greatest	  
capacity	  to	  internalise	  the	  BCR	  (Coulter,	  manuscript	  submitted).	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Figure	   5.16	   Deuterium	   enrichment	   in	   entire	   CLL	   population	   and	   sub-­‐populations	  
defined	  according	  to	  BCR	  internalisation	  
	  CLL	  cells	  were	  labelled	  in-­‐vivo	  (n=2)	  and	  viable	  CLL	  cells	  were	  sorted	  according	  to	  BCR	  
internalisation,	   taking	   top	   (BCR	   int	  Hi),	  middle	   (BCR	   int	   Int)	   and	  bottom	   (BCR	   int	   Lo)	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5.4.12	  Sub-­‐clonal	  heterogeneity	  in	  telomere	  length	  
Having	   identified	   a	   seemingly	   quiescent	   subpopulation	   of	   CLL	   cells	   characterised	   by	  
CXCR4hi/	   CD5lo,	   low	   sIgM	   expression	   and	   low	   BCR	   internalisation,	   we	   investigated	  
telomere	   length	   in	  sub-­‐populations,	   taking	   the	  highest	  and	   lowest	  10	  %	  according	  to	  
BCR	  internalisation.	  Our	  hypothesis	  was	  that	  if	  the	  functional	  properties	  of	  this	  cohort	  
of	   cells	  were	   fixed,	   telomere	   length	  would	   inversely	   correlate	  with	   the	   proliferation	  
rate.	   Figure	  5.17	   illustrates	   telomere	   length	   (measured	  by	   STELA)	   in	   sub-­‐populations	  
defined	   by	   BCR	   internalisation.	   In	   one	   of	   three	   patients	   (K10),	   telomere	   length	  was	  
shortened	  in	  the	  sub-­‐population	  with	  the	  highest	  BCR	  internalisation.	  Additionally,	  the	  
clonal	  proliferation	  rate	   in	  this	  patient	  was	  more	  than	  2	  x	  that	  of	  the	  two	  patients	   in	  
which	  no	  difference	  in	  telomere	  length	  was	  observed.	  
Figure	  5.17	  Telomere	  length	  in	  CLL	  cells	  according	  to	  BCR	  internalisation	  
CLL	  cells	  were	  flow	  sorted	  according	  to	  ability	  to	  internalise	  the	  BCR.	  The	  highest	  and	  
lowest	  10	  %	  cells	  were	  collected	  and	  DNA	  extracted	  for	  telomere	  length	  analysis	  using	  
the	   STELA	   assay.	   XpYp	   gels	   display	   the	   telomere	   profiles	   in	   CLL	   cell	   subpopulations	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5.5.	  Discussion	  
The	  purpose	  of	  this	  investigation	  was	  to	  use	  in-­‐vivo	  labelling	  to	  further	  characterise	  the	  
relationship	   between	   trafficking	   and	   proliferation	   that	   underpins	   the	   clinical	  
heterogeneity	  in	  CLL.	  
The	   In-­‐Vivo	  Kinetics	  Study	  was	  successful	   in	  recruiting	  to	  target	   (n=10)	  and	  collecting	  
data	   at	   all	   pre-­‐specified	   time-­‐points,	   amounting	   to	   16	   hospital	   attendances	   per	  
participant.	  We	  set	  out	  to	  recruit	  a	  cohort	  of	  patients	  with	  early-­‐stage,	  non-­‐progressive	  
CLL	   in	   whom	   kinetics	   studies	   could	   be	   performed	   over	   a	   sixteen-­‐week	   period.	   This	  
specification	  unintentionally	   resulted	   in	   the	   recruitment	  of	   a	   cohort	  of	   patients	  with	  
M-­‐CLL.	   Although	   this	   enabled	   the	   interrogation	   of	   a	   seemingly	   biologically	  
‘homogeneous’	   cohort	   of	   patients,	   findings	   from	   this	   study	   are	   only	   applicable	   to	  
patients	  with	  M-­‐CLL.	  A	  major	  amendment	  has	  been	  agreed	  to	  enable	  the	  recruitment	  
of	   patients	  with	   UM-­‐CLL	   to	   an	   abbreviated	   period	   of	   study.	   Importantly,	   within	   our	  
cohort	  of	  patients,	   three	  expressed	  CD38	  at	  ≥	  7%;	  discordance	  being	  associated	  with	  
an	  intermediate	  clinical	  prognosis	  (Hamblin	  et	  al.,	  2002).	  	  
First,	  we	  measured	  the	  clonal	  proliferation	  rate	  in	  each	  patient;	  the	  proliferation	  rate	  
in	   our	   study	   was	   highly	   heterogeneous	   (0.08	   %/day	   -­‐	   0.95	   %/day)	   and	   the	   mean	  
proliferation	   rate	   was	   lower	   than	   that	   previously	   reported	   by	   Messmer	   et	   al,	  
consistent	  with	  the	  clinical	  profile	  of	  our	  cohort.	  In	  contrast,	  the	  ‘Messmer’	  cohort	  of	  
patients	   included	  more	  patients	  with	  adverse	  prognostic	   features;	  50	  %	  had	  UM-­‐CLL,	  
expressed	  CD38	  and	  exhibited	  progressive	  disease	  (Messmer	  et	  al.,	  2005).	  	  
There	  was	  excellent	  intra-­‐patient	  correlation	  in	  proliferation	  rates,	  demonstrating	  that	  
deuterated	  glucose	  labelling	  could	  be	  used	  to	  measure	  the	  effect	  of	  a	  drug	  on	  in-­‐vivo	  
proliferation	   in	   clinical	   trials.	   In	   one	   exceptional	   patient,	  who	  had	   a	   small	   clone	   size	  
and	  had	  recently	  been	  diagnosed	  with	  CD38+	  CLL,	  there	  was	  an	  apparent	  doubling	  in	  
proliferation	  rate	  between	  cycles	  1	  and	  2.	  
An	   investigation	   into	   the	   relationship	   between	  BCR	   expression,	   BCR	   signalling,	   CD38	  
expression,	   proliferation	   and	   telomere	   length	   was	   necessary	   in	   view	   of	   recent	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translational	  studies	  that	  have	  emphasised	  the	   importance	  of	  the	  BCR	  axis	   in	  disease	  
pathogenesis.	   Importantly,	   we	   found	   that	   the	   highest	   proliferation	   rates	   were	  
associated	  with	   CD38	   expression	   and	   trisomy	   12.	   Expression	   of	   CD38	   has	   previously	  
been	   associated	   with	   increased	   propensity	   to	   migrate	   into	   the	   tumour	  
microenvironment,	   where	   cells	   receive	   pro-­‐survival	   signalling	   and	   undergo	  
proliferation	  (Vaisitti	  et	  al.,	  2010).	  Trisomy	  12	  is	  associated	  with	  increased	  expression	  
of	   CD11a,	   CD38,	   CD49d,	   the	   latter	   being	   strongly	   associated	   with	   trans-­‐endothelial	  
migration	  and	  capacity	  to	  activate	  T	  cells	  in	  the	  lymph-­‐node	  compartment	  (D'Arena	  et	  
al.,	  2001;	  Pasikowska	  et	  al.,	  2016;	  Su'ut	  et	  al.,	  1998;	  Zucchetto	  et	  al.,	  2013).	  In	  the	  two	  
patients	  with	  trisomy	  12,	  sIgM	  expression	  was	  low	  and	  there	  was	  no	  evidence	  of	  pERK	  
activation	   in	   response	   to	   BCR	   ligation,	   suggesting	   that	   BCR	   signalling	   was	   not	  
responsible	  for	  the	  higher	  proliferation	  rates	  in	  these	  patients.	  
There	  was	  no	  direct	  relationship	  between	  sIgM	  expression,	  BCR	  signalling	  in	  response	  
to	  agonistic	   sIgM	   ligation	  and	  proliferation	   rate	   in	  our	  cohort	  of	  patients	  with	  M-­‐CLL	  
and	   this	   remains	   an	   outstanding	   area	   of	   investigation	   in	   patients	   with	   UM-­‐CLL.	  
However,	   not	   all	   patients	   displayed	   anergy	   to	   BCR	   ligation;	   two	   patients	   exhibited	  
activation	  of	  pERK	  in	  response	  to	  BCR	  ligation;	  one	  of	  these	  patients	  had	  a	  high	  level	  of	  
sIgM	  expression	  (K2)	  and	  proliferation	  rates	   in	  both	  patients	  were	  above	  the	  median	  
(0.255	  %/day).	  Telomere	  length,	  only	  measurable	  in	  one	  of	  the	  two	  patients,	  was	  the	  
shortest	   in	   our	   cohort	   –	   possibly	   suggesting	   a	   relationship	   between	   BCR	  
responsiveness	   and	   sustained	   proliferation.	   However,	   a	   larger	   study	   is	  warranted	   to	  
investigate	  this	  further.	  
Our	  study	  was	  the	  first	  to	  formally	  study	  release	  and	  disappearance	  rates	  of	   labelled	  
CLL	   cells	   in	   a	   cohort	   of	   patients	   with	  well-­‐defined	   biological	   characteristics.	   Release	  
rates	   were	   heterogeneous	   and	   surprisingly	   slow,	   particularly	   in	   patients	   with	  
splenomegaly.	   The	   patient	  with	   the	   slowest	   release	   rate	   (K4)	   had	   the	   largest	   spleen	  
and	   significantly	   higher	   sIgM	   expression.	   Slow	   appearance	   of	   labelled	   cells,	   in	   the	  
context	  of	  splenomegaly,	  was	  reported	  in	  a	  very	  early	  study	  of	  tumour	  kinetics	  in	  CLL	  
that	   used	   in-­‐vivo	   tritiated	   thymidine	   labelling	   (Zimmerman	   et	   al.,	   1968)	   and	   more	  
recently	  in	  deuterated	  water	  studies,	  where	  late	  appearance	  was	  associated	  with	  high	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CXCR4	  expression.	  One	  explanation	   for	  slow	  release	   in	  patients	  with	  splenomegaly	   is	  
increased	  tissue	  retention	  resulting	  from	  interaction	  between	  CXCR4	  on	  CLL	  cells	  and	  
SDF-­‐1	   expressed	   by	   stromal	   cells.	   Expression	   of	   S1P1,	   required	   for	   leucocyte	   egress,	  
and	  reported	  to	  be	  defective	   in	  CLL	  (Capitani	  et	  al.,	  2012;	  Sic	  et	  al.,	  2014),	  should	  be	  
investigated	  in	  relation	  to	  release	  rates.	  
Disappearance	   rates	   were	   heterogeneous	   both	   between	   and	   within	   patients	  
suggesting	  the	  existence	  of	  sub-­‐populations	  with	  variable	  rates	  of	  cell	  turn-­‐over.	  More	  
specifically,	  the	  initial	  rapid	  decline	  may	  arise	  from	  a	  population	  of	  cells	  with	  a	  fast	  rate	  
of	   cell-­‐turnover	   whilst	   the	   subsequent	   slower	   rate	   of	   decline	   may	   result	   from	   a	  
population	   with	   a	   slow	   rate	   of	   proliferation	   and	   cell-­‐death.	   The	   observation	   that	  
labelled	  cells	  were	  detected	  after	  12	  weeks	   in	   the	   three	  patients	  who	  underwent	  an	  
extended	  period	  of	  monitoring	   suggests	   that	   significantly	   reduced	   rates	  of	   apoptosis	  
compared	  to	  healthy	  B	   lymphocytes	  may	  contribute	  to	  pathogenesis	   in	  patients	  with	  
M-­‐CLL.	  
Calissano	  et	   al	   have	  previously	  demonstrated	   that	   recently	   proliferated	  CLL	   cells	   are	  
characterised	  by	   low	  CXCR4	  and	  high	  CD5	  expression	   (Calissano	  &	  Damle,	  2011).	  We	  
confirmed	  this	  finding	  and	  by	  sorting	  cells	  according	  to	  CXCR4/	  CD5	  expression	  at	  pre-­‐
specified	   time-­‐points	  over	  an	  eight-­‐week	  period,	  we	   found	  that	   there	  was	  continuity	  
between	  CXCR4lo/	  CD5hi	  and	  intermediate	  populations	  (CXCR4int/	  CD5int),	  consistent	  
with	  CXCR4	   re-­‐expression	   in	   the	   circulation.	  However,	  most	   strikingly,	   the	  decade	  of	  
cells	  with	   the	  highest	  CXCR4/	   lowest	  CD5	   remained	  unlabeled	   throughout	   the	  eight-­‐
week	  period	  of	   investigation.	  This	   suggests	   that	   recently	  proliferated	  cells	   re-­‐express	  
CXCR4	   to	   an	   intermediate	   level	   but	   not	   to	   a	   high	   level,	   to	   re-­‐enter	   the	   lymph-­‐node.	  
This	   goes	   against	   the	   hypothesis	   that	   recently	   proliferated	   CLL	   cells	   maximally	   re-­‐
express	  CXCR4	  to	  enable	  lymph-­‐node	  re-­‐entry	  and	  suggests	  that	  this	  population	  is	  an	  
independent	  sub-­‐population,	  fixed	  in	  a	  state	  of	  quiescence.	  	  
To	   investigate	   the	   proposed	   model	   of	   lymph-­‐node	   re-­‐entry,	   we	   performed	   paired	  
peripheral	  blood	  and	  lymph-­‐node	  sampling	  over	  the	  three	  weeks	  post	  labelling.	  In	  one	  
patient,	  there	  was	  increased	  labelling	  in	  the	  lymph-­‐node	  compartment	  between	  days	  7	  
and	   28,	   consistent	  with	  migration	   of	   recently	   proliferated	   leukaemic	   cells.	   However,	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this	  patient	  was	  unusual	  in	  that	  peripheral	  blood	  labelling	  was	  greater	  the	  lymph-­‐node	  
labelling	   and	   that	   the	   prominent	   clinical	   feature	   was	   of	   splenomegaly.	   Studies	   of	  
proliferation	  in	  the	  spleen	  are	  few	  but	  it	  has	  been	  reported	  that	  proliferation	  centres	  
do	   exist	   in	   spleens	   of	   patients	   with	   CLL	   (Lampert,	   Wotherspoon,	   Van	   Noorden,	   &	  
Hasserjian,	  1999),	  and	  it	  is	  possible	  that	  the	  spleen	  was	  the	  major	  site	  of	  proliferation	  
in	   this	   case.	   Again,	   this	   study	   should	   be	   extended	   to	   a	   larger	   cohort	   of	   patients	   to	  
further	   investigate	   trafficking	   between	   the	   peripheral	   blood	   and	   lymph-­‐node	  
compartments.	  
To	  further	  interrogate	  the	  relationship	  between	  CLL	  sub-­‐populations	  defined	  by	  CXCR4	  
and	   CD5	   expression	   and	   trafficking	   between	   the	   peripheral	   blood	   and	   lymph-­‐node	  
compartments,	  we	  went	  on	  to	  measure	  deuterium	  enrichment	  in	  lymph-­‐node	  derived	  
sub-­‐populations.	  Importantly,	  we	  found	  that	  lymph-­‐node	  derived	  CLL	  sub-­‐populations	  
had	  diverse	  characteristics	  of	  proliferation.	  The	  decade	  of	  cells	  with	  the	  highest	  CXCR4	  
and	   lowest	   CD5	   expression	   remained	   unlabelled	   over	   a	   28-­‐day	   period	   ie	   appeared	  
quiescent.	   However,	   the	   decade	   of	   cells	   with	   the	   reciprocal	   phenotype	   had	   the	  
greatest	  degree	  of	  labelling	  and	  as	  this	  was	  comparable	  with	  the	  labelling	  of	  unsorted	  
CLL	   cells,	   suggests	   that	   a	   large	  proportion	  of	   cells	   in	   the	   lymph-­‐node	  are	  CXCR4low/	  
CD5hi	  and	  are	  proliferating.	  It	  is	  notable	  that	  on	  day	  28,	  there	  was	  a	  loss	  of	  labelling	  in	  
the	  CXCR4low/CD5	  hi	  population	  and	  a	  gain	  in	  labelling	  in	  the	  intermediate	  population,	  
possible	   reflecting	   lymph-­‐node	   re-­‐entry	   of	   cells	   that	   have	   re-­‐expressed	   CXCR4	   to	   an	  
intermediate	   level	   in	   the	   circulation.	   This	   is	   consistent	  with	   the	   observed	   continuity	  
between	  these	  populations	  in	  the	  peripheral	  blood.	  
Our	   investigation	   into	   the	   dynamics	   of	   sIgM	  expression	   in	   recently	   proliferated	   cells	  
yielded	  two	  important	  findings.	  First	  and	  foremost,	  we	  found	  that	  recently	  proliferated	  
CLL	   cells	   are	   consistently	   characterised	  by	   high	   sIgM	  expression	   and	   that	   labelling	   is	  
rapidly	   lost	   from	   this	   compartment.	   This	   is	   in	   agreement	   with	   the	   observation	   that	  
sIgM	   expression	   in	   the	   lymph-­‐node	   is	   greater	   than	   in	   the	   peripheral	   blood	   (Coulter,	  
manuscript	  submitted)	  and	  with	  recent	  reports	  that	  sIgM	  is	  upregulated	  in	  response	  to	  
IL4	  signalling	  in	  the	  CLL	  lymph-­‐node	  (Aguilar-­‐Hernandez	  et	  al.,	  2016;	  Guo	  et	  al.,	  2016).	  
However,	  it	  challenges	  the	  model	  proposed	  by	  Coelho	  et	  al	  that	  the	  BCR	  is	  internalised	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in	   the	   lymph-­‐node	  and	   that	   recently	  proliferated	  cells	  are	  characterised	  by	   low	  sIgM	  
expression	  and	  unresponsiveness	   to	  BCR	   ligation	   (Coelho	  et	  al.,	   2013).	   Secondly,	   the	  
sub-­‐population	   with	   the	   lowest	   sIgM	   expression	   appeared	   as	   an	   independent	   sub-­‐
population	  with	  minimal	   deuterium	   labelling	   throughout	   the	   period	   of	   investigation,	  
similar	  to	  the	  quiescent	  sub-­‐population	  characterised	  by	  CXCR4hi/	  CD5	  low	  expression.	  
Finally,	   we	   went	   on	   to	   investigate	   the	   relationship	   between	   BCR	   internalisation	  	  
(reflective	  of	  BCR	  function)	  and	  proliferation	  and	  the	  dynamics	  of	  BCR	  internalisation	  
over	  time.	  Consistent	  with	  the	  enrichment	  of	  the	  sIgM	  high	  fraction	  with	  proliferating	  
cells,	   the	   cohort	  of	   cells	  with	   the	   greatest	  BCR	   internalisation	  exhibited	   the	   greatest	  
degree	  of	  proliferation.	  Labelling	  was	  rapidly	  lost	  from	  the	  decade	  of	  CLL	  cells	  with	  the	  
greatest	  BCR	   internalisation,	  suggesting	  that	  there	   is	  rapid	  dilution	  of	  this	  population	  
with	   unlabelled	  proliferating	   cells.	   Again	  we	   showed	   that	   there	  was	   an	   independent	  
sub-­‐population	  of	  cells	  characterised	  by	  low	  BCR	  internalisation.	  
By	  tracking	  the	  labelling	  in	  sub-­‐populations	  of	  cells	  defined	  by	  CXCR4/	  CD5	  hi,	  sIgM	  and	  
BCR	  internalisation,	  we	  were	  able	  to	  investigate	  the	  phenotypic	  changes	  that	  recently	  
proliferated	   cells	   undergo	   over	   an	   eight-­‐week	   period.	   Critically,	   we	   identified	   a	  
discrete,	   quiescent	   sub-­‐population	   characterised	   by	   CXCR4hi/	   CD5low,	   low	   sIgM	  
expression	   and	   low	   BCR	   internalisation	   in	   our	   cohort	   of	   patients	   with	   M-­‐CLL.	   Our	  
limited	   telomere	   length	   analysis	   found	   that	   in	   one	   patient	   (with	   the	   second	   highest	  
proliferation	   rate),	   telomere	   length	   was	   shortest	   in	   the	   sub-­‐population	   with	   the	  
highest	   BCR	   internalisation,	   suggesting	   that	   this	   cohort	   of	   cells	   has	   undergone	  
significantly	  more	  proliferation.	  The	  studies	  into	  the	  relationship	  between	  phenotype,	  
function,	  proliferation	  and	  telomere	  length	  were	  limited	  to	  a	  small	  number	  of	  patients	  
and	  a	  larger	  cohort	  study	  is	  necessary	  to	  further	  investigate	  our	  preliminary	  findings.	  
The	  size	  of	  the	  quiescent	  population	  was	  not	  determined	  in	  this	  investigation	  in	  which	  
deuterium	  labelling	  was	  measured	  in	  fixed	  populations	  each	  accounting	  for	  10	  %	  of	  the	  
total	   population.	  However,	  when	   looking	  at	  deuterium	  enrichment	   in	   the	   three	   sub-­‐
populations	  relative	  to	  the	  entire	  CLL	  population,	  the	  degree	  of	  dilution	  of	  the	  highly	  
labelled	   population	   suggests	   that	   the	   quiescent	   phenotype	   accounts	   for	   a	   large	  
proportion	  of	  cells.	  The	  exact	  size	  of	  proliferating	  and	  quiescent	  populations	  is	  likely	  to	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be	  heterogeneous	  and	   could	  be	  more	  accurately	  estimated	  by	  measuring	  deuterium	  
enrichment	  in	  all	  ten	  decades	  of	  cells	  within	  the	  CLL	  clone.	  
The	  identification	  of	  a	  population	  of	  quiescent	  CLL	  cells	  is	  relevant	  to	  the	  observation	  
that	  patients	  with	  M-­‐CLL	  treated	  with	  the	  BCR	  antagonist	  ibrutinib,	  frequently	  develop	  
a	  persistent	  lymphocytosis	  and	  in	  whom	  the	  persisting	  lymphocytes	  are	  characterised	  
by	   constitutive	   ERK	   phosphorylation,	   and	   Ki67	   negativity	   (Woyach,	   Smucker,	   et	   al.,	  
2014c).	   Furthermore,	   the	   observation	   that	   mean	   CLL	   cell	   expression	   of	   CXCR4	  
increases	  as	  patients	  respond	  to	   ibrutinib	  (Herman,	  Niemann,	  et	  al.,	  2014b)	  could	  be	  
interpreted	   as	   enrichment	   of	   the	   sub-­‐population	   of	   CXCR4hi/	   CD5low	   cells	   as	   the	  
population	  with	   the	  opposing	  phenotype	   is	  eliminated.	   In-­‐vivo	   labelling	  studies	  using	  
deuterated	  glucose	  to	  study	  the	  kinetics	  of	  proliferating	  cells	  in	  patients	  commencing	  
treatment	  with	  ibrutinib	  are	  warranted.	  
Full	   phenotypic,	   functional	   and	   genetic	   characterisation	   of	   the	   quiescent	   sub-­‐
population	   is	   now	  necessary	   to	   establish	   the	  biological	   properties	   if	   these	   cells.	   This	  
investigation	   should	   include	   assessment	   of	   features	   of	   anergy	   i.e.	   constitutive	  
activation	   of	   NFAT	   and	   pERK	   and	   ability	   to	   ‘signal’	   in	   response	   to	   agonistic	   sIgM	  
ligation.	   Ultimately,	   we	   need	   to	   establish	   whether	   this	   population	   is	   genetically	  
distinct;	   this	   requires	   assessment	   if	   the	   mutational	   profile	   using	   next	   generation	  
sequencing	  (NGS).	  
Finally,	  we	  propose	  a	  model	  of	  CLL	  trafficking	  whereby	  recently	  proliferated	  CLL	  cells	  
released	   from	   the	   lymph-­‐node	   are	   characterised	   by	   CXCR4low/	   CD5hi,	   high	   sIgM	  
expression	   and	   high	   BCR	   internalisation	   and	   that	   within	   the	   peripheral	   blood	  
compartment	  CXCR4	   is	   re-­‐expressed	   to	  an	   intermediate	   level,	  with	   reciprocal	   loss	  of	  
CD5	   and	   sIgM	   expression.	   CLL	   cells	   that	   re-­‐enter	   the	   lymph-­‐node	   express	   an	  
intermediate	   level	   of	   CXCR4	   and	   are	   derived	   from	   the	   CXCR4low/CD5	   hi	   population	  
whilst	  the	  CXCR4hi/CD5low/	  sIgM	  low	  sub-­‐population	  remains	  independent	  in	  patients	  
with	  M-­‐CLL.	  	  
An	   investigation	   into	   tumour	   kinetics	   in	   patients	   with	   UM-­‐CLL	   is	   now	   necessary	   to	  
determine	  whether	  the	  quiescent	  sub-­‐population	  is	  a	  unique	  to	  patients	  with	  M-­‐CLL	  or	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whether	   it	   is	   relevant	   to	   all	   patients	   regardless	   of	   IgVH	   mutational	   status.	   The	  
observation	   that	   patients	  with	  UM-­‐CLL	   treated	  with	   ibrutinib	   tend	   not	   to	   develop	   a	  
persistent	   lymphocytosis	  of	  non-­‐proliferating	  cells,	  suggests	  that	   it	  may	  be	  specific	  to	  
M-­‐CLL.	   Secondly,	   it	   would	   be	   interesting	   to	   compare	   sIgM	   expression,	   BCR	  
internalisation,	   proliferation	   and	   disappearance	   rates	   in	   patients	   with	   UM-­‐CLL	   with	  
patients	  with	  M-­‐CLL,	   in	  whom	  BCR	   signalling	   and	   proliferation	   are	   considered	   to	   be	  
less	  active.	  
Overall,	   our	   detailed	   investigation	   using	   in-­‐vivo	   labelling	   to	   study	   tumour	   kinetics	   in	  
CLL	   provides	   an	   important	   insight	   into	   the	   relationship	   between	   phenotypic	   and	  
functional	  characteristics	  of	  CLL	  cells	  and	  their	  propensity	  to	  migrate	  and	  proliferate.	  
This	  study	  has	  contributed	  to	  the	  characterisation	  of	  the	  processes	  that	  underpin	  the	  
clinical	   heterogeneity	   in	   CLL.	   Further	   studies	   are	   planned	   to	   investigate	   the	   in-­‐vivo	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  General	  Discussion	  Chapter	  6
6.1	  CLL	  Pathophysiology	  
Chronic	   Lymphocytic	   Leukaemia	   is	   a	   B	   cell	   lymphoproliferative	   disease	   characterised	  
by	   significant	   biological	   and	   clinical	   heterogeneity	   where	   interactions	   between	  
malignant	   cells	   and	   the	   microenvironment	   contribute	   to	   disease	   pathogenesis.	  
Although	  for	  many	  years	  it	  was	  considered	  to	  be	  a	  disease	  of	  failed	  apoptosis,	  there	  is	  
now	  a	  wealth	  of	  evidence	  to	  support	  the	  role	  of	  proliferation	  in	  the	  biology	  of	  CLL.	  The	  
in-­‐vivo	   labelling	   study	   performed	   by	   Messmer	   et	   al	   was	   a	   pivotal	   study	   that	  
demonstrated	  that	  in	  patients	  with	  progressive	  CLL,	  ‘birth-­‐rates’	  could	  be	  as	  high	  as	  2	  
%	  of	  the	  malignant	  clone	  each	  day	  (Messmer	  et	  al.,	  2005).	  Consistent	  with	  this	  finding	  
was	  the	  observation	  that	  telomere	  length	  is	  critically	  shortened	  in	  CLL,	  reflective	  of	  a	  
significant	   replicative	   history	   (Lin	   et	   al.,	   2010).	   More	   recently,	   next	   generation	  
sequencing	   of	   leukaemic	   B	   cells	   at	   sequential	   time-­‐points	   has	   neatly	   demonstrated	  
that	   proliferating	   cells	   can	   undergo	   clonal	   evolution,	   particularly	   in	   the	   face	   of	   the	  
‘selection	  pressure’	  of	  chemotherapy	  (Landau	  et	  al.,	  2013;	  A.	  Schuh	  et	  al.,	  2012).	  
6.2	  The	  Tumour	  Microenvironment	  
A	  major	  contribution	  to	  the	  field	  of	  CLL	  biology	  was	  the	  finding	  that	  the	  proliferation	  of	  
CLL	   cells	   takes	   place	   within	   the	   lymph-­‐node	   compartment	   (Herishanu	   et	   al.,	   2011;	  	  
Jaksic	   et	   al.,	   2010).	   Characterisation	   of	   the	   processes	   that	   take	   in	   the	   lymph-­‐node	  
compartment	  has	  been	  an	  area	  of	  intense	  investigation	  and	  continues	  to	  shed	  light	  on	  
the	   processes	   that	   drive	   the	   survival	   and	   proliferation	   of	   CLL	   cells.	   Interactions	  
between	  malignant	  cells	  and	  components	  of	  the	  tumour	  microenvironment	   including	  
endothelial	   cells,	   stromal	  cells	  and	  nurse-­‐like	  cells	  are	  complex	  and	  bidirectional	  and	  
involve	  both	  direct	  contact	  and	  cytokine	  signalling	  (Buggins	  et	  al.,	  2008;	  J.	  A.	  Burger	  et	  
al.,	  2000;	  Ghia	  et	  al.,	  2002).	  	  
6.3	  BCR	  Signalling	  in	  CLL	  
B	  cell	  receptor	  signalling	  is	  most	  active	  in	  the	  lymph-­‐node	  and	  has	  been	  shown	  to	  be	  
enhanced	  by	  IL4	  that	  upregulates	  CD79b	  and	  sIgM	  expression	  (Guo	  et	  al.,	  2016).	  The	  
degree	   of	   sIgM	   expression	   and	   BCR	   signalling	   in	   CLL	   cells	   is	   heterogeneous	   and	   is	  
closely	  related	  to	  the	  IgVH	  mutational	  status	  of	  the	  patient.	  In	  patients	  with	  unmutated	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IgVH	   genes,	   there	   is	   greater	   sIgM	   expression	   and	   enhanced	   calcium	   mobilisation	  
following	  BCR	  ligation	  (Muzio	  et	  al.,	  2008).	  In	  patients	  with	  mutated	  IgVH	  genes,	  there	  
is	   a	   tendency	   towards	   ‘anergy’,	   where	   leukaemic	   B	   cells	   are	   characterised	   by	  
constitutive	  activation	  of	  NFAT	  and	  ERK	  and	  failure	  to	  mobilise	  calcium	  following	  BCR	  
ligation	   (Muzio	   et	   al.,	   2008).	   Clinically,	   patients	   with	   unmutated	   IgVH	   genes	   have	   a	  
more	   proliferative	   disease	   with	   a	   shorter	   time	   to	   first	   treatment	   and	   a	   shortened	  
overall	  survival	  (Damle	  et	  al.,	  1999;	  Hamblin	  et	  al.,	  1999).	  
Recently,	   it	  has	  been	  demonstrated	  that	  drugs	  that	  target	  BCR	  signalling	  have	  potent	  
effects	   both	   in-­‐vitro	   and	   in-­‐vivo	   and	   that	   in	   addition	   to	   inhibiting	   signalling	   down-­‐
stream	  of	  the	  BCR	  and	  reducing	  proliferation,	  they	  impact	  on	  the	  trafficking	  of	  CLL	  cells	  
between	   the	   lymph-­‐node	   and	  peripheral	   blood	   compartments	   (Herman,	  Mustafa,	   et	  
al.,	  2014a;	  Herman,	  Niemann,	  et	  al.,	  2014b).	  However,	  the	  relationship	  between	  BCR	  
signalling,	   proliferation	   and	   trafficking	   of	   leukaemic	   cells	   has	   not	   been	   fully	  
determined.	   Of	   note,	   a	   small	   number	   of	   patients	   have	   failed	   ibrutinib	   therapy	   as	   a	  
result	  of	  expansion	  of	   sub-­‐clones	  harbouring	  mutations	   that	   render	  cells	   resistant	   to	  
the	   drug	   (Liu	   et	   al.,	   2015;	   Woyach	   et	   al.,	   2014b).	   Full	   characterisation	   of	   the	  
mechanisms	  of	  resistance	  is	  necessary	  to	  develop	  effective	  treatments	  in	  this	  cohort	  of	  
patients.	  
6.4	  The	  Role	  of	  Activated	  CD4	  T	  Cells	  in	  CLL	  
Our	  group	  and	  others	  have	  focused	  on	  the	  role	  of	  activated	  CD4	  T	  cells	  that	  contribute	  
to	  the	  proliferation	  of	  CLL	  cells	  in	  the	  lymph-­‐node	  compartment.	  Patten	  demonstrated	  
that	  recently	  proliferated	  CLL	  cells	  frequently	  contact	  activated	  CD4	  T	  cells	  and	  that	  co-­‐
culture	  of	  CLL	  cells	  with	  activated	  autologous	  T	  cells	  leads	  to	  the	  upregulation	  of	  CD38	  
expression	  and	   to	   the	  proliferation	  of	  CLL	   cells	   (Patten	  et	  al.	  2008b;	  Willimott	  et	  al.,	  
2007).	  Bagnara	  et	  al	  subsequently	  reported	  that	  activated	  autologous	  CD4	  T	  cells	  are	  
required	  for	  the	  engraftment	  and	  proliferation	  of	  CLL	  cells	  in	  the	  NSG	  mouse	  model	  of	  
CLL	  (Bagnara	  et	  al.,	  2011).	  
The	   mechanism	   whereby	   CD4	   T	   cells	   activate	   CLL	   cells	   has	   been	   shown	   to	   be	  
multifactorial.	   Activated	   CD4	   T	   cells	   express	   CD40L	   that	   induces	   NFκB	   translocation	  
and	  leads	  to	  enhanced	  survival,	  activation	  and	  proliferation	  of	  CLL	  cells	  (Furman	  et	  al.,	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2000;	  Hamilton	  et	  al.,	  2012).	  In	  addition	  to	  direct	  contact,	  cytokines	  including	  IL4,	  IL21	  
and	  IFNγ	  have	  been	  shown	  to	  activate	  CLL	  cells	  and	  to	  induce	  proliferation	  (Ahearne	  et	  
al.,	  2013;	  Bürgler	  et	  al.,	  2015;	  Pascutti	  et	  al.,	  2013).	  
6.5	  Manipulation	  of	  the	  Tumour	  Microenvironment	  
In	  view	  of	  the	  fact	  that	  T	  cells	  appear	  to	  play	  a	  considerable	  role	  in	  the	  pathogenesis	  of	  
CLL,	   we	   investigated	   whether	   manipulation	   of	   the	   tumour	   microenvironment	   by	  
suppressing	  T	  cell	  activity	  could	  reduce	  the	  proliferation	  rate	  of	  CLL	  cells.	  Targeting	  the	  
microenvironment	   as	   opposed	   to	   the	   malignant	   cells	   is	   a	   novel	   strategy	   that	   is	  
particularly	   desirable	   because	   it	   should	   not	   contribute	   to	   clonal	   evolution	   and	  
therapeutic	  resistance.	  
Ciclosporin	   (CsA)	   was	   selected	   as	   the	   drug	   of	   choice	   due	   to	   its	   potent	   anti-­‐T	   cell	  
properties	  and	  because	  of	   the	  extensive	   clinical	   experience	  gained	   in	   the	  use	  of	   this	  
drug	  including	  that	  in	  the	  context	  of	  autoimmune	  complications	  of	  CLL.	  Furthermore,	  
CsA	  has	  been	  reported	  to	  have	  anti-­‐tumour	  activity	  in	  a	  proportion	  of	  patients	  with	  CLL	  
(Cortes	  et	  al.,	  2001).	  
Ciclosporin	   is	   a	   calcineurin	   inhibitor	   that	   inhibits	   T	   cell	   activation	   by	   inhibiting	   the	  
nuclear	   translocation	  of	  NFAT	  and	  NFκB.	  However,	  NFAT	  and	  NFκB	  play	  a	   significant	  
role	   in	   signalling	   downstream	   of	   the	   BCR	   in	   CLL	   cells	   that	   contributes	   to	   disease	  
pathogenesis	   (Hewamana	   et	   al.,	   2008;	   Le	   Roy	   et	   al.,	   2012).	   Indeed,	   Apollonio	   et	   al	  
demonstrated	   that	   inhibition	   of	   NFAT-­‐C1	   signalling	   using	   the	   cell	   permeable	   VIVIT	  
peptide	  in	  MEC-­‐1	  transplanted	  xenograft	  mice	  reduced	  the	  rate	  of	  tumour	  growth	  and	  
increased	   survival	   (Apollonio	   et	   al.,	   2013).	  We	   therefore	   designed	   a	   comprehensive	  
series	  of	   in-­‐vitro	   assays	   to	  determine	  whether	  CsA	   inhibits	  T	   cell	   activation	   in	  CLL	  or	  
whether	  its	  effects	  are	  due	  to	  disruption	  of	  BCR	  signalling.	  Although	  it	  is	  possible	  that	  
CsA	   inhibits	   signalling	   from	   other	   components	   of	   the	   tumour	   microenvironment	  
including	  stromal	  cells,	  endothelial	  cells	  and	  nurse-­‐like	  cells,	  we	  considered	  the	  T	  cell:	  
CLL	  cell	  axis	  to	  be	  critical	  and	  this	  remained	  the	  focus	  of	  our	  investigation.	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6.6	  In-­‐vitro	  Studies	  into	  the	  Effect	  of	  CsA	  on	  CLL	  B	  and	  T	  cells	  
CLL	   T	   cells	   have	   a	   distinct	   phenotype,	   characterised	   by	   an	   inversion	   of	   the	   normal	  
CD4:CD8	  ratio,	  a	  preponderance	  of	  effector	  memory	  cells	  and	  relative	  absence	  of	  naïve	  
precursors	   (Görgün	   et	   al.,	   2005;	   Nunes	   et	   al.,	   2012).	   We	   therefore	   started	   by	  
investigating	  the	  effect	  of	  CsA	  on	  CLL	  T	  cells.	  Crucially,	  we	  observed	  that	  CsA	   inhibits	  
the	  co-­‐expression	  of	  IFNγ	  and	  CD69	  by	  CLL	  CD4	  and	  CD8	  T	  cells.	  IFNγ	  has	  been	  shown	  
to	  be	  a	  major	  mechanism	  whereby	  CLL-­‐specific	  Th1	  cells	  upregulate	  CD38	  expression	  
by	  CLL	  cells	  (Bürgler	  et	  al.,	  2015).	  Secondly,	  CD69	  is	  a	  leukocyte	  activation	  antigen	  that	  
plays	  a	  role	  in	  the	  retention	  of	  CLL	  cells	  within	  the	  lymph-­‐node	  compartment	  (Shiow	  et	  
al.,	   2006;	   Sic	   et	   al.,	   2014).	   Furthermore,	  we	   demonstrated	   that	   CsA	   has	   a	   profound	  
effect	  on	  the	  expression	  of	  CD40L	  by	  CD4	  T	  cells;	  CD40L	  has	  been	  shown	  to	  play	  a	  key	  
role	   in	   the	   survival	   and	   proliferation	   of	   CLL	   cells	   (Ghia	   et	   al.,	   2002;	   Hamilton	   et	   al.,	  
2012).	  	  
We	  investigated	  the	  effect	  of	  CsA	  on	  the	  expression	  of	  IL21,	  a	  cytokine	  that	  has	  been	  
shown	   to	   contribute	   to	   the	   proliferation	   of	   CLL	   cells	   in	   response	   to	   CD40L	  
activation(Ahearne	  et	  al.,	  2013;	  Pascutti	  et	  al.,	  2013).	  IL21	  is	  under	  the	  transcriptional	  
control	  of	  NFAT	  and	  has	  previously	  been	   reported	   to	  be	  sensitive	   to	  CsA	   (Kim	  et	  al.,	  
2005).	  However,	  we	  did	  not	  demonstrate	  that	  IL21	  expression	  is	  sensitive	  to	  CsA	  and	  
this	  should	  be	  further	  investigated.	  	  
Investigation	  of	  the	  effect	  of	  CsA	  on	  transcription	  factor	  signalling	  in	  CLL	  T	  cells	  using	  
image	   flow-­‐cytometry	   revealed	   that	  both	  NFAT-­‐C2	  and	  NFκB	  signalling	   is	   inhibited	   in	  
the	  presence	  of	  CsA.	  NFAT-­‐C2	  and	  NFκB	  are	  key	  regulators	  of	  the	  transcription	  of	  IL2,	  
IL4,	   IL6,	   IL21,	   TNFα	   and	   IFNγ	   and	   CD40L,	   inhibition	   of	  which	  would	   be	   predicted	   to	  
have	  a	  significant	  detrimental	  effect	  on	  CLL	  cells	  in	  the	  tumour	  microenvironment.	  
Having	  demonstrated	  that	  CsA	  is	  effective	  in	  inhibiting	  components	  of	  T	  cell	  signalling	  
that	   are	   considered	   to	   play	   an	   important	   role	   in	   the	   biology	   of	   CLL,	  we	  went	   on	   to	  
investigate	   whether	   CsA	   has	   any	   direct	   effect	   on	   the	   activation	   of	   CLL	   cells.	  
Importantly,	  NFAT-­‐C2	  and	  NFκB-­‐p65	  are	  upregulated	  in	  CLL	  cells	  compared	  to	  healthy	  
B	   lymphocytes	   and	   inhibition	   has	   been	   shown	   to	   reduce	   the	   viability	   of	   the	   tumour	  
cells	  (Apollonio	  et	  al.,	  2013;	  Hewamana	  et	  al.,	  2008;	  Le	  Roy	  et	  al.,	  2012).	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We	  found	  that	   the	  mechanism	  of	  activation	  of	  CLL	  cells	  played	  a	  role	   in	  determining	  
the	   sensitivity	   to	   CsA.	   CD40L	   activated	   CLL	   cells	   were	   resistant	   to	   CsA;	   nuclear	  
translocation	  of	  NFAT-­‐C2	  and	  NFκB-­‐p65	  was	  induced	  by	  CD40L	  and	  was	  unaffected	  by	  
CsA,	  as	  was	  expression	  of	  the	  activation	  markers	  CD25	  and	  CD69.	  However,	  in	  CLL	  cells	  
activated	   through	   the	   BCR,	   there	   was	   a	   small	   inhibitory	   effect	   of	   CsA	   on	   CD69	  
expression	   suggesting	   that	   BCR	   signalling	   is	   sensitive	   to	   CsA.	   These	   findings	   are	  
consistent	  with	   the	  observation	   that	   in	  healthy	  B-­‐lymphocytes,	   proliferation	   induced	  
by	   agonistic	   sIgM	   is	   sensitive	   to	   CsA	   whereas	   proliferation	   induced	   by	   CD40L	   is	  
resistant	  (Wortis	  et	  al.,	  1995).	  
In	  view	  of	  previous	  reports	  that	  inhibition	  of	  NFAT	  signalling	  using	  the	  cell-­‐permeable	  
VIVIT	  peptide	  reduces	  the	  metabolic	  activity	  of	  CLL	  cells	  that	  are	  ‘signalling-­‐competent’	  
and	  reverses	  anergy	  and	  induces	  apoptosis	  in	  those	  that	  are	  not	  signalling-­‐competent,	  
we	  investigated	  the	  effect	  of	  CsA	  on	  the	  viability	  of	  CLL	  cells	  (Apollonio	  et	  al.,	  2013;	  Le	  
Roy	  et	  al.,	  2012).	  CLL	  cells	  were	  cultured	  either	  alone	  or	  as	  PBMCs	  to	  assess	  whether	  
any	   effect	   of	   CsA	  on	   the	   viability	   of	   tumour	   cells	  was	  direct	   or	   dependent	  upon	   the	  
presence	  of	  T	   cells.	  Consistent	  with	   the	   literature,	  we	   found	   that	   the	  viability	  of	  CLL	  
cells	  was	  greater	  when	  cultured	  as	  PBMCs.	  In	  the	  presence	  of	  CsA,	  there	  was	  a	  trend	  
towards	  reduced	  viability	  regardless	  of	  the	  cell-­‐purity,	  suggesting	  that	  any	  reduction	  in	  
viability	  was	  not	  dependent	  on	  the	  presence	  of	  T	  cells.	  
Further	  investigation	  into	  the	  effect	  of	  CsA	  on	  CLL	  viability	  should	  take	  BCR	  signalling-­‐
capacity	   into	   account.	   It	   is	   possible	   that	   the	  effect	  of	  CsA	  on	   the	   viability	  of	   tumour	  
cells	  is	  partly	  determined	  by	  whether	  the	  cells	  display	  constitutive	  activation	  of	  NFAT,	  
which	  is	  associated	  with	  non-­‐responsiveness	  to	  BCR	  signalling.	  
In	  order	  to	  determine	  the	  effect	  of	  CsA	  on	  the	  interaction	  between	  CLL	  B	  and	  T	  cells	  as	  
may	  be	  expected	  in	  the	  lymph-­‐node	  compartment,	  we	  employed	  a	  co-­‐culture	  system	  
whereby	  CLL	  cells	  where	  CLL	  cells	  were	  co-­‐cultured	  with	  activated	  autologous	  T	  cells.	  
Importantly,	   we	   observed	   that	   CsA	   lead	   to	   a	   profound	   T	   cell	   dependent	   inhibitory	  
effect	  on	  CLL	  cell	  activation.	  However,	  in	  addition	  to	  the	  T	  cell-­‐dependent	  effect,	  there	  
was	  a	  smaller	  but	  significant	  direct	  effect	  on	  the	  expression	  of	  CD69	  by	  CLL	  cells.	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In	  conclusion,	  the	  in-­‐vitro	  studies	  demonstrated	  that	  CsA	  reduces	  the	  activation	  of	  CLL	  
derived	  CD4	  T	  cells	  by	  inhibition	  of	  both	  NFAT-­‐C2	  and	  NFκB-­‐p65	  and	  that	  this	  leads	  to	  a	  
secondary	   reduction	   in	   CLL	   cell	   activation.	   This	   confirmed	   that	   manipulation	   of	   the	  
tumour	  microenvironment,	   in	   order	   to	   disrupt	   the	   pathogenesis	   of	   CLL,	   was	   a	   valid	  
strategy	  to	  test	  in-­‐vivo.	  
6.7	  In-­‐vivo	  Studies	  into	  the	  Effect	  of	  CsA	  in	  Patients	  with	  Early,	  Unfavourable	  Risk	  CLL	  
We	   launched	  a	  Phase	   II	   study	   to	   intensively	   investigate	   the	  effect	  of	  CsA	  on	  CLL	   in	  a	  
small	   cohort	   of	   patients	   with	   early-­‐phase,	   adverse	   risk	   disease	   defined	   by	   the	  
expression	  of	  CD38	  who	  did	  not	  meet	  the	  standard	  criteria	  for	  treatment	  (Hallek	  et	  al.,	  
2008).	  Although	   this	  cohort	  of	  patients	   is	   recognised	  as	  having	  an	   inferior	  prognosis,	  
no	   early	   therapeutic	   intervention	   has	   been	   shown	   to	   alter	   the	   clinical	   outcome	   and	  
these	  patients	  are	  managed	  with	  a	  ‘watch	  and	  wait’	  strategy.	  
The	   primary	   outcome	   of	   the	   study	   was	   change	   in	   in-­‐vivo	   CLL	   cell	   proliferation	   rate	  
measured	  using	  deuterated	  glucose	  labelling,	  the	  first	  time	  that	  this	  method	  has	  been	  
used	  to	  measure	  drug-­‐effect.	  	  
In	  preparation	  for	  the	  clinical	  trial,	  intra-­‐patient	  variation	  in	   in-­‐vivo	  proliferation	  rates	  
was	  measured	  in	  a	  purely	  observational	  study	  (In-­‐vivo	  Kinetics	  in	  Chronic	  Lymphocytic	  
Leukaemia).	   It	  was	  considered	  to	  be	  excessive	  to	  assess	  this	  within	  the	  CyCLLe	  study.	  
Although	   the	   initial	   trial	   protocol	   for	   the	   observational	   study	   included	   only	   patients	  
with	   CD38+	   non-­‐progressive	   CLL,	   difficulties	  with	   recruitment	  meant	   that	   it	   became	  
necessary	   to	   relax	   the	   eligibility	   criteria	   to	   include	   all	   patients	   with	   non-­‐progressive	  
disease.	  Overall,	  there	  was	  significant	  correlation	  of	  in-­‐vivo	  proliferation	  rates	  between	  
the	  two	  ‘labelling	  cycles’	  	  (n=10;	  r	  =0.633,	  p	  =0.048),	  providing	  an	  excellent	  foundation	  
to	  investigate	  the	  effect	  of	  a	  therapeutic	  intervention.	  
The	  CyCLLe	  study	  was	  opened	  at	  KCH	  an	  UHW	  with	   the	  help	  of	   the	  Bloodwise	  Trials	  
Acceleration	   Program.	   However,	   recruitment	   to	   this	   study	   was	   a	   major	   challenge.	  
Barriers	  to	  recruitment	  included	  the	  limited	  number	  of	  patients	  with	  non-­‐progressive,	  
CD38+	  CLL	  and	   the	  considerable	  patient	  commitment	   required	   (number	  of	  visits	  and	  
duration	   of	   trial).	   A	   trial	   amendment	  was	  made	   to	   abbreviate	   the	   protocol	   (Cycle	   1	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became	  an	  optional	   cycle)	  and	  an	  extra	   trial	   site	  was	  opened	   (Southampton	  General	  
Hospital).	   Four	   patients	   completed	   the	   study	   (one	   was	   withdrawn	   following	   the	  
development	  of	  atrial	  fibrillation	  and	  a	  myocardial	   infarction	  that	  were	  considered	  to	  
be	  unrelated	  to	  CsA	  therapy).	  	  
Baseline	  proliferation	  rates	  amongst	  the	  five	  patients	  recruited	  to	  CyCLLe	  were	  lower	  
that	   the	  mean	  proliferation	   rates	   reported	   by	  Messmer	   et	   al.	   The	   deuterated	  water	  
studies,	   in	   contrast	   to	   CyCLLe,	   included	   patients	  with	   progressive	   disease	   associated	  
with	  higher	  proliferation	  rates	  (Messmer	  et	  al.,	  2005).	  	  	  
There	  was	   no	   demonstrable	   effect	   of	   CsA	   on	   proliferation	   rates	   after	   four	  weeks	   of	  
therapy	   despite	   CsA	   levels	   being	   maintained	   within	   the	   therapeutic	   range.	   CLL	   is	   a	  
highly	  heterogenous	  disease	  so	  the	  absence	  of	  drug-­‐effect	  in	  four	  patients	  with	  diverse	  
biological	  characteristics	  is	  insufficient	  evidence	  to	  conclude	  that	  CsA	  does	  not	  reduce	  
proliferation	   in	  CLL.	  Baseline	  proliferation	  rates	   in	  our	  cohort	  of	  patients	  with	  CD38+	  
CLL	   were	   low,	   making	   it	   challenging	   to	   demonstrate	   a	   reduction	   in	   proliferation.	  
Inclusion	  of	  patients	  with	  CD38+	  CLL	  who	  additionally	  had	  UM-­‐IgVH	  genes	  may	  have	  
selected	   a	   more	   ‘proliferative’	   population.	   However,	   such	   patients	   frequently	   have	  
progressive	  disease	  that	  warrants	  conventional	  therapy.	  Also,	  narrowing	  the	  eligibility	  
criteria	  would	  have	  lead	  to	  further	  difficulties	  with	  recruitment.	  Secondly,	  it	  is	  feasible	  
that	  dilution	  of	  a	  sub-­‐population	  of	  proliferating	  cells	  by	  a	  large	  pool	  of	  quiescent	  cells	  
could	  mask	   a	   change	   in	   proliferation.	  One	  way	   of	   focusing	   on	   the	   proliferating	   sub-­‐
fraction	   would	   be	   to	   measure	   deuterium	   labelling	   in	   lymph-­‐node	   derived	   CLL	   cells,	  
although	  this	  may	  be	  altered	  by	  changes	  in	  the	  trafficking	  of	  CLL	  cells	  in	  the	  presence	  
of	  CsA.	  	  
In	   view	   of	   the	   in-­‐vitro	   findings	   relating	   to	   the	   effect	   of	   CsA	   in	   CLL,	   an	   alternative	  
explanation	  for	  the	  unchanged	  tumour	  proliferation	  rates	  includes	  the	  possibility	  that	  
in-­‐vivo,	   CLL	   cells	   are	   activated	   by	   CsA	   insensitive	   mechanisms	   involving	   other	  
components	  of	  the	  tumour	  microenvironment.	  	  
Secondary	  outcome	  measures	   included	  the	  toxicity	  of	  therapy	  and	  clinical	  responses.	  
Treatment	   was	   generally	   well	   tolerated;	   drug-­‐related	   adverse	   events	   were	   mostly	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grade	  2	  or	  less	  and	  importantly,	  there	  were	  no	  severe	  infections.	  None	  of	  the	  patients	  
studied	   had	   an	   objective	   clinical	   response	   to	   CsA,	   consistent	   with	   the	   unchanged	  
proliferation	   rates.	   This	   is	   in	   contrast	   to	   the	   report	   from	   Cortes	   et	   al	   that	  
approximately	   20	  %	   had	   anti-­‐tumour	   responses;	   one	   third	   of	   those	   being	   sustained	  
(Cortes	   et	   al.,	   2001).	   However	   a	   short-­‐lived	   lymphocytosis	   was	   observed	   in	   4/5	  
patients	  immediately	  following	  the	  commencement	  of	  CsA.	  A	  possible	  explanation	  for	  
this	  phenomenon	  is	  that	  CsA	  inhibits	  CD69	  expression	   in	  CLL	  cells	  activated	  by	  either	  
autologous	  CD4	  T	  cells	  or	  through	  the	  BCR,	  and	  may	  therefore	  disrupt	  the	  retention	  of	  
tumour	   cells	   in	   the	   CLL	   lymph-­‐node.	   This	   is	   in-­‐common	   with	   the	   observation	   that	  
patients	   treated	   with	   ibrutinib,	   there	   is	   a	   rapid	   inhibition	   of	   CD69	   expression	  
associated	   with	   the	   release	   of	   proliferating	   cell	   from	   the	   lymph-­‐node	   into	   the	  
peripheral	  blood	   (Herman,	  Niemann,	  et	  al.,	   2014b).	  However,	   it	   is	  hypothesised	   that	  
this	   ‘egress’	   is	   related	   to	   down-­‐regulation	   of	   CXCR4	   expression	   in	   the	   presence	   of	  
ibrutinib.	   Expression	   of	   CXCR4	   by	   leukaemic	   B	   cells	   could	   have	   been	   measured	   in	  
patients	   treated	  with	  CsA	  to	   further	   investigate	  the	  biological	  process	  underlying	  the	  
lymphocytosis.	  
Translational	   studies	  were	  performed	  on	  peripheral	  blood	  derived	  CLL	  and	  T	   cells	   to	  
determine	   the	   effect	   of	   calcineurin	   inhibition	   in-­‐vivo.	   We	   found	   that	   there	   was	   no	  
statistically	  significant	  change	  in	  the	  resting	  phenotype	  of	  CLL	  or	  CD4	  T	  cells	  following	  
in-­‐vivo	   CsA	   therapy.	  However,	   there	  was	   a	   trend	   towards	   inhibition	   of	  NFAT-­‐C2	   and	  
NFκB-­‐p65	   translocation	  and	  expression	  of	  CD25	  and	  CD69	   in	  activated	  CD4	  T	  cells	   in	  
the	  presence	  of	  CsA.	  During	   in-­‐vivo	  CsA	  therapy,	   there	  was	  a	   trend	  towards	   reduced	  
activation	   of	   CLL	   cells	   when	   co-­‐cultured	   with	   activated	   autologous	   CD4	   T	   cells,	  
suggesting	  that	  CsA	  may	   inhibit	   the	  ability	  of	  CD4	  T	  cells	   to	  activate	  CLL	  cells	   in-­‐vivo.	  
Additionally,	   there	   was	   a	   trend	   towards	   reduced	   NFAT-­‐C2	   and	   NFκB-­‐p65	   nuclear	  
translocation	   and	   CD69	   expression	   in	   CLL	   cells	   activated	   with	   CD40L,	   suggestive	   of	  
reduced	  responsivess	  to	  activation.	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In	  conclusion,	  the	  in-­‐vitro	  studies	  provided	  evidence	  for	  a	  two-­‐pronged	  effect	  of	  CsA	  in	  
CLL;	   with	   both	   T	   cell	   dependent	   and	   direct	   effects	   on	   CLL	   cell	   activation	   that	   were	  
inhibited	  in	  the	  presence	  of	  CsA.	  The	  in-­‐vitro	  studies,	  in	  addition	  to	  previous	  reports	  of	  
the	  anti-­‐tumour	  effect	  of	  CsA	  in-­‐vivo	  lead	  to	  the	  justification	  of	  a	  small	  cohort	  study	  to	  
intensively	   investigate	   the	   effect	   of	   CsA	   in	   early-­‐stage	   adverse	   risk	   disease	   (CyCLLe).	  
Manipulation	   of	   the	   tumour	   microenvironment	   to	   inhibit	   proliferation	   of	   malignant	  
cells	  was	  a	  novel	  approach,	  justified	  by	  the	  wealth	  of	  evidence	  for	  the	  role	  of	  activated	  
autologous	  T	  cells	  in	  the	  pathogenesis	  of	  CLL.	  
Recruitment	   was	   the	   greatest	   challenge	   to	   the	   success	   of	   this	   study	   and	   the	   small	  
number	   of	   patients	   who	   completed	   studies	   limited	   the	   significance	   of	   the	   findings.	  
Baseline	   in-­‐vivo	   proliferation	   rates	   were	   low	   and	   remained	   unchanged	   after	   four	  
weeks	   of	   CsA	   therapy	   suggesting	   that	   this	   approach	   of	   manipulating	   the	   tumour	  
microenvironment	   may	   not	   be	   effective	   in	   patients	   with	   early	   stage,	   adverse	   risk	  
disease.	  	  
It	   is	   notable	   the	   German	   CLL	   Study	   Group	   (DCLLSG)	   has	   also	   recognised	   that	   the	  
standard	   approach	   of	   ‘watchful	   waiting’	   in	   patients	   with	   early-­‐phase,	   adverse	   risk	  
disease	  should	  be	  challenged.	   In	  view	  of	  the	  clinical	  heterogeneity	   in	  this	  population,	  
the	  GCLLSG	  has	  recently	  launched	  a	  multi-­‐centre,	  phase	  three,	  placebo	  controlled	  trial	  
(The	  CLL	  12	  trial)	  where	  patients	  with	  intermediate	  to	  very	  high	  risk	  Binet	  stage	  A	  CLL	  
are	   randomised	   to	   ibrutinib	   or	   placebo.	   The	   risk	   is	   calculated	   according	   to	   the	  
comprehensive	   CLL	   score	   that	   takes	   into	   account:	   age,	   stage,	   performance	   status,	  
serum	  β2M,	  serum	  thymidine	  kinase,	  mutational	  state	  of	   IgVH	  genes	  and	  presence	  of	  
adverse	   risk	   FISH.	   Interestingly,	   CD38	   expression	   (>30	   %)	   was	   not	   found	   to	   be	  
predictive	   of	   overall	   survival	   in	   univariate	   analysis	   and	  was	   therefore	   excluded	   from	  
the	  prognostic	  score.	  The	  results	  of	  this	  study	  will	  inform	  whether	  patients	  with	  early	  
stage,	   adverse	   risk	   disease	   defined	   by	   a	   range	   of	   factors,	   benefit	   from	   early	  
intervention.	  However,	  direct	  targeting	  of	  the	  malignant	  cells	  at	  an	  earlier	  stage	  may	  
drive	   mechanisms	   of	   resistance,	   beyond	   which	   alternative	   treatment	   options	   are	  
limited.	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In	   view	  of	   the	   fact	   that	  CLL	   cells	   appear	   to	  be	   ‘addicted’	   to	   the	  microenvironmental	  
signals	   in	  order	   to	  proliferate,	   characterisation	  of	   the	  process	  of	   trafficking	  between	  
the	  lymph-­‐node	  and	  peripheral	  blood	  is	  a	  key	  area	  of	  investigation.	  Furthermore,	  CLL	  is	  
a	   disease	   characterised	   by	   significant	   clinical	   heterogeneity	   that	   reflects	   key	  
differences	  in	  disease	  biology.	  We	  therefore	  performed	  a	  detailed	  in-­‐vivo	  investigation	  
into	   the	   relationship	   between	   CLL	   cell	   phenotype,	   function,	   trafficking	   and	  
proliferation	   in	  order	  to	  better	  define	  the	  relationship	  between	  these	  characteristics.	  
This	   investigation	   was	   performed	   as	   part	   of	   the	   observational	   ‘In-­‐Vivo	   Kinetics	   in	  
Chronic	   Lymphocytic	   Leukaemia	   Study’	   that	   involved	   in-­‐vivo	   labelling	  of	   proliferating	  
cells	  using	  deuterated	  glucose.	  	  
The	   observational	   study	   was	   aligned	   to	   the	   CyCLLe	   study,	   we	   therefore	   initially	  
included	  patients	  with	  non-­‐progressive	  CD38+	  CLL.	  However,	  due	  to	  slow	  recruitment,	  
we	  amended	  the	  protocol	  to	  include	  all	  patients	  with	  non-­‐progressive	  CLL	  regardless	  of	  
CD38	  expression.	  By	  chance,	  all	  patients	  recruited	  had	  mutated	  IgVH	  genes,	  associated	  
with	  a	  state	  of	  non-­‐responsiveness	   to	  agonistic	  BCR	   ligation	  and	  a	   favourable	  overall	  
prognosis	  (Damle	  et	  al.,	  1999;	  Hamblin	  et	  al.,	  1999;	  Mockridge	  et	  al.,	  2007).	  	  
The	  mean	  proliferation	  rate	  in	  this	  cohort	  of	  patients	  with	  non-­‐progressive	  disease	  as	  
expected,	  was	   slightly	   lower	   than	   that	   reported	   by	  Messmer	   et	   al	   using	   deuterated	  
water	   labelling	  and	  Defoiche	  et	  al	  using	  deuterated	  glucose	   labelling	  (Defoiche	  et	  al.,	  
2008;	  Messmer	  et	  al.,	  2005).	  	  
We	   found	   that	   proliferation	   was	   greatest	   in	   patients	   that	   expressed	   CD38	   and	   was	  
unrelated	  to	  BCR	  signalling	  capacity;	   two	  of	   three	  patients	  expressing	  CD38	  had	  high	  
proliferation	  rates	  and	  neither	  patient	  exhibited	  active	  signalling	  through	  the	  BCR.	  The	  
two	   patients	  with	   the	   highest	   proliferation	   rates	   harboured	   trisomy	   12;	   importantly	  
the	  presence	  of	   trisomy	  12	   is	  associated	  with	  expression	  of	  CD11c,	  CD38	  and	  CD49d	  
and	  a	  propensity	  towards	  migration	  into	  the	  tumour	  microenvironment	  (Deaglio	  et	  al.,	  
2007;	  Pasikowska	  et	  al.,	  2016;	  Riches	  et	  al.,	  2014;	  Vaisitti	  et	  al.,	  2010).	  Full	  phenotypic	  
assessment	  of	  the	  leukaemic	  cells,	  including	  CD49d	  and	  CXCR4	  expression	  would	  have	  
been	   useful	   in	   establishing	   the	   relationship	   between	   trisomy	   12,	   trafficking	   and	  
proliferation	  in	  these	  cases.	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In	   our	   small	   cohort	   of	   patients,	   we	   found	   no	   direct	   relationship	   between	   sIgM	  
expression,	  BCR	  signalling	  and	  CLL	  proliferation	  rates.	  A	   larger	  cohort	  study	   including	  
more	   patients	  with	   active	   signalling	   through	   the	   BCR	  would	   be	   required	   to	   formally	  
investigate	  this	  relationship.	  
Telomere	   length,	   previously	   correlated	   with	   risk	   factors	   including	   CD38	   expression,	  
IgVH	   mutational	   status	   and	   advanced	   clinical	   stage,	   was	   measured	   to	   assess	   the	  
relationship	  between	  point	  proliferation	   rate	  and	   replicative	  history.	   Single	   telomere	  
length	   analysis	   (STELA)	   in	   our	   small	   cohort	   of	   patients	   revealed	   no	   clear	   association	  
between	   point	   proliferation	   and	   telomere	   length,	   although	   we	   did	   note	   that	   the	  
patient	  with	  the	  lowest	  CLL	  proliferation	  rate	  had	  the	  longest	  telomeres.	  This	  is	  at	  odds	  
with	   large	   clinical	   studies	   that	   have	   reported	   an	   association	   between	   biological	  
characteristics	   associated	   with	   proliferation	   and	   should	   be	   investigated	   in	   a	   larger	  
cohort	  study	  including	  patients	  with	  UM-­‐CLL	  (Lin	  et	  al.,	  2010;	  Rossi	  et	  al.,	  2009).	  
6.8	  In-­‐vivo	  Study	  of	  Proliferation	  and	  Trafficking	  of	  Tumour	  Cells	  in	  Patients	  with	  CLL	  
In	  view	  of	  the	  fact	  that	  proliferation	  takes	  place	  in	  the	  lymph-­‐node	  compartment	  and	  
that	   migration	   into	   the	   lymph-­‐node	   appears	   to	   be	   an	   important	   determinant	   of	  
proliferation,	   we	   went	   on	   to	   investigate	   the	   trafficking	   of	   proliferating	   cells	   in-­‐vivo	  
using	   deuterated	   glucose	   labelling.	   ‘Pulse-­‐labelling’	   is	   a	   unique	   selling	   point	   of	  
deuterated	   glucose;	   a	   ten-­‐hour	   labelling	   period	   achieves	   a	   well-­‐defined	   pulse	   of	  
labelled	  cells	  that	  can	  be	  tracked	  over	  time.	  We	  measured	  the	  appearance	  of	  labelled	  
cells	   in	   the	  peripheral	  blood	   (release	  rate)	   followed	  by	  the	  disappearance	  of	   labelled	  
cells	   by	  measuring	   the	   deuterium	   enrichment	   in	   purified	   peripheral	   blood	   CLL	   cells.	  
Release	  rates	  are	  of	  particular	  interest	  in	  CLL	  given	  the	  fact	  that	  disregulation	  of	  S1P1	  
is	   thought	   to	   impair	  egress	  of	  CLL	   cells	   (Capitani	  et	  al.,	  2012;	  Sic	  et	  al.,	  2014)	  and	   in	  
view	   of	   the	   profound	   lymphocytosis	   observed	   upon	   the	   commencement	   of	   BCR	  
antagonists	  (Herman,	  Niemann,	  et	  al.,	  2014b).	  
The	   release	   rate	   of	   CLL	   cells	  was	   found	   to	   be	   slower	   than	   that	   reported	   for	   healthy	  
lymphocytes	   and	   slowest	   in	   patients	   with	   splenomegaly,	   consistent	   with	   studies	  
performed	   using	   tritiated	   thymidine	   labelling	   (Zimmerman	   et	   al.,	   1968).	   Delayed	  
release	  has	  previously	  been	  associated	  with	  higher	  CXCR4	  expression,	  which,	  in	  turn	  is	  
	   208	  
associated	  with	  inferior	  clinical	  outcomes	  in	  CLL	  (Calissano	  et	  al.,	  2009;	  Pepper	  et	  al.,	  
2015).	  Further	   investigation	   into	   the	  biology	  of	   ‘egress’	   should	   include	  measurement	  
of	  S1P1	  expression	  by	  deuterium	  labelled	  CLL	  cells.	  
Disappearance	   rates	   in	   this	   study	   were	   significantly	   slower	   than	   those	   reported	   for	  
healthy	   B	   lymphocytes,	   suggesting	   that	   impaired	   apoptosis	   may	   play	   a	   role	   in	   the	  
pathogenesis	   of	   CLL	   with	   mutated	   IgVH	   genes.	   Crucially,	   there	   appeared	   to	   be	  
heterogeneous	  rates	  of	  loss	  of	  CLL	  cells	  within	  patients,	  suggestive	  of	  sub-­‐clones	  with	  
discordant	  proliferative	  characteristics.	  
We	   subsequently	   looked	  at	   the	   trafficking	  of	   recently	  proliferated	   cells	   between	   the	  
lymph-­‐node	  and	  peripheral	  blood	  by	  performing	  paired	  sampling	  at	  regular	  intervals	  in	  
three	  patients	  with	  palpable	  lymph-­‐nodes.	  Lymph-­‐node	  re-­‐entry	  was	  observed	  in	  one	  
patient	  in	  this	  limited	  study,	  a	  remarkable	  finding	  in	  that	  it	  is	  the	  first	  time	  that	  lymph-­‐
node	  re-­‐entry	  has	  been	  observed.	  To	  investigate	  this	  further,	  more	  patients	  should	  be	  
studied	  with	  paired	  sampling	  over	  a	  longer	  time-­‐period.	  
The	   relationship	   between	   the	   proliferation	   and	   trafficking	   of	   CLL	   cells	   between	   the	  
lymph-­‐node	   and	   peripheral	   blood	   compartments	   is	   best	   studied	   in-­‐vivo,	   where	   the	  
malignant	  cells	  are	  able	  to	  interact	  with	  the	  microenvironment	  in	  its	  entirety.	  Using	  in-­‐
vivo	   labelling	   with	   deuterated	   water,	   Calissano	   et	   al	   elegantly	   demonstrated	   that	  
recently	   proliferated	   CLL	   cells	   are	   characterised	   by	   high	   expression	   of	   CD5	   and	   low	  
expression	   of	   CXCR4,	   a	   chemokine	   receptor	   that	   is	   downregulated	   following	   binding	  
with	   SDF-­‐1	   in	   the	   lymph-­‐node	   (Calissano	   &	   Damle,	   2011).	   The	   authors	   proposed	   a	  
model	  whereby	  recently	  proliferated	  CLL	  cells	  re-­‐express	  CXCR4	  and	  downreulate	  CD5	  
expression	  in	  the	  circulation,	  leading	  to	  the	  re-­‐entry	  of	  cells	  to	  the	  lymph-­‐node.	  	  
We	  performed	  ‘pulse-­‐labelling’	  using	  deuterated	  glucose	  to	  assess	  dynamic	  changes	  in	  
labelling	   in	  peripheral	  blood	  sub-­‐clones	  described	  by	  Calissano	  et	  al.	  Remarkably,	  we	  
identified	  a	  non-­‐proliferating	  sub-­‐clone	  in	  all	  three	  patients	  assessed,	  characterised	  by	  
CXCR4hi/	  CD5	  low.	  There	  appeared	  to	  be	  continuity	  between	  CXCR4	  low/	  CD5	  high	  and	  
CXCR4int/	   CD5int	   populations,	   suggestive	   of	   re-­‐expression	   of	   CXCR4	   to	   an	  
intermediate	  level	  in	  the	  peripheral	  blood.	  However,	  the	  sub-­‐population	  characterised	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by	   CXCR4hi/	   CD5low	   remained	   unlabelled	   throughout	   and	   did	   not	   interact	   with	   the	  
other	  sub-­‐populations	  suggesting	  that	  it	  is	  a	  distinct,	  quiescent	  sub-­‐population.	  	  
Strikingly,	  we	  found	  evidence	  of	  all	  three	  sub-­‐populations	  defined	  by	  CXCR4	  and	  CD5	  
expression	  in	  the	  lymph-­‐node.	  The	  population	  characterised	  by	  CXCR4low/	  CD5hi	  was	  
the	  most	  highly	   labelled	  population	  and	   in	  view	  of	   the	  fact	   that	   this	  closely	  matched	  
the	  labelling	  in	  the	  entire	  cohort	  of	  CLL	  cells,	  this	  population	  accounted	  for	  the	  bulk	  of	  
CLL	   cells	   in	   the	   lymph-­‐node.	   After	   28	   days,	   label	  was	   lost	   from	   the	   CXCRlow/	   CD5hi	  
population	   and	   gained	   in	   the	   intermediate	   population	   possible	   suggesting	   that	  
CXCR4low/	   CD5hi	   labelled	   cells	   had	   left	   the	   lymph-­‐node	   whilst	   cells	   with	   an	  
intermediate	  phenotype	  had	  entered.	  Similar	   to	   the	  CXCR4hi/	  CD5	   low	  population	   in	  
the	  peripheral	  blood,	  this	  population	  remained	  unlabelled	  i.e	  did	  not	  proliferate	  in	  the	  
lymph-­‐node.	  
In	  view	  of	  the	  relationship	  between	  BCR	  signalling	  and	  proliferation	  in	  the	  lymph-­‐node	  
(Herishanu	  et	  al.,	  2011),	  we	  used	  deuterated	  glucose	   labelling	   to	  assess	  proliferation	  
and	  trafficking	  in	  CLL	  subpopulations	  defined	  by	  sIgM	  expression.	  Again,	  we	  found	  that	  
there	  was	  minimal	   labelling	   in	   the	   decade	   of	   cells	  with	   the	   lowest	   sIgM	   expression,	  
consistent	   with	   a	   state	   of	   quiescence.	   The	   decade	   of	   cells	   with	   the	   highest	   sIgM	  
expression	  was	  highly	  enriched	  with	  labelled	  cells,	  with	  a	  proliferation	  rate	  30x	  that	  of	  
the	  opposite	  phenotype.	   	  The	  observation	  that	  the	  sub-­‐population	  with	  highest	  sIgM	  
expression	   is	   most	   enriched	   with	   proliferating	   cells	   is	   consistent	   with	   reports	   that	  
lymph-­‐node	   derived	   CLL	   cells	   are	   characterised	   by	   high	   expression	   of	   sIgM	   (Coulter,	  
Manuscript	   submitted)	   but	   challenges	   the	   hypothesis	   that	   sIgM	   expression	   is	   down-­‐
regulated	   upon	   proliferation	   (Coelho	   et	   al.,	   2013).	   Mechanistically,	   IL4	   has	   recently	  
been	   reported	   to	   induce	   the	   expression	   of	   sIgM	   by	   CLL	   cells	   in	   the	   lymph-­‐node	  
(Aguilar-­‐Hernandez	  et	  al.,	  2016).	  	  
To	  investigate	  a	  functional	  relationship	  between	  sIgM	  expression	  and	  proliferation,	  we	  
went	   on	   to	   measure	   the	   deuterium	   enrichment	   in	   CLL	   cells	   according	   to	   ability	   to	  
internalise	   the	   BCR.	  We	   found	   that	   sub-­‐populations	   of	   CLL	   cells	   sorted	   according	   to	  
BCR	   internalisation	   mirrored	   those	   sorted	   according	   to	   sIgM	   expression.	   This	  
observation	   suggests	   a	   process	   whereby	   within	   the	   lymph-­‐node,	   CLL	   cells	   exhibit	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enhanced	  sIgM	  expression,	  BCR	  internalisation	  and	  proliferation.	  Upon	  release	  into	  the	  
peripheral	  blood,	  recently	  proliferated	  CLL	  cells	  down-­‐regulate	  sIgM	  expression	  and	  no	  
longer	  proliferate.	  
Critically,	  a	  sub-­‐population	  of	  quiescent	  cells	  that	  appeared	  to	  be	  independent	  of	  other	  
sub-­‐populations	   was	   identified	   in	   all	   patients.	   This	   apparently	   non-­‐proliferative	  
population	   had	   the	   characteristics	   of	   CXCR4hi/	   CD5low,	   sIgM	   low	   and	   low	   BCR	  
internalisation.	   In	   order	   to	   investigate	   whether	   the	   proliferative	   history	   of	   the	  
quiescent	  subpopulation,	  telomere	  length	  was	  measured	  in	  three	  patients,	  taking	  the	  
highest	   and	   lowest	   decade	   of	   cells	   according	   to	   BCR	   internalisation.	   In	   the	   most	  
proliferative	   patient,	   with	   a	   proliferation	   rate	   more	   than	   twice	   that	   of	   the	   other	  
patients,	   we	   found	   that	   telomere	   length	   was	   2.2kB	   longer	   in	   the	   decade	   with	   the	  
lowest	   BCR	   internalisation.	   Although	   conclusions	   cannot	   be	   drawn	   from	   a	   single	  
observation,	  this	  may	  suggest	  that	  there	  is	  reduced	  telomere	  attrition	  in	  the	  quiescent	  
sub-­‐population	  and	  should	  be	  further	  investigated.	  
The	  non-­‐proliferative	  population	  of	  cells	  is	  of	  particular	  interest	  in	  the	  era	  of	  drugs	  that	  
inhibit	   BCR	   signalling,	   where	   it	   has	   been	   observed	   that	   up	   to	   a	   third	   of	   patients	  	  
(particularly	   those	   with	   mutated	   IgVH	   genes)	   develop	   a	   persistent	   lymphocytosis	  
(Woyach,	  Smucker,	  et	  al.,	  2014c).	  Detailed	  characterisation	  of	  the	  persistent	  CLL	  cells	  
has	  demonstrated	   features	  of	  anergy,	   specifically	   inability	   to	   signal	   through	   the	  BCR,	  	  
constitutive	   activation	   of	   ERK	   and	   absent	   proliferation	   (Woyach,	   Smucker,	   et	   al.,	  
2014c).	  	  
To	  understand	  the	  relationship	  between	  the	  quiescent	  sub-­‐population	  observed	  in	  our	  
deuterated	  glucose	  studies	  and	  the	  persistent	  population	  of	  CLL	  cells	  seen	  in	  patients	  
treated	   with	   ibrutinib,	   deuterated	   glucose	   studies	   should	   be	   performed	   in	   patients	  
commencing	   treatment	   with	   this	   drug.	   We	   are	   yet	   to	   learn	   the	   significance	   of	   the	  
prolonged	  lymphocytosis	  in	  patients	  receiving	  ibrutinib	  therapy;	  it	  is	  currently	  unclear	  
whether	  it	  is	  an	  inert	  sub-­‐population	  or	  whether	  it	  can	  undergo	  genetic	  evolution	  and	  
give	  rise	  to	  resistance.	  One	  strategy	  could	  be	  to	  reverse	  anergy	  and	  induce	  apoptosis	  
through	  targeted	  inhibition	  of	  NFAT	  signaling	  and	  it	  would	  be	  reasonable	  to	  test	  CsA	  in	  
this	  setting.	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A	  larger	  cohort	  of	  patients	  with	  mutated	  IgVH	  genes	  should	  be	  studied	  to	  characterise	  
the	   phenotype	   and	   function	   of	   the	   quiescent	   sub-­‐population	   with	   an	   emphasis	   on	  
assessing	   BCR	   signalling	   capacity.	   Ultimately,	   targeted	   sequencing	   should	   be	  
performed	   to	   assess	   whether	   the	   quiescent	   sub-­‐population	   has	   a	   distinct	   genetic	  
profile	  that	  underpins	  its	  functional	  characteristics.	  
Finally,	  it	  is	  necessary	  to	  investigate	  in-­‐vivo	  tumour	  kinetics	  in	  patients	  with	  unmutated	  
IgVH	  genes.	  Patients	  with	  UM-­‐CLL	  have	  a	  shorter	  time	  to	  first	  treatment	  and	  reduced	  
overall	  survival	   (Damle	  et	  al.,	  1999;	  Hamblin	  et	  al.,	  1999).	  The	  adverse	  prognosis	   is	  a	  
consequence	   of	   distinct	   biological	   characteristics	   including	   increased	   signalling	  
thorough	   the	   BCR	   and	   proliferation,	   shorter	   telomeres	   and	   adverse-­‐risk	   mutations	  
(Herishanu	  et	  al.,	  2011;	  Hultdin	  et	  al.,	  2003;	  Mockridge	  et	  al.,	  2007;	  Rossi	  et	  al.,	  2013).	  
However,	  it	  is	  interesting	  that	  patients	  with	  UM-­‐CLL	  respond	  particularly	  well	  to	  drugs	  
that	   inhibit	   signalling	   through	   the	   BCR	   and	   do	   not	   tend	   to	   develop	   a	   persistent	  
lymphocytosis	  (Woyach,	  Smucker,	  et	  al.,	  2014c).	  This	  may	  be	  due	  to	  the	  fact	  that	  the	  
entire	   CLL	   clone	   undergoes	   proliferation	   and	   that	   sub-­‐population	   of	   quiescent	   cells	  
does	  not	  exist	  in	  these	  patients.	  
The	   in-­‐vivo	   studies	  of	   tumour	  kinetics	   significantly	  advance	   the	  understanding	  of	   the	  
relationship	   between	   sIgM	   expression,	   BCR	   internalisation,	   proliferation	   and	  
subsequent	   trafficking	   of	   CLL	   cells	   between	   the	   lymph-­‐node	   and	   peripheral	   blood	  
compartments.	  The	  ‘pulse-­‐labelling’	  feature	  of	  deuterated	  glucose	  enabled	  release	  and	  
disappearance	  rates	   to	  be	  studied	   for	   the	   first	   time	   in	  a	  cohort	  of	  well-­‐characterised	  
patients	   with	   M-­‐CLL.	   Although	   deuterated	   water	   studies	   have	   demonstrated	   the	  
importance	  of	  proliferation	  in	  the	  pathogenesis	  of	  CLL,	  the	  deuterated	  glucose	  studies	  
presented	  here	  provide	  evidence	  of	   long-­‐lived	  CLL	  cells	  and	   in	  patients	  with	  mutated	  
IgVH	   genes.	   This	   finding	   revives	   the	  debate	   regarding	   the	   role	  of	  defective	  apoptosis	  
versus	  proliferation	  in	  the	  aetiology	  of	  CLL.	  
There	  was	  remarkable	  heterogeneity	  in	  our	  cohort	  of	  ten	  patients	  and	  a	  larger	  cohort	  
study	  is	  now	  warranted	  to	  further	  investigate	  these	  preliminary	  findings.	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It	   is	   hoped	   that	   this	   investigation	   demonstrates	   the	   importance	   of	   studying	   the	  
proliferation	  and	  trafficking	  of	  tumour	  cells	   in-­‐vivo	   in	  order	  to	  accurately	  characterise	  
the	   pathogenesis	   of	   CLL.	   By	   further	   developing	   in-­‐vivo	   labelling	   studies,	  many	  more	  
important	   questions	   regarding	   the	   biology	   of	   CLL	   and	   impact	   of	   targeted	   therapies	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